TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

TABLE 39A 

LIST OF PUBLICATIONS REFERRED TO IN THE GUIDE 

1.1 Paul M et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination 

therapy for sepsis. Cochrane Database Syst Rev 2006;1:CD003344. 

1.2 Paul M et al. β-lactam monotherapy versus β-lactam aminoglycoside combination therapy for sepsis 

in immunocompetent patients: systematic review and meta-analysis of randomised trials. Br Med J 

2004;328:668-81. 

1.3 Safdar N et al. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? 

A meta-analysis. Lancet Infect Dis 2004;4:519-27. 

1.4 Paul M et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever 

with neutropenia: systematic review and meta-analysis. Br Med J 2003;326:1111-9. 

1.5 Furno P et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment 

of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231-42. 

1.6 Yates AB. Management of patients with a history of allergy to beta-lactam antibiotics. Am J Med 

2008;121:572-6. 

1.7 Weiss ME. Evaluation and treatment of patients with prior reactions to β-lactams. Curr Clin Top Infect 

Dis 1993;13:131-45. 

1.8 Robinson JL et al. Practical aspects of choosing an antibiotic for patients with a reported allergy to an 

antibiotic. Clin Infect Dis 2002;35:26-31. 

1.9 Rijnders BJ et al. Beleid en antibioticakeuze bij patiënten met een allergie voor penicilline. Ned Tijdschr 

Geneeskd 1999;143:336-41. 

1.10 Salkind AR et al. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of 

penicillin allergy. J Am Med Assoc 2001;285:2498-505. 

1.11 Gruchalla RS et al. Antibiotic allergy. N Engl J Med 2006;354:601-9. 

1.12 Park MA et al. Diagnosis and management of penicillin allergy. Mayo Clin Proc 2005;80:405-10. 

1.13 Romano A et al. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity 

to penicillins. Ann Intern Med 2004;141:16-22. 

1.14 Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation 

for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005;115: 

1048-57. 

1.15 Pichichero ME. Cephalosporins can be prescribed safely for penicillin-allergic patients. J Fam Pract 

2006;55:106-12. 

1.16 Romano A et al. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics 

2008;122:521-7. 

1.17 Prescott WA et al. Incidence of carbapenem-associated allergic-type reactions among patients with 

versus patients without a reported penicillin allergy. Clin Infect Dis 2004;38:1102-7. 

1.18 Frumin J et al. Allergic cross-sensitivity between penicillin, carbapenem and monobactam antibiotics: 

what are the chances? Ann Pharmacother 2009;43:304-15. 

1.19 Frumin J et al. Allergic cross-sensitivity between penicillin, carbapenem and monobactam antibiotics: 


1.20 Patriarca G et al. Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to beta-lactams. 

Int J Immunopathol Pharmacol 2008;21:375-9. 

1.21 Harris AD et al. Penicillin skin testing: a way to optimize antibiotic utilization. Am J Med 1999;107: 

166-8. 

1.22 Solensky R. Drug hypersensitivity. Med Clin North Am 2006;90:233-60. 

1.23 Solomkin JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and 

children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. 

Clin Infect Dis 2010;50:133-64. 

1.24 Laterre PF. Progress in medical management of intra-abdominal infection. Curr Opin Infect Dis 

2008;21:393-8. 

1.25 Rahimian J al. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis 2004; 

39:1654-9. 

1.26 Arisoy ES et al. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. 


1.27 Safdar N et al. Infected bilomas in liver transplant recipients: clinical features, optimal management 

and risk factors for mortality. Clin Infect Dis 2004;39:517-25. 

1.28 Strasberg SM. Acute acalculous cholecystitis. N Engl J Med 2008;358:2804-11. 

1.29 Pomerantz BJ. Biliary tract interventions. Tech Vasc Intervent Radiol 2009;12:162-70. 

1.30 Pomerantz BJ. Biliary tract interventions. Tech Vasc Intervent Radiol 2009;12:162-70. 

1.31 Jacobs DO. Diverticulitis. N Engl J Med 2007;357:2057-66. 

1.32 De Waele JJ. Use of antibiotics in severe acute pancreatitis. Expert Rev Anti Infect Ther 2010;8: 

317-24. 

1.33 Whitcomb DC. Acute pancreatitis. N Engl J Med 2006;354:2142-50. 

1.34 Nathens AB et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care 

Med 2004;32:2524-36. 

1.35 Bai Y et al. Antibiotic prophylaxis in acute necrotizing pancreatitis: an update. Am J Gastroenterol 

2010;105:705-7. 

1.36 Bai Y et al. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute 

necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol 

2008;103:104-10. 

1.37 Dellinger EP et al. Early antibiotic treatment for severe acute necrotizing pancreatitis. A randomized, 

double-blind, placebo-controlled trial. Ann Surg 2007;245:674-83. 

1.38 Villatoro E et al. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute 

pancreatitis. Cochrane Database Syst Rev 2006;4:CD002941. 

1.39 Isenmann R et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: 

a placebo controlled, double blind trial. Gastroenterology 2004;126:997-1004. 

1.40 Isenmann R et al. Prevention of infectious complications in severe acute pancreatitis with systemic 

antibiotics: where are we now? Expert Rev Anti Infect Ther 2005;3:393-401. 

1.41 Strauss E et al. Spontaneous bacterial peritonitis: a therapeutic update. Expert Rev Anti Infect Ther 

2006;4:249-60. 

1.42 Cheong HS et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial 

peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009;48:1230-6.

1.43 Sort P et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis 

and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9. 

1.44 Bhuva M et al. Spontaneous bacterial peritonitis: an update on evaluation, management, and prevention. 

Am J Med 1994;97:169-75. 

1.45 Roehrborn A et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001;33:1513-9. 

1.46 Seguin P et al. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis 

requiring intensive care. J Antimicrob Chemother 2010;65:342-6. 

1.47 Montravers P et al. Clinical and microbiological profiles of community-acquired and nosocomial intraabdominal 

infections: results of the French prospective, observational EBIIA study. J Antimicrob 

Chemother 2009;63:785-94. 

1.48 Eggimann P et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical 

patients. Crit Care Med 1999;27:1066-72. 

1.49 Wilson ML et al. Laboratory diagnosis of bone, joint, soft tissue, and skin infections. Clin Infect Dis 

2008;46:453-7. 

1.50 Pineda C et al. Imaging of osteomyelitis: current concepts. Infect Dis Clin North Am 2006;20:789- 

825. 

1.51 Lew DP et al. Osteomyelitis. Lancet 2004;364:369-79. 

1.52 Lazzarini L et al. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical 

trials? Int J Infect Dis 2005;9:127-38. 

1.53 Calhoun JH et al. Adult osteomyelitis. Infect Dis Clin North Am 2005;19:765-86. 

1.54 Landersdorfer CB et al. Penetration of antibacterials into bone: pharmacokinetic, pharmaco-dynamic 

and bioanalytical considerations. Clin Pharmacokinet 2009;48:89-124. 

1.55 Ferroni A. Epidémiologie et diagnostic bactériologique des infections ostéoarticulaires aiguës de l'enfant. 

Arch Pediatr 2007;14(suppl. 2):S91-6. 

1.56 Kaplan SL. Osteomyelitis in children. Infect Dis Clin North Am 2005;19:787-97. 

1.57 Harik NS et al. Management of acute hematogenous osteomyelitis in children. Expert Rev Anti Infect 

Ther 2010;8:175-81. 

1.58 Dessí A et al. Osteo-articular infections in newborns: diagnosis and treatment. J Chemother 2008; 

20:542-50. 

1.59 Ecury-Goossen GM et al. Sequential intravenous-oral antibiotic therapy for neonatal osteomyelitis. 

Pediatr Infect Dis J 2009;28:72-3. 

1.60 Chometon S et al. Specific real-time polymerase chain reaction places Kingella kingae as the most 

common cause of osteoarticular infections in young children. Pediatr Infect Dis J 2007;26:377-81. 

1.61 Darouiche RO. Spinal epidural abscess. N Engl J Med 2006;355:2012-20. 

1.62 Weichert S et al. Acute haematogenous osteomyelitis in children: is there any evidence for how long 

we should treat? Curr Opin Infect Dis 2008;21:258-62. 

1.63 Zaoutis T et al. Prolonged intravenous therapy versus early transition to oral antimicrobial therapy for 

acute osteomyelitis in children. Pediatrics 2009;123:636-42. 

1.64 Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect 

Ther 2006;4:853-60. 

1.65 Zimmerli W. Vertebral osteomyelitis. N Engl J Med 2010;362:1022-9. 

1.66 Marculescu CE et al. Outcome of prosthetic joint infections treated with debridement and retention of 

components. Clin Infect Dis 2006;42:471-8. 

1.67 Kowalski TJ et al. The management and outcome of spinal implant infections: contemporary retrospective 

cohort study. Clin Infect Dis 2007;44:913-20. 

1.68 Senneville E et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: 

concordance with ulcer swab cultures. Clin Infect Dis 2006;42:57-62. 

1.69 Lewis JS et al. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists 

be concerned? Clin Infect Dis 2005;40:280-5. 

1.70 Dohin B et al. Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive Staphylococcus 

aureus. Pediatr Infect Dis J 2007;26:1042-8. 

1.71 Lovering AM et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing 

routine hip replacement. J Antimicrob Chemother 2002;50:73-7. 

1.72 Dohin B et al. Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive 

Staphylococcus aureus. Pediatr Infect Dis J 2007;26:1042-8. 

1.73 Paviour S et al. Corynebacterium species isolated from patients with mastitis. Clin Infect Dis 2002; 

35:1434-40. 

1.74 Moazzez A et al. Breast abscess bacteriologic features in the era of community-acquired methicillinresistant 

Staphylococcus aureus epidemics. Arch Surg 2007;142:881-4. 

1.75 Araco A et al. Infections of breast implants in aesthetic breast augmentations: a single-center review 

of 3,002 patients. Aesthetic Plast Surg 2007;31:325-9. 

1.76 Pittet B et al. Infection in breast implants. Lancet Infect Dis 2005;5:94-106. 

1.77 Lu CH et al. Strategies for the management of bacterial brain abscess. J Clin Neurosci 2006;13: 

979-85. 

1.78 Hakan T et al. Bacterial brain abscesses: an evaluation of 96 cases. J Infect 2006;52:359-66. 

1.79 Tonon E et al. Brain abscess: clinical aspects of 100 patients. Int J Infect Dis 2006;10:103-9. 

1.80 Roche M et al. A twelve-year review of central nervous system bacterial abscesses; presentation and 

aetiology. Clin Microbiol Infect 2003;9:803-9. 

1.81 de Oliveira Penido N et al. Intracranial complications of otitis media: 15 years of experience in 33 patients. 

Otolaryngol Head Neck Surg 2005;132:37-42. 

1.82 McClelland S et al. Postoperative central nervous system infection: incidence and associated factors 

in 2111 neurosurgical procedures. Clin Infect Dis 2007;45:55-9. 

1.83 Bayston R et al. Use of antibiotics in penetrating craniocerebral injuries. Lancet 2000;355:1813-7. 

1.84 Brown-Elliott BA et al. Clinical and laboratory features of the Nocardia spp. based on current molecular 

taxonomy. Clin Microbiol Rev 2006;19:259-82. 

1.85 Hitti W et al. Two cases of multidrug-resistant Nocardia farcinica infection in immunosuppressed patients 

and implications for empiric therapy. Eur J Clin Microbiol Infect Dis 2005;24:142-4. 

1.86 Gomez-Flores A et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. 

Antimicrob Agents Chemother 2004;48:832-7. 

1.87 Ntziora F et al. Linezolid for the treatment of patients with central nervous system infection. Ann 

Pharmacother 2007;41:296-308. 

1.88 Jodlowski TZ et al. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother 2007; 

41:1694-9.

1.89 Laupland KB. Vascular and parameningeal infections of the head and neck. Infect Dis Clin North 

Am 2007;21:577-90. 

1.90 Osborn MK et al. Subdural empyema and other suppurative complications of paranasal sinusitis. 

Lancet Infect Dis 2007;7:62-7. 

1.91 Tunkel AR et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases 

Society of America. Clin Infect Dis 2008;47:303-27. 

1.92 Douvoyiannis M et al. Neurologic manifestations associated with parvovirus B19 Infection. Clin Infect 

Dis 2009;48:1713-23. 

1.93 Mailles A et al. Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis 

2009;49:1838-47. 

1.94 Fitch MT et al. Emergency department management of meningitis and encephalitis. Infect Dis Clin 

North Am 2008;22:33-52. 

1.95 Glaser CA et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect 

Dis 2006;43:1565-77. 

1.96 Whitley RJ et al. Viral encephalitis: familiar infections and emerging pathogens. Lancet 2002;359: 

507-14. 

1.97 Steiner I et al. Viral encephalitis: a review of diagnostic methods and guidelines for management. Eur 

J Neurol 2005;12:1-13. 

1.98 Jaussaud R et al. L‘encéphalite virale à tiques. Rev Med Interne 2001;22:542-8. 

1.99 Kupila L et al. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology 2006; 

66:75-80. 

1.100 Christie LJ et al. Pediatric encephalitis: what is the role of Mycoplasma pneumoniae? Pediatrics 

2007;120:305-13. 

1.101 Bitnun A et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin Infect Dis 2001;32: 

1674-84. 

1.102 Koskiniemi M et al. Acute central nervous system complications in varicella zoster virus infections. J 

Clin Virol 2002;25:293-301. 

1.103 Logan SA et al. Viral meningitis. Br Med J 2008;336:36-40. 

1.104 Ihekwaba UK et al. Clinical features of viral meningitis in adults: significant differences in cerebrospinal 

fluid findings among herpes simplex virus, varicella zoster virus, and enterovirus infections. Clin 

Infect Dis 2008;47:783-9. 


Dis 2009;48:1713-23. 

1.106 Zarrouk V et al. Evaluation of the management of postoperative aseptic meningitis. Clin Infect Dis 

2007;44:1555-9. 

1.107 Kupila L et al. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology 2006; 

66:75-80. 

1.108 Logan SA et al. Viral meningitis. Br Med J 2008;336:36-40. 

1.109 Moris G et al. The challenge of drug-induced aseptic meningitis. Arch Intern Med 1999;159:1185-94. 

1.110 Fitch MT et al. Emergency department management of meningitis and encephalitis. Infect Dis Clin 

North Am 2008;22:33-52. 

1.111 Schut ES et al. Community-acquired bacterial meningitis in adults. Pract Neurol 2008;8:8-23. 

1.112 Clarke ET et al. Current concepts in the treatment of bacterial meningitis beyond the neonatal period. 

Expert Rev Anti Infect Ther 2006;4:663-74. 

1.113 Fitch MT et al. Emergency diagnosis and treatment of adult meningitis. Lancet Infect Dis 2007;7: 

191-200. 

1.114 Adriani KS et al. Community-acquired recurrent bacterial meningitis in adults. Clin Infect Dis 2007; 

45:e46-51. 

1.115 Hart CA et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90. 

1.116 Sáez-Llorens X et al. Bacterial meningitis in children. Lancet 2003;361:2139-48. 

1.117 Tunkel AR al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 

39:1267-84. 

1.118 van de Beek D et al. Clinical features and prognostic factors in adults with bacterial meningitis. N 

Engl J Med 2004;351:1849-59. 

1.119 van de Beek D et al. Community-acquired bacterial meningitis in adults. N Engl J Med 2006;354:44- 

53. 

1.120 Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis 2010;10:32-42. 

1.121 Tebruegge M et al. Epidemiology, etiology, pathogenesis and diagnosis of recurrent bacterial meningitis. 

Clin Microbiol Rev 2008;21:519-37. 

1.122 Hasbun R et al. Computed tomography of the head before lumbar puncture in adults with suspected 

meningitis. N Engl J Med 2001;345:1727-33. 

1.123 Pollard AJ et al. Emergency management of meningococcal disease: eight years on. Arch Dis Child 

2007;92:283-6. 

1.124 Stephens DS et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 

2007;369:2196-210. 

1.125 Thompson MJ et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 

2006;367:397-403. 

1.126 Prasad K et al. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial 

meningitis. Cochrane Database Syst Rev 2007;4:CD001832. 

1.127 O‘Neill E et al. Third-generation cephalosporin resistance among Gram-negative bacilli causing meningitis 

in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. J Antimicrob 

Chemother 2006;57:356-9. 

1.128 Ricard JD et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids 

to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect 

Dis 2007;44:250-5. 

1.129 Mai NT et al. Immunological and biochemical correlates of adjunctive dexamethasone in Vietnamese 

adults with bacterial meningitis. Clin Infect Dis 2009;49:1387-92. 

1.130 Peltola H et al. Hearing impairment in childhood bacterial meningitis is little relieved by dexamethasone 

or glycerol. Pediatrics 2010;125:e1-8. 

1.131 Peltola H et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial 

meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 

2007;45:1277-86. 

1.132 Assiri AM et al. Corticosteroid administration and outcome of adolescents and adults with acute

acterial meningitis: a meta-analysis. Mayo Clin Proc 2009;84:403-9. 

1.133 Mai NT et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl 

J Med 2007:357:2431-40. 

1.134 Scarborough M et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J 

Med 2007:357:2441-50. 

1.135 Mongelluzzo J. Corticosteroids and mortality in children with bacterial meningitis. J Am Med Assoc 

2008;299:2048-55. 

1.136 van de Beek D et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 

2007;1:CD004405. 

1.137 van de Beek D et al. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet 

Infect Dis 2004;4:139-43. 

1.138 Fitch MT et al. Drug insights: steroids in CNS infectious diseases – new indications for an old therapy. 

Nat Clin Pract Neurol 2008;4;97-104. 

1.139 Peltola H et al. Improving the outcomes in children with bacterial meningitis. Curr Opin Infect Dis 

2009;22:250-5. 

1.140 Peltola H et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial 

meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 

2007;45:1277-86. 

1.141 Galiza EP et al. Improving the outcome of neonatal meningitis. Curr Opin Infect Dis 2009;22:229- 

34. 

1.142 van der Horst CM et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency 

syndrome. N Engl J Med 1997;337:15-21. 

1.143 Ng J et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular 

or intrathecal colistin: case series and literature review. J Antimicrob Chemother 

2006;58:1078-81. 

1.144 McClelland S et al. Postoperative central nervous system infection: incidence and associated factors 

in 2111 neurosurgical procedures. Clin Infect Dis 2007;45:55-9. 

1.145 Kim BN et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect 

Dis 2009;9:245-55. 

1.146 van de Beek D et al. Nosocomial bacterial meningitis. N Engl J Med 2010;362:146-54. 

1.147 Conen A et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections 

in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008;47:73-82. 

1.148 Tunkel AR et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 

2004;39:1267-84. 

1.149 Ng J et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular 

or intrathecal colistin: case series and literature review. J Antimicrob Chemother 

2006;58:1078-81. 

1.150 Reefhuis J et al. Risk of bacterial meningitis in children with cochlear implants. N Engl J Med 2003; 

349:435-45. 

1.151 Biernath KR et al. Bacterial meningitis among children with cochlear implants beyond 24 months after 

implantation. Pediatrics 2006;117:284-9. 

1.152 Brouwer MC et al. Community-acquired Haemophilus influenzae meningitis in adults. Clin Microbiol 

Infect 2007;13:439-42. 

1.153 Merle-Melet M et al. Is amoxicillin-cotrimoxazole the most appropriate antibiotic regimen for Listeria 

meningoencephalitis? Review of 22 cases and the literature. J Infect 1996;33:79-85. 

1.154 Brouwer MC et al. Community-acquired Listeria monocytogenes meningitis in adults. Clin Infect Dis 

2006;43:1233-8. 


2007;369:2196-210. 

1.156 Hart CA et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90. 

1.157 Ritchie SR et al. Flucloxacillin treatment of Staphylococcus aureus meningitis. Eur J Clin Microbiol 

Infect Dis 2007;26:501-4. 

1.158 Ntziora F et al. Linezolid for the treatment of patients with central nervous system infection. Ann 


1.159 Peppard WJ et al. Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. 


1.160 Kessler AT et al. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with 

linezolid. Infection 2007;35:271-4. 

1.161 Arda B et al. Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): review of 10 cases. 

Int J Antimicrob Agents 2005;25:414-8. 

1.162 Clarke ET et al. Current concepts in the treatment of bacterial meningitis beyond the neonatal period. 


1.163 Karageorgopoulos DE et al. Short versus long duration of antibiotic therapy for bacterial meningitis: a 

meta-analysis of randomised controlled trials in children. Arch Dis Child 2009;94:607-14. 

1.164 Ricard JD et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunct corticosteroids 

to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect 

Dis 2007;44:250-5. 

1.165 Prasad K et al. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 

2008;1:CD002244. 

1.166 Lo Re V et al. Eosinophilic meningitis. Am J Med 2003;114:217-23. 

1.167 Ongkasuwan J et al. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant 

serotype 19A isolates. Pediatrics 2008;122:34-9. 

1.168 Thompson PL et al. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort 

study using the United Kingdom General Practice Research Database. Pediatrics 2009;124: 

424-30. 

1.169 Rubin Grandis J et al. The changing face of malignant (necrotising) external otitis: clinical, radiological 

and anatomic correlations. Lancet Infect Dis 2004;4:34-9. 

1.170 Thompson PL et al. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort 

study using the United Kingdom General Practice Research Database. Pediatrics 2009;124: 

424-30. 

1.171 American Academy of Pediatrics and American Academy of Family Physicians. Diagnosis and management 

of acute otitis media. Pediatrics 2004;113:1451-65. 

1.172 Tan T et al. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary

of NICE guidance. Br Med J 2008;337:232-4. 

1.173 Segal N et al. Acute otitis media caused by Streptococcus pyogenes in children. Clin Infect Dis 

2005;41:35-41. 

1.174 Heslop A et al. Severe acute middle ear infections: microbiology and treatment. Int J Pediatr Otorhinolaryngol 

2006;70:1811-6. 

1.175 Heikkinen T et al. Importance of respiratory viruses in acute otitis media. Clin Microbiol Rev 2003; 

16:230-41. 

1.176 Chonmaitree et al. Viral upper respiratory tract infection and otitis media complication in young children. 


1.177 Powers JH. Diagnosis and treatment of acute otitis media: evaluating the evidence. Infect Dis Clin 

North Am 2007;21:409-26. 

1.178 Rovers MM. The burden of otitis media. Vaccine 2008;26(suppl. 7):G2-4. 

1.179 Williamson I. The rocky road to rational prescribing. Vaccine 2008;26(suppl. 7):G11-5. 

1.180 Pelton SI et al. Recent advances in otitis media. Pediatr Infect Dis J 2009;28(suppl.):S133-7. 

1.181 Leibovitz E et al. Current management of pediatric acute otitis media. Expert Rev Anti Infect Ther 

2010;8:151-61. 

1.182 Vergison A. Microbiology of otitis media: a moving target. Vaccine 2008;26(suppl. 7):G5-10. 

1.183 Casey JR et al. new patterns in the otopathogens causing acute otitis media six to eight years after 

introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010;29:304-9. 

1.184 Broides A et al. Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics. 


1.185 Vergison A et al. Otitis media and its consequences: beyond the earache. Lancet Infect Dis 2010; 

10:195-203. 

1.186 Spiro DM et al. Wait-and-see prescription for the treatment of acute otitis media. A randomized controlled 

trial. J Am Med Assoc 2006;296:1235-41. 

1.187 McCormick DP et al. Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful 

waiting versus immediate antibiotic treatment. Pediatrics 2005;115:1455-65. 

1.188 Rovers MM et al. Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not 

treated initially with antibiotics: a meta-analysis of individual patient data. Pediatrics 2007;119:579- 

85. 

1.189 Vouloumanou EK et al. Antibiotics versus placebo or watchful waiting for acute otitis media: a metaanalysis 

of randomized controlled trials. J Antimicrob Chemother 2009;64:16-24. 

1.190 Rovers MM et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 

2006;368:1429-35. 

1.191 American Academy of Pediatrics Subcommittee on Otitis Media with Effusion et al. Otitis media with 

effusion. Pediatrics 2004;113:1412-29. 

1.192 Chantzi FM et al. Otitis media with effusion: an effort to understand and clarify the uncertainties. Expert 

Rev Anti Infect Ther 2005;3:117-29. 

1.193 Kowalski RP et al. Ocular bacterial infections: current and future treatment options. Expert Rev Anti 

Infect Ther 2005;3:131-9. 

1.194 Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev 2003;16:730-97. 

1.195 Leibowitz HM. The red eye. N Engl J Med 2000;343:345-51. 

1.196 Kodjikian L et al. Ocular zoonoses. Expert Rev Ophthalmol 2009;4:331-49. 

1.197 Mueller JB et al. Ocular infection and inflammation. Emerg Med Clin North Am 2008;26:57-72. 

1.198 Fulmer NL et al. Lacrimal canaliculitis. Am J Emerg Med 1999;17:385-6. 

1.199 Wald ER. Periorbital (preseptal) cellulitis in children. Expert Rev Ophthalmol 2008;3:645-54. 

1.200 Nageswaran S et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006;25:695-9. 

1.201 Bilyk JR. Periocular infection. Curr Opin Ophthalmol 2007;18:414-23. 

1.202 Wald ER. Periorbital and orbital infections. Infect Dis Clin North Am 2007;21:393-408. 

1.203 Everitt HA et al. A randomised controlled trial of management strategies for acute bacterial conjunctivitis 

in general practice. Br Med J 2006;333:321-4. 

1.204 Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008;86:5-17. 

1.205 Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. 

Expert Opin Pharmacother 2007;8:1903-21. 

1.206 Sheikh A et al. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst 

Rev 2006;2:CD001211. 

1.207 Sheikh A et al. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and 

meta-analysis update. Br J Gen Pract 2005;55:962-4. 

1.208 Gambhir L et al. Trachoma: transmission, infection, and control. Lancet Infect Dis 2007;7:420-7. 

1.209 Wright HR. Trachoma. Lancet 2008:371:1945-54. 

1.210 Solomon AW et al. Diagnosis and assessment of trachoma. Clin Microbiol Rev 2004;17:982-1011. 

1.211 Schwartz SG et al. Endophthalmitis: classification and current management. Expert Rev Ophthalmol 

2007;2:385-96. 

1.212 Callegan MC et al. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium host interactions. 


1.213 Aiello LP et al. Evolving guidelines for intravitreous injections. Retina 2004;24(suppl. 5):S3-19. 

1.214 Shah CP et al. Ocular candidiasis: a review. Br J Ophthalmol 2008;92:466-8. 

1.215 Lemley CA et al. Endophthalmitis. A review of current evaluation and management. Retina 2007;27: 

662-80. 

1.216 Callegan MC et al. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium host interactions. 


1.217 Galloway G et al. Macular infarction after intravitreal amikacin: mounting evidence against amikacin. 

Br J Ophthalmol 2002;86:359-60. 

1.218 Sallam A et aL. Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther 2006:4:675-85. 

1.219 Busbee BG. Endophthalmitis: A reappraisal of incidence and treatment. Curr Opin Ophthalmol 

2006;17:287-91. 

1.220 Hanscom TA. Postoperative endophthalmitis. Clin Infect Dis 2004;38:542-6. 

1.221 Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized 

trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative 

bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-96. 

1.222 Galloway G et al. Macular infarction after intravitreal amikacin: mounting evidence against amikacin. 

Br J Ophthalmol 2002;86:359-60. 

1.223 Thomas PA et al. Infectious keratitis. Curr Opin Infect Dis 2007;20:129-41.

1.224 Panda A et al. Management approach for bacterial and fungal corneal ulcers. Expert Rev Ophthalmol 

2008;3:471-9. 

1.225 Suwan-apichan O et al. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane 

Database Syst Rev 2007;4:CD005430. 

1.226 FlorCruz NV et al. Medical interventions for fungal keratitis. Cochrane Database Syst Rev 2008;1: 

CD004241. 

1.227 Shukla PK et al. Mycotic keratitis: an overview of diagnosis and therapy. Mycoses 2008;51:183-99. 

1.228 Prakash G et al. Evaluation of intrastromal injection of voriconazole as therapeutic adjunctive for the 

management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008;146:56-9. 

1.229 Dart JK et al. Acanthamoeba keratitis: diagnosis and treatment. Update 2009. Am J Ophthalmol 

2009;148:487-99. 

1.230 Hammersmith KM. Diagnosis and management of Acanthamoeba keratitis. Curr Opin Ophthalmol 

2006;17:327-31. 

1.231 Awwad ST et al. Updates in Acanthamoeba keratitis. Eye Contact Lens 2007;33:1-8. 

1.232 Marciano-Cabral F et al. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 

2003;16:273-307. 

1.233 Seal D. Treatment of Acanthamoeba keratitis. Expert Rev Anti Infect Ther 2003;1:205-8. 

1.234 Woods CR. Gonococcal infections in infants and young children. Semin Pediatr Infect Dis 2005;16: 

258-70. 

1.235 Rours IG et al. Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants. Pediatrics 

2008;121:e321-6. 

1.236 Darville T. Chlamydia trachomatis infections in neonates and young children. Semin Pediatr Infect 

Dis 2005;16:235-44. 

1.237 Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on 

criteria for including patients in research studies. Diabetes Metab Res Rev 2004;20(suppl. 1):S90-5. 

1.238 Butalia S et al. Does this patient with diabetes have osteomyelitis of the lower extremity? J Am Med 

Assoc 2008;299:806-13. 

1.239 Dinh MT et al. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis 

underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis 2008;47:519-27. 

1.240 Lipsky BA. Bone of contention: diagnosing diabetic foot osteomyelitis. Clin Infect Dis 2008;47:528- 

30. 

1.241 Senneville E et al. Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients 

with diabetes and suspected osteomyelitis of the foot. Clin Infect Dis 2009;48:888-93. 

1.242 Senneville E et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: 

concordance with ulcer swab cultures. Clin Infect Dis 2006;42:57-62. 

1.243 Embil JM et al. Microbiological evaluation of diabetic foot osteomyelitis. Clin Infect Dis 2006:42:63-5. 

1.244 Lavery LA et al. Validation of the Infectious Diseases Society of America‘s diabetic foot infection classification 

system. Clin Infect Dis 2007;44:562-5. 

1.245 Cheer K et al. Managing complications of the diabetic foot. Br Med J 2009;339:1304-7. 

1.246 Rao N et al. Optimising antimicrobial therapy in diabetic foot infections. Drugs 2007;67:195-214. 

1.247 Cavanagh PR et al. Treatment for diabetic foot ulcers. Lancet 2005;366:1725-35. 

1.248 Boulton AJ et al. Neuropathic diabetic foot ulcers. N Engl J Med 2004;351:48-55. 

1.249 Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004;39(suppl. 2):S104-14. 

1.250 Berendt AR et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review 

of treatment. Diabetes Metab Res Rev 2008;24(suppl. 1):S145-61. 

1.251 Wraight PR et al. Creation of a multidisciplinary, evidence based, clinical guideline for the assessment, 

investigation and management of acute diabetes related foot complications. Diabet Med 2005; 

22:127-36. 

1.252 Lipsky BA et al. Diagnosis and management of diabetic foot infections. Clin Infect Dis 2004;39:885- 

910. 

1.253 Cohen SH et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by 

the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of 

America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55. 

1.254 Bauer MP et al. European Society for Clinical Microbiology and Infectious Diseases (ESCMID): treatment 

guidance for Clostridium difficile infection. Clin Microbiol Infect 2009;15:1067-79. 

1.255 Gerding DN et al. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl. 1):S32- 

42. 

1.256 DuPont HL et al. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, 

treatment and control. Curr Opin Infect Dis 2008;21:500-7. 

1.257 Kelly CP et al. Clostridium difficile. More difficult than ever. N Engl J Med 2008;359:1932-40. 

1.258 Bryant K et al. Clostridium difficile infections in children. Pediatr Infect Dis J 2009;28:145-6. 

1.259 Shannon-Lowe J et al. Prevention and medical management of Clostridium difficile infection. Br Med 

J 2010;340:c1296. 

1.260 Gerding DN et al. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl. 1):S32- 

42. 

1.261 Bartlett JG. Antibiotic associated diarrhea. N Engl J Med 2002;346:334-9. 

1.262 Yassin SF et al. Clostridium difficile associated diarrhea and colitis. Mayo Clin Proc 2001;76:725-30. 

1.263 Aslam S et al. Treatment of Clostridium difficile associated disease: old therapies and new strategies. 


1.264 Starr J. Clostridium difficile associated diarrhoea: diagnosis and treatment. Br Med J 2005;331:498- 

501. 

1.265 Bauer MP et al. Clostridium difficile: controversies and approaches to management. Curr Opin Infect 

Dis 2009;22:517-24. 

1.266 Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007;45 

(suppl. 2):S122-8. 

1.267 Voth DE et al. Clostridum difficile toxins: mechanism of action and role in disease. Clin Microbiol 

Rev 2005;18:247-63. 

1.268 Hoge Gezondheidsraad. Belgische aanbevelingen voor de beheersing en preventie van infecties met 

Clostridium difficile in acute ziekenhuizen en in woon- en zorgcentra. Available at: https://portal. 

health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG/HOMEPAGE_MENU/ABOUTUS1_MENU/INSTI 

TUTIONSAPPARENTEES1_MENU/HOGEGEZONDHEIDSRAAD1_MENU/BROCHURES1_HIDE/B 

ROCHURES1_DOCS/HGR_8365_NL.PDF. Accessed on August 21 st 2010. 

1.269 Conseil Supérieur de la Santé. Recommandations belges pour le contrôle et la prévention des infec-

tions à Clostridium difficile dans les hôpitaux aigus et dans les maisons de repos et de soins. Available 

at: https://portal.health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG /HOMEPAGE_MENU/ A 

BOUTUS1_MENU/ INSTITUTIONSAPPARENTEES1_MENU/HOGEGEZONDHEIDSRAAD1_MENU 

/BROCHURES1_HIDE/BROCHURES1_DOCS/CSS_8365_FR.PDF. Accessed on August 21 st 2010. 

1.270 Gerding DN et al. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 

2008;46(suppl. 1):S43-9. 

1.271 Dubberke ER et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect 

Control Hosp Epidemiol 2008;29(suppl. 1):S81-92. 

1.272 Vonberg RP et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol 

Infect 2008;14(suppl. 5):2-20. 

1.273 Owens RC et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 

2008;46(suppl. 1):S19-31. 

1.274 Dial S et al. Use of gastric acid suppressive agents and the risk of community acquired Clostridium 

difficile associated disease. J Am Med Assoc 2005;294:2989-95. 

1.275 Wilcox MH et al. A case-control study of community-associated Clostridium difficile infection. J Antimicrob 

Chemother 2008;62:388-96. 

1.276 Crobach MJ et al. European Society for Clinical Microbiology and Infectious Diseases (ESCMID): data 

review and recommendations for diagnosing Clostridium difficile infection. Clin Microbiol Infect 

2009;15:1053-66. 

1.277 Bartlett JG et al. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 

2008;46(suppl. 1):S12-18. 

1.278 Kelly CP et al. A 76-year old man with recurrent Clostridium difficile associated diarrhea: review of 

Clostridium difficile Infection. J Am Med Assoc 2009;301:954-62. 

1.279 Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. 

J Infect 2009;58:403-10. 

1.280 Pépin J et al. Management and outcomes of a first recurrence of Clostridium difficile associated disease 

in Quebec, Canada. Clin Infect Dis 2006;42:758-64. 

1.281 Kyne L et al. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152-3. 

1.282 McFarland LV et al. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium 

difficile disease. Am J Gastroenterol 2002;97:1769-75. 

1.283 Wanahita A et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 

2003;115:543-6. 

1.284 Wanahita A et al. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention 

to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002;34:1585-92. 

1.285 Goorhuis A et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase 

chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70. 

1.286 Kuijper EJ et al. Emergence of Clostridium difficile-associated disease in North America and Europe. 

Clin Microbiol Infect 2006;12(suppl. 6):2-18. 

1.287 Delmée M et al. Epidemiology of Clostridium difficile toxinotype III, PCR-ribotype 027 associated disease 

in Belgium, 2006. Available at: http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId= 

3045. Accessed on August 21 st 2010. 

1.288 Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. 

Ann Intern Med 2006;145:758-764. 

1.289 Blossom DB et al. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 

2007;45:222-7. 

1.290 Koo HL et al. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect 

Dis 2009;48:598-605. 

1.291 Gerding DN. Antimotility agents for the treatment of Clostridium difficile infection: is the juice worth the 

squeeze? Clin Infect Dis 2009;48:606-8. 

1.292 Al-Nassir WN et al. Comparison of clinical and microbiological response to treatment of Clostridium 

difficile associated disease with metronidazole and vancomycin. Clin Infect Dis 2008;47:56-62. 

1.293 Kuijper EJ et al. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? 


1.294 Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database 

Syst Rev 2007;3:CD004610. 

1.295 Musher DM et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. 


1.296 Pépin J et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. 


1.297 Gerding DN. Metronidazole for Clostridium difficile associated disease: is it okay for mom? Clin Infect 

Dis 2005;40:1598-600. 

1.298 Zar FA et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated 

diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7. 

1.299 Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. 


1.300 Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive 

bullet really magic? Clin Infect Dis 2008;46:1493-8. 

1.301 Apisarnthanarak A et al. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case 

series and review of the literature. Clin Infect Dis 2002;35:690-6. 

1.302 Parkes GC et al. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficileassociated 

diarrhoea. Lancet Infect Dis 2009;9:237-44. 

1.303 Hickson M et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: 

randomised double blind placebo controlled trial. Br Med J 2007;335:80-4. 

1.304 Johnson S et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial 

therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8. 

1.305 Musher DM et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to 

nitazoxanide. J Antimicrob Chemother 2007;59:705-10. 

1.306 Juang P et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile associated 

diarrhea. Am J Infect Control 2007;35:131-7. 

1.307 Aas J et al. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor 

stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580-5. 

1.308 Högenauer C et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic 

colitis. N Engl J Med 2006;355:2418-26.

1.309 Zollner-Schwetz I et al. Role of Klebsiella oxytoca in antibiotic-associated diarrhea. Clin Infect Dis 

2008;47:e74-8. 

1.310 Guerrant RL et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 

2001;32:331-50. 

1.311 DuPont HL. Bacterial diarrhea. N Engl J Med 2009;361:1560-9. 

1.312 Musher DM et al. Contagious gastro-intestinal infections. N Engl J Med 2004;351:2417-27. 

1.313 Thielman NM et al. Acute infectious diarrhea. N Engl J Med 2004;350:38-47. 

1.314 O‘Ryan M et al. An update on management of severe acute infectious gastroenteritis in children. Expert 


1.315 Phavichitr N et al. Acute gastroenteritis in children: what role for antibacterials? Pediatr Drugs 2003; 

5:279-90. 

1.316 Dennehy PH. Acute diarrheal disease in children: epidemiology, prevention, and treatment. Infect Dis 

Clin North Am 2005;19:585-602. 

1.317 Chao HC et al. Bacterial enteric infections in children: etiology, clinical manifestations and antimicrobial 

therapy. Expert Rev Anti Infect Ther 2006;4:629-38. 

1.318 Elliott EJ. Acute gastroenteritis in children. Br Med J 2007;334:35-40. 

1.319 Barclay AR et al. Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol 

Nutr 2007;45:569-76. 

1.320 Moss RL et al. Laparatomy versus peritoneal drainage for necrotizing enterocolitis and perforation. N 

Engl J Med 2006;354:2225-34. 

1.321 Flake AW. Necrotizing enterocolitis in preterm infants. Is laparatomy necessary? N Engl J Med 2006; 

354:2275-76. 

1.322 Sears CL et al. Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. 


1.323 Tribble DR et al. Traveler‘s diarrhea in Thailand: randomized, double-blind trial comparing single-dose 

and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 

44:338-46. 

1.324 DuPont HL. Azithromycin for the self-treatment of traveler‘s diarrhea. Clin Infect Dis 2007;44:347-9. 

1.325 Shlim DR. Update in traveler‘s diarrhea. Infect Dis Clin North Am 2005;19:137-49. 

1.326 Diemert DJ. Prevention and self-treatment of traveler‘s diarrhea. Clin Microbiol Rev 2006;19:583-94. 

1.327 DuPont HL. Therapy for and prevention of traveler‘s diarrhea. Clin Infect Dis 2007;45(suppl. 1):S78- 

84. 

1.328 Sanders JW et al. Azithromycin and loperamide are similar to levofloxacin and loperamide for the 

treatment of traveler‘s diarrhea in military personnel in Turkey. Clin Infect Dis 2007;45:294-301. 

1.329 Okhuysen PC. Current concepts in traveler‘s diarrhea: epidemiology, antimicrobial resistance and 

treatment. Curr Opin Infect Dis 2005;18:522-6. 

1.330 Leggat PA et al. Thavellers‘ diarrhoea: health advice for travellers. Travel Med Infect Dis 2004;2:17- 

22. 

1.331 Koo HL et al. Current and future developments in traveler‘s diarrhea therapy. Expert Rev Anti Infect 

Ther 2006;4:417-27. 

1.332 Yates J. Traveler‘s diarrhea. Am Fam Physician 2005;71:2095-100. 

1.333 Al-Abri SS et al. Traveller‘s diarrhoea. Lancet Infect Dis 2005;5:349-60. 

1.334 Adachi JA et al. Empirical antimicrobial therapy for traveler‘s diarrhea. Clin Infect Dis 2000;31:1079- 

83. 

1.335 Sack DA et al. Cholera. Lancet 2004;363:223-33. 

1.336 Kartalija M et al. Diarrhea and AIDS in the era of highly active antiretroviral therapy. Clin Infect Dis 

1999;28:701-7. 

1.337 Peghini PL et al. Improvement of chronic diarrhea after treatment for intestinal spirochetosis. Dig Dis 

Sci 2000;45:1006-10. 

1.338 Brooke CJ et al. In vitro antimicrobial susceptibility of Brachyspira pilosicoli isolates from humans. Antimicrob 

Agents Chemother 2003;47:2354-7. 

1.339 Koteish A et al. Colonic spirochetosis in children and adults. Am J Clin Pathol 2003;120:828-32. 

1.340 Evans MR et al. Short-term and medium-term clinical outcomes of quinolone-resistant Campylobacter 

infection. Clin Infect Dis 2009;48:1500-6. 

1.341 Ternhag A et al. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused 

by infection with Campylobacter species. Clin Infect Dis 2007;44:696-700. 

1.342 Ruiz-Palacios GM. The health burden of Campylobacter infection and the impact of antimi-crobial 

resistance: playing chicken. Clin Infect Dis 2007;44:701-3. 

1.343 Lecuit M et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N 

Engl J Med 2004;350:239-48. 

1.344 Feodoroff FB et al. Severe diarrhoea caused by highly ciprofloxacin-susceptible Campylobacter isolates. 

Clin Microbiol Infect 2009;15:188-92. 

1.345 Rogers TJ et al. Therapeutic strategies for shigatoxin-producing Escherichia coli infections. Expert 


1.346 Palermos MS et al. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert 


1.347 Goldwater PN. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic 

uremic syndrome. Expert Rev Anti Infect Ther 2007;5:653-63. 

1.348 Tarr PI et al. Shiga toxin producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 

365:1073-86. 

1.349 Thorpe CM. Shiga toxin producing Escherichia coli infection. Clin Infect Dis 2004;38:1298-303. 

1.350 Tzipori S et al. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. 


1.351 Orth D et al. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. 


1.352 Majowicz SE et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 

2010;50:882-9. 

1.353 Saha D et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006;354: 

2452-62. 

1.354 Abraham C et al. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78. 

1.355 Eckburg PB et al. The role of microbes in Crohn‘s disease. Clin Infect Dis 2007;44:256-62. 

1.356 Collins P et al. Ulcerative colitis: diagnosis and management. Br Med J 2006;333:340-3. 

1.357 Feller M et al. Long-term antibiotic treatment for Crohn‘s disease: systematic review and meta-analy-

sis of placebo-controlled trials. Clin Infect Dis 2010;50:473-80. 

1.358 Steinhart AH et al. Combined budesonide and antibiotic therapy for active Crohn‘s disease: a randomized 

controlled trial. Gastroenterology 2002;123:33-40. 

1.359 Sandborn WJ et al. Medical management of mild to moderate Crohn‘s disease: evidence-based treatment 

algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007;26:987- 

1003. 

1.360 Qu Z et al. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential 

diagnosis. Hum Pathol 2009;40:572-7. 

1.361 Wallis RS. Infectious complications of tumor necrosis blockade. Curr Opin Infect Dis 2009;22:403-9. 

1.362 Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect 

Dis 2008;8:601-11. 

1.363 Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents 

against tumor necrosis factor alpha. Morb Mortal Wkly Rep 2004;53:683-6. 

1.364 McMillan A et al. The 2007 European guideline (International Union against Sexually Transmitted Infections/World 

Health Organization) on the management of proctitis, proctocolitis and enteritis caused 

by sexually transmissible pathogens. Int J STD AIDS 2007;18:514-20. 

1.365 Davis TW et al. Sexually transmitted infections as a cause of proctitis in men who have sex with men. 

Dis Colon Rectum 2009;52:507-12. 

1.366 Rompalo AM. Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. Clin 

Infect Dis 1999;28(suppl. 1):S84-90. 

1.367 Gomez L et al. Neutropenic enterocolitis: spectrum of the disease and comparison of definite and 

possible cases. Clin Infect Dis 1998;27:695-9. 

1.368 Gorschlüter M et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J 

Haematol 2005:75:1-13. 

1.369 Cardona AF et al. From case reports to systematic reviews in neutropenic enterocolitis. Eur J Haematol 

2005;75:445-6. 

1.370 Picardo M et al. Improved management of neutropenic enterocolitis using early ultrasound scan and 

vigorous medical treatment. Clin Infect Dis 2007;45:403-4. 

1.371 Gorschlüter M et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of 

pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006;6:35. 

1.372 Chey WD et al. American College of Gastroenterology guideline on the management of Helicobacter 

pylori infection. Am J Gastroenterol 2007;102:1808-25. 

1.373 Fuccio L et al. Treatment of Helicobacter pylori infection. Br Med J 2008;337:746-50. 

1.374 Kusters JG et al. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Infect 2006;19:449- 

90. 

1.375 Salles N et al. Current management of Helicobacter pylori infections in the elderly. Expert Rev Anti 

Infect Ther 2007;5:845-56. 

1.376 Suerbaum S et al. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86. 

1.377 McColl KE. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604. 

1.378 Nakayama Y et al. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect 

Ther 2004;2:599-610. 

1.379 Calvet X et al. Accuracy of diagnostic tests for Helicobacter pylori: a reappraisal. Clin Infect Dis 

2009;48:1385-91. 

1.380 Gisbert JP et al. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a 

systematic review and meta-analysis. Am J Gastroenterol 2006;101:1921-30. 

1.381 Shah R. Dyspepsia and Helicobacter pylori. Br Med J 2007;334;41-3. 

1.382 Malfertheiner P et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. 

Aliment Pharmacol Ther 2003;18:615-25. 

1.383 Veldhuyzen van Zanten S et al. Absence of symptomatic benefit of lansoprazole, clarithromycin and 

amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (non ulcer) dyspepsia. 

Am J Gastroenterol 2003,98:1963-9. 

1.384 Gerits MM et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical 

implications. Lancet Infect Dis 2006;6:699-709. 

1.385 Graham DY et al. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat 

Clin Pract Gastroenterol Hepatol 2008;5:321-31. 

1.386 Fuccio L et al. Meta-analysis: Duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter 

pylori eradication. Ann Intern Med 2007;147:553-62. 

1.387 Raoult D et al. Tropheryma whipplei in children with gastroenteritis. Emerg Infect Dis 2010;16:776- 

82. 

1.388 Schneider T et al. Whipple‘s disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 

2008;8:179-90. 

1.389 Fenollar F et al. Whipple‘s disease. N Engl J Med 2007;356:55-66. 

1.390 Schneider T et al. Whipple‘s disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 

2008;8:178-90. 

1.391 Scheld WM. Whipple disease of the central nervous system. J Infect Dis 2003;188:797-800. 

1.392 Maiwald M et al. Cultivation of Tropheryma whipplei from cerebrospinal fluid. J Infect Dis 2003;188: 

801-8. 

1.393 Kellogg N et al. The evaluation of sexual abuse in children. Pediatrics 2005;116:506-12. 

1.394 Kaufman M et al. Care of the adolescent sexual assault victim. Pediatrics 2008;122:462-70. 

1.395 Girardet RG et al. Epidemiology of sexually transmitted infections in suspected child victims of sexual 

assault. Pediatrics 2009;124:79-86. 

1.396 Joishy M et al. Do we need to treat vulvovaginitis in prepubertal girls? Br Med J 2005;330:186-8. 

1.397 Welch J et al. Rape and sexual assault. Br Med J 2007;334:1154-8. 

1.398 Kawsar M et al. Child sexual abuse and sexually transmitted infections: review of joint genito-urinary 

medicine and paediatric examination practice. Int J STD AIDS 2008;19:349-50. 

1.399 Centers for Disease Control and Prevention (CDC). Update to CDC‘s sexually transmitted diseases 

guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. 

Morb Mortal Wkly Rep 2007;56:332-6. 

1.400 Ghanem KG et al. Fluoroquinolone-resistant Neisseria gonorrhoeae: the inevitable epidemic. Infect 

Dis Clin North Am 2005;19:351-65. 

1.401 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases. Treatment guidelines 

2006. Morb Mortal Wkly Rep 2006;55(RR-11):1-94. 

1.402 Greer L et al. Rapid diagnostic methods in sexually transmitted infections. Infect Dis Clin North Am

2008;22:601-17. 

1.403 Donders GG. Management of genital infections in pregnant women. Curr Opin Infect Dis 2006;19: 

55-61. 

1.404 Geisler WM. Approaches to the management of uncomplicated genital Chlamydia trachomatis infections. 


1.405 Peipert JF. Genital chlamydial infections. N Engl J Med 2003;349:2424-30. 

1.406 Bébéar C et al. Genital Chlamydia trachomatis infections. Clin Microbiol Infect 2009;15:4-10. 

1.407 Kalwij S et al. Screening and treatment of Chlamydia trachomatis infections. Br Med J 2010;340: 

c1915. 

1.408 Geisler WM. Management of uncomplicated Chlamydia trachomatis infections in adolescents and 

adults: evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted 

diseases treatment guidelines. Clin Infect Dis 2007;44(suppl. 3):S77-83. 

1.409 Lewis DA. Chancroid: clinical manifestations, diagnosis, and management. Sex Transm Infect 2003; 

79:68-71. 

1.410 Newman LM et al. Update on the management of gonorrhea in adults in the United States. Clin Infect 

Dis 2007;44(suppl. 3):S84-101. 

1.411 Bignell C. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in 

adults. Int J STD AIDS 2009;20:453-7. 

1.412 Schachter J et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis 

and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for 

both infections. Sex Transm Dis 2005;32:725-8. 

1.413 Cook RL et al. Systematic review: non invasive testing for Chlamydia trachomatis and Neisseria 

gonorrhoeae. Ann Intern Med 2005;142:914-25. 

1.414 Rice PA. Gonococcal arthritis (disseminated gonococcal infection). Infect Dis Clin North Am 2005; 

19:853-61. 

1.415 Hart G. Donovanosis. Clin Infect Dis 1997;25:24-32. 

1.416 Prichens J. Donovanosis (granuloma inguinale). Sex Transm Infect 2006;82(suppl. 4):iv21-2. 

1.417 McLean CA et al. Treatment of lymphogranuloma venereum. Clin Infect Dis 2007;44(suppl. 3): 

S147-52. 

1.418 White JA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis 

2009;22:57-66. 

1.419 Richardson D et al. Lymphogranuloma venereum: an emerging cause of proctitis in men who have 

sex with men. Int J STD AIDS 2007;18:11-16. 

1.420 Van der Bij AK et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in 

men who have sex with men: a retrospective case control study. Clin Infect Dis 2006;42:186-94. 

1.421 de Vries HJ et al. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline 

treatment. Clin Infect Dis 2009;48:e53-6. 

1.422 Katz KA et al. Azithromycin resistance in Treponema pallidum. Curr Opin Infect Dis 2008;21:83-91. 

1.423 French P et al. IUSTI: 2008 European guidelines on the management of syphilis. Int J STD AIDS 

2009;20:300-9. 

1.424 Gayet-Ageron A et al. Assessment of a real-time PCR test to diagnose syphilis from diverse biological 

samples. Sex Transm Infect 2009;85:264-9. 

1.425 Hook EW et al. Syphilis control. A continuing challenge. N Engl J Med 2004;351:122-4. 

1.426 Stoner BP. Current controversies in the treatment of adult syphilis. Clin Infect Dis 2007;44(suppl. 3): 

S130-46. 

1.427 French P. Syphilis. Br Med J 2007;334:143-7. 

1.428 Baughn RE et al. Secondary syphilitic lesions. Clin Microbiol Rev 2005;18:205-16. 

1.429 Ghanem et al. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. 

Clin Infect Dis 2006;42:e45-9. 

1.430 Wong T et al. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine 

penicillin. Am J Med 2008;121:903-8. 

1.431 Bai ZG et al. Azithromycin vs benzathine penicillin G for early syphilis: a meta-analysis of randomized 

clinical trials. Int J STD AIDS 2008;19:217-21. 

1.432 Centers for Disease Control nad Prevention (CDC). Symptomatic early neurosyphilis among HIV-positive 

men who have sex with men – four cities, United States, January 2002-June 2004. Morb 

Mortal Wkly Rep 2007;56:625-8. 

1.433 Lynn WA et al. Syphilis and HIV: a dangerous combination. Lancet Infect Dis 2004;4:456-66. 

1.434 Marra CM et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical 

and laboratory features. J Infect Dis 2004;189:369-76. 

1.435 Marra CM et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does 

HIV status matter? Clin Infect Dis 2004;38:1001-6. 

1.436 Gaydos C et al. Mycoplasma genitalium compared to Chlamydia, gonorrhoea and Trichomonas as an 

aetiological agent of urethritis in men attending STD clinics. Sex Transm Infect 2009;85:438-40. 

1.437 Shahmanesh M et al. 2009 European guideline on the management of male non-gonococcal urethritis. 

Int J STD AIDS 2009;20:458-64. 

1.438 Bradshaw CS et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with 

orogenital exposure. J Infect Dis 2006;193:336-45. 

1.439 Geisler WM. Management of uncomplicated Chlamydia trachomatis infections in adolescents and 

adults: evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted 

diseases treatment guidelines. Clin Infect Dis 2007;44(suppl. 3):S77-83. 

1.440 Mena LA et al. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma 

genitalium-positive urethritis in men. Clin Infect Dis 2009;48:1649-54. 

1.441 Jensen JS. Single-dose azithromycin treatment for Mycoplasma genitalium-positive urethritis: best 

but not good enough. Clin Infect Dis 2009;48:1655-6. 

1.442 Yokoi S et al. The role of Mycoplasma genitalium and Ureaplasma urealyticum biovar 2 in postgonococcal 

uerthritis. Clin Infect Dis 2007;45:866-71. 

1.443 Schwebke JR et al. High rates of Trichomonas vaginalis among men attending a sexually transmitted 

diseases clinic: implications for screening and urethritis management. J Infect Dis 2003;188:465-8. 





Dis Clin North Am 2005;19:351-65.

1.446 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases. Treatment guidelines 


1.447 Hollier LM et al. Treatment of sexually transmitted infections in women. Infect Dis Clin North Am 

2008;22:665-91. 

1.448 Lusk MJ et al. Cervicitis: a review. Curr Opin Infect Dis 2008;21:49–55. 

1.449 Ross J et al. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 

2007;18:662-6. 

1.450 Walker CK et al. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease 

Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 

2007;44(suppl. 3):S111-22. 

1.451 Faro C et al. Postoperative pelvic infections. Infect Dis Clin North Am 2008;22:653-663. 

1.452 Judlin P. Current concepts in managing pelvic inflammatory disease. Curr Opin Infect Dis 2010;23: 

83-7. 

1.453 Lareau SM et al. Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am 

2008;22:693-708. 

1.454 Haggerty CL et al. Newest approaches to treatment of pelvic inflammatory disease: a review of recent 

randomized clinical trials. Clin Infect Dis 2007;44:953-60. 

1.455 Short VL et al. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae 

infection among women with pelvic inflammatory disease. Clin Infect Dis 2009;48:41-7. 

1.456 Haggerty C et al. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. Curr 

Opin Infect Dis 2008;21:65-9. 

1.457 Eckert LO. Acute vulvovaginitis. N Engl J Med 2006;355:1244-52. 

1.458 Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis 2009;22:82–6. 

1.459 Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am 2008;22:637- 

52. 

1.460 Fethers KA et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. 


1.461 Verstraelen H et al. Bacterial vaginosis: an update on diagnosis and treatment. Expert Rev Anti Infect 

Ther 2009;7:1109-24. 

1.462 Okun N et al. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic 

review. Obstet Gynecol 2005;105:857-68. 

1.463 Sobel JD. What‘s new in bacterial vaginosis and trichomoniasis? Infect Dis Clin North Am 2005;19: 

387-406. 

1.464 Spence D et al. Vaginal discharge. Br Med J 2007;335:1147-51. 

1.465 Marrazzo JM. Evolving issues in understanding and treating bacterial vaginosis. Expert Rev Anti Infect 

Ther 2004;2:913-22. 

1.466 Bradshaw CS et al. High recurrence rates of bacterial vaginosis over the course of 12 months after 

oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478-86. 

1.467 De Backer E et al. Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis 2006;6:51. 

1.468 Ugwumadu A et al. Effect of early clindamycin on late miscarriage and preterm delivery in asymptomatic 

women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 

2003;361:983-8. 

1.469 Yudin MH et al. Screening and management of bacterial vaginosis in pregnancy. J Obstet Gynaecol 

Can 2008;30:702-8. 

1.470 Schwebke JR et al. A randomized trial of the duration of therapy with metronidazole plus or minus 

azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007;44:213-9. 






1.473 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases. Treatment guide- 

lines 2006. Morb Mortal Wkly Rep 2006;55(RR-11):1-94. 

1.474 Ludwig M. Diagnosis and therapy of acute prostatitis, epididymitis and orchitis. Andrologia 2008;40: 

76-80. 

1.475 Edwards SK. European guideline for the management of balanoposthitis. Int J STD AIDS 2001;12 

(suppl. 3):68-72. 

1.476 Lisboa C et al. Infectious balanoposthitis: management, clinical and laboratory features. Int J Dermatol 

2009;48:121-4. 

1.477 Horner PJ. European guideline for the management of epididymo-orchitis and syndromic management 

of acute scrotal swelling. Int J STD AIDS 2001;12(suppl. 3):88-93. 

1.478 Schaeffer AJ. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006;355: 

1690-8. 

1.479 McNaughton Collins M et al. Diagnosis and treatment of chronic abacterial prostatitis: a systematic 

review. Ann Intern Med 2000;133:367-81. 

1.480 Alexander RB et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome. 

Ann Intern Med 2004;141:581-9. 

1.481 Lipsky BA et al. Treatment of bacterial prostatitis. Clin Infect Dis 2010;50:1641-52. 

1.482 Domingue GJ et al. Prostatitis. Clin Microbiol Rev 1998;11:604-13. 

1.483 Wagenlehner FM et al. Antimicrobial treatment of prostatitis. Expert Rev Anti Infect Ther 2003;1: 

275-82. 

1.484 Wagenlehner FM et al. Current challenges in the treatment of complicated urinary tract infections and 

prostatitis. Clin Microbiol Infect 2006;12(suppl. 3):67-80. 

1.485 Schaeffer AJ. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 2006;355: 

1690-8. 

1.486 Tosti R et al. Empiric antibiotics for acute infections of the hand. J Hand Surg 2010;35:125-8. 

1.487 Clark DC. Common acute hand infections. Am Fam Physician 2003;68:2167-76. 

1.488 Spann M et al. Hand infections: basic principles and management. Surg Infect 2004;5:210-20. 

1.489 Rigopulos D et al. Acute and chronic paronychia. Am Fam Physician 2008;77:339-46. 

1.490 Baddour LM et al. Nonvalvular cardiovascular device-related infections. Circulation 2003;108:2015- 

31. 

1.491 Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004;350: 

1422-9.

1.492 Sohail MR et al. Management and outcome of permanent pacemaker and implantable cardioverterdefibrillator 

infections. J Am Coll Cardiol 2007;49:1851-9. 

1.493 Sohail MR et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator 

infection. Mayo Clin Proc 2008;83:46-53. 

1.494 Sopeña B et al. Individualized management of bacteraemia in patients with a permanent endocardial 

pacemaker. Clin Microbiol Infect 2010;16:274-80. 

1.495 Aslam S et al. Risk factors and outcomes of fungal ventricular-assist device infections. Clin Infect 

Dis 2010;50:664-71. 

1.496 Simon D et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 

2005;40:1108-15. 

1.497 Gordon RJ et al. Ventricular assist device-related infections. Lancet Infect Dis 2006;6:426-37. 

1.498 American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC 

/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation 2006; 

114:e84-132. 

1.499 Aksoy O et al. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin 

Infect Dis 2007;44:364-72. 

1.500 Dickerman SA et al. The relationship between the initiation of antimicrobial therapy and the incidence 

of stroke in infective endocarditis: An analysis from the ICE Prospective Cohort Study (ICE-PCS). Am 

Heart J 2007;154:1086-94. 

1.501 Muñoz P et al. Heart valves should not be routinely cultured. J Clin Microbiol 2008;46:2897-901. 

1.502 Morris AJ et al. Bacteriological outcome after valve surgery for active infective endocarditis: implications 

for duration of treatment after surgery. Clin Infect Dis 2005;41:187-94. 

1.503 Buchholtz K et al. Severity of gentamicin‘s nephrotoxic effect on patients with infective endocarditis: a 

prospective observational cohort study of 373 patients. Clin Infect Dis 2009;48:65-71. 

1.504 Frippiat F et al. Gentamicin in infective endocarditis: how to use it? Clin Infect Dis 2009;49:320-1. 

1.505 Buchholtz K et al. Gentamicin in infective endocarditis: how to use it? Clin Infect Dis 2009;49:321-2. 

1.506 Baddour LM et al. Infective endocarditis: diagnosis, antimicrobial therapy and management of complications. 

Circulation 2005;111:e394-433. 

1.507 Nishimura RA et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on 

infective endocarditis: a report of the American College of Cardiology/American Heart Association 

Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society 

for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons. Circulation 

2008;118:887-96. 

1.508 Nishimura RA et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on 

infective endocarditis: a report of the American College of Cardiology/American Heart Association 

Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society 

for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons. J Am Coll 

Cardiol 2008;52:676-85. 

1.509 Habib G et al. Guidelines on the prevention, diagnosis and treatment of infective endocarditis (new 

version 2009) by the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis 

of the European Society of Cardiology (ESC) endorsed by the European Society of Clinical Microbiology 

and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy 

(ISC) for Infection and Cancer. Eur Heart J 2009;30:2369-413. 

1.510 Elliott TS al. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working 

Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004;54:971- 

81. 

1.511 Hill EE et al. Evolving trends in infective endocarditis. Clin Microbiol Infect 2006;12:5-12. 

1.512 Mylonakis E et al. Infective endocarditis in adults. N Engl J Med 2001;345:1318-1330. 

1.513 Moreillon P et al. Infective endocarditis. Lancet 2004;363:139-49. 

1.514 Beynon RP et al. Infective endocarditis. Br Med J 2006;333:334-9. 

1.515 Paterick TE et al. Complexity and subtlety of infective endocarditis. Mayo Clin Proc 2007;82:615-21. 

1.516 Tak T et al. Current diagnosis and treatment of infective endocarditis. Expert Rev Anti Infect Ther 

2003;1:639-54. 

1.517 Le T et al. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003;36:615-21. 

1.518 Fenollar F et al. Whipple‘s endocarditis: review of the literature and comparisons with Q fever, Bartonella 

infection, and blood culture-positive endocarditis. Clin Infect Dis 2001;33:1309-16. 

1.519 Houpikian P et al. Blood culture-negative endocarditis in a reference center. Etiologic diagnosis of 

348 cases. Medicine 2005;84:162-73. 

1.520 Brouqui P et al. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 2001;14:177- 

207. 

1.521 Fournier PE et al. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective 

study of 819 new cases. Clin Infect Dis 2010;51:131-40. 

1.522 Brouqui P et al. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 2001;14:177- 

207. 

1.523 Miro JM et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from 

the International Collaboration on Endocarditis merged database. Clin Infect Dis 2005;41:507-14. 

1.524 Millar BC et al. Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis. 

J Antimicrob Chemother 2008;61:1-7. 

1.525 Chu VH et al. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. 


1.526 Knoll B et al. Infective endocarditis due to penicillin-resistant viridans group streptococci. Clin Infect 

Dis 2007;44:1585-92. 

1.527 Falagas ME et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the 

published evidence. J Antimicrob Chemother 2006;58:273-80. 

1.528 Muñoz P et al. Linezolid therapy for infective endocarditis. Clin Microbiol Infect 2007;13:211-5. 

1.529 Beck M et al. Comprehensive study of strains previously designated Streptococcus bovis consecutively 

isolated from human blood cultures and emended description of Streptococcus gallolyticus and 

Streptococcus infantarius subsp. coli. J Clin Microbiol 2008;46:2966-72. 

1.530 Beck M et al. Comprehensive study of strains previously designated Streptococcus bovis consecutively 



1.531 Gavaldà J et al. Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann 

Intern Med 2007;146:574-9.

1.532 Olaison L et al. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides 

be used? Clin Infect Dis 2002;34:159-66. 

1.533 McDonald JR et al. Enterococcal endocarditis: 107 cases from the International Collaboration on Endocarditis 

merged database. Am J Med 2005;118:759-66. 

1.534 Stevens MP et al. Endocarditis due to vancomycin-resistant enterococci: case report and review of 

the literature. Clin Infect Dis 2005;41:1134-42. 

1.535 Rolain JM et al. Recommendations for treatment of human infections caused by Bartonella species. 


1.536 Hartzell JD et al. Q fever: epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83:574-9. 

1.537 Wiener-Well Y et al. Q fever endocarditis: not always expected. Clin Microbiol Infect 2010;16:359- 

62. 

1.538 Raoult D et al. Case 5-2007: a 53-year old man with a prosthetic aortic valve and recent onset of 

fatigue, dyspnea, weight loss, and sweats. N Engl J Med 2007;356:715-25. 

1.539 Carcopino X et al. Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. 


1.540 Raoult D et al. Treatment of Q fever endocarditis. Comparison of 2 regimens containing doxycycline 

and ofloxacin or hydroxychloroquine. Arch Intern Med 1999;159:167-73. 

1.541 Fenollar F et al. Endocarditis after acute Q fever in patients with previously undiagnosed valvulopathies. 


1.542 Paturel L et al. Actinobacillus actinomycetemcomitans endocarditis. Clin Microbiol Infect 2004;10: 

98-118. 

1.543 Wang A et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. J Am Med 

Assoc 2007;297:1354-61. 

1.544 Ruiz ME et al. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure 

with linezolid. Clin Infect Dis 2002;35:1018-20. 

1.545 Anderson DJ et al. Enterococcal prosthetic valve infective endocarditis: report of 45 episodes from 

the International Collaboration on Endocarditis merged database. Eur J Clin Microbiol Infect Dis 

2005;24:665-70. 

1.546 Stevens MP et al. Endocarditis due to vancomycin-resistant enterococci: case report and review of 

the litereature. Clin Infect Dis 2005;41:1134-42. 

1.547 Sohail MR et al. Infective endocarditis due to Propionibacterium species. Clin Microbiol Infect 2009; 

15:387-94. 

1.548 Parikh SV et al. Purulent pericarditis report of 2 cases and review of the literature. Medicine 2009;88: 

52-65. 

1.549 Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of 

the Council on Cardiovascular Disease in the Young of the American Heart Association. Guidelines 

for the diagnosis of rheumatic fever: Jones criteria, updated 1992. Circulation 1993;87:302-7. 



for the diagnosis of rheumatic fever: Jones criteria, 1992 update. J Am Med Assoc 1992;268:2069- 

73. 

1.551 Carapetis JR et al. Acute rheumatic fever. Lancet 2005;366:155-68. 

1.552 Carlin EM et al. European guideline for the management of sexually acquired reactive arthritis. Int J 

STD AIDS 2001;12(suppl. 3):94-102. 

1.553 Townes JM. Reactive arthritis after enteric infections in the United States: the problem of definition. 


1.554 Colmegna I et al. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. 


1.555 Aviles RJ et al. Poststreptococcal reactive arthritis in adults: a case series. Mayo Clin Proc 2000;75: 

144-7. 



for the diagnosis of rheumatic fever: Jones criteria, updated 1992. Circulation 1993;87:302-7. 



for the diagnosis of rheumatic fever: Jones criteria, 1992 update. J Am Med Assoc 1992;268:2069- 

73. 

1.558 Petersel DL et al. Reactive arthritis. Infect Dis Clin North Am 2005;19:863-83. 

1.559 Carter JD. Reactive arthritis: defined etiologies, emerging physiopathology, and unresolved treatment. 

Infect Dis Clin North Am 2006;20:827-47. 

1.560 García-De La Torre I. Advances in the management of septic arthritis. Infect Dis Clin North Am 

2006;20:773-88. 

1.561 Wilson ML et al. Laboratory diagnosis of bone, joint, soft tissue, and skin infections. Clin Infect Dis 

2008;46:453-7. 

1.562 Ferroni A. Epidémiologie et diagnostic bactériologique des infections ostéoarticulaires aiguës de l'enfant. 

Arch Pediatr 2007;14(suppl. 2):S91-6. 

1.563 Mathews CJ et al. Management of septic arthritis: a systematic review. Postgrad Med J 2008;84: 

265-70. 

1.564 Ross JJ. Septic arthritis. Infect Dis Clin North Am 2005;19:799-817. 

1.565 Shirtliff ME et al. Acute septic arthritis. Clin Microbiol Rev 2002;15:527-44. 

1.566 Mathews CJ et al. Bacterial septic arthritis in adults. Lancet 2010;375:846-55. 

1.567 Dessí A et al. Osteo-articular infections in newborns: diagnosis and treatment. J Chemother 2008; 

20:542-50. 

1.568 Ecury-Goossen GM et al. Sequential intravenous-oral antibiotic therapy for neonatal osteomyelitis. 


1.569 Kang SN et al. The management of septic arthritis in children. Systematic review of the English language 

literature. J Bone Joint Surg Br 2009;91:1127-33. 

1.570 Chometon S et al. Specific real-time polymerase chain reaction places Kingella kingae as the most 

common cause of osteoarticular infections in children. Pediatr Infect Dis J 2007;26:377-81. 

1.571 Thompson A et al. Acute pediatric monoarticular arthritis: distinguishing Lyme arthritis from other etiologies. 

Pediatrics 2009;123:959-65. 

1.572 Hu L. Lyme arthritis. Infect Dis Clin North Am 2005;19:947-61. 

1.573 Peltola H et al. Prospective, Randomized trial of 10 days versus 30 days of antimicrobial treatment,

including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis 

2009;48:1201-10. 

1.574 Darley ES et al. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 

2004;53:928-35. 


19:853-61. 


19:853-61. 

1.577 Babcock HM et al. Postarthroscopy surgical site infections: review of the literature. Clin Infect Dis 

2002;34:65-71. 

1.578 Bejon P et al. Two-stage revision for prosthetic joint infection: predictors of outcome and the role of 

reimplantation microbiology. J Antimicrob Chemother 2010;65:569-75. 

1.579 Berbari EF et al. Outcome of prosthetic joint infections in patients with rheumatoid arthritis: the impact 

of medical and surgical therapy in 200 episodes. Clin Infect Dis 2006;42:216-23. 

1.580 Marculescu CE et al. Outcome of prosthetic joint infections treated with debridement and retention of 

components. Clin Infect Dis 2006;42:471-8. 

1.581 Bernard L et al. Trends in the treatment of orthopaedic prosthetic infections. J Antimicrob Chemother 

2004;53:127-9. 

1.582 Byren I et al. One hundred and twelve infected arthroplasties treated with ‗DAIR‘ (debridement, antibiotics 

and implant retention): antibiotic duration and outcome. J Antimicrob Chemother 2009;63: 

1264-71. 

1.583 Del Pozo JL et al. Infection associated with prosthetic joints. N Engl J Med 2009;361:787-94. 

1.584 Anguita-Alonso P et al. Prosthetic joint infection. Expert Rev Anti Infect Ther 2005;3:797-804. 

1.585 Zimmerli W et al. Prosthetic joint infections. N Engl J Med 2004;351:1645-54. 

1.586 Sia IG et al. Prosthetic joint infections. Infect Dis Clin North Am 2005;19:885-914. 

1.587 Fernandez Sampedro M et al. Infections associated with long-term prosthetic devices. Infect Dis Clin 

North Am 2007;21:785-819. 

1.588 Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin 


1.589 Darley ES et al. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 

2004;53:928-35. 

1.590 Aboltins CA et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis 

retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007;13:586-91. 

1.591 Berbari EF et al. Culture-negative prosthetic joint infection. Clin Infect Dis 2007;45:1113-9. 

1.592 El Helou OC et al. Outcome of enterococcal prosthetic joint infection: is combination systemic therapy 

superior to monotherapy? Clin Infect Dis 2008;47:903-9. 

1.593 Martínez-Pastor JC et al. Outcome of acute prosthetic joint infections due to Gram-negative bacilli 

treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother 

2009;53:4772-7. 

1.594 Hsieh PH et al. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin 

Infect Dis 2009;49:1036-43. 

1.595 Samuel JR et al. Prosthetic joint infections: single versus combination therapy. J Antimicrob Chemother 

2010;65:18-23. 

1.596 Nguyen S et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole 

combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009;15: 

1163-9. 

1.597 Stein A et al. Ambulatory treatment of multidrug resistant Staphylococcus-infected orthopedic implants 

with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 

1998;42:3086-91. 

1.598 Zimmerli W et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. 

A randomized controlled trial. J Am Med Assoc 1998;279:1537-41. 

1.599 Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents 

against tumor necrosis factor alpha. Morb Mortal Wkly Rep 2004;53:683-6. 

1.600 Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect 

Dis 2008;8:601-11. 

1.601 Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009;22: 

403-9. 

1.602 Bongartz T et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections 

and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled 

trials. J Am Med Assoc 2006;295:2275-85. 

1.603 Zimmermann B et al. Septic bursitis. Semin Arthritis Rheum 1995;24:391-410. 

1.604 Small LN et al. Suppurative tenosynovytis and septic bursitis. Infect Dis Clin North Am 2005;19: 

991-2005. 

1.605 Nicolle LE et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of 

asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40:643-54. 

1.606 Colgan R et al. Asymptomatic bacteriuria in adults. Am Fam Physician 2006;74:985-90. 

1.607 Schnarr J et al. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur 

J Clin Invest 2008;38(suppl. 2):50-7. 

1.608 U.S. Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults: U.S. Preventive 

Services Task Force reaffirmation recommendation statement. Ann Intern Med 2008;149:43-7. 

1.609 Hooton TM et al. Diagnosis, prevention and treatment of catheter-associated urinary tract infection in 

adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. 


1.610 Siroky MB. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med 

2002;113(suppl. 1A):67S-79S. 

1.611 Warren JW et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and 

acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58. 

1.612 Brown P et al. Acute pyelonephritis among adults. Cost of illness and considerations for the economic 

evaluation of therapy. Pharmacoeconomics 2005;23:1123-42. 

1.613 Schnarr J et al. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur 

J Clin Invest 2008;38(suppl. 2):50-7. 

1.614 Wagenlehner FM et al. Current challenges in the treatment of complicated urinary tract infections and 

prostatitis. Clin Microbiol Infect 2006;12(suppl. 3):67-80.

1.615 Muder RR et al. Isolation of Staphylococcus aureus from the urinary tract: association of isolation with 

symptomatic urinary tract infection and subsequent staphylococcal bacteremia. Clin Infect Dis 2006; 

42:46-50. 

1.616 Hooton TM et al. Diagnosis, Prevention and treatment of catheter-associated urinary tract infection in 



1.617 Trautner BW. Management of catheter-associated urinary tract infection. Curr Opin Infect Dis 2010; 

23:76-82. 

1.618 Hermanides HS et al. Development of quality indicators for the antibiotic treatment of complicated urinary 

tract infections: a first step to measure and improve care. Clin Infect Dis 2008;46:703-11. 

1.619 Jacobsen SM et al. Complicated catheter-associated urinary tract infections due to Escherichia coli 

and Proteus mirabilis. Clin Microbiol Rev 2008;21:26-59. 

1.620 Zorc JJ et al. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 

2005;18:417-22. 

1.621 Mori R et al. Diagnosis and management of urinary tract infection in children: summary of NICE guidance. 

Br Med J 2007;335:395-7. 

1.622 American Academy of Pediatrics Committee on Quality Improvement Subcommittee on Urinary Tract 

Infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection 

in febrile infants and young children. Pediatrics 1999;103:843-52. 

1.623 Neuhaus TJ et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children 

with pyelonephritis. Eur J Pediatr 2008;167:1037-47. 

1.624 Hodson EM et al. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 

2007;4:CD003772. 

1.625 Shaikh N et al. Prevalence of urinary tract infection in children. A meta-analysis. Pediatr Infect Dis J 

2008;27:302-8. 

1.626 Preda I et al. Normal dimercaptosuccinic acid scintigraphy makes voiding cystourethrography unnecessary 

after urinary tract infection. J Pediatr 2007;151:581-4. 

1.627 Montini G et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled 

non-inferiority trial. Br Med J 2007;335:386-92. 

1.628 Hoberman A et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile 

children. Pediatrics 1999;104:79-86. 

1.629 Nicolle LE. Urinary tract infection in diabetes. Curr Opin Infect Dis 2005;18:49-53. 

1.630 Wagenlehner FM et al. Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic 

principles. Expert Rev Anti Infect Ther 2004;2:923-31. 

1.631 Abrahamian FM et al. Urinary tract infections in the emergency department. Infect Dis Clin North 

Am 2008;22:73-87. 

1.632 Warren JW et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and 

acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58. 

1.633 Car J. Urinary tract infections in women: diagnosis and management in primary care. Br Med J 2006; 

332:94-7. 

1.634 De Backer D et al. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary 

tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 

10 year interval. J Antimicrob Chemother 2008;62:364-8. 

1.635 Little P et al. Presentation, pattern, and natural course of severe symptoms, and role of antibiotics 

and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection 

in primary care: observational study. Br Med J 2010;340:b5633. 

1.636 Mehnert-Kay SA. Diagnosis and management of uncomplicated urinary tract infections. Am Fam 

Physician 2005;72:451-6. 

1.637 Hooton TM et al. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed 

approach to empirical therapy. Clin Infect Dis 2004;39:75-80. 

1.638 Fihn SD. Acute uncomplicated urinary tract infection in women. N Engl J Med 2003;349:259-66. 

1.639 Gupta K et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. 

Arch Intern Med 2007;167:2207-12. 

1.640 Knottnerus BJ et al. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated 

urinary tract infections in adult female patients in the Netherlands? J Antimicrob Chemother 

2008;62:356-9. 

1.641 Katchman EA et al. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic 

review and meta-analysis. Am J Med 2005;118:1196-207. 

1.642 van Nieuwkoop C et al. Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized 

placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional 

treatment (14 days). BMC Infect Dis 2009;9:131. 

1.643 Gupta K et al. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young 

women. Ann Intern Med 2001;135:9-16. 

1.644 Raz R et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 2000;30: 

152-6. 

1.645 van der Meulen J et al. Self management for men with lower urinary tract infections: randomised controlled 

trial. Br Med J 2007;334:25-8. 

1.646 Dow G et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary 

tract infection in patients with spinal cord injury. Clin Infect Dis 2004;39:658-64. 

1.647 Gupta K et al. Duration of therapy for urinary tract infection: the long and the short of it. Clin Infect 

Dis 2004;39:665-6. 

1.648 Bartlett AH et al. Thoracic actinomycosis in children. Case report and review of the literature. Pediatr 

Infect Dis J 2008;27:165-9. 

1.649 Subcommittee on Diagnosis and Management of Bronchiolitis of the AAP. Diagnosis and management 

of bronchiolitis. Pediatrics 2006;118:1774-93. 

1.650 Zorc JJ et al. Bronchiolitis: Recent evidence on diagnosis and management. Pediatrics 2010;125: 

342-9. 

1.651 Breese Hall C et al. The burden of respiratory syncytial virus infection in young children. N Engl J 

Med 2009;360:588-98. 

1.652 Smyth RL et al. Bronchiolitis. Lancet 2006;368:312-22. 

1.653 Bush A et al. Acute bronchiolitis. Br Med J 2007;335:1037-41. 

1.654 Corneli HM et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N 

Engl J Med 2007;357:331-9.

1.655 Committee on Infectious Diseases of the American Academy of Pediatrics. Modified recommendations 

for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 

124:1694-701. 

1.656 Ilowite J et al. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr 


1.657 O‘Donnell AE. Bronchiectasis. Chest 2008;134:815-23. 

1.658 Nseir S et al. Nosocomial tracheobronchitis. Curr Opin Infect Dis 2009;22:148-53. 

1.659 Tan T et al. Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary 


1.660 Regamey N et al. Viral etiology of acute respiratory infections with cough in infancy. A community-based 

birth cohort study. Pediatr Infect Dis J 2008;27:100-5. 

1.661 Wenzel RP et al. Acute bronchitis. N Engl J Med 2006;355:2125-30. 



1.663 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, 

and prevention of chronic obstructive pulmonary disease, updated 2009. Available at: 

http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003. Acessed on August 21 st 2010. 

1.664 Woodhead M et al. Guidelines for the management of adult lower respiratory tract infections. Eur 

Respir J 2005;26:1138-80. 

1.665 Sethi S et al. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N 

Engl J Med 2008;359:2355-65. 

1.666 Cosio BG et al. Update in chronic obstructive pulmonary disease 2009. Am J Respir Crit Care Med 

2010;181:655-60. 

1.667 Rothberg MB et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations 

of chronic obstructive pulmonary disease. J Am Med Assoc 2010;303:2035-42. 

1.668 Sethi S. Antibiotics in acute exacerbations of chronic bronchitis. Expert Rev Anti Infect Ther 2010;8: 

405-17. 

1.669 Martínez-Solano L et al. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary 

disease. Clin Infect Dis 2008;47:1526-33. 

1.670 Murphy TF. The many faces of Pseudomonas aeruginosa in chronic obstructive pulmonary disease. 


1.671 Murphy TF et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir 

Crit Care Med 2008;177:853-60. 

1.672 Vanhoof R et al. 10 th survey of antimicrobial resistance in noninvasive clinical isolates of Streptococcus 

pneumoniae collected in Belgium during winter 2007-2008. Pathol Biol 2010;58:147-51. 

1.673 Vanhoof R et al. 10 th survey of antimicrobial resistance in noninvasive clinical isolates of Streptococcus 


1.674 O‘Sullivan BP et al. Cystic fibrosis. Lancet 2009;373:1891-904. 

1.675 Flume PA et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J 

Respir Crit Care Med 2009;180:802-8. 

1.676 Mogayzel PJ et al. Update in cystic fibrosis 2009. Am J Respir Crit Care Med 2010;181:539-44. 

1.677 Flume PA et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung 

health. Am J Respir Crit Care Med 2007;176:957-69. 

1.678 Rowe SM et al. Cystic fibrosis. N Engl J Med 2005;352:1992-2001. 

1.679 Gibson RL et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J 


1.680 Waters V et al. Multidrug-resistant organisms in cystic fibrosis: management and infection-control 

issues. Expert Rev Anti Infect Ther 2006;4:807-19. 

1.681 LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010;23:299- 

323. 

1.682 Döring G et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European 

consensus. Eur Respir J 2000;16:749-67. 

1.683 Gibson et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. 

Am J Respir Crit Care Med 2003;167:841-9. 

1.684 Elkin S et al. Pseudomonal infection in cystic fibrosis: the battle continues. Expert Rev Anti Infect 

Ther 2003;1:609-18. 

1.685 Smyth A et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations 

of cystic fibrosis – the TOPIC study: a randomised controlled trial. Lancet 2005;365:573-8. 

1.686 Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-70. 

1.687 Saiman L et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas 

aeruginosa. A randomized, controlled trial. J Am Med Assoc 2003;290:1749-56. 

1.688 Tramper-Stranders GA et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis. 

Long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect 

Dis J 2007;26:8-12. 

1.689 Light RW. Pleural effusion. N Engl J Med 2002;346:1971-7. 

1.690 Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis 

2007;45:1480-6. 

1.691 Maskell NA et al. The bacteriology of pleural infection by genetic and standard methods and its mortality 

significance. Am J Respir Crit Care Med 2006;174:817-23. 

1.692 Le Monnier A et al. Microbiological diagnosis of empyema in children: comparative evaluations by culture, 

polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. Clin Infect Dis 

2006;42:1135-40. 

1.693 Balfour-Lynn IM et al. BTS guidelines for the management of pleural infection in children. Thorax 

2005;60(suppl. I):i1-21. 

1.694 Proesmans M et al. Clinical practice: treatment of childhood empyema. Eur J Pediatr 2009;168:639- 

45. 

1.695 Diacon AH et al. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. 


1.696 Bouros D et al. Intrapleural streptokinase for pleural infection. A step forward in managing pleural effusions? 

Br Med J 2006;332:133-4. 

1.697 Levinson GM et al. Intrapleural fibrinolytics combined with image-guided chest tube drainage for 

pleural infection. Mayo Clin Proc 2007:82:407-13. 

1.698 Maskell NA et al. UK controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med

2005;352:865-74. 



1.700 Valerio Minero M et al. Nocardiosis at the turn of the century. Medicine 2009;88:250-61. 

1.701 Gomez-Flores A et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob 


1.702 Moylett EH et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect 

Dis 2003;36:313-8. 

1.703 Heininger U. Update on pertussis in children. Expert Rev Anti Infect Ther 2010;8:163-73. 

1.704 McIntosh K. Community acquired pneumonia in children. N Engl J Med 2002;346:429-37. 


1.706 British Thoracic Society of Standards of Care Committee. BTS guidelines for the management of 

community acquired pneumonia in childhood. Thorax 2002;57(suppl. I):i1-24. 

1.707 Grant GB et al. Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect 

Dis 2009;9:185-96. 

1.708 Nohynek H et al. Childhood bacterial respiratory diseases: past, present, and future. Pediatr Infect 

Dis J 2009;28(suppl. 10):S127-32. 


1.710 British Thoracic Society of Standards of Care Committee. BTS guidelines for the management of 

community acquired pneumonia in childhood. Thorax 2002;57(suppl. I):i1-24. 

1.711 Lahti E et al. Influenza pneumonia. Pediatr Infect Dis J 2006;25:160-4. 

1.712 Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 

2008;6:509-21. 

1.713 Principi N et al. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric 

respiratory tract infections. Lancet Infect Dis 2001;1:334-44. 

1.714 Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines 

on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 

(suppl. 2):S27-72. 

1.715 Ramsdell J et al. Management of community acquired-pneumonia in the home. An American College 

of Chest Physicians clinical position statement. Chest 2005;127:1752-63. 

1.716 Lim WS et al. BTS guidelines for the management of community acquired pneumonia in adults: update 

2009. Thorax 2009;64(suppl. 3):iii1-55. 

1.717 Levy ML et al. Primary care summary of the British Thoracic Society guidelines for the management 

of community acquired pneumonia in adults: 2009 update. Prim Care Respir J 2010;19:21-7. 

1.718 Woodhead M et al. Guidelines for the management of adult lower respiratory tract infections. Eur 

Respir J 2005;26:1138-80. 

1.719 File TM. Case studies of lower respiratory tract infections: community-acquired pneumonia. Am J 

Med 2010;123(suppl. 4):S4-15. 

1.720 Torres A et al. Update in community-acquired and nosocomial pneumonia. Am J Respir Crit Care 

Med 2010;181:782-7. 

1.721 Siempos II et al. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob 

Chemother 2008;62:661-8. 

1.722 Gutíerrez F et al. Evaluation of the immunochromotographic Binax NOW assay for detection of Streptococcus 

pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in 

Spain. Clin Infect Dis 2003;36:286-92. 

1.723 Marcos MA et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired 

pneumonia in adults. Eur Respir J 2003;21:209-14. 

1.724 Lim WS et al. Defining community acquired pneumonia severity on presentation at hospital: an international 

derivation and validation study. Thorax 2003;58:377-82. 

1.725 Aujesky D et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired 

pneumonia. Am J Med 2005;118:384-92. 

1.726 Vanhoof R et al. 10th survey of antimicrobial resistance in noninvasive clinical isolates of Streptococcus 


1.727 Smith LG. Mycoplasma pneumonia and its complications. Infect Dis Clin North Am 2010;24:57-60. 

1.728 Blasi F et al. Chlamydophila pneumoniae. Clin Microbiol Infect 2009;15:29-35. 

1.729 Burillo A et al. Chlamydophila pneumoniae. Infect Dis Clin North Am 2010;24:61-71. 

1.730 Beeckman DS et al. Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clin Microbiol 

Infect 2009;15:11-7. 

1.731 Pannekoek Y et al. Chlamydophila psittaci infections in The Netherlands. Drugs Today 2009;45 

(suppl. B):151-7. 

1.732 Stewardson AJ et al. Psittacosis. Infect Dis Clin North Am 2010;24:7-25. 

1.733 von Baum H et al. Community-acquired Legionella pneumonia: new insights from the German Competence 

Network for Community Acquired Pneumonia. Clin Infect Dis 2008;46:1356-64. 

1.734 Carratalà J et al. An update on Legionella. Curr Opin Infect Dis 2010;23:152-7. 

1.735 Garcia-Vidal C et al. Current clinical management of Legionnaires‘ disease. Expert Rev Anti Infect 

Ther 2006;4:995-1004. 

1.736 Rubinstein E et al. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 

2008;46(suppl. 5):S378-85. 

1.737 Luna CM et al. Management of methicillin-resistant Staphylococcus aureus pneumonia. Curr Opin 

Infect Dis 2010;23:179-84. 

1.738 Hageman JC et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003- 

2004 influenza season. Emerg Infect Dis 2006,12:894-9. 

1.739 Schramm GE et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of 

appropriate initial antimicrobial treatment. Crit Care Med 2006;34:2069-74. 

1.740 Loeb M. Epidemiology of community- and nursing home-acquired pneumonia in older adults. Expert 


1.741 Garcia-Vidal C et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin 

Microbiol Infect 2009;15:1033-8. 

1.742 Li JZ et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a metaanalysis. 

Am J Med 2007;120:783-90. 

1.743 Daneman N et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient 

management. Clin Infect Dis 2006;43:432-8. 

1.744 Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infec-

tions does result in clinical failure. Clin Infect Dis 2002;35:565-9. 

1.745 Lonks JR et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant 

Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64. 

1.746 Chen DK et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. 

N Engl J Med 1999;341:233-9. 

1.747 Fuller JD et al. A review of Streptococcus pneumoniae infection treatment failures associated with 

fluoroquinolone resistance. Clin Infect Dis 2005;41:118-21. 

1.748 Clay KD et al. Severe hepatotoxicity of telithromycin: three case reports and literature review. Ann 

Intern Med 2006;144:415-20. 

1.749 Mills GD et al. Effectiveness of β lactam antibiotics compared with antibiotics active against atypical 

pathogens in non-severe community acquired pneumonia: meta-analysis. Br Med J 2005;330:456- 

60. 

1.750 Oosterheert JJ et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community 

acquired pneumonia: multicentre randomised trial. Br Med J 2006;333:1193-7. 

1.751 Janssens JP et al. Pneumonia in the very old. Lancet Infect Dis 2004;4:112-24. 

1.752 Vanhoof R et al. 10th survey of antimicrobial resistance in noninvasive clinical isolates of Streptococcus 


1.753 Mykietiuk A et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria 

era: the influence of levofloxacin therapy. Clin Infect Dis 2005;40:794-9. 

1.754 Blázquez Garrido RM et al. Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus 

macrolides. Clin Infect Dis 2005;40:800-6. 

1.755 Liapikou A et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society 

of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin 

Infect Dis 2009;48:377-85. 

1.756 Niven DJ et al. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy. 


1.757 Martínez JA et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated 

with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect 

Dis 2003;36:389-95. 

1.758 Baddour LM et al. Combination antibiotic therapy lowers mortality among severely ill patients with 

pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-4. 

1.759 Metersky ML et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not 

fluoroquinolones. Chest 2007;131:466-73. 

1.760 Rodríguez A et al. Combination antibiotic therapy improves survival in patients with community-acquired 

pneumonia and shock. Crit Care Med 2007;35:1493-8. 

1.761 Blot S et al. Antibiotic therapy for community-acquired pneumonia with septic shock: Follow the guidelines. 

Crit Care Med 2007;35:1617-8. 

1.762 Mykietiuk A et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria 

era: the influence of levofloxacin therapy. Clin Infect Dis 2005;40:794-9. 

1.763 Blázquez Garrido RM et al. Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus 

macrolides. Clin Infect Dis 2005;40:800-6. 

1.764 Kollef MH et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, 

management, and outcomes – proceedings of the HCAP summit. Clin Infect Dis 2008;46 

(suppl. 4):S296-334. 

1.765 Brito V et al. Healthcare-associated pneumonia is a heterogeneous disease and all patients do not 

need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect 

Dis 2009;22:316-25. 

1.766 Carratalà J et al. What is healthcare-associated pneumonia and how is it managed? Curr Opin Infect 

Dis 2008;21:168-73. 

1.767 Torres A et al. Defining, treating and preventing hospital acquired pneumonia: European perspective. 

Intensive Care Med 2009;35:9-29. 

1.768 American Thoracic Society et al. Guidelines for the management of adults with hospital-acquired, 

ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171: 

388-416. 

1.769 Rotstein C et al. Clinical practice guidelines for nosocomial pneumonia and ventilator-associated 

pneumonia in adults. Can J Infect Dis Med Microbiol 2008:19:19-53. 

1.770 Masterton RG et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report 

of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. 


1.771 Torres A et al. Update in community-acquired and nosocomial pneumonia. Am J Respir Crit Care 

Med 2010;181:782-7. 

1.772 Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill 

patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect 

Dis 2006;42(suppl. 2):S72-81. 

1.773 Levin AS. Nosocomial legionellosis: prevention and management. Expert Rev Anti Infect Ther 

2009;7:57-68. 

1.774 Grammatikos AP et al. Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. 


1.775 Torres A et al. Defining, treating and preventing hospital acquired pneumonia: European perspective. 

Intensive Care Med 2009;35:9-29. 

1.776 American Thoracic Society et al. Guidelines for the management of adults with hospital-acquired, 

ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171: 

388-416. 

1.777 Rotstein C et al. Clinical practice guidelines for nosocomial pneumonia and ventilator-associated 

pneumonia in adults. Can J Infect Dis Med Microbiol 2008:19:19-53. 

1.778 Masterton RG et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report 

of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. 


1.779 Foglia E et al. Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. 


1.780 Klompas M. Does this patient have ventilator-associated pneumonia? J Am Med Assoc 2007;297: 

1583-93. 

1.781 Srinivasan R et al. A prospective study of ventilator-associated pneumonia in children. Pediatrics

2009;123:1108-15. 

1.782 Ellis MW. Affect of linezolid in ventilator-associated pneumonia caused by MRSA. Expert Rev Anti 

In-fect Ther 2009;7:183-8. 

1.783 Rubinstein E et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients 

with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 

2001;32:402-12. 

1.784 Wunderink RG et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with 

methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97. 

1.785 Kollef MH et al. Clinical cure and survival in Gram-positive, ventilator-associated pneumonia: retrospective 

analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care 

Med 2004;30:388-94. 

1.786 Powers JH et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial 

pneumonia. The subtleties of subgroup analyses. Chest 2004;126:314-6. 

1.787 Ellis MW. Affect of linezolid in ventilator-associated pneumonia caused by MRSA. Expert Rev Anti 

In-fect Ther 2009;7:183-8. 

1.788 Rubinstein E et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized 

patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 

2001;32:402-12. 

1.789 Wunderink RG et al. Linezolid vs vancomycin: analysis of two double blind studies of patients with 

methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97. 

1.790 Kollef MH et al. Clinical cure and survival in Gram-positive, ventilator-associated pneumonia: retrospective 

analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care 

Med 2004;30:388-94. 

1.791 Powers JH et al. Linezolid and vancomycin for methicillin resistant Staphylococcus aureus nosocomial 

pneumonia. The subtleties of subgroup analyses. Chest 2004;126:314-6. 

1.792 Feldman C. Pneumonia associated with HIV infection. Curr Opin Infect Dis 2005;18:165-70. 

1.793 Ender PT et al. Pneumonia associated with near-drowning. Clin Infect Dis 1997;25:896-907. 

1.794 Bartlett JG. The role of anaerobic bacteria in lung abscess. Clin Infect Dis 2005;40:923-5. 

1.795 Polenakovik H et al. Moxifloxacin is efficacious for treatment of community-acquired lung abscesses 

in adults. Clin Infect Dis 2005;41:764-5. 

1.796 Sandrock C et al. Acute febrile respiratory illness in the ICU: reducing disease transmission. Chest 

2008;133:1221-31. 

1.797 Marcos MA et al. Viral pneumonia. Curr Opin Infect Dis 2009;22:143-7. 

1.798 Parappil A et al. Pyrexia of unknown origin: Kikuchi-Fujimoto disease. Clin Infect Dis 2004;39:138- 

43. 

1.799 Hutchinson CB et al. Kikuchi-Fujimoto disease. Arch Pathol Lab Med 2010;134:289-93. 

1.800 Abramson JS et al. Case 27-2009: a 56-year old woman with fever, rash, and lymphadenopathy. N 

Engl J Med 2009;361:900-11. 

1.801 Al-Dajani N et al. Cervical lymphadenitis, suppurative parotitis, thyroiditis, and infected cysts. Infect 


1.802 Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 non tuberculous 

cases with long term follow-up. Clin Infect Dis 1995;20:954-63. 

1.803 English R. Cat-scratch disease. Pediatr Rev 2006;27:123-8. 

1.804 Maman E et al. Musculoskeletal manifestations of cat scratch disease. Clin Infect Dis 2007;45:1535- 

40. 

1.805 Ben-Ami R et al. Cat scratch disease in elderly patients. Clin Infect Dis 2005;41:969-74. 



1.807 Rolain JM et al. Lymph node biopsy specimens and diagnosis of cat-scratch disease. Emerg Infect 

Dis 2006;12:1338-44. 

1.808 Sjögren J et al. Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuumassisted 

closure therapy and presentation of the Lund University Hospital mediastinitis algorithm. Eur 

J Cardiothorac Surg 2006;30:898-905. 

1.809 Rautemaa R et al. Oral infections and systemic disease – an emerging problem in medicine. Clin Microbiol 

Infect 2007;13:1041-7. 

1.810 Parahitiyawa NB et al. Microbiology of odontogenic bacteremia: beyond endocarditis. Clin Microbiol 

Rev 2009;22:46-64. 

1.811 Bilezikian JP. Osteonecrosis of the jaw – do biphosphonates pose a risk? N Engl J Med 2006;355: 

2278-81. 

1.812 Sharkawy AA. Cervicofacial actinomycosis and mandibular osteomyelitis. Infect Dis Clin North Am 

2007;21:543-56. 

1.813 Al-Dajani N et al. Cervical lymphadenitis, suppurative parotitis, thyroiditis, and infected cysts. Infect 


1.814 Horz HP et al. Diagnosis and anti-infective therapy of periodontitis. Expert Rev Anti Infect Ther 

2007; 5:703-15. 

1.815 Loesche WJ et al. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. 


1.816 Scully C. Aphthous ulceration. N Engl J Med 2006;355:165-72. 

1.817 Femiano F et al. Guidelines for diagnosis and management of aphthous stomatitis. Pediatr Infect Dis 

J 2007;26:728-32. 

1.818 Bjornson CL et al. Croup. Lancet 2008;371:329-39. 

1.819 Cherry JD. Croup. N Engl J Med 2008;358:384-91. 

1.820 Alcaide ML et al. Pharyngitis and epiglottitis. Infect Dis Clin North Am 2007;21:449-69. 

1.821 Reynolds SC et al. Life-threatening infections of the peripharyngeal and deep fascial spaces of the 

head and neck. Infect Dis Clin North Am 2007;21:557-76. 



1.823 Shulman St et al. Group A streptococcal pharyngitis and immune-mediated complications: from diagnosis 

to management. Expert Rev Anti Infect Ther 2010;8:137-50. 

1.824 Alcaide ML et al. Pharyngitis and epiglottitis. Infect Dis Clin North Am 2007;21:449-69. 

1.825 Park SY et al. Clinicians‘ management of children and adolescents with acute pharyngitis. Pediatrics 

2006;117:1871-8. 

1.826 Bisno AL et al. Practice guidelines for the diagnosis and management of group A streptococcal pha-

yngitis. Clin Infect Dis 2002;35:113-25. 

1.827 Sheeler RD et al. Rapid streptococcal testing for sore throat and antibiotic resistance. Clin Microbiol 

Infect 2006;12(suppl. 9):3-7. 

1.828 Ota KV et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia 

trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect 

Dis 2009;48:1237-43. 

1.829 Altamimi S et al. Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis 

in children. Cochrane Database Syst Rev 2009;1:CD004872. 

1.830 Casey JR et al. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal 

tonsillopharyngitis in adults. Clin Infect Dis 2004;38:1526-34. 

1.831 Falagas ME et al. Effectiveness and safety of short-course vs long-course antibiotic therapy for group 

a β-hemolytic streptococcal tonsillopharyngitis: a meta-analysis of randomized trials. Mayo Clin Proc 

2008;83:880-9. 

1.832 Kneen R et al. Penicillin versus erythromycin in the treatment of diphtheria. Clin Infect Dis 1998;27: 

845-50. 

1.833 Klug TE et al. Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark. 


1.834 Riordan T. Human infection with Fusobacterium necrophorum (necrobacillosis) with a focus on Lemierre‘s 

syndrome. Clin Microbiol Rev 2007;20:622-59. 

1.835 Venglarcik J. Lemierre‘s syndrome. Pediatr Infect Dis J 2003;22:922-3. 

1.836 Young J et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of 

individual patient data. Lancet 2008;371:908-14. 

1.837 Falagas ME et al. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-anaysis 

of randomised controlled trials. Lancet Infect Dis 2008;8:543-52. 



1.839 Hwang PH et al. 51-year-old woman with acute onset of facial pressure, rhinorrhea, and tooth pain: 

review of acute rhinosinusitis. J Am Med Assoc 2009;301:1798-807. 

1.840 Wald ER et al. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial 

sinusitis in children. Pediatrics 2009;124:9-15. 

1.841 Ah-See KW et al. Sinusitis and its management. Br Med J 2007;334:358-61. 

1.842 Brook I. Acute and chronic bacterial sinusitis. Infect Dis Clin North Am 2007;21:427-48. 

1.843 Butkus Small C et al. Judicious antibiotic use and intranasal corticosteroids in acute rhinosinusitis. 

Am J Med 2007;120:289-94. 

1.844 Arroll B et al. Are antibiotics effective for acute purulent rhinitis? Systematic review and meta-analysis 

of placebo controlled randomised trials. Br Med J 2006;333:279-82. 

1.845 Sande MA et al. Acute community acquired bacterial sinusitis: continuing challenges and current management. 

Clin Infect Dis 2004;39(suppl. 3):S151-8. 

1.846 American Academy of Pediatrics Subcommittee on Management of Sinusitis and Committee on Quality 

Improvement. Clinical practice guideline: management of sinusitis. Pediatrics 2001;108:798-808. 

1.847 Garbutt JM et al. A randomized, placebo controlled trial of antimicrobial treatment for children with clinically 

diagnosed acute sinusitis. Pediatrics 2001;107:619-25. 

1.848 Payne SC et al. Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a metaanalysis. 


1.849 Anon JB. Upper respiratory infections. Am J Med 2010;123(suppl. 4):S16-25. 

1.850 Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. 

Otolaryngol Head Neck Surg 2004;130:1-45. 

1.851 Westergren V et al. Ventilator associated sinusitis: a review. Clin Infect Dis 1998;27:851-64. 

1.852 Stein M et al. Nosocomial sinusitis: a unique subset of sinusitis. Curr Opin Infect Dis 2005;18:147- 

50. 

1.853 deShazo RD et al. Fungal sinusitis. N Engl J Med 1997;337:254-9. 

1.854 Brook I. Acute and chronic bacterial sinusitis. Infect Dis Clin North Am 2007;21:427-48. 

1.855 Cherry WB et al. Chronic rhinosinusitis in adults. Am J Med 2008;121:185-9. 

1.856 Garey KW et al. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary 

diseases. Chest 2003;123:261-5. 

1.857 Gorwitz RJ. A review of community-acquired methicillin-resistant Staphylococcus aureus skin and soft 

tissue infections. Pediatr Infect Dis J 2008;27:1-7. 

1.858 Moellering RC. Current treatment options for community-acquired methicillin-resistant Staphylococcus 

aureus infection. Clin Infect Dis 2008;46:1032-7. 

1.859 Nygaard TK et al. Community-associated methicillin-resistant Staphylococcus aureus skin infections: 

advances toward identifying the key virulence factors. Curr Opin Infect Dis 2008;21:147-52. 

1.860 Elliott DJ et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of 

methicillin-resistant Staphylococcus aureus. Pediatrics 2009;123:e959-66. 

1.861 Ruhe JJ et al. Community-onset Staphylococcus aureus skin and soft-tissue infections: impact of 

antimicrobial therapy on outcome. Clin Infect Dis 2007;44:777-784. 

1.862 Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N 

Engl J Med 2007;357:380-90. 

1.863 Moran GJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. 

N Engl J Med 2006;355:666-74. 

1.864 Stryjewski ME et al. Skin and soft-tissue infections caused by community-acquired methicillin-resistant 

Staphylococcus aureus. Clin Infect Dis 2008;46(suppl. 5);S368-77. 

1.865 Abrahamian FM et al. Management of skin and soft-tissue infections in the emergency department. 


1.866 Eisenstein BI. Treatment challenges in the management of complicated skin and soft-tissue infections. 


1.867 Stevens DL et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. 


1.868 May AK et al. Treatment of complicated skin and soft tissue infections. Surg Infect 2009;10:467-99. 

1.869 Lopez FA et al. Skin and soft tissue infections. Infect Dis Clin North Am 2006;20:759-72. 

1.870 Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis 2008;21: 

122-8. 

1.871 Vinh DC et al. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005;5:501-13. 

1.872 Alikhan A et al. The role of tetracyclines in rosacea. Am J Clin Dermatol 2010;11:79-87.

1.873 Korting HC et al. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol 

Venereol 2009;23:876-82. 

1.874 Powell FC. Rosacea. N Engl J Med 2005;352:793-803. 

1.875 Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in 

the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999;40:961-5. 

1.876 Wilson ML et al. Laboratory diagnosis of bone, joint, soft-tissue, and skin infections. Clin Infect Dis 

2008;46:453-7. 

1.877 Bershad SV. Acne. Ann Intern Med 2008;149:ITC1-16. 

1.878 Zaenglein AL et al. Expert committee recommendations for acne management. Pediatrics 2006;118: 

1188-99. 

1.879 Purdy S et al. Acne. Br Med J 2006;333:949-53. 

1.880 James WD. Acne. N Engl J Med 2005;352:1463-72. 

1.881 Katsambas A et al. Acne: systemic treatment. Clin Dermatol 2004;22:412-8. 

1.882 Garner SE et al. Minocycline for acne vulgaris: efficacy and safety (review). Cochrane Database 

Syst Rev 2003;1:CD002086. 

1.883 Ozolins M et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory 

facial acne vulgaris in the community: randomised, controlled trial. Lancet 2004;364:2188-95. 

1.884 Smego RA et al. Actinomycosis. Clin Infect Dis 1998;26:1255-63. 

1.885 Coremans G et al. Actinomycosis, a rare and unsuspected cause of anal fistulous abscess: report of 

three cases and review of the literature. Dis Colon Rectum 2005;48:575-81. 

1.886 Endo S et al. Surgical considerations for pulmonary actinomycosis. Ann Thorac Surg 2002;74:185- 

90. 

1.887 Sudhakar SS et al. Short-term treatment of actinomycosis: two cases and a review. Clin Infect Dis 

2004;38:444-7. 

1.888 Cinquetti G et al. Three related cases of anthrax in France: clinical and laboratory aspects. Medicine 

2009;88:371-5. 

1.889 Nakamuro Y et al. Use of appropriate antimicrobials in wound management. Emerg Med Clin North 

Am 2007;25:159-76. 

1.890 Brook I. Management of human and animal bitewounds: an overview. Adv Skin Wound Care 2005; 

18:197-203. 

1.891 Morgan M. Hospital management of human and animal bites. J Hosp Infect 2005;61:1-10. 

1.892 Morgan M et al. Dog bites. Br Med J 2007;334:413-7. 

1.893 Oehler RL et al. Bite-related and septic syndromes caused by cats and dogs. Lancet Infect Dis 

2009;9:439-47. 

1.894 Talan DA et al. Clinical presentation and bacteriologic analysis of infected human bites in patients 

presenting to emergency departments. Clin Infect Dis 2003;37:1481-9. 

1.895 Denis O et al. Methicillin-resistant Staphylococcus aureus ST398 in swine farm personnel, Belgium. 

Emerg Infect Dis 2009;15:1098-101. 

1.896 Smet A et al. Comparative analysis of extended-spectrum-β-lactamase-carrying plasmids from different 

members of Enterobacteriaceae isolated from poultry, pigs and humans: evidence for a shared 

β-lactam resistance gene pool? J Antimicrob Chemother 2009;63:1286-8. 

1.897 Cohen JI et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine 

herpesvirus 1). Clin Infect Dis 2002;35:1191-203. 

1.898 Elliott SP. Rat bite fever and Streptobacillus moniliformis. Clin Microbiol Rev 2007;20:13-22. 

1.899 Warrell DA. Treatment of bites by adders and exotic venomous snakes. Br Med J 2005;331:1244-7. 

1.900 Williams D et al. The Global Snake Bite Initiative: an antidote for snake bite. Lancet 2010;375:89-91. 

1.901 Van den Enden E. Bites by venomous snakes. Acta Clin Belg 2003;58:350-5. 

1.902 Swanson DL et al. Bites of brown recluse spiders and suspected arachnidism. N Engl J Med 2005; 

352:700-7. 

1.903 Church D et al. Burn wound infections. Clin Microbiol Rev 2006;19:403-34. 

1.904 Sheridan RL et al. Case 6-2004: a 35-year old woman with extensive, deep burns from a nightclub fire. 

N Engl J Med 2004;350:810-21. 

1.905 Benson A et al. Burns. Br Med J 2006;332:649-52. 

1.906 DeSanti L. Pathophysiology and current management of burn injury. Adv Skin Wound Care 2005; 

18:323-32. 

1.907 Falagas ME et al. Narrative review: diseases that masquerade as infectious cellulitis. Ann Intern 

Med 2005;142:47-55. 

1.908 Swartz MN. Cellulitis. N Engl J Med 2004;350:904-12. 

1.909 Bross mH et al. Vibrio vulnificus infection: diagnosis and treatment. Am Fam Physician 2007;76: 

539-44. 

1.910 Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect 

2005;133:383-91. 

1.911 Livesley NJ et al. Infected pressure ulcers in elderly individuals. Clin Infect Dis 2002;35:1390-6. 

1.912 Requena L et al. Erythema nodosum. Dermatol Clin 2008;26:425-38. 

1.913 Delgado-Jimenez Y et al. Infective panniculitis. Dermatol Clin 2008;26:471-80. 

1.914 Douvoyiannis M et al. Panniculitis, infection and dermatomyositis: case and literature review. Clin 

Rheumatol 2009;28(suppl. 1):S57-63. 

1.915 Blaise G et al. Corynebacterium associated skin infections. Int J Dermatol 2008;47:884-90. 

1.916 Duong M et al. Randomized, controlled trial of antibiotics in the management of community-acquired 

skin abscesses in the pediatric patient. Ann Emerg Med 2010;55:401-7. 

1.917 Chambers HF et al. Management of skin and soft-tissue infection. N Engl J Med 2008;359:1063-7. 

1.918 Hammond SP et al. Management of skin and soft-tissue infection. Polling results. N Engl J Med 

2008;359:e20. 

1.919 Tibbles PM et al. Hyperbaric-oxygen therapy. N Engl J Med 1996;334:1642-8. 

1.920 Çimşit M et al. Hyperbaric oxygen therapy as an anti-infective. Expert Rev Anti Infect Ther 2009;7: 

1015-26. 

1.921 Shah N. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician 2005;72:1547-52. 

1.922 Beshara MA. Hidradenitis suppurativa: a clinician‘s tool for early diagnosis and treatment. Adv Skin 

Wound Care 2010;23:328-32. 

1.923 Johnston GA. Treatment of bullous impetigo and the staphylococcal scalded skin syndrome. Expert 


1.924 Stanley JR et al. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N 

Engl J Med 2006;355:1800-10.

1.925 Koning S et al. Interventions for impetigo. Cochrane Database Syst Rev 2003;2:CD003261. 

1.926 Koning S et al. Interventions for impetigo. Cochrane Database Syst Rev 2003;2:CD003261. 

1.927 Filbin MR et al. Case 2-2009: A 25-year-old man with pain and swelling of the right hand and hypotension. 

N Engl J Med 2009;360:281-90. 

1.928 Anaya DL et al. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007; 

44:705-10. 

1.929 Hasham S et al. Necrotising fasciitis. Br Med J 2005;330:830-3. 

1.930 Young MH et al. Necrotizing fasciitis: pathogenesis and treatment. Expert Rev Anti Infect Ther 

2005;3:279-94. 



1.932 Jodlowski TZ et al. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother 2007; 

41:1694-9. 

1.933 Crum-Cianflone MF. Bacterial, fungal, parasitic and viral myositis. Clin Microbiol Rev 2008;21:473- 

94. 

1.934 Small LN et al. Tropical and temporate pyomyositis. Infect Dis Clin North Am 2005;19:981-9. 

1.935 Stanley JR et al. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N 

Engl J Med 2006;355:1800-10. 

1.936 Patel GK. Treatment of staphylococcal scalded skin syndrome. Expert Rev Anti Infect Ther 2004;2: 

575-87. 

1.937 Johnston GA. Treatment of bullous impetigo and the staphylococcal scalded skin syndrome. Expert 


1.938 Zeegelaar JE et al. Imported tropical ulcers in travelers. Am J Clin Dermatol 2008;9:219-32. 

1.939 Singer AJ et al. Current management of acute cutaneous wounds. N Engl J Med 2008;359:1037-46. 

1.940 Nichols RL et al. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect 

Dis 2001;33(suppl. 2):S84-93. 

1.941 Moran GJ et al. Antimicrobial prophylaxis for wounds and procedures in the emergency department. 


1.942 Zalavras CG et al. Management of open fractures. Infect Dis Clin North Am 2005;19:915-29. 

1.943 Nakamuro Y et al. Use of appropriate antimicrobials in wound management. Emerg Med Clin North 

Am 2007;25:159-76. 

1.944 Leaper D et al. Prevention and treatment of surgical site infection: summary of NICE guidance. Br 

Med J 2008;337:1049-51. 

1.945 Nichols RL et al. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect 

Dis 2001;33(suppl. 2):S84-93. 

1.946 Thompson C et al. Coinfecting deer-associated zoonoses: Lyme disease, babesiosis, and ehrlichiosis. 


1.947 Krause PJ et al. Disease specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human 

granulocytic ehrlichiosis, and Lyme disease. Clin Infect Dis 2002;34:1184-91. 

1.948 Centers for Disease Control and Prevention (CDC). Diagnosis and management of tickborne rickettsial 

diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis. Morb Mortal Wkly 

Rep 2006;55(RR-4):1-27. 

1.949 Swanson SJ et al. Coinfections acquired from Ixodes ticks. Clin Microbiol Rev 2006;19:708-27. 

1.950 Heyman P et al. A clear and present danger: tick-borne diseases in Europe. Expert Rev Anti Infect 

Ther 2010;8:33-50. 

1.951 Jensenius M et al. Threats to international travellers posed by tick-borne diseases. Travel Med Infect 

Dis 2006;4:4-13. 

1.952 Centers for Disease Control and Prevention (CDC). Diagnosis and management of tickborne rickettsial 

diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis. Morb Mortal Wkly 

Rep 2006;55(RR-4):1-27. 

1.953 Foucault C et al. Bartonella quintana characteristics and clinical management. Emerg Infect Dis 

2006;12:217-23. 

1.954 Wormser GP. Discovery of new infectious diseases: Bartonella species. N Engl J Med 2007;356: 

2346-7. 



1.956 Wormser GP. Discovery of new infectious diseases: Bartonella species. N Engl J Med 2007;356: 

2346-7. 

1.957 Eremeeva ME et al. Bacteremia, fever, and splenomegaly caused by a newly recognized Bartonella 

species. N Engl J Med 2007;357:2381-7. 

1958 Al-Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 2008;6:109- 

20. 

1.959 Skalsky K et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised 

controlled trials. Br Med J 2008;336:701-4. 

1.960 Franco MP et al. Human brucellosis. Lancet Infect Dis 2007;7:775-86. 

1.961 Mesner O et al. The many faces of human-to-human transmission of brucellosis: congenital infection 

and outbreak of nosocomial disease related to an unrecognized clinical case. Clin Infect Dis 2007; 

45:e135-40. 

1.962 Pappas G et al. Brucellosis. N Engl J Med 2005;352:2325-36. 

1.963 Lim ML et al. Brucellosis. Infect Dis Clin Pract 2004;12:7-14. 

1.964 Solera J et al. A randomized, double-blind study to assess the optimal duration of doxycycline treatment 

for human brucellosis. Clin Infect Dis 2004;39:1176-82. 

1.965 Falagas ME et al. Quinolones for treatment of human brucellosis: critical review of the evidence from 

microbiological and clinical studies. Antimicrob Agents Chemother 2006;50:22-33. 

1.966 Pappas G et al. Quinolones for brucellosis: treating old diseases with new drugs. Clin Microbiol 

Infect 2006;12:823-5. 

1.967 Solera J et al. Brucellar spondylitis: review of 35 cases and literature survey. Clin Infect Dis 1999;29: 

1440-9. 

1.968 Colmenero JD et al. Clinical findings, therapeutic approach and outcome of brucellar vertebral osteomyelitis. 


1.969 Wormser GP et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic 

anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society 

of America. Clin Infect Dis 2006;43:1089-134.

1.970 Thomas RJ et al. Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis 

and Ehrlichia ewingii ehrlichiosis. Expert Rev Anti Infect Ther 2009;7:709-22. 

1.971 Dumler JS et al. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis and treatment. 


1.972 Schutze GE. Ehrlichiosis. Pediatr Infect Dis J 2006;25:71-2. 

1.973 Paddock CD et al. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev 

2003;16:37-64. 

1.974 Stone JH et al. Human monocytic ehrlichiosis. J Am Med Assoc 2004;292:2263-70. 

1.975 Bakken JS et al. Human granulocytic anaplasmosis. Infect Dis Clin North Am 2008;22:433-48. 

1.976 Guillaume B et al. Seroprevalence of human granulocytic ehrlichiosis infection in Belgium. Eur J Clin 

Microbiol Infect Dis 2002;21:397-400. 

1.977 Buller RS et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 

1999;341:148-55. 

1.978 Suputtamongkol Y et al. An Open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime 

for patients with severe leptospirosis. Clin Infect Dis 2004;39:1417-24. 

1.979 Griffith ME et al. Antimicrobial therapy of leptospirosis. Curr Opin Infect Dis 2006;19:533-7. 

1.980 Edwards CN et al. Prevention and treatment of leptospirosis. Expert Rev Anti Infect Ther 2004;2: 

293-8. 

1.981 McBride AJ et al. Leptospirosis. Curr Opin Infect Dis 2005;18:376-86. 

1.982 Panaphut T et al. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. 


1.983 Bharti AR et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003;3: 

757-71. 

1.984 Steere AC et al. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 2008;47:188- 

95. 

1.985 Aguero-Rosenfeld ME. Lyme disease: laboratory issues. Infect Dis Clin North Am 2008;22:301-13. 

1.986 Aguero-Rosenfeld ME et al. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 2005;18:484-509. 

1.987 Cerar T et al. Comparison of PCR methods and culture for the detection of Borrelia spp. in patients 

with erythema migrans. Clin Microbiol Infect 2008;14:653-8. 

1.988 Wormser GP et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic 


of America. Clin Infect Dis 2006;43:1089-134. 

1.989 Société de Pathologie Infectieuse de Langue Française. Borréliose de Lyme: démarches diagnostiques, 

thérapeutiques et préventives. Presse Med 2009;37:1748-55. 

1.990 International Lyme and Associated Diseases Society. Evidence-based guidelines for the management 

of Lyme disease. Expert Rev Anti Infect Ther 2004;2(suppl. 1):S1-13. 

1.991 Corapi KM et al. Management of Lyme disease. Expert Rev Anti Infect Ther 2008;6:241-50. 

1.992 O‘Connell S. Lyme borreliosis: current issues in diagnosis and management. Curr Opin Infect Dis 

2010;23:231-5. 

1.993 Stanek G et al. Lyme borreliosis. Lancet 2003;362:1639-47. 

1.994 Stanek G et al. Lyme borreliosis: a European perspective on diagnosis and clinical management. 

Curr Opin Infect Dis 2009;22:450-4. 

1.995 Nadelman RB et al. Reinfection in patients with Lyme disease. Clin Infect Dis 2007;45:1032-8. 

1.996 Feder HM. Lyme disease in children. Infect Dis Clin North Am 2008;22:315-26. 

1.997 Wormser GP et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, 

placebo-controlled trial. Ann Intern Med 2003;138:697-704. 

1.998 Baker PJ. Perspectives on ―chronic Lyme disease‖. Am J Med 2008;121:562-4. 

1.999 Lantos PM et al. Final report of the Lyme Disease Review Panel of the Infectious Diseases Society of 

America. Clin Infect Dis 2010;51:1-5. 

1.1000 Marques A. Chronic Lyme disease: a review. Infect Dis Clin North Am 2008;22:341-60. 

1.1001 Auwaerter PG. Point: antibiotic therapy is not the answer for patients with persisting symptoms attributable 

to Lyme disease. Clin Infect Dis 2007;45:143-8. 

1.1002 Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with 

Lyme disease. Clin Infect Dis 2007;45:149-57. 

1.1003 Feder HM et al. A critical appraisal of ―chronic Lyme disease‖. N Engl J Med 2007;357:1422-30. 

1.1004 Gammons M et al. Tick removal. Am Fam Physician 2002;66:643-5. 

1.1005 Puius YA et al. Lyme arthritis: pathogenesis, clinical presentation, and management. Infect Dis Clin 

North Am 2008;22:289-300. 

1.1006 Hu L. Lyme arthritis. Infect Dis Clin North Am 2005;19:947-61. 

1.1007 Fish AE et al. Lyme carditis. Infect Dis Clin North Am 2008;22:275-288. 

1.1008 Costello JM et al. Lyme carditis in children: presentation, predictive factors and clinical course. Pediatrics 

2009;123:e835-41. 

1.1009 Dandache P et al. Erythema migrans. Infect Dis Clin North Am 2008;22:235-60. 

1.1010 Wormser GP. Early Lyme disease. N Engl J Med 2006;354:2794-801. 

1.1011 Halperin JJ et al. Treatment of nervous system Lyme disease (an evidence-based review). Neurology 

2007;69:91-102. 

1.1012 Skogman BH et al. Lyme neuroborreliosis in children a prospective study of clinical features, prognosis 

and outcome. Pediatr Infect Dis J 2008;27:1089-94. 

1.1013 Tuerlinckx D et al. Lyme neuroborreliosis in children. Expert Rev Anti Infect Ther 2010;8:455-63. 

1.1014 Tuerlinckx D et al. Prediction of Lyme meningitis based on a logistic regression model using clinical 

and cerebrospinal fluid analysis. A European study. Pediatr Infect Dis J 2009;28:394-7. 

1.1015 Halperin JJ. Nervous system Lyme disease. Infect Dis Clin North Am 2008;22:261-74. 

1.1016 Strle F et al. Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from 

cerebrospinal fluid. Clin Infect Dis 2006;43:704-10. 

1.1017 Ljøstad U et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: 

a multicentre, non inferiority, double-blind, randomised trial. Lancet Neurol 2008;7:690-5. 

1.1018 Halperin JJ et al. Treatment of nervous system Lyme disease (an evidence-based review). 

Neurology 2007;69:91-102. 

1.1019 Skogman BH et al. Lyme neuroborreliosis in children a prospective study of clinical features, prognosis 

and outcome. Pediatr Infect Dis J 2008;27:1089-94. 

1.1020 Tuerlinckx D et al. Lyme neuroborreliosis in children. Expert Rev Anti Infect Ther 2010;8:455-63. 

1.1021 Tuerlinckx D et al. Prediction of Lyme meningitis based on a logistic regression model using clinical 

and cerebrospinal fluid analysis. A European study. Pediatr Infect Dis J 2009;28:394-7.

1.1022 Halperin JJ. Nervous system Lyme disease. Infect Dis Clin North Am 2008;22:261-74. 

1.1023 Strle F et al. Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from 

cerebrospinal fluid. Clin Infect Dis 2006;43:704-10. 

1.1024 Ljøstad U et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: 

a multicentre, non inferiority, double-blind, randomised trial. Lancet Neurol 2008;7:690-5. 

1.1025 Butler T. Plague into the 21st century. Clin Infect Dis 2009;49:736-42. 

1.1026 Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 2005;40:1166- 

72. 

1.1027 Prentice MB et al. Plague. Lancet 2007;369:1196-207. 

1.1028 Mwengee W et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in 

Tanzania. Clin Infect Dis 2006;42:614-21. 

1.1029 Tissot-Dupont H et al. Q fever. Infect Dis Clin North Am 2008;22:505-514. 

1.1030 Marrie TJ . Q fever pneumonia. Infect Dis Clin North Am 2010;24:27-41. 

1.1031 Hartzell JD et al. Q Fever: epidemiology, diagnosis and treatment. Mayo Clin Proc 2008;83:574-9. 

1.1032 Raoult D et al. Natural history and pathophysiology of Q fever. Lancet Infect Dis 2005;5:219-26. 

1.1033 Parker NR et al. Q fever. Lancet 2006;367:679-88. 

1.1034 Maurin M et al. Q fever. Clin Microbiol Rev 1999;12:518-53. 

1.1035 Terheggen U et al. Clinical manifestations of Q fever in adults and children. Travel Med Infect Dis 

2007;5:159-64. 

1.1036 Gikas A et al. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents 

Chemother 2001;45:3644-6. 

1.1037 Raoult D et al. Treatment of Q fever endocarditis. Comparison of 2 regimens containing doxycycline 

and ofloxacin or hydroxychloroquine. Arch Intern Med 1999;159:167-73. 

1.1038 Raoult D et al. Q fever during pregnancy. Diagnosis, treatment, and follow-up. Arch Intern Med 

2002;162:701-4. 

1.1039 Carcopino X et al. Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. 


1.1040 Dworkin MS et al. Tick-borne relapsing fever. Infect Dis Clin North Am 2008;22:449-68. 

1.1041 Larsson C et al. Current issues in relapsing fever. Curr Opin Infect Dis 2009;22:443-9. 

1.1042 Cutler SJ et al. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol 

Infect 2009;15:400-6. 

1.1043 Assous MV et al. Relapsing fever borreliosis in Eurasia: forgotten, but certainly not gone! Clin Microbiol 

Infect 2009;15:407-14. 

1.1044 Cutler SJ. Possibilities for relapsing fever reemergence. Emerg Infect Dis 2006;12:369-74. 

1.1045 Hasin T et al. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. 

N Engl J Med 2006;355:148-55. 

1.1046 Walker DH. Rickettsiae and rickettsial infections: the current state of knowledge. Clin Infect Dis 

2007; 45(suppl. 1):S39-44. 

1.1047 Botelho-Nevers E et al. Fever of unknown origin due to rickettsioses. Infect Dis Clin North Am 2007; 

21:997-1011. 

1.1048 Jensenius M et al. Rickettsioses and the international traveler. Clin Infect Dis 2004;39:1493-9. 

1.1049 Walker DH. Rickettsial diseases in travelers. Travel Med Infect Dis 2003;1:35-40. 

1.1050 Parola P et al. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. 


1.1051 Chen LF et al. What‘s new in Rocky Mountain spotted fever? Infect Dis Clin North Am 2008;22:415- 

32. 

1.1052 Masters EJ et al. Rocky Mountain spotted fever. A clinician‘s dilemma. Arch Intern Med 2003,163: 

769-74. 

1.1053 Minniear TD et al. Managing Rocky Mountain spotted fever. Expert Rev Anti Infect Ther 2009;7: 

1131-7. 

1.1054 Dantas-Torres F. Rocky Mountain spotted fever. Lancet Infect Dis 2007;7:724-32. 

1.1055 Rovery C et al. Questions on Mediterranean spotted fever a century after its discovery. Emerg Infect 

Dis 2008;14:1360-7. 

1.1056 Rovery C et al. Mediterranean spotted fever. Infect Dis Clin North Am 2008;22:515-30. 

1.1057 Cazorla C et al. Tick-borne diseases: tick-borne spotted fever rickettsioses in Africa. Infect Dis Clin 

North Am 2008;22:531-44. 

1.1058 Roch N et al. African tick bite fever in elderly patients: 8 cases in French tourists returning from South 

Africa. Clin Infect Dis 2008;47:e28-35. 

1.1059 Paddock CD et al. Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the 

United States. Clin Infect Dis 2004;38:805-11. 

1.1060 Paddock CD et al. Rickettsia parkeri rickettsiosis and its clinical distinction from Rocky Mountain spotted 

fever. Clin Infect Dis 2008;47:1188-96. 

1.1061 Bechah Y et al. Epidemic typhus. Lancet Infect Dis 2008;8:417-26. 

1.1062 Lutwick LI. Brill-Zinsser disease. Lancet 2001;357:1198-200. 

1.1063 Civen R et al. Murine typhus: an unrecognized suburban vectorborne disease. Clin Infect Dis 2008; 

46:913-8. 

1.1064 Pérez-Osorio CE et al. Rickettsia felis as emergent global threat for humans. Emerg Infect Dis 2008; 

14:1019-23. 

1.1065 Kelly DJ et al. Scrub typhus: the geographic distribution of phenotypic and genotypic variants of 

Orientia tsutsugamushi. Clin Infect Dis 2009;48(suppl. 3):S203-30. 

1.1066 Phimda K et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob 


1.1067 Kim YS et al. A comparative trial of a single dose of azithromycin versus doxycycline for the treatment 

of mild scrub typhus. Clin Infect Dis 2004;39:1329-35. 

1.1068 Benenson S et al. The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia. 

Am J Med 2001;110:60-3. 

1.1069 Thomas LD et al. Tularemia pneumonia. Infect Dis Clin North Am 2008;22:43-55. 

1.1070 Nigrovic LE et al. Tularemia. Infect Dis Clin North Am 2008;22:489-504. 

1.1071 Hepburn MJ et al. Tularemia: current diagnosis and treatment options. Expert Rev Anti Infect Ther 

2008;6:231-40. 

1.1072 Ellis J et al. Tularemia. Clin Microbiol Rev 2002;15:631-46. 

1.1073 Sobel J. Botulism. Clin Infect Dis 2005;41:1167-73. 

1.1074 Kongsaengdao S et al. An outbreak of botulism in Thailand: clinical manifestations and management

of severe respiratory failure. Clin Infect Dis 2006;43:1247-56. 

1.1075 Koepke R et al. Global occurrence of infant botulism, 1976-2006. Pediatrics 2008;122:e73-82. 

1.1076 Rowley AH et al. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 

2010;8:197-203. 

1.1077 Pinna GS et al. Kawasaki disease: an overview. Curr Opin Infect Dis 2008;21:263-70. 

1.1078 Son MB et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 

2006. Pediatrics 2009;124:1-8. 

1.1079 Newburger JW et al. Diagnosis, treatment and long-term management of Kawasaki disease. Circulation 

2004;110:2747-71. 

1.1080 Burns JC et al. Kawasaki syndrome. Lancet 2004;364:533-44. 

1.1081 Mason WH et al. Kawasaki syndrome. Clin Infect Dis 1999;28:169-87. 

1.1082 Burgner D et al. Kawasaki disease: what is the epidemiology telling us about the etiology? Int J 

Infect Dis 2005;9:185-94. 

1.1083 Esper F et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 

2005;191:499-502. 

1.1084 Kobayashi T et al. risk stratification in the decision to include prednisolone with intravenous immunoglobulin 

in primary therapy of Kawasaki disease. Pediatr Infect Dis J 2009;28:498-502. 

1.1085 Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr 2003;142:601-3. 

1.1086 Sundel RP et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized 

trial. J Pediatr 2003;142:611-6. 

1.1087 Newburger JW et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki 

disease. N Engl J Med 2007;356:663-75. 

1.1088 Burns JC. The riddle of Kawasaki disease. N Engl J Med 2007;356:659-61. 

1.1089 Furukawa T et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. 

Arch Dis Child 2008;93:142-6. 

1.1090 Wallace CA et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 

2000;105:e78. 

1.1091 Hashino K et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study 

of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-7. 

1.1092 Carapetis JR et al. Acute rheumatic fever. Lancet 2005;366:155-68. 

1.1093 Cilliers AM. Rheumatic fever and its management. Br Med J 2006;333:1153-6. 

1.1094 Lever A et al. Sepsis: definition, epidemiology, and diagnosis. Br Med J 2007;335:879-83. 

1.1095 Holmes CL et al. Vasopressin. Semin Respir Crit Care Med 2004;25:705-11. 

1.1096 Russell JA et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J 

Med 2008;358:877-87. 

1.1097 Levy MM et al. The Surviving Sepsis Campaign: results of an international guideline-based performance 

improvement program targeting severe sepsis. Intensive Care Med 2010;36:222-31. 

1.1098 Garnacho-Montero J et al. Impact of adequate empirical antibiotic therapy on the outcome of patients 

admitted to the intensive care unit with sepsis.Crit Care Med 2003;31:2742-51. 

1.1099 MacArthur RD et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience 

from the MONARCS trial. Clin Infect Dis 2004;38:284-8. 

1.1100 Kumar A et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical 

determinant of survival in human septic shock.Crit Care Med 2006;34:1589-96. 

1.1101 Ferrer R et al. Effectiveness of treatments for severe sepsis. A prospective, multicenter, observational 

study. Am J Respir Crit Care Med 2009;180:861-6. 

1.1102 Nguyen HB et al. Implementation of a bundle of quality indicators for the early management of severe 

sepsis and septic shock is associated with decreased mortality.Crit Care Med 2007;35:1105-12. 

1.1103 Drgona L et al. The need for aminoglycosides in combination with β-lactams for high-risk febrile neutropaenic 

patients with leukaemia. Eur J Cancer Suppl 2007;5:13-22. 

1.1104 Paul M et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination 


1.1105 Paul M et al. β-lactam monotherapy versus β-lactam aminoglycoside combination therapy for sepsis 


2004;328:668-81. 

1.1106 Safdar N et al. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? 


1.1107 Paul M et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever 


1.1108 Furno P et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment 


1.1109 Rivers E et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl 

J Med 2001;345:1368-77. 

1.1110 Annane D et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality 

in patients with septic shock. J Am Med Assoc 2002;288:862-71. 

1.1111 Sligl W et al. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review 

and meta-analysis. Clin Infect Dis 2009;49:93-101. 

1.1112 Minneci PC et al. The effects of steroids during sepsis depend on dose and severity of illness: an updated 

meta-analysis. Clin Microbiol Infect 2009;15:308-18. 

1.1113 Annane D et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults. A systematic 

review. J Am Med Assoc 2009;301:2362-75. 

1.1114 Sprung CL et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111- 

24. 

1.1115 Keh D et al. Corticosteroid therapy in patients with severe sepsis and septic shock. Semin Respir 

Crit Care Med 2004;25:713-9. 

1.1116 Bernard GR et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N 

Engl J Med 2001;344:699-709. 

1.1117 Abraham E et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N 

Engl J Med 2005;353:1332-41. 

1.1118 Houston G et al. Activated protein C for the treatment of severe sepsis. Clin Microbiol Infect 2009; 

15:319-24. 

1.1119 Toussaint S et al. Activated protein C for sepsis. N Engl J Med 2009;361:2646-52. 

1.1120 Nadel S et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised 

controlled trial. Lancet 2007;369:836-43.

1.1121 Vincent JL. Drotrecogin alfa (activated) in the treatment of severe sepsis. Expert Rev Anti Infect 

Ther 2006;4:537-47. 

1.1122 Kreymann KG et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic 

shock. Crit Care Med 2007;35:2677-85. 

1.1123 Laupland KB et al. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and 

septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35: 

2686-92. 

1.1124 Werdan K et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit 

Care Med 2007;35:2693-701. 

1.1125 Soylemez Wiener R et al. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. 

J Am Med Assoc 2008;300:933-44. 

1.1126 Finfer S et al. Tight glycemic control in critically ill adults. J Am Med Assoc 2008;300:963-5. 

1.1127 COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock 

in adults. A randomized controlled trial. J Am Med Assoc 2010;303:341-8. 

1.1128 Brunkhorst FM et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl 

J Med 2008;358:125-39. 

1.1129 NICE-SUGAR investigators. Intensive versus conventional glucose control in critically ill patients. N 

Engl J Med 2009;360:1283-97. 

1.1130 Dellinger RP et al. Surviving Sepsis Campaign: international guidelines for management of severe 

sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327. 


sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60. 


sepsis and septic shock: 2008. Intensive Care Med 2008;34:783-85. 

1.1133 O‘Grady NO et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update 

from the American College of Critical Care Medicine and the Infectious Diseases Society of America. 

Crit Care Med 2008;36:1330-49. 

1.1134 Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-713. 

1.1135 Mackenzie I et al. Management of sepsis. Br Med J 2007;335:929-32. 

1.1136 O‘Brien JM et al. Sepsis. Am J Med 2007;120:1012-22. 

1.1137 Annane D et al. Septic shock. Lancet 2005;365:63-78. 

1.1138 Sharma VK et al. Treatment options for severe sepsis and septic shock. Expert Rev Anti Infect Ther 

2006;4:395-403. 

1.1139 Hotchkiss RS et al. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50. 

1.1140 Talan DA et al. Severe sepsis and septic shock in the emergency department. Infect Dis Clin North 

Am 2008;22:1-31. 

1.1141 Venkatesh MP et al. Management of neonatal sepsis by Gram-negative pathogens. Expert Rev Anti 

Infect Ther 2008;6:929-38. 

1.1142 Schrag SJ et al. Early-onset neonatal sepsis in the era of widespread intrapartum chemoprophylaxis. 


1.1143 Hart AC et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90. 


2007;369:2196-210. 

1.1145 Hart AC et al. Meningococcal disease and its management in children. Br Med J 2006;333:685-90. 


2007;369:2196-210. 

1.1147 Cunha BA. Fever of unknown origin: clinical overview of classic and current concepts. Infect Dis Clin 

North Am 2007;21:867-915. 

1.1148 Knockaert DC. Recurrent fevers of unknown origin. Infect Dis Clin North Am 2007;21:1189-211. 

1.1149 Hughes WT et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. 


1.1150 Marti Marti F et al. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol 

2009;20(suppl. 4):iv166-69. 

1.1151 Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based 

clinical practice guideline. J Clin Oncol 2006;24:3187-205. 

1.1152 Cometta A et al. Empirical use of anti-Gram-positive antibiotics in febrile neutropenic cancer patients 

with acute leukaemia. Eur J Cancer Suppl 2007;5:23-31. 

1.1153 Antoniadou A et al. Fever of unknown origin in febrile leukopenia. Infect Dis Clin North Am 2007;21: 

1055-90. 

1.1154 Aoun M. Empiric therapy for febrile neutropenia: what are the choices? Expert Rev Anti Infect Ther 

2007;5:507-15. 

1.1155 Castagnola E et al. Management of bacteremia in patients undergoing hematopoietic stem cell transplantation. 


1.1156 Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer 2009;101 

(suppl. 1):S18-22. 

1.1157 Meckler G et al. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am 

2009;27:525-44. 

1.1158 Ellis M. Febrile neutropenia. Ann NY Acad Sci 2008;1138:329-350. 

1.1159 Attygalle D et al. New trends in the management of tetanus. Expert Rev Anti Infect Ther 2004;2:73- 

84. 

1.1160 Brook I. Current concepts in the management of Clostridum tetani infection. Expert Rev Anti Infect 

Ther 2008;6:327-36. 

1.1161 Ahmadsyah I et al. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin 

and metronidazole. Br Med J 1985;291:648-50. 

1.1162 Kabura L et al. Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or 

equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health 2006;11: 

1075-81. 

1.1163 Lappin E et al. Gram-positive toxic shock syndromes. Lancet Infect Dis 2009;9:281-90. 

1.1164 Fischer M et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. 

N Engl J Med 2005;353:2352-60. 

1.1165 Sinave C et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion 

disease. Clin Infect Dis 2002;35:1441-3.

1.1166 Aldape MJ et al. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives 

on diagnosis and treatment. Clin Infect Dis 2006;43:1436-46. 

1.1167 Fjerstad M et al. Rates of serious infection after changes in regimens for medical abortion. N Engl J 

Med 2009;361:145-51. 

1.1168 Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock 

syndrome. Rationale and consensus definition. J Am Med Assoc 1993;269:390-1. 

1.1169 Shah SS et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin 

Infect Dis 2009;49:1369-76. 

1.1170 Schrage B et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize 

streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. 


1.1171 Stevens DL. The flesh-eating bacterium: what‘s next? J Infect Dis 1999;179(suppl. 2):S366-74. 

1.1172 Sendi P et al. Bacterial phenotype variants in group b streptococcal toxic shock syndrome. Emerg Infect 

Dis 2009;15:223-32. 

1.1173 Stevens DL et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive 

and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-11. 

1.1174 Crump JA et al. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010;50:241-6. 

1.1175 Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. Br Med J 2006;333:78- 

82. 

1.1176 Bhan MK et al. Typhoid and paratyphoid fever. Lancet 2005;366:749-62. 

1.1177 Connor BA et al. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005;5;623-8. 

1.1178 Huang DB et al. Problem pathogens: extra-intestinal complications of Salmonella enterica serotype 

Typhi infection. Lancet Infect Dis 2005;5:341-8. 

1.1179 Thaver D et al. A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: a 

meta-analysis. Br Med J 2009;338:b1865. 

1.1180 Lynch MF et al. Typhoid fever in the United States, 1999-2006. J Am Med Assoc 2009;302:859-65. 

1.1181 Frenck RW et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children 

and adolescents. Clin Infect Dis 2004;38:951-7. 

1.1182 Hoffman SL et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose 

dexamethasone. N Engl J Med 1984;310:82-8. 

1.1183 Raad I et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal 

bacteremia: remove or retain? Clin Infect Dis 2009;49:1187-94. 

1.1184 Casey AL et al. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. 


1.1185 Rijnders BJ et al. Watchful waiting versus immediate catheter removal in UCI patients with suspected 

catheter-related infection: a randomized trial. Intensive Care Med 2004:30:1073-80. 

1.1186 Worthington T et al. Diagnosis of central venous catheter related infection in adult patients. J Infect 

2005;51:267-80. 

1.1187 Bouza E et al. A randomized and prospective study of 3 procedures for the diagnosis of catheter-related 

bloodstream infection without catheter withdrawal. Clin Infect Dis 2007;44:820-6. 

1.1188 Mermel LA et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related 

infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 

2009;49:1-45. 

1.1189 Perlman SE at al. Risk factors for late-onset healthcare-associated bloodstream infections in patients 

in neonatal intensive care units. Am J Infect Control 2007;35:177-82. 

1.1190 Raad I et al. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. 


1.1191 Pagani JL et al. Management of catheter-related infection. Expert Rev Anti Infect Ther 2008;6:31-7. 

1.1192 Parienti JJ et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring 

acute renal replacement therapy. A randomized controlled trial. J Am Med Assoc 2008;299: 

2413-22. 

1.1193 Lorente L et al. Arterial catheter-related infection of 2,949 catheters. Crit Care 2006;10:R83. 

1.1194 McBryde ES et al. Comparison of contamination rates of catheter-drawn and peripheral blood cultures. 

J Hosp Infect 2005;60:118-21. 

1.1195 Raad I et al. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream 

infections. Ann Intern Med 2004;140:18-25. 

1.1196 Yahav D et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular 

catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, 

controlled trials. Clin Infect Dis 2008;47:83-93. 

1.1197 Rijnders BJ et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic 

lock: randomized, placebo-controlled trial. J Antimicrob Chemother 2005;55:90-4. 

1.1198 Garland JS et al. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infections 

in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized 

trial. Pediatrics 2005;116:e198-205. 

1.1199 Toltzis P. Antibiotic lock technique to reduce central venous catheter-related bacteremia. Pediatr Infect 

Dis J 2006;25:449-50. 

1.1200 Korbila IP et al. Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current 

evidence. Expert Rev Anti Infect Ther 2007;5:639-52. 

1.1201 Safdar N et al. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infections 

associated with central venous access devices: a meta-analysis of prospective, randomized 

trials. Clin Infect Dis 2006;43:474-84. 

1.1202 Falagas ME et al. Intravenous heparin in combination with antibiotics for the treatment of deep vein 

septic thrombophlebitis: a systematic review. Eur J Pharmacol 2007;557:93-8. 

1.1203 Volkow P et al. Catheter-related septic thrombophlebitis of the great central veins successfully treated 

with low-dose streptokinase thrombolysis and antimicrobials. Thromb J 2005;3:11. 

1.1204 Mertz D et al. Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis 

in injection drug users. Clin Infect Dis 2008;46:741-4. 

1.1205 Faro C et al. Postoperative pelvic infections. Infect Dis Clin North Am 2008;22:653-63. 

1.1206 Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and 

soft tissue infections. Pediatr Infect Dis J 2008;27:1-7. 

1.1207 Grundmann H et al. Geographic distribution of Staphylococcus aureus causing invasive infections in 

Europe: a molecular-epidemiological analysis. PLoS Med 2010;7:e1000215. 

1.1208 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of oppor-

tunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 

207. 

1.1209 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of 

opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009; 

58(RR-11):1-167. 

2A.1 Zheng X et al. Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates. 

J Clin Microbiol 2004;42:4323-6. 

2A.2 Gómez-Cerezo J et al. Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases. Eur 

J Clin Microbiol Infect Dis 2003;22:360-3. 

2A.3 Yildiz O et al. Actinomycoses and Nocardia pulmonary infections. Curr Opin Pulm Med 2006;12: 

228-34. 

2A.4 Smith AJ et al. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial 

agents. J Antimicrob Chemother 2005;56:407-9. 

2A.5 von Graevenitz A. The role of Aeromonas in diarrhea: a review. Infection 2007;35:59-64. 

2A.6 Sader HS et al. Antimicrobial susceptibility of uncommonly isolated non enteric Gram negative bacilli. 


2A.7 Streit JM et al. Prevalence and antimicrobial susceptibility patterns among gastro-enteritis causing 

pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream 

infections in North America and Latin America: report from the SENTRY antimicrobial surveillance 

program (2003). Int J Antimicrob Agents 2006;27:378-86. 

2A.8 Janda JM et al. The genus Aeromonas: taxonomy, pathogenicity and infection. Clin Microbiol Rev 

2010;23:35-73. 

2A.9 Lamy B et al. Prospective nationwide study of Aeromonas infections in France. J Clin Microbiol 

2009; 47:1234-7. 

2A.10 Nørskov-Lauritsen N et al. Reclassification of Actinobacillus actinomycetemcomitans, Haemophilus 

aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans, 

gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter 

segnis comb. nov., and emended description of Aggregatibacter aphrophilus to include V factor-dependent 

and V factor-independent isolates. Int J Syst Evol Microbiol 2006;56:2135-46. 

2A.11 Nørskov-Lauritsen N et al. Reclassification of Actinobacillus actinomycetemcomitans, Haemophilus 

aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans, 

gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter 

segnis comb. nov., and emended description of Aggregatibacter aphrophilus to include V factor-dependent 

and V factor-independent isolates. Int J Syst Evol Microbiol 2006;56:2135-46. 

2A.12 Baddour LM et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. 

Circulation 2005;111:e394-433. 

2A.13 Sader HS et al. Antimicrobial susceptibility of uncommonly isolated non enteric Gram negative bacilli. 


2A.14 Dumler JS et al. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. 


2A.15 Horowitz HW et al. Antimicrobial susceptibility of Ehrlichia phagocytophila. Antimicrob Agents Chemother 

2001;45:786-8. 

2A.16 Branger S et al. Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeen-sis and 

Anaplasma phagocytophilum by real time PCR. Antimicrob Agents Chemother 2004;48:4822-8. 

2A.17 Carlson P et al. Antimicrobial susceptibility of Arcanobacterium haemolyticum. Antimicrob Agents 

Chemother 1994;38:142-3. 

2A.18 Carlson P et al. Antimicrobial susceptibilities and biotypes of Arcanobacterium haemolyticum blood 

isolates. Eur J Clin Microbiol Infect Dis 1999;18:915-7. 

2A.19 Athamna A et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time 

kill activity. J Antimicrob Chemother 2004;53:247-51. 

2A.20 Jones ME et al. Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the 

potential to be used in biowarfare. Clin Microbiol Infect 2003;9:984-6. 

2A.21 Werlinger KD et al. Therapy of other bacterial infections. Dermatol Ther 2004;17:505-12. 

2A.22 Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev 2010;23:382-98. 

2A.23 Snydman DR et al. Lessons learned from the anaerobe survey: historical perspective and review of 

the most recent data (2005-2007). Clin Infect Dis 2010;50(suppl. 1):S26-33. 

2A.24 Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007;20:593- 

621. 

2A.25 Wybo I et al. Third Belgian multicentre survey of antibiotic susceptibility of anerobic bacteria. J Antimicrob 

Chemother 2007;59:132-9. 

2A.26 Glupczynski Y et al. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by Etest 

methodology. Eur J Clin Microbiol Infect Dis 2009;28:261-7. 

2A.27 Pendle S et al. Antimicrobial susceptibility of Bartonella henselae using E-test methodology. J Antimicrob 

Chemother 2006;57:761-3. 

2A.28 Foucault C et al. Bartonella quintana characteristics and clinical management. Emerg Infect Dis 

2006;12:216-23. 

2A.29 Rolain JM et al. Recommendations for treatment of human infections caused by Bartonella species. 


2A.30 Moubareck C et al. Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother 2005;55: 

38-44. 

2A.31 Altunaiji S et al. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007;3: 

CD004404. 

2A.32 Mattoo S et al. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections 

due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326- 

82. 

2A.33 Cutler SJ et al. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol 

Infect 2009;15:400-6. 

2A.34 Ružić-Sabljić E et al. Susceptiblility of Borrelia afzelii strains to antimicrobial agents. Int J Antimicrob 

Agents 2005;25:474-8. 

2A.35 Hunfeld KP et al. In vitro susceptibility of Borrelia burgdorferi sensu lato isolates cultured from patients 

with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 

2005;49:1294-301.

2A.36 Wormser GP. Early Lyme disease. N Engl J Med 2006;354:2794-801. 

2A.37 Halperin JJ et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based 

review). Report of the American Academy of Neurology Quality Standards Subcomittee. Neurology 

2007;69:91-102. 

2A.38 Skalsky K et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised 

controlled trials. Br Med J 2008;336:701-4. 

2A.39 Baykam N et al. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 

2004;23:405-7. 

2A.40 Franco MP et al. Human brucellosis. Lancet Infect Dis 2007;7:775-86. 

2A.41 Avgeri SE et al. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a 

systematic review of the clinical evidence. Int J Antimicrob Agents 2009:33:394-404. 

2A.42 Mahenthiralingam E et al. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 

2005;3:144-56. 

2A.43 Wuthiekanun V et al. Management of melioidosis. Expert Rev Anti Infect Ther 2006;4:445-55. 

2A.44 Thibault FM et al. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia 

mallei to 35 antimicrobial agents. J Antimicrob Chemother 2004;54:1134-8. 

2A.45 Cheng AC et al. Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev 

2005;18:383-416. 

2A.46 Peacock SJ. Melioidosis. Curr Opin Infect Dis 2006;19:421-8. 

2A.47 Chierakul W et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination 

with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 

2005;41:1105-13. 

2A.48 Estes MD et al. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev 

Anti Infect Ther 2010;8:325-38. 

2A.49 Vandenberg O et al. Antimicrobial susceptibility of clinical isolates of non jejuni/coli Campylobacter 

and Arcobacter from Belgium. J Antimicrob Chemother 2006;57:908-13. 

2A.50 Gibreel A et al. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob 

Chemother 2006;58:243-55. 

2A.51 Blasi F et al. Chlamydophila pneumoniae. Clin Microbiol Infect 2009;15:29-35. 

2A.52 Haggerty CL et al. Newest approaches to treatment of pelvic inflammatory disease: a review of recent 

randomized clinical trials. Clin Infect Dis 2007;44:953-60. 

2A.53 Bauer MP et al. Clostridium difficile: controversies and approaches to management. Curr Opin Infect 

Dis 2009;22:517-24. 

2A.54 Nelson R. Antibiotic treatment of Clostridium difficile-associated diarrhea in adults. Cochrane Database 

Syst Rev 2007;3:CD004610. 

2A.55 Johnson S et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial 

therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8. 

2A.56 Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007;45 

(suppl. 2):S122-8. 

2A.57 Brook I. Current concepts in the management of Clostridium tetani infection. Expert Rev Anti Infect 

Ther 2008;6:327-36. 

2A.58 Kneen R et al. Penicillin versus erythromycin in the treatment of diphtheria. Clin Infect Dis 1998;27: 

845-50. 

2A.59 Parker NR et al. Q fever. Lancet 2006;367:679-88. 

2A.60 Tissot-Dupont H et al. Q fever. Infect Dis Clin North Am 2008;22:505-14. 

2A.61 Klaassen CH et al. Multigenotype Q fever outbreak, the Netherlands. Emerg Infect Dis 2009;15:613- 

4. 

2A.62 Stock I et al. Natural antibiotic susceptibilities of Edwardsiella tarda, Edwardsiella ictaluri and Edwardsiella 

hoshinae. Antimicrob Agents Chemother 2001;45:2245-55. 

2A.63 Dumler JS et al. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. 


2A.64 Branger S et al. Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis and 

Anaplasma phagocytophilum by real time PCR. Antimicrob Agents Chemother 2004;48:4822-8. 

2A.65 Sheng WS et al. Clinical features of patients with invasive Eikenella corrodens infections and microbiological 

characteristics of the causative isolates. Eur J Clin Microbiol Infect Dis 2001;20:231-6. 

2A.66 Kim KK et al. Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia 

gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola 

comb. nov. Int J Syst Evol Microbiol 2005;55:1287-93. 

2A.67 Kirby JT et al. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium 

spp.: report from the SENTRY antimicrobial surveillance program (1997-2001). J Clin Microbiol 

2004;42:445-8. 

2A.68 Di Pentima MC et al. In vitro antibiotic synergy against Flavobacterium meningosepticum: implications 

for therapeutic options. Clin Infect Dis 1998;26:1169-76. 

2A.69 Fidalgo SG et al. Susceptibility of Erysipelothrix rhusiopathiae to antimicrobial agents and home disinfectants. 

Pathology 2002;34:462-5. 

2A.70 Kaper JB et al. Pathogenic Eschericha coli. Nat Rev Microbiol 2004;2:123-40. 

2A.71 De Backer D et al. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary 

tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 

10 year interval. J Antimicrob Chemother 2008;62:364-8. 

2A.72 Ikäheimo I et al. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and 

animals. J Antimicrob Chemother 2000;46:287-90. 

2A.73 Tärnvik A et al. New approaches to diagnosis and therapy of tularaemia. Ann NY Acad Sci 2007; 

1105:378-404. 

2A.74 Nigrovic LE et al. Tularemia. Infect Dis Clin North Am 2008;22:489-504. 

2A.75 Nyfors S et al. Emergence of penicillin resistance among Fusobacterium nucleatum populations of 

commensal oral flora during early childhood. J Antimicrob Chemother 2003;51:107-12. 



2A.77 Collins MD et al. The genus Abiotrophia (Kawamura et al.) is not monophyletic: proposal of Granulicatella 

gen. nov., Granulicatella adiacens comb. nov., Granulicatella elegans comb. nov. and Granulicatella 

balaenopterae comb. nov. Int J Syst Evol Microbiol 2000;50:365-9. 

2A.78 Roy-Leon JE et al. In vitro and in vivo activity of combination antimicrobial agents on Haemophilus 

ducreyi. J Antimicrob Chemother 2005;56:552-8.

2A.79 Tristram S et al. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007;20: 

368-89. 

2A.80 Harrison CJ et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including 

serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. 


2A.81 Felmingham D et al. The Alexander project: the benefits from a decade of surveillance. J Antimicrob 

Chemother 2005;56(suppl. S2):ii3-21. 

2A.82 Janda JM et al. The genus Hafnia: from soup to nuts. Clin Microbiol Rev 2006;19:12-28. 

2A.83 Stock I et al. Natural antimicrobial susceptibility patterns and biochemical identification of Escherichia 

albertii and Hafnia alvei strains. Diagn Microbiol Infect Dis 2005;51:151-63. 

2A.84 Boyanova L et al. Geographic map and evolution of primary resistance of Helicobacter pylori to antibacterial 

agents. Expert Rev Anti Infect Ther 2010;8:59-70. 

2A.85 Vakil N et al. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001. 

2A.86 Gisbert JP et al. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 

2007;12(suppl. 2):50-8. 

2A.87 Kusters JG et al. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-60. 

2A.88 Dubnov-Raz G et al. Invasive Kingella kingae infections in children: clinical and laboratory characteristics. 

Pediatrics 2008;122:1305-9. 

2A.89 Stock I et al. Natural antibiotic susceptibility of Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella 

planticola, Klebsiella ornithinolytica and Klebsiella terrigena strains. J Med Microbiol 2001;50:396- 

406. 

2A.90 Botelho-Nevers E et al. Chronic nasal infection caused by Klebsiella rhinoscleromatis or Klebsiella 

ozaenae: two forgotten infectious diseases. Int J Infect Dis 2007;11:423-9. 

2A.91 Cannon JP et al. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. 

Eur J Clin Microbiol Infect Dis 2005;24:31-40. 

2A.92 Salminen MK et al. Lactobacillus bacteremia, species identification and antimicrobial susceptibility of 

85 blood isolates. Clin Infect Dis 2006;42:e35-44. 

2A.93 Pedro-Botet L et al. Legionella: macrolides or quinolones? Clin Microbiol Infect 2006;12(suppl. 

3):25-30. 

2A.94 Dunbar LM et al. Activity of telithromycin and comparators against isolates of Legionella pneumophila 

collected from patients with community-acquired respiratory tract infections: PROTECT years 1-5. 


2A.95 Stout JE et al. Comparative activity of quinolones, macrolides and ketolides against Legionella species 

using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents 2005; 

25:302-7. 

2A.96 Garcia-Vidal C et al. Current clinical management of legionnaires‘ disease. Expert Rev Anti Infect 

Ther 2006;4:995-1004. 

2A.97 Panaphut T et al. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. 


2A.98 Felmingham D et al. The Alexander project: the benefits from a decade of surveillance. J Antimicrob 

Chemother 2005;56(suppl. S2):ii3-21. 




2A.100 Murphy TF et al. Moraxella catarrhalis, a human respiratory tract pathogen Clin Infect Dis 2009;49: 

124-31. 

2A.101 Mena LA et al. Randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma 

genitalium-positive urethritis in men. Clin Infect Dis 2009;48:1649-54. 

2A.102 Shahmanesh M et al. 2009 European guideline on the management of male non-gonococcal urethritis. 

Int J STD AIDS 2009;20:458-64. 

2A.103 Sánchez-Vargas et al. Mycoplasma pneumoniae – an emerging extra-pulmonary pathogen. Clin Microbiol 

Infect 2008;14:105-15. 

2A.104 Waites KB et al. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 

2004;17:697-728. 

2A.105 Centers for Disease Control and Prevention (CDC). Update to CDC‘s sexually transmitted diseases 

treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. 


2A.106 Workowski KA et al. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to 

strengthen prevention strategies. Ann Intern Med 2008;148:606-13. 

2A.107 Newman LM et al. Update on the management of gonorrhea in adults in the United States. Clin 


2A.108 Bignell C. 2009 European (IUSTI/WHO) guideline on the diagnosis and treatment of gonorrhoea in 

adults. Int J STD AIDS 2009;20:453-57. 

2A.109 Jorgensen JH et al. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization 

of resistance mechanisms affecting some agents. J Clin Microbiol 2005;43:3162-71. 

2A.110 Vázquez JA et al. Antibiotic resistant meningococci in Europe: any need to act? FEMS Microbiol Rev 

2007;31:64-70. 

2A.111 Stephens DS et al. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 

2007;369:2196-210. 

2A.112 Lai CC et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials 

against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob 

Chemother 2009;64:73-8. 

2A.113 Jodlowski TZ et al. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother 2007; 

41:1694-9. 

2A.114 Brown-Elliott BA et al. Clinical and laboratory features of the Nocardia spp. based on current molecular 


2A.115 Gomez-Flores A et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob 


2A.116 Lion C et al. Antimicrobial susceptibilities of Pasteurella strains isolated from humans. Int J Antimicrob 

Agents 2006;27:290-3. 


Chemother 2007;59:132-9. 

2A.118 Glupczynski Y et al. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-

test methodology. Eur J Clin Microbiol Infect Dis 2009;28:261-7. 

2A.119 Stock I et al. Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains. J Antimicrob 

Chemother 2001;48:803-11. 


Chemother 2007;59:132-9. 



2A.122 Oprica C et al. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. 


2A.123 Amin K et al. Common and alternate oral antibiotic therapies for acne vulgaris: a review. J Drugs 

Dermatol 2007;6:873-80. 

2A.124 Coates P et al. Prevalence of antibiotic resistant propionibacteria on the skin of acne patients: 10year 

surveillance data and snapshot distribution study. Br J Dermatol 2002;146:840-8. 

2A.125 Yamshchikov A et al. Rhodococcus equi infection. Lancet Infect Dis 2010;10:350-9. 

2A.126 Gabriels P et al. Recurrent Rhodococcus equi infection with fatal outcome in an immunocompetent 

patient. Eur J Clin Microbiol Infect Dis 2006;25:46-8. 

2A.127 Weinstock DM et al. Rhodococcus equi: an emerging pathogen. Clin Infect Dis 2002;34:1379-85. 

2A.128 Cascio A et al. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in 

children: a randomized, controlled trial. Clin Infect Dis 2002;34:154-8. 

2A.129 Walker DH et al. Emerging and re-emerging tick-transmitted rickettsial and ehrlichial infections. Med 

Clin North Am 2008;92;1345-61. 

2A.130 Dé A et al. Clinical significance of Roseomonas species isolated from catheter and blood samples: 

analysis of 36 cases in patients with cancer. Clin Infect Dis 2004;38:1579-84. 

2A.131 Boudewijns M et al. Rothia dentocariosa, endocarditis and mycotic aneurysms: case report and review 

of the literature. Clin Microbiol Infect 2003;9:222-9. 

2A.132 Parry CM et al. Antimicrobial resistance in typhoidal and nontyphoidal Salmonellae. Curr Opin Infect 

Dis 2008;21:531-8. 

2A.133 Smith AM et al. Quinolone-resistant Salmonella typhi in South Africa, 2003-2007. Epidemiol Infect 

2010;138:86-90. 

2A.134 Cooke FJ et al. The emergence of antibiotic resistance in typhoid fever. Travel Med Infect Dis 2004; 

2:67-74. 





2A.136 Pickering LK. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis 2004;15: 

71-7. 

2A.137 Vrints M et al. Surveillance of antibiotic susceptibility patterns among Shigella sonnei strains isolated 

in Belgium during the 18-Year Period 1990 to 2007. J Clin Microbiol 2009;47:1379-85. 





2A.139 Pickering LK. Antimicrobial resistance among enteric pathogens. Semin Pediatr Infect Dis 2004;15: 

71-7. 

2A.140 Frank KL et al. From clinical microbiology to infection pathogenesis: how daring to be different works 

for Staphylococcus lugdunensis. Clin Microbiol Rev 2008;21:111-33. 

2A.141 Hellbacher C et al. Staphylococcus lugdunensis: clinical spectrum, antibiotic susceptibility and phenotypic 

and genotypic patterns of 39 isolates. Clin Microbiol Infect 2006;12:43-9. 

2A.142 Tan TY et al. Microbiological characteristics, presumptive identification, and antibiotic susceptibilities 

of Staphylococcus lugdunensis. J Clin Microbiol 2008;46:2393-5. 

2A.143 Raz R et al. Who are you Staphylococcus saprophyticus? Clin Infect Dis 2005;40:896-8. 

2A.144 Falagas ME et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond cotrimoxazole: 

a systematic review. J Antimicrob Chemother 2008;62:889-94. 

2A.145 Looney WJ et al. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet 

Infect Dis 2009;9;312-23. 

2A.146 Safsar A et al. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in 

patients with cancer. Clin Infect Dis 2007;45:1602-9. 

2A.147 Denton M et al. Microbiological and clinical aspects of infection associated with Stenotrophomonas 

maltophilia. Clin Microbiol Rev 1998;11:57-80. 

2A.148 Looney WJ et al; Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet 

Infect Dis 2009;9:312-23. 

2A.149 Elliott SP. Rat bite fever and Streptobacillus moniliformis. Clin Microbiol Rev 2007;20:13-22. 

2A.150 Beck M et al. Comprehensive study of strains previously designated Streptococcus bovis consecutively 



2A.151 Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 

2009;15(suppl. 3):7-11. 




2A.153 Malhotra-Kumar S et al. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus 

pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. J Antimicrob 

Chemother 2009;63:886-94. 

2A.154 Richter SS et al. Increasing telithromycin resistance among Streptococcus pyogenes in Europe. J 

Antimicrob Chemother 2008;61:603-11. 

2A.155 Mulla ZD et al. Invasive group A streptococcal infections in Florida. South Med J 2003;96:968-73. 

2A.156 Butler T. Plague into the 21st century. Clin Infect Dis 2009;49:736-42. 

2B.1 Briceño DF et al. Treatment options for multidrug-resistant nonfermenters. Expert Rev Anti Infect 

Ther 2010;8:303-15. 

2B.2 Peleg AY et al. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 

2008;21:538-82.

2B.3 Karageorgopoulos DE et al. Current control and treatment of multidrug-resistant Acinetobacter baumannii 

infections. Lancet Infect Dis 2008;8:751-62. 

2B.4 Zavascki AP et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance 

mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93. 

2A.5 Perez F et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents 

Chemother 2007;51:3471-84. 

2B.6 Munoz-Price LS et al. Acinetobacter infection. N Engl J Med 2008;358:1271-81. 

2B.7 Gootz TD et al. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect 

Ther 2008;6:309-325. 

2B.8 Maragakis LL et al. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment 

options. Clin Infect Dis 2008;46:1254-63. 

2B.9 Appleman MD et al. In vitro activities of non traditional antimicrobials against multiresistant Acinetobacter 

baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother 

2000;44:1035-40. 

2B.10 Murray CK et al. Treatment of multidrug resistant Acinetobacter. Curr Opin Infect Dis 2005;18:502- 

6. 

2B.11 Fournier PE et al. The epidemiology and control of Acinetobacter baumannii in health care facilities. 


2B.12 Sengstock DM et al. Multidrug‐resistant Acinetobacter baumannii: an emerging pathogen among older 

adults in community hospitals and nursing homes. Clin Infect Dis 2010;50:1611-6. 

2B.13 Yoon J et al. In vitro double and triple synergistic activities of polymyxin B, imipenem and rifampin 

against multidrug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753- 

7. 

2B.14 Roberts JA et al. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. 


2B.15 Gordon NC et al. A review of clinical and microbiological outcomes following treatment of infections 

involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 

2009;63:775-80. 

2B.16 Moland ES et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii 

and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 2008;52:2940-2. 

2B.17 Scheetz MH et al. In vitro activities of various antimicrobials alone and in combination with tigecycline 

against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 

2007;51:1621-6. 

2B.18 Karageorgopoulos DE et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) 

Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 

2008;62:45-55. 

2B.19 Anthony KB et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant 

Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70. 

2B.20 Peleg AY et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary 

report. J Antimicrob Chemother 2007;59:128-31. 

2B.21 Capone AJ et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. J 


2B.22 Navon-Venezia S et al. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J 


2B.23 Bassetti M et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii 

infections. J Antimicrob Chemother 2008;61:417-20. 

2B.24 Garnacho-Montero J et al. Treatment of multidrug resistant Acinetobacter baumannii ventilator associated 

pneumonia (VAP) with intravenous colistin: a comparison with imipenem susceptible VAP. Clin 

Infect Dis 2003;36:1111-8. 

2B.25 Levin AS et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant 

Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11. 

2B.26 Falagas ME et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative 

bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 

35:194-9. 

2B.27 Li J et al. Colistin: the re-emerging antibiotic for multidrug-resistant, Gram-negative bacterial infections. 


2B.28 Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative 

bacterial infections. Clin Infect Dis 2005;40:1333-41. 

2B.29 Falagas ME et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting 

Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int 

J Antimicrob Agents 2009;34:111-20. 

2B.30 Drapeau CM et al. Rifampicin combined regimens for Gram-negative infections: data from the literature. 


2B.31 Plachouras D et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after 

intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. 


2B.32 Giske CG et al. Redefining extended-spectrum β-lactamases: balancing science and clinical need. J 




2B.34 Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing 

epidemiology and drug treatment choices. Drugs 2010;70:313-33. 

2B.35 Glupczynski Y et al. In vitro activity of temocillin against prevalent extended spectrum beta-lactamases 

producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 

2007;26:777-83. 

2B.36 Castanheira M et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials 

tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report 

from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008;52: 

570-3. 

2B.37 Arias CA et al. Emergence and management of drug-resistant enterococcal infections. Expert Rev 


2B.38 Gavaldà J et al. Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann 

Intern Med 2007;146:574-9.

2B.39 Cookson BD et al. Guidelines for the control of glycopeptide resistant enterococci in hospitals. J 

Hosp Infect 2006;62:6-21. 

2B.40 Zirakzadeh A et al. Vancomycin resistant enterococci: colonization, infection, detection and treatment. 

Mayo Clin Proc 2006;81:529-36. 

2B.41 Murray BE. Vancomycin resistant enterococcal infections. N Engl J Med 2000;342:710-21. 

2B.42 Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000;31:586-9. 

2B.43 Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. 


2B.44 Arias CA et al. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 

2010; 16:555-62. 

2B.45 Parkash V et al. Oral and parenteral therapeutic options for outpatient urinary infections caused by 

Enterobacteriaceae producing CTX-M extended-spectrum β-lactamases. Antimicrob Agents Chemother 

2009;53:1278-80. 

2B.46 Rodríguez-Baño J et al. Clinical significance of extended-spectrum β-lactamases. Expert Rev Anti 

Infect Ther 2008;6:671-83. 

2B.47 Paterson DL et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production 

of extended beta-lactamases. Clin Infect Dis 2004;39:31-7. 

2B.48 Giske CG et al. Redefining extended-spectrum β-lactamases: balancing science and clinical need. J 


2B.49 Hirsch EB et al. Duration and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): 

an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010;65:1119-25. 

2B.50 Pitout JD. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect 

Ther 2008;6:657-69. 



2B.52 Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing 

epidemiology and drug treatment choices. Drugs 2010;70:313-33. 

2B.53 Glupczynski Y et al. In vitro activity of temocillin against prevalent extended spectrum beta-lactamases 

producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 

2007;26:777-83. 

2B.54 Rodriguez-Villalobos H et al. In vitro activity of temocillin against extended spectrum β-lactamase 

producing Escherichia coli. J Antimicrob Chemother 2006;57:771-4. 

2B.55 Kelesidis T et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic 

review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008;62: 

895-904. 

2B.56 Castanheira M et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials 

tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: 

report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008; 

52:570-3. 

2B.57 Nordmann P et al. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. 


2B.58 Briceño DF et al. Treatment options for multidrug-resistant nonfermenters. Expert Rev Anti Infect 

Ther 2010;8:303-15. 

2B.59 Zavascki AP et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: 

resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93. 

2B.60 Mesaros N et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new 

millennium. Clin Microbiol Infect 2007;13:560-78. 

2B.61 Jones RN et al. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience 

from the SENTRY antimicrobial surveillance program (1997-2007). Diagn Microbiol Infect 

Dis 2009;65:331-4. 

2B.62 Paul M et al. β-lactam monotherapy versus β-lactam aminoglycoside combination therapy for sepsis 


2004;328:668-81. 

2B.63 Safdar N et al. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? 


2B.64 Paul M et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever 


2B.65 Furno P et al. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment 


2B.66 Paul M et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination 


2B.67 Paul M et al. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. 


2B.68 Levin AS et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug resistant 

Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11. 

2B.69 Falagas ME et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative 

bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 

35:194-9. 

2B.70 Li J et al. Colistin: the re-emerging antibiotic for multidrug-resistant, Gram-negative bacterial infections. 


2B.71 Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative 


2B.72 Falagas ME et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect 

Dis 2008;46:1069-77. 

2B.73 Falagas ME et al. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting 

Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int 

J Antimicrob Agents 2009;34:111-20. 

2B.74 Drapeau CM et al. Rifampicin combined regimens for Gram-negative infections: data from the literature. 


2B.75 Plachouras D et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after 



2B.76 Garau J et al. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol

Infect 2009;15:125-36. 

2B.77 Ratnaraja NV et al. Current challenges in treating MRSA; what are the options? Expert Rev Anti Infect 

Ther 2008;6:601-18. 

2B.78 Gold FK et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus 

aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009;63:849-61. 

2B.79 Cosgrove SE et al. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect 

Dis 2008;46(suppl. 5):S386-93. 

2B.80 Deresinski S. Methicillin resistant Staphylococcus aureus: an evolutionary, epidemiologic and therapeutic 

odyssey. Clin Infect Dis 2005;40:562-73. 

2B.81 Hsu LY et al. Management of healthcare associated methicillin resistant Staphylococcus aureus. Expert 


2B.82 Kluytmans J et al. Meticillin resistant Staphylococcus aureus in the hospital. Br Med J 2009;338:532- 

7. 

2B.83 Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillinresistant 

Staphylococcus aureus infections. Clin Infect Dis 2009;49:1072-9. 

2B.84 Dryden M et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus 

aureus infection: current clinical opinion and practice. Clin Microbiol Infect 2010;16(suppl. 1):3-30. 

2B.85 Denis O et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) among residents 

of nursing homes in Belgium. J Antimicrob Chemother 2009;64:1299-306. 

2B.86 Nguyen HM et al. Limitations of antibiotic options for invasive infections caused by methicillin-resistant 

Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother 2010;65: 

24-36. 

2B.87 Teng CS et al. The role of antimicrobial therapy for treatment of uncomplicated skin and soft tissue infections 

from methicillin-resistant Staphylococcus aureus in children. J Microbiol Immunol Infect 

2009;42:324-8. 

2B.88 Stryjewski ME et al. Skin and soft-tissue infections caused by community-acquired methicillin-resistant 

Staphylococcus aureus. Clin Infect Dis 2008;46(suppl. 5):S368-77. 

2B.89 Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N 

Engl J Med 2007;357:380-90. 

2B.90 Zetola N et al. Community acquired methicillin resistant Staphylococcus aureus: an emerging threat. 


2B.91 Kowalski TJ et al. Epidemiology, treatment and prevention of community acquired methicillin resistant 

Staphylococcus aureus infections. Mayo Clin Proc 2005;80:1201-8. 

2B.92 Ellis MW et al. Treatment approaches for community acquired methicillin resistant Staphylococcus 

aureus infections. Curr Opin Infect Dis 2005;18:496-501. 

2B.93 Kollef MH et al. Methicillin resistant Staphylococcus aureus: a new community acquired pathogen? 


2B.94 Diederen BM et al. The emergence of infections with community associated methicillin resistant Staphylococcus 

aureus. J Infect 2006;52:157-68. 

2B.95 Denis O et al. Polyclonal emergence and importation of community acquired methicillin resistant Staphylococcus 

aureus strains harbouring Panton-Valentine leucocidin genes in Belgium. J Antimicrob 

Chemother 2005;56:1103-6. 

2B.96 Fergie J et al. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. 

Pediatr Infect Dis J 2008;27-67-8. 

2B.97 Moellering RC. Current treatment options forcommunity acquired methicillin resistant Staphylococcus 

aureus infection. Clin Infect Dis 2008;46:1032-7. 

2B.98 Powell JP et al. Antibiotic options for treating community-acquired MRSA. Expert Rev Anti Infect 

Ther 2008;6:299-307. 

2B.99 Nathwani D et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant 

Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 

2008;61:976-94. 

2B.100 Cenizal MJ et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole 

or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant 

Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:2628-30. 

2B.101 Elliott DJ et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of 

methicillin-resistant Staphylococcus aureus. Pediatrics 2009;123:e959-66. 

2B.102 Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. 


2B.103 Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus 


2B.104 Kale-Pradhan P et al. Treatment and recurrence management of staphylococcal infections: community-acquired 

MRSA. Expert Rev Anti Infect Ther 2008;6:909-15. 

2B.105 DeLeo F et al. Community-associated methicillin-resistant Staphylococcus aureus. Lancet 2010;375: 

1557-68. 

2B.106 Sievert DM et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin 

Infect Dis 2008;46:668-74. 

2B.107 Sakoulas G et al. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus 

strains. Clin Infect Dis 2008;46(suppl. 5):S360-7. 

2B.108 Pillai SK et al. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus 

aureus. Clin Infect Dis 2009;49:1169-74. 

2B.109 Howden BP et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate 

and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory 

detection and clinical implications. Clin Microbiol Rev 2010;23:99-139. 

2B.110 Nonhoff C et al. Low prevalence of methicillin resistant Staphylococcus aureus with reduced susceptibility 

to glycopeptides in Belgian hospitals. Clin Microbiol Infect 2005;11:214-20. 

2B.111 Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol 

Infect 2008;14(suppl. 2):3-9. 

2B.112 Chang S et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance 

gene. N Engl J Med 2003;348:1342-7. 

2B.113 Weinstein MP et al. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus 

pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009;48: 

1596-600. 

2B.114 Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect

2009;15(suppl. 3):7-11. 

2B.115 Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev 


2B.116 Vergison A et al. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive 

surveillance is not enough. Pediatrics 2006;118:e801-9. 

4A.1 Price VE et al. The prevention and management of infections in children with asplenia or hyposplenia. 


4A.2 Kyaw MH et al. Evaluation of severe infection and survival after splenectomy. Am J Med 2006;119: 

276.e1-7. 

4A.3 American Academy of Pediatrics Committee on Infectious Diseases. Children with asplenia. Red 

Book 2009;28:84-6. 

4A.4 American Academy of Pediatrics Committee on Infectious Diseases. Haemophilus influenzae infections. 

Red Book 2009;28:314-21. 

4A.5 American Academy of Pediatrics Committee on Infectious Diseases. Meningococcal infections. Red 

Book 2009;28:455-63. 

4A.6 American Academy of Pediatrics Committee on Infectious Diseases. Pneumococcal infections. Red 

Book 2009;28:524-35. 

4A.7 American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations 

for the prevention of pneumococcal infections, including the use of pneumococcal conjugate 

vaccine, pneumococcal polysaccharide vaccine and antibiotic prophylaxis. Pediatrics 2000;106:362- 

6. 

4A.8 American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations 

for the prevention of Streptococcus pneumoniae infections in infants and children, use of 13-valent 

pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine 

(PPSV23). Pediatrics 2010;126:186-90. 

4A.9 Morgan M et al. Dog bites. Br Med J 2007;334:313-7. 

4A.10 Nakamura Y et al. Use of appropriate antimicrobials in wound management. Emerg Med Clin North 

Am 2007;25:159-76. 

4A.11 O‘Donnell AE. Bronchiectasis. Chest 2008;134:815-23. 

4A.12 Church D et al. Burn wound infections. Clin Microbiol Rev 2006;19:403-34. 

4A.13 Benson A et al. Burns. Br Med J 2006;332:649-52. 

4A.14 DeSanti L. Pathophysiology and current management of burn injury. Adv Skin Wound Care 2005; 

18:323-32. 

4A.15 D‘Avignon LC et al. Prevention and management of infections associated with burns in the combat 

casualty. J Trauma 2008;64(suppl.):S277-86. 

4A.16 Sharma BR. Infection in patients with severe burns: causes and prevention thereof. Infect Dis Clin 

North Am 2007;21:745-59. 

4A.17 Gomez M et al. Improved survival following thermal injury in adult patients treated at a regional burn 

center. J Burn Care Res 2008;29:130-7. 

4A.18 Avni T et al. Prophylactic antibiotics for burns patients: systematic review and meta-analysis. Br Med 

J 2010;340:c241. 

4A.19 Garcia-Tsao G et al. Prevention and management of gastroesophageal varices and variceal hemorrhage 

in cirrhosis. Hepatology 2007;46:922-38. 

4A.20 Soares-Weiser K et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. 

Cochrane Database Syst Rev 2002;2:CD002907. 

4A.21 Steffen R et al. Cholera: assessing the risk to travellers and identifying methods of protection. Travel 

Med Infect Dis 2003;1:80-8. 

4A.22 Starner TD et al. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to 

eradicate bacteria. Ann Intern Med 2005;143:816-22. 

4A.23 Ratjen F et al. Cystic fibrosis. Lancet 2003;361:681-9. 

4A.24 Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-70. 

4A.25 Gibson RL et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J 


4A.26 Ramsey BW et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N 

Engl J Med 1999;340:23-30. 

4A.27 Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001;120(3 

suppl.):107S-13S. 

4A.28 Shlim DR. Update in traveler‘s diarrhea. Infect Dis Clin North Am 2005;19:137-49. 

4A.29 Diemert DJ. Prevention and self-treatment of traveler‘s diarrhea. Clin Microbiol Rev 2006;19:583- 

94. 

4A.30 DuPont HL. Therapy for and prevention of traveler‘s diarrhea. Clin Infect Dis 2007;45(suppl. 1):S78- 

84. 

4A.31 Leggat PA et al. Travellers‘ diarrhoea: health advice for travellers. Travel Med Infect Dis 2004;2:17- 

22. 

4A.32 Rendi-Wagner P et al. Drug prophylaxis for traveler‘s diarrhea. Clin Infect Dis 2002;34:628-33. 

4A.33 Jaffer Y et al. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheterrelated 

infection. Am J Kidney Dis 2008;51:233-41. 

4A.34 Barraclough KA et al. Prevention of access-related infection in dialysis. Expert Rev Anti Infect Ther 

2009;7:1185-200. 

4A.35 Labriola L et al. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: 

a meta-analysis of prospective randomized trials. Nephrol Dial Transplant 2008;23:1666-72. 

4A.36 Kallen AJ et al. Preventing infections in patients undergoing hemodialysis. Expert Rev Anti Infect 

Ther 2010;8:643-55. 

4A.37 Yahav D et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular 

catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, 

controlled trials. Clin Infect Dis 2008;47:83-93. 

4A.38 James MT et al. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. 

Ann Intern Med 2008;148:596-605. 

4A.39 Berbari EF et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based 

prospective case-control study. Clin Infect Dis 2010;50:8-16. 

4A.40 Zimmerli W et al. Antibiotics for prevention of periprosthetic joint infection following dentistry: time to 

focus on data. Clin Infect Dis 2010;50:17-9.

4A.41 Edwards CN et al. Prevention and treatment of leptospirosis. Expert Rev Anti Infect Ther 2004;2: 

293-8. 

4A.42 Bharti AR et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003;3: 

757-71. 

4A.43 Clark RP et al. Prevention of Lyme disease and other tick-borne infections. Infect Dis Clin North Am 

2008;22:381-96. 

4A.44 Nadelman RB et al. Reinfection in patients with Lyme disease. Clin Infect Dis 2007;45:1032-8. 

4A.45 Wormser GP et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic 



4A.46 Nadelman RB et al. Prophylaxis with single dose doxycycline for the prevention of Lyme disease after 

an Ixodes scapularis tick bite. N Engl J Med 2001;345:79-84. 

4A.47 Shapiro ED. Doxycycline for tick bites, not for everyone. N Engl J Med 2001;345:133-4. 

4A.48 American Academy of Pediatrics Committee on Infectious Diseases. Prevention of Lyme disease. 

Pediatrics 2000;105:142-7. 

4A.49 Gammons M et al. Tick removal. Am Fam Physician 2002;66:643-5. 

4A.50 American Academy of Pediatrics Committee on Infectious Diseases. Haemophilus influenzae infections. 

Red Book 2009;28:314-21. 

4A.51 Girgis N et al. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by 

Neisseria meningitidis. Pediatr Infect Dis J 1998;17:816-9. 

4A.52 Girgis N et al. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by 

Neisseria meningitidis. Pediatr Infect Dis J 1998;17:816-9. 

4A.53 American Academy of Pediatrics Committee on Infectious Diseases. Meningococcal infections. Red 

Book 2009;28:455-63. 

4A.54 Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. 

Morb Mortal Wkly Rep 2005;54(RR-7):1-21. 

4A.55 Memish ZA. Meningococcal disease and travel. Clin Infect Dis 2002;34:84-90. 

4A.56 Simmons G et al. Equivalence of ceftriaxone and rifampicin in eliminating nasopharyngeal carriage of 

serogroup B Neisseria meningitidis. J Antimicrob Chemother 2000;45:909-11. 

4A.57 Fraser A et al. Prophylactic use of antibiotics for prevention of meningococcal infections: review and 

meta-analysis of randomised trials. Eur J Clin Microbiol Infect Dis 2005;24:172-81. 

4A.58 Gardner P. Prevention of meningococcal disease. N Engl J Med 2006;355:1466-73. 

4A.59 Fraser A et al. Antibiotics for preventing meningococcal disease. Cochrane Database Syst Rev 

2006;4:CD004785. 

4A.60 Bucaneve G et al. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. 

Eur J Cancer Suppl 2007;5:5-12. 

4A.61 Schlesinger A et al. Infection-control interventions for cancer patients after chemotherapy: a systematic 

review and meta-analysis. Lancet Infect Dis 2009;9:97-107. 

4A.62 Gafter-Gvili A et al. Meta-analysis: antibiotic propylaxis reduces mortality in neutropenic patients. Ann 

Intern Med 2005;142:979-95. 

4A.63 Bucaneve G et al. Levofloxacin to prevent bacterial infections in patients with cancer and neutropenia. 

N Engl J Med 2005;353:977-87. 

4A.64 Cullen M et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl 

J Med 2005;353:988-98. 

4A.65 Reuter S et al. Impact of fluoroquinolone prophylaxis on reduced infection related mortality among patients 

with neutropenia and hematologic malignancies. Clin Infect Dis 2005;40:1087-93. 

4A.66 Zinner SH. Fluoroquinolone prophylaxis in patients with neutropenia. Clin Infect Dis 2005;40:1094-5. 

4A.67 Cornely OA et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. 

N Engl J Med 2007;356:348-59. 

4A.68 Ullmann AJ et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N 

Engl J Med 2007;356:335-47. 

4A.69 Bai Y et al. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute 

necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol 

2008;103:104-10. 

4A.70 Nathens AB et al. Management of the critically ill patient with severe acute panceratitis. Crit Care 

Med 2004;32:2524-36. 

4A.71 Dellinger EP et al. Early antibiotic treatment for severe acute necrotizing pancreatitis. A randomized, 

double-blind, placebo-controlled trial. Ann Surg 2007;245:674-83. 

4A.72 Villatoro E et al. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute 

pancreatitis. Cochrane Database Syst Rev 2006;4:CD002941. 

4A.73 Isenmann R et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: 

a placebo controlled, double blind trial. Gastroenterology 2004;126:997-1004. 

4A.74 Isenmann R et al. Prevention of infectious complications in severe acute pancreatitis with systemic 

antibiotics: where are we now? Expert Rev Anti Infect Ther 2005;3:393-401. 

4A.75 Fernández J et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome 

and improves survival in cirrhosis. Gastroenterology 2007;133:818-24. 

4A.76 Terg R et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized 

placebo-controlled study. J Hepatol 2008;48:774-9. 

4A.77 Pastore Celentano L et al. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005;24:761-5. 

4A.78 Altunaiji S et al. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007;3: 

CD004404. 

4A.79 Singh M et al. Whooping cough: the current scene. Chest 2006;130:1547-53. 

4A.80 Watanabe M et al. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert 


4A.81 Centers for Disease Control and Prevention (CDC). Recommended antimicrobial agents for the treatment 

and postexposure prophylaxis of pertussis. Morb Mortal Wkly Rep 2005;54(RR-14):1-16. 

4A.82 Wirsing von König CH et al. Pertussis of adults and infants. Lancet Infect Dis 2002;2:744-50. 

4A.83 Hewlett EL et al. Pertussis – not just for kids. N Engl J Med 2005;352:1215-22. 

4A.84 American Academy of Pediatrics Committee on Infectious Diseases. Pertussis (whooping cough). 

Red Book 2009;28:504-19. 

4A.85 Forsyth K. Pertussis, still a formidable foe. Clin Infect Dis 2007;45:1487-91. 

4A.86 Mattoo S et al. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections 

due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326-

82. 

4A.87 de Smet AM et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J 

Med 2009;360:20-31. 

4A.88 Wilhelm J et al. Selective decontamination of the digestive tract and oropharynx: new findings for an 

old approach still under discussion. Expert Rev Anti Infect Ther 2009;7:399-402. 

4A.89 Coffin SE et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect 


4A.90 Craven DE. Preventing ventilator-associated pneumonia in adults: sowing seeds of change. Chest 

2006;130:251-60. 

4A.91 Collard HR et al. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. 

Ann Intern Med 2003;138:494-501. 

4A.92 Chan EY et al. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: 

systematic review and meta-analysis. Br Med J 2007;334:889-99. 

4A.93 de Smet AM et al. Selective decontamination of the digestive tract. Curr Opin Infect Dis 2008;21: 

179-83. 

4A.94 Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit 

Care Med 2004;32:1396-405. 

4A.956 Dodek P et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated 

pneumonia. Ann Intern Med 2004;141:305-13. 

4A.96 Koeman M et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated 

pneumonia. Am J Respir Crit Care Med 2006;173:1348-55. 

4A.97 Chan EY et al. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: 

systematic review and meta-analysis. Br Med J 2007;334:889-99. 

4A.98 Wip C et al. Bundles to prevent ventilator-associated pneumonia: how valuable are they? Curr Opin 

Infect Dis 2009;22:159-66. 

4A.99 Carapetis JR et al. Acute rheumatic fever. Lancet 2005;366:155-68. 

4A.100 Gilad J et al. Prevention of catheter-related bloodstream infections in the neonatal intensive care setting. 


4A.101 Bhutta A et al. Reduction of bloodstream infections associated with catheters in paediatric intensive 

care unit: stepwise approach. Br Med J 2007;334:362-5. 

4A.102 Pronovost P et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N 

Engl J Med 2006;355:2725-32. 

4A.103 Wenzel RP et al. Team-based prevention of catheter-related infections. N Engl J Med 2006;355: 

2781-3. 

4A.104 Raad I et al. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. 


4A.105 Gilad J et al. Prevention of catheter-related bloodstream infections in the neonatal intensive care unit 

setting. Expert Rev Anti Infect Ther 2006;4:861-73. 

4A.106 Bhutta A et al. Reduction of bloodstream infections associated with catheters in paediatric intensive 

care unit: stepwise approach. Br Med J 2007;334:362-5. 

4A.107 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention of intravascular catheter-related 

infections. Morb Mortal Wkly Rep 2002;51(RR-10):1-29. 

4A.108 Crnich CJ et al. The promise of novel technology for the prevention of intravascular device-related 

bloodstream infection. Part I: pathogenesis and short-term devices. Clin Infect Dis 2002;34:1232-42. 

4A.109 Crnich CJ et al. The promise of novel technology for the prevention of intravascular device-related 

bloodstream infection. Part II: long-term devices. Clin Infect Dis 2002;34:1362-8. 

4A.110 Marshall J et al. Strategies to prevent central line-associated bloodstream infections in acute care 

hospitals. Infect Control Hosp Epidemiol 2008;29(suppl. 1):S22-30. 

4A.111 O‘Grady NP et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect 

Dis 2002;35:1281-307. 

4A.112 McGee DC et al. Preventing complications of central venous catheterization. N Engl J Med 2003; 

348:1123-33. 

4A.113 Echevarria-Guanilo ME et al. Preventing infections due to intravascular catheters in burn victims. Expert 


4A.114 Rupp ME et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver 

sulfadiazine on central-catheter related infections. A randomized, controlled trial. Ann Intern Med 

2005;143:570. 

4A.115 Kaufman M et al. Care of the adolescent sexual assault victim. Pediatrics 2008;122:462-70. 

4A.116 Centers for Disease Control and prevention (CDC). Sexually transmitted diseases. Treatment guidelines 


4A.117 Beck-Sagué CM et al. Sexually transmitted diseases in abused children and adolescent and adult victims 

of rape: review of selected literature. Clin Infect Dis 1999;28(suppl. 1):S74-83. 

4A.118 Welch J et al. Rape and sexual assault. Br Med J 2007;334:1154-8. 

4A.119 Low N et al. Global control of sexually transmitted infections. Lancet 2006;368:2001-16. 

4A.120 Golden MR et al. Innovative approaches to the prevention and control of bacterial sexually transmitted 

infections. Infect Dis Clin North Am 2005;19:513-40. 

4A.121 American Academy of Pediatrics Committee on Infectious Diseases. Sexual victimization and STIs. 

Red Book 2009;28:167-72. 

4A.122 Groep ter Opsporing, Studie en Preventie van de Infecties in de Ziekenhuizen (GOSPIZ). Richtlijnen 

voor de beheersing en preventie van overdracht van methicilline-resistente Staphylococcus aureus 

(MRSA) in Belgische ziekenhuizen. Available at: http://www.belgian infectioncontrolsociety.be/index. 

php?page=mrsa&hl=nl_NL. Accessed on August 5 th 2010. 

4A.123 Groupement pour le Dépistage, l‘Etude et la Prévention des Infections Hospitalières (GDEPIH). Recommandations 

pour le contrôle et la prévention de la transmission de Staphylococcus aureus résistant 

à la méthicilline dans les hôpitaux belges. Available at: http://www. belgian infectioncontrolsocie 

ty. be/index.php?page=mrsa&hl=fr_FR. Accessed on August 5 th 210. 

4A.124 Groep ter Opsporing, Studie en Preventie van de Infecties in de Ziekenhuizen (GOSPIZ). Richtlijnen 

ter preventie van overdracht van methicilline-resistente Staphylococcus aureus (MRSA) in woon- en 

zorgcentra. Available at: http://www.belgian infection controlsociety.be/ index.php?page=mrsa&hl=nl

_NL. Accessed on August 5 th 2010. 

4A.125 Groupement pour le Dépistage, l‘Etude et la Prévention des Infections Hospitalières (GDEPIH). Mesures 

préventives de la transmission du Staphylococcus aureus résistant à la méthicilline (MRSA) 

dans les maisons de repos et de soins. Available at: http://www. belgian infectioncontrolsociety.be/in 

dex.php?page=mrsa&hl=fr_FR. Accessed on August 5 th 210. 

4A.126 Wiese-Posselt M et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive 

methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002- 

2005. Clin Infect Dis 2007;44:e88-95. 

4A.127 van Rijen MM et al. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical 

patients with nasal carriage: a systematic review. J Antimicrob Chemother 2008;61:254-61. 

4A.128 Coia JE et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus 

(MRSA) in healthcare facilities. J Hosp Infect 2006;63(suppl. 1):S1-44. 

4A.129 Loveday HP et al. A systematic review of the evidence for interventions for the prevention and control 

of methicillin resistant Staphylococcus aureus (1996-2004): report to the Joint MRSA Working party 

(subgroup A). J Hosp Infect 2006;63(suppl. 1):S45-70. 

4A.130 Simor AE et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, 

and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus 

aureus colonization. Clin Infect Dis 2007;44:178-85. 

4A.131 Hammerlaan AS et al. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic 

review. Clin Infect Dis 2009;48:922-30. 

4A.132 Coates T et al. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses 

and future prospects. J Antimicrob Chemother 2009;64:9-15. 

4A.133 Gould FK et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus 

aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009;63:849-61. 

4A.134 Calfee DP et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in 

acute care hospitals. Infect Control Hosp Epidemiol 2008;29(suppl. 1):S62-80. 

4A.135 Wertheim HF et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in 

non surgical patients. Ann Intern Med 2004;140:419-25. 

4A.136 Ellis MW et al. Targeted intranasal mupirocin to prevent colonization and infection by community-acquired 

methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled 

trial. Antimicrob Agents Chemother 2007;51:3591-8. 

4A.137 Bode LG et al. Preventing surgical site infections in nasal carriers of Staphylococcus aureus. N Engl 

J Med 2010;362:9-17. 

4A.138 van Rijen MM et al. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical 


4A.139 Belgian Health Council. Prevention of perinatal group B streptococcal infections. Available at: 

http://www.health.belgium.be/internet2Prd/groups/public/@public/@shc/documents/ie2divers/444839 

1.pdf. Accessed on August 5th 2010. 

4A.140 Edwards MS. Issues of antimicrobial resistance in group B Streptococcus in the era of intrapartum 

antibiotic prophylaxis. Semin Pediatr Infect Dis 2006;17:149-52. 

4A.141 Baltimore RS. Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin 

Perinatol 2007;31:33-8. 

4A.142 Apgar BS et al. Prevention of group B streptococcal disease in the newborn. Am Fam Physician 

2005;71:903-10. 

4A.143 Puopolo KM et al. Early onset group B streptococcal disease in the era of maternal screening. Pediatrics 

2005;115:1240-6. 

4A.144 American Academy of Pediatrics Committee on Infectious Diseases. Group B streptococcal infections. 

Red Book 2009;28:628-34. 

4A.145 American College of Obstetricians and Gynecologists. Premature rupture of membranes. Obstet Gynecol 

2007;109:1007-19. 

4A.146 Ledger WJ. Prophylactic antibiotics in obstetrics – gynecology: a current asset, a future liability? Expert 


4A.147 Moore MR et al. Effects of intrapartum antimicrobial prophylaxis for prevention of group B streptococcal 

disease on the incidence and ecology of early onset neonatal sepsis. Lancet Infect Dis 2003;3: 

201-13. 

4A.148 Hooton TM et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in 



4A.149 Trautner BW. Management of catheter-associated urinary tract infection. Curr Opin Infect Dis 2010; 

23:76-82. 

4A.150 Lo E et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. 

Infect Control Hosp Epidemiol 2008;29(suppl. 1):S41-50. 

4A.151 Jepson RG et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 

2008;1:CD001321. 

4A.152 Guay DR. Cranberry and urinary tract infections. Drugs 2009;69:775-807. 

4A.153 McMurdo ME et al. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? 

A randomized controlled trial in older women. J Antimicrob Chemother 2009;63:389-95. 

4A.154 Cimolai N et al. The cranberry and the urinary tract. Eur J Clin Microbiol Infect Dis 2007;26:767-76. 

4A.155 American Academy of Pediatrics Committee on Quality Improvement Subcommittee on Urinary Tract 

Infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection 

in febrile infants and young children. Pediatrics 1999;103:843-52. 

4A.156 National Institute for Health and Clinical Excellence. Urinary tract infection in children; diagnosis, 

treatment and long-term management. Available at: http://www.nice.org.uk/nicemedia/pdf/CG54full 

guideline.pdf. Accessed on August 5th 2010. 

4A.157 Hodson EM et al. Interventions for primary vesicoureteric reflux. Cochrane Database Syst Rev 

2007; 3:CD001532. 

4A.158 Conway PH et al. Recurrent urinary tract infections in children. Risk factors and association with prophylactic 

antimicrobials. J Am Med Assoc 2007;298:179-186. 

4A.159 Garin EH et al. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis

after acute pyelonephritis: a multicentre, randomized, controlled study. Pediatrics 2006;117:626-32. 

4A.160 Hayashi Y et al. Is antibiotic prophylaxis effective in preventing urinary tract infection in patients with 

vesicoureteral reflux. Expert Rev Anti Infect Ther 2010;8:51-8. 

4A.161 Williams G et al. Prevention of recurrent urinary tract infection in children. Curr Opin Infect Dis 2009; 

22:72-6. 

4A.162 Williams GJ et al. Long-term antibiotics for preventing recurrent urinary tract infection in children. 

Cochrane Database Syst Rev 2006;3:CD001534. 

4A.163 Roussey-Kesler G et al. Antibiotic prophylaxis for the prevention of urinary tract infection in children 

with low grade vesicoureteral reflux: results from a prospective randomized study. J Urol 2008;179: 

674-9. 

4A.164 Montini G et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, 

controlled, noninferiority trial. Pediatrics 2008;122:1064-71. 

4A.165 Craig JC et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med 

2009;361:1748-59. 

4A.166 Pennesi M et al. Is antibiotic prophylaxis in children with vesicoureteric reflux effective in preventing 

pyelonephritis and renal scars? A randomized controlled trial. Pediatrics 2008;121:e1489-94. 

4A.167 Conway PH et al. Recurrent urinary tract infections in children. Risk factors and association with 

prophylactic antimicrobials. J Am Med Assoc 2007;298:179-86. 

4A.168 Garin EH et al. Clinical significance of primary vesicoureteric reflux and urinary antibiotic prophylaxis 

after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 2006;117:626-32. 

4A.169 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic 

infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 

207. 

4A.170 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of 


58(RR-11):1-167. 

4B.1 Anderson DJ et al. Strategies to prevent surgical site infections in acute care hospitals. Infect 


4B.2 Leaper D et al. Prevention and treatment of surgical site infection: summary of NICE guidance. Br 

Med J 2008;337:1049-51. 

4B.3 Uçkay I et al. Preventing surgical site infections. Expert Rev Anti Infect Ther 2010;8:657-70. 

4B.4 Casey AL et al. Progress in the prevention of surgical site infection. Curr Opin Infect Dis 2008;22: 

370-5. 

4B.5 Hedrick TL et al. Prevention of surgical site infections. Expert Rev Anti Infect Ther 2006;4:223-33. 

4B.6 Bratzler DW et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgeon 

Infection Prevention Project. Clin Infect Dis 2004;38:1706-15. 

4B.7 American Academy of Pediatrics Committee on Infectious Diseases. Antimicrobial prophylaxis in pediatric 

surgical patients. Red Book 2009;28:824-8. 

4B.8 Bode LG et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl 

J Med 2010;362:9-17. 

4B.9 van Rijen MM et al. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical 


4B.10 Sessler DI et al. Nonpharmacological prevention of surgical wound infections.Clin Infect Dis 2002; 

35:1397-404. 

4B.11 Belda FJ et al. Supplemental peri-operative oxygen and the risk of surgical wound infection. J Am 

Med Assoc 2005;294:2035-42. 

4B.12 Qotan M et al. Perioperative supplemental oxygen therapy and surgical site infection. A meta-analysis 

of randomized controlled trials. Arch Surg 2009;144:359-66. 

4B.13 Meyhoff CS et al. Effect of high perioperative oxygen fraction on surgical site infection and pulmonary 

complications after abdominal surgery the PROXI randomized clinical trial. J Am Med Assoc 2009; 

302:1453-50. 

4B.14 Kriaras I et al. Evolution of antimicrobial prophylaxis in cardiovascular surgery. Eur J Cardiothorac 

Surg 2000;18:440-6. 

4B.15 Segers P et al. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx 

and oropharynx with chlorhexidine gluconate. A randomized controlled trial. J Am Med Assoc 

2006;296:2460-6. 

4B.16 Da Costa A et al. Antibiotic prophylaxis for permanent pacemaker implantation. A meta-analysis. Circulation 

1998;97:1796-1801. 

4B.17 American Society for Gastrointestinal Endoscopy. Antibiotic prophylaxis for GI endoscopy. Gastrointest 

Endosc 2008;67:791-8. 

4B.18 Edmiston CE et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve 

therapeutic levels? Surgery 2004;136:738-47. 

4B.19 Sharma VK et al. Meta-analysis of randomized, controlled trials of antibiotic prophylaxis before percutaneous 

endoscopic gastrostomy. Am J Gastroenterol 2000;95:3133-6. 

4B.20 Guenaga KK et al. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database 

Syst Rev 2009;1:CD001544. 

4B.21 Sanchez-Manuel FJ et al. Antibiotic prophylaxis for hernia repair. Cochrane Database Syst Rev 

2007;3:CD003769. 

4B.22 American College of Obstetricians and Gynecologists. Antibiotic prophylaxis for gynecologic procedures. 

Obstet Gynecol 2009;113:1180-9. 

4B.23 Smaill FM et al. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean 

section. Cochrane Database Syst Rev 2010;1:CD007482. 

4B.24 Ratilal B et al. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. Cochrane 

Database Syst Rev 2006;3:CD005365. 

4B.25 British Society for Antimicrobial Chemotherapy Infection in Neurosurgery Working Party. Antimicrobial 

prophylaxis in neurosurgery and after head injury. Lancet 1994;344:1547-51. 

4B.26 Bayston R et al. Use of antibiotics in penetrating craniocerebral injuries. Lancet 2000;355:1813-7. 

4B.27 Ciulla TA et al. Bacterial endophthalmitis prophylaxis for cataract surgery. An evidence based update. 

Ophthalmology 2002;109:13-26. 

4B.28 Barry P et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery. 

Preliminary report of principal results from a European multicenter study. J Cataract Refract Surg

2006;32:407-10. 

4B.29 Yu-Wai-Man P et al. Efficacy of intracameral and subconjunctival cefuroxime in preventing endophthalmitis 

after cataract surgery. J Cataract Refract Surg 2008;34:447-51. 

4B.30 Yeh S et al. Current trends in the management of intraocular foreign bodies. Curr Opin Ophthalmol 

2008;19:225-33. 

4B.31 Marculescu CE et al. Antibiotic prophylaxis in orthopedic prosthetic surgery. Infect Dis Clin North 

Am 2005;19:931-46. 

4B.32 van Kasteren ME et al. Antibiotic prophylaxis and the risk of surgical site infections following total hip 

arthroplasty: timely administration is the most important factor. Clin Infect Dis 2007;44:921-7. 

4B.33 Solomkin JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and 

children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. 


4B.34 Bootsma AM et al. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol 2008; 

54:1270-86. 

4B.35 Wolf JS et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 

2008;178:1379-90. 

4C.1 Wilson W et al. Prevention of infective endocarditis. Guidelines of the American Heart Association 

Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease 

in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, 

and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 

2007;116:1736-54. 

4C.2 Nishimura RA et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on 

infective endocarditis. A report of the American College of Cardiology/American Heart Association 

Task Force on Practice Guidelines. Circulation 2008;118:887-96. 

4C.3 Shanson D. New British and American guidelines for the antibiotic prophylaxis of infective endocarditis: 

do the changes make sense? A critical review. Curr Opin Infect Dis 2008;21:191-9. 

4C.4 Habib G et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new 

version 2009). Eur Heart J 2009;30:2369-413. 

4D.1 Kabura L et al. Intrathecal vs. intramuscular administration of human antitetanus immunoglobulin or 

equine tetanus antitoxin in the treatment of tetanus: a meta-analysis. Trop Med Int Health 2006;11: 

1075-81. 

4D.2 Brook I. Current concepts in the management of Clostridum tetani infection. Expert Rev Anti Infect 

Ther 2008;6:327-36. 

5A.1 Pai MP et al. Antimicrobial dosing considerations in obese adult patients: insights from the Society of 

Infectious Diseases Pharmacists. Pharmacotherapy 2007;27:1081-91. 

5A.2 Erstad BL. Dosing of medications in morbidly obese patients in the intensive care setting. Intensive 

Care Med 2004:30:18-32. 

5A.3 Wurtz R et al. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-8. 

5A.4 Falagas ME et al. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 

2010;375:248-51. 

5A.5 Udy AA et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin 

Pharmacokinet 2010;49:1-16. 

5A.6 Stalam M et al. Antibiotic agents in the elderly. Infect Dis Clin North Am 2004;18:533-49. 

5A.7 Segal AR et al. Cutaneous reactions to drugs in children. Pediatrics 2007;120:e1082-96. 

5A.8 Kaye D. Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect 


5A.9 Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 2003;17: 

503-28. 

5A.10 Drusano GL et al. Back to the future: using aminoglycosides again and how to dose them optimally. 


5A.11 Leibovici L et al. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob 

Chemother 2009;63:246-51. 

5A.12 Jacobs MR. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections 

based on pharmacodynamic principles. Expert Rev Anti Infect Ther 2005;3:353-60. 

5A.13 Martin SI et al. Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin North 

Am 2004:18:603-19. 

5A.14 Maertens J et al. False positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004; 

39:289-90. 

5A.15 Hoorn EJ et al. Severe hypokalaemia caused by flucloxacillin. J Antimicrob Chemother 2008;61: 

1396-8. 

5A.16 Lodise TP et al. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications 

of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63. 

5A.17 Gin A et al. Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev Anti 

In-fect Ther 2007;5:365-83. 

5A.18 Viscoli C et al. False positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. 


5A.19 Adam O et al. Treatment with piperacillin-tazobactam and false positive Aspergillus galactomannan 

antigen test results for patients with hematological malignancies. Clin Infect Dis 2004;38:917-20. 

5A.20 Maertens J et al. False positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004; 

39:289-90. 

5A.21 Walsh TJ et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam 

and correlations between in vitro, in vivo and clinical properties of the drug antigen interaction. J Clin 

Microbiol 2004;42:4744-8. 

5A.22 Peralta FG et al. Incidence of neutropenia during treatment of bone related infections with piperacillintazobactam. 


5A.23 Livermore DM et al. Temocillin revived. J Antimicrob Chemother 2009;63:243-5. 

5A.24 De Jongh R et al. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin

for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic 

studies and breakpoint selection. J Antimicrob Chemother 2008;61:382-8. 

5A.25 Gerding DN. Clindamycin, cephalosporins, fluoroquinolones and Clostridium difficile associated diarrhea: 

this is an antimicrobial resistance problem. Clin Infect Dis 2004;38:646-8. 

5A.26 Romano A et al. Crossreactivity and tolerability of cephalosporins in patients with immediate hypersensitivity 

to penicillins. Ann Intern Med 2004;141:16-22. 

5A.27 Endimiani A et al. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert 


5A.28 Yahav D et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect 

Dis 2007;7:338-48. 

5A.29 Nguyen TD et al. Cefepime therapy and all-cause mortality. Clin Infect Dis 2009;48:902-4. 

5A.30 Gomez L et al. Mortality associated with cefepime therapy among neutropenic patients. Clin Infect 

Dis 2009;48:987. 

5A.31 Martin SI et al. Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin North 

Am 2004:18:603-19. 

5A.32 Chatellier D et al. Cefepime induced neurotoxicity: an underestimated complication of antibiotherapy 

in patients with acute renal failure. Crit Care Med 2002;28:214-7. 

5A.33 Alou L et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion 

with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob 

Chemother 2005;55:209-13. 

5A.34 Roberts JA et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? 

A randomized controlled pilot study. J Antimicrob Chemother 2007;59:285-91. 

5A.35 Centers for Disease Control and Prevention (CDC). Ceftriaxone associated biliary complications of 

treatment of suspected disseminated Lyme disease. Morb Mortal Wkly Rep 1993;42:39-42. 

5A.36 Prescott WA et al. Incidence of carbapenem associated allergic type reactions among patients with 

versus patients without a reported penicillin allergy. Clin Infect Dis 2004;38:1102-7. 

5A.37 Sodhi M et al. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob 

Chemother 2004;54:1155-7. 

5A.38 Romano A et al. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 

2006;354:2835-7. 

5A.39 Roman A et al. Tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. 

Ann Intern Med 2007;146:266-9. 

5A.40 Frumin J et al. Allergic cross-sensitivity between penicillin, carbapenem and monobactam antibiotics: 


5A.41 Frumin J et al. Allergic cross-sensitivity between penicillin, carbapenem and monobactam antibiotics: 


5A.42 Patriarca G et al. Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to beta-lactams. 

Int J Immunopathol Pharmacol 2008;21:375-9. 

5A.43 Kattan JN et al. New developments in carbapenems. Clin Microbiol Infect 2008;14:1102-11. 

5A.44 Adkinson NF et al. Cross-allergenicity and immunogenicity of aztreonam. Rev Infect Dis 1985;7 

(suppl. 4):S613-21. 

5A.45 European Medicines Agency (EMA). European assessment report (EPAR). Doribax TM , summary of 

product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR 

_-_Product_Information/human/000891/WC500037148.pdf. Accessed on August 4th 2010. 

5A.46 Paterson DL et al. Doripenem. Clin Infect Dis 2009;49:291-8. 

5A.47 Dedhia HV et al. Doripenem in clinical practice. Expert Rev Anti Infect Ther 2009;7:507-14. 

5A.48 Keam SJ. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 2008;68: 

2021-57. 

5A.49 Matthews SJ et al. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther 

2009;31:42-63. 

5A.50 Livermore DM. Doripenem: antimicrobial profile and clinical potential. Diagn Microbiol Infect Dis 

2009; 63:455-8. 

5A.51 Zhanel G et al. Overview of seizure-inducing potential of doripenem. Drug Saf 2009;32:709-16. 

5A.52 Berthoin K et al. Stability of meropenem and doripenem solutions for administration by continuous 

infusion. J Antimicrob Chemother 2010;65:1073-5. 

5A.53 Lamoth F et al. Reassessment of recommended imipenem doses in febrile neutropenic patients with 

hematological malignancies. Antimicrob Agents Chemother 2009;53:785-7. 

5A.54 Rodloff AC et al. Two decades of imipenem therapy. J Antimicrob Chemother 2006;58:916-29. 

5A.55 Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. 


5A.56 Koppel BS et al. Seizures in the critically ill: the role of imipenem. Epilepsia 2001;42:1590-3. 

5A.57 Norrby SR. Carbapenems in serious infections, a risk benefit assessment. Drug Saf 2000;22:191-4. 

5A.58 Heikkilä A et al. Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob 


5A.59 Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008; 

47(suppl. 1):S32-40. 

5A.60 Mohr JF. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. 


5A.61 Norrby SR et al. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. 

Scand J Infect Dis 1999;31:3-10. 

5A.62 Norrby SR. Carbapenems in serious infections, a risk benefit assessment. Drug Saf 2000;22:191-4. 

5A.63 Berthoin K et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. 


5A.64 Roberts JA et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: 

intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous 

tissue distribution. J Antimicrob Chemother 2009;64:142-50. 

5A.65 Jaruratanasirikul S et al. Comparison of the pharmacodynamics of meropenem in patients with ventilator 

associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob


5A.66 Krueger WA et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem 

administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob 


5A.67 Kuti JL et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy 

for meropenem. J Clin Pharmacol 2003;43:1116-23. 

5A.68 Sendzik J et al. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical 

data. Int J Antimicrob Agents 2009;33:194-200. 

5A.69 American Academy of Pediatrics Committee on Infectious Diseases. The use of systemic fluoroquinolones. 

Pediatrics 2006;118:1287-92. 

5A.70 Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect 

Ther 2006;4:853-60. 

5A.71 Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19: 

617-28. 

5A.72 Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr 

Infect Dis J 2007;26:865-7. 

5A.73 Dagan R et al. Potential role of fluoroquinolone therapy in childhood otitis media. Pediatr Infect Dis J 

2004;23:390-8. 

5A.74 Gendrel D et al. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet 

Infect Dis 2003;3:537-46. 

5A.75 Zacher JL et al. False positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother 

2004;38:1525-8. 

5A.76 Baden LR et al. Quinolones and false positive urine screening for opiates by immunoassay technology. 

J Am Med Assoc 2001;286:3115-9. 

5A.77 Rubinstein E et al. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002;49:593-6. 

5A.78 Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, 

gatifloxacin and moxifloxacin. Pharmacotherapy 2001;12:1468-72. 

5A.79 Owens RC et al. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect 

Dis 2006;43:1603-11. 

5A.80 van der Linden PD et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous 

reports in the period 1988 to 1998. Arthritis Care Res 2001;45:235-9. 

5A.81 van der Linden PD et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use, 

especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003;163:1801-7. 

5A.82 Khaliq Y et al. Fluoroquinolone associated tendinopathy: a critical review of the literature. Clin Infect 

Dis 2003;36:1404-10. 

5A.83 Van Bambeke F et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80. 

5A.84 Sode J et al. Use of fluoroquinolone and risk of Achilles tendon rupture: a population-based cohort 

study. Eur J Clin Pharmacol 2007;63:499-503. 

5A.85 Chhajed PN et al. Achilles tendon disease in lung transplant recipients: association with ciprofloxacin. 

Eur Respir J 2002;19:469-71. 

5A.86 Fish DN. Levofloxacin: update and perspectives on one of the original ―respiratory quinolones‖. Expert 


5A.87 Kelesidis T et al. Levofloxacin-induced hypoglycemia: a rare but life-threatening side effect of a widely 

used antibiotic. Am J Med 2009;122:e3-4. 

5A.88 Kelesidis T et al. Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side 

effect. Am J Med 2010;123:e5-6. 

5A.89 Aspinall SL et al. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009; 

49:402-8. 



5A.91 Caeiro JP et al. Moxifloxacin: a novel fluoroquinolone with a broad spectrum of activity. Expert Rev 


5A.92 Burkhardt O et al. 10 years‘ experience with the pneumococcal quinolone moxifloxacin. Expert Rev 




5A.94 Rybak MJ et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from 

the Infectious Diseases Society of America, the American Society of Health-System Pharmacists and 

the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7. 

5A.95 Giuliano C et al. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of 

MRSA infections. Expert Rev Anti Infect Ther 2010;8:95-106. 

5A.96 Thomson AH et al. Development and evaluation of vancomycin dosage guidelines designed to achieve 

new target concentrations. J Antimicrob Chemother 2009;63:1050-7. 

5A.97 Frymoyer A et al. Current recommended dosing of vancomycin for children with invasive methicillinresistant 

Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2008;28:398-402. 

5A.98 Chua K et al. Treating Gram-positive infections: vancomycin update and the whys, wherefores and 

evidence base for continuous infusion of anti-Gram-positive antibiotics. Curr Opin Infect Dis 2009; 

22:525-34. 

5A.99 Boffi el Amari E et al. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis 

2004;36:712-7. 

5A.100 Wang JT et al. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob 

Chemother 2001;47:246. 

5A.101 Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J 2010;29:462-4. 

5A.102 Hazlewood KA et al. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? 

Am J Med 2010;123:182.e1-7. 

5A.103 Lodise TP et al. Larger vancomycin doses (at least four grams per day) are associated with an increased 

incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-6. 

5A.104 Lodise TP et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity

among hospitalized patients. Clin Infect Dis 2009;49:507-14. 

5A.105 Jeffres MN et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients 

with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 

2007;29:1107-15. 

5A.106 Lewis MD et al. A 63-year old man with skin eruptions. Clin Infect Dis 2004;38:442-3. 

5A.107 Von Drygalski A et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007;356:904- 

10. 

5A.108 Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin 

North Am 2004;18:621-49. 

5A.109 Maglio D et al. Impact of pharmacodynamics on dosing of macrolides, ketolides, and azalides. Infect 


5A.110 Bradford DR et al. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity: a case 

report. Ann Otol Rhinol Laryngol 2000;109:435-7. 

5A.111 Kasten MJ. Clindamycin, metronidazole and chloramphenicol. Mayo Clin Proc 1999;74:825-33. 

5A.112 Mishra A et al. The effects of erythromycin on the electrocardiogram. Chest 1999;115:983-6. 

5A.113 Drici MD et al. Cardiac actions of erythromycin: influence of female sex. J Am Med Assoc 1998;280: 

1774-6. 

5A.114 Mahon BE et al. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors 

for infantile hypertrophic pyloric stenosis. J Pediatr 2001;139:380-4. 

5A.115 Owens RC et al. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect 

Dis 2006;43:1603-11. 

5A.116 Ray WA et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 

2004;351:1089-96. 

5A.117 Rubinstein E et al. Spiramycin renaissance. J Antimicrob Chemother 1998;42:572-6. 

5A.118 European Medicines Agency (EMA). European assessment report (EPAR). Ketek TM , summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/ docu-ment_library/EPAR_- 

_Product_Information/human/000354/WC500041895.pdf. Accessed on August 4 th 2010. 

5A.119 Brown SD. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia. 

Drug Saf 2008;31:561-75. 

5A.120 Clay KD et al. Severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern 

Med 2006;144:415-20. 

5A.121 Turner M et al. Telithromycin. Ann Intern Med 2006;144:447-8. 

5A.122 Graham DJ. Telithromycin and acute liver failure. N Engl J Med 2006;355:2260-1. 

5A.123 Roberts MC. Tetracycline therapy: update. Clin Infect Dis 2003;36:462-7. 

5A.124 Smilack JD. The tetracyclines. Mayo Clin Proc 1999;74:727-9. 

5A.125 El-Hallak M et al. Chronic minocycline-induced autoimmunity in children. J Pediatr 2008;153:314-9. 

5A.126 European Medicines Agency (EMA). European assessment report (EPAR). Tygacil TM , summary of 

product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR 


5A.127 Stein GE et al. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-24. 

5A.128 Schafer JJ et al. Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev 


5A.129 Hung WY et al. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob 

Agents 2009;34:486-9. 

5A.130 Knueppel RC et al. Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect 

Dis 2007;45:136-7. 

5A.131 Löfmark S et al. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect 

Dis 2010;50(suppl. 1):S16-23. 

5A.132 Kasten MJ. Clindamycin, metronidazole and chloramphenicol. Mayo Clin Proc 1999;74:825-33. 

5A.133 Woodruff BK et al. Reversible metronidazole induced lesions of the cerebellar dentate nuclei. N Engl 

J Med 2002;346:68-9. 

5A.134 Tabak F et al. Ornidazole-induced liver damage: report of three cases and review of the literature. Liver 

Int 2003;23:351-4. 

5A.135 Nailor MD et al. Tinidazole for bacterial vaginosis. Expert Rev Anti Infect Ther 2007;5:343-8. 

5A.136 Manes G et al. Tinidazole: from protozoa to Helicobacter pylori. The past, present and future of a 

nitro-imidazole with pecularities. Expert Rev Anti Infect Ther 2004;2:695-705. 

5A.137 Fung HB et al. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005;27:1859-84. 

5A.138 Nation RL. Colistin in the 21 st century. Curr Opin Infect Dis 2009;22:535-43. 

5A.139 Paul M et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob 

Chemother 2010;65:1019-27. 

5A.140 Landman D et al. Polymyxins revisited. Clin Microbiol Rev 2008;21:449-65. 



5A.142 Hermsen ED et al. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical 

applications. Infect Dis Clin North Am 2003;17:545-52. 

5A.143 Li J et al. Colistin: the re-emerging antibiotic for multidrug-resistant, Gram-negative bacterial infections. 


5A.144 Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant Gramnegative 


5A.145 Falagas ME et al. Use of international units when dosing colistin will help decrease confusion related 

to various formulations of the drug around the world. Antimicrob Agents Chemother 2006;50:2274- 

5. 

5A.146 Li J et al. Defining the dosage units of colistin methanesulfonate: urgent need for internatio-nal harmonization. 


5A.147 Tamma PD et al. Use of colistin in children. Pediatr Infect Dis J 2009;28:534-5. 

5A.148 Plachouras D et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after 


Antimicrob Agents Chemother 2009;53:3430-6.

5A.149 Hartzell JD et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment 

at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8. 

5A.150 Falagas ME et al. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009; 

48:1729-31. 

5A.151 Wahby K et al. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis 2010; 

50:e38-40. 

5A.152 Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect 

Ther 2006;4:947-52. 

5A.153 Herrmann DJ et al. Linezolid for the treatment of drug-resistant infections. Expert Rev Anti Infect 

Ther 2008;6:825-48. 

5A.154 Falagas ME et al. Linezolid versus glycopeptide or β-lactam for the treatment of Gram-positive bacterial 

infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66. 

5A.155 De Vriese AS et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 

2006;42:1111-7. 

5A.156 McKee EE et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob 


5A.157 Stevens DL et al. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 

2004;2:51-9. 

5A.158 Bassetti M et al. Role of linezolid in the treatment of orthopedic infections. Expert Rev Anti Infect 

Ther 2005;3:343-52. 

5A.159 Razonable RR et al. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004;79:1137-44. 

5A.160 Wu VC et al. High frequency of linezolid-associated thrombocytopenia and anemia along patients 

with end-stage renal disease. Clin Infect Dis 2006;42:66-72. 

5A.161 Attassi K et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34:695-8. 

5A.162 de Antonio JM et al. Thrombocytopenia and anemia associated with linezolid in patients with kidney 

failure. Clin Infect Dis 2006;42:1500. 

5A.163 Apodaca AA et al. Linezolid induced lactic acidosis. N Engl J Med 2003;348:86-7. 

5A.164 Bressler AM et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect 

Dis 2004;4:528-31. 

5A.165 Linam WL et al. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 

2009;28:149-51. 

5A.166 Frippiat F et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob 

Chemother 2004;53:1114-5. 

5A.167 Saijo T et al. Linezolid induced optic neuropathy. Am J Ophthalmol 2005;139:1114-6. 

5A.168 Lawrence KR et al. Serotonin toxicity associated with the use of linezolid: a review of post-marketing 

data. Clin Infect Dis 2006;42:1578-83. 

5A.169 Taylor JJ et al. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 

2006;43:180-7. 

5A.170 Wigen CL et al. Serotonin syndrome and linezolid. Clin Infect Dis 2002;34:1651-2. 

5A.171 Bernard L et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin 

Infect Dis 2003;36:1197. 

5A.172 Hammer MC et al. Linezolid-induced acute interstitial nephritis. Infect Dis Clin Pract 2009;17:61-2. 

5A.173 Velema MS et al. DRESS syndrome caused by nitrofurantoin. Neth J Med 2009;67:147-9. 

5A.174 Forrest GN et al. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 

2010;23:14-34. 



5A.176 Strevel EL et al. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet 

Infect Dis 2006;6:178-82. 

5A.177 Masters PA et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10. 

5A.178 Strevel EL et al. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet 

Infect Dis 2006;6:178-82. 

5A.179 Trepanier LA et al. Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole 

nitroso in HIV infection. J Acquir Immune Defic Syndr 2004;36:1041-50. 

5B.1 Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 

46(topic T1):17-24. 

5B.2 Van Bambeke F et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80. 

5C.1 American Academy of Pediatrics Committee in Fetus and Newborn. Age terminology during the perinatal 

period. Pediatrics 2004;114:1362-4. 

5C.2 Henry NK et al. Antimicrobial therapy for infants and children: guidelines for the inpatient and outpatient 

practice of pediatric infectious diseases. Mayo Clin Proc 2000;75:86-97. 

5C.3 American Academy of Pediatrics Committee on Infectious Diseases. Antibacterial drugs for pediatric 

patients beyond the newborn period. Red Book 2009;28:747-57. 

5C.4 Bowlware Kl et al. Antibacterial agents in pediatrics. Infect Dis Clin North Am 2004;18:513-31. 

5C.5 Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect 

Ther 2006;4:853-60. 

5C.6 Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19: 

617-28. 

5C.7 Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr 

Infect Dis J 2007;26:865-7. 

5C.8 Gendrel D et al. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet 

Infect Dis 2003;3:537-46. 

5C.9 Tamma P et al. Use of colistin in children. Pediatr Infect Dis J 2009;28:534-5. 

5C.10 Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J 2010;29:462-4. 

5C.11 Frymoyer A et al. Current recommended dosing of vancomycin for children with invasive methicillinresistant 

Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009;28:398-402. 

5C.12 Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect

Ther 2006;4:947-52. 

5D.1 Demirovic JA et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst 

Pharm 2009;66:642-8. 

5D.2 Pai MP et al. Antimicrobial dosing considerations in obese adult patients: insights from the Society of 


5D.3 Erstad BL. Dosing of medications in morbidly obese patients in the intensive care setting. Intensive 

Care Med 2004:30:18-32. 

5D.4 Wurtz R et al. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-8. 

5D.5 Falagas M et al. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 

2010;375:248-51. 

5D.6 Mushatt DM et al. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009;49:433-7. 

5D.7 Livornese LL et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2004;18: 

551-79. 

5D.8 Trotman RL et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement 

therapy. Clin Infect Dis 2005;41:1159-66. 

5D.9 Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a 

new prediction equation. Ann Intern Med 1999;130:461-70. 

5D.10 Lee NL et al. β-lactam antibiotic and β-lactamase inhibitor combinations. J Am Med Assoc 2001; 

285:386-8. 

5E.1 Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006;119(6 suppl.): 

S37-44. 

5E.2 Scaglione F et al. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing 

regimen selection. Expert Rev Anti Infect Ther 2006;4:479-90. 

5E.3 Schuck EL et al. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev 


5E.4 Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ―bug and drug‖. Nat Rev Microbiol 

2004;2:289-300. 

5E.5 Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 2004;18:451-65. 

5E.6 Ambrose PG et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it‘s not just for mice 

anymore. Clin Infect Dis 2007;44:79-86. 

5E.7 Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007;45 

(suppl. 1):S89-95. 

5E.8 Trexler Hessen M et al. Principles of use of antibacterial agents. Infect Dis Clin North Am 2004;18: 

435-50. 

5E.9 Bergman SJ et al. Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. 


5E.10 Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, 

glycopeptides and linezolid. Infect Dis Clin North Am 2003;17:479-501. 

5E.11 Ambrose PG et al. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003;17: 

529-43. 

5E.12 Maglio D et al. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect 


5F.1 Rea RS et al. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 

2007;28:596-603. 

5F.2 Begg EJ et al. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001;52 

(suppl. 1):35S-43S. 

5F.3 Kitzis MD et al. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. 


5F.4 Rybak M et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the 

American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the 

Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. 

5F.5 Rybak M et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from 

the Infectious Diseases Society of America, the American Society of Health System Pharmacists and 

the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7. 


(suppl. 1):35S-43S. 

5F.7 MacGowan AP. Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides.Ther 

Drug Monit 1998;20:473-7. 

5F.8 MacGowan AP. Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides.Ther 

Drug Monit 1998;20:473-7. 

5F.9 Soy D et al. Teicoplanin population pharmacokinetic analysis in hospitalized patients. Ther Drug Monit 

2006;28:737-43. 

5F.10 Wilson A et al. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000;39:167-83. 


(suppl. 1):35S-43S. 

5F.12 Pea F et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing 

the importance of a loading dose. J Antimicrob Chemother 2003;51:971-5. 

5F.13 Lamont E et al. Development of teicoplanin dosing guidelines for patients treated with an outpatient 

parenteral therapy (OPAT) programme. J Antimicrob Chemother 2009;64:181-7. 

6A.1 Lipsky BA et al. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 2009;49: 

1541-9. 

6A.2 Lio PA et al. Topical antibacterial agents. Infect Dis Clin North Am 2009;23:945-63. 

6A.3 Elston DM. Topical antibiotics in dermatology: emerging patterns of resistance. Dermatol Clin 2009; 

27:25-31. 

6A.4 Pangilinan R et al. Topical antibiotic treatment for uncomplicated skin and skin structure infections: 

review of the literature. Expert Rev Anti Infect Ther 2009;7:957-65. 

6A.5 Greenhalgh DG et al. Topical antimicrobial agents for burn wounds. Clin Plast Surg 2009;36:597- 

606.

6A.6 Del Rosso JQ et al. A review of the anti-inflammatory properties of clindamycin in the treatment of acne 

vulgaris. Cutis 2010;85:15-24. 

6A.7 Schöfer H et al. Fusidic acid in dermatology: an updated review. Eur J Dermatol 2010;20:6-15. 

6A.8 Korting HC et al. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol 

Venereol 2009;23:876-82. 

6A.9 Patel JB et al. Mupirocin resistance. Clin Infect Dis 2009;49:935-41. 

6A.10 European Medeines Agency (EMA). European assessment report (EPAR). Altargo TM , summary of 



6A.11 Scangarella-Oman NE et al. Microbiological profile of a new topical antibacterial: retapamulin ointment 

1%. Expert Rev Anti Infect Ther 2009;7:269-79. 

6A.12 Woodford N et al. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to 

fusidic acid and mupirocin. J Antimicrob Chemother 2008;62:766-8. 

6C.1 Liesegang TJ. Bacterial keratitis. Infect Dis Clin North Am 1992;6:815-29. 

7.1 Nucci M et al. Emerging fungi. Infect Dis Clin North Am 2006;20:563-79. 

7.2 Nucci M et al. Emerging fungal diseases. Clin Infect Dis 2005;41:521-6. 

7.3 Pfaller MA et al. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43 

(suppl. 1):S3-14. 

7.4 De Pauw B et al. Revised definitions of invasive fungal disease from the European Organization for 

Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National 

Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group. 


7.5 Alexander BD et al. Contemporary tools for the diagnosis and management of invasive mycoses. Clin 


7.6 Lass-Flörl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. 


7.7 Mukherjee PK et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 

18:163-94. 

7.8 Nivoix Y et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive 

fungal infections. J Infect 2006;52:67-74. 

7.9 Bille J et al. Changing face of health care associated fungal infections. Curr Opin Infect Dis 2005; 

18:314-9. 

7.10 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic 


207. 



58(RR-11):1-167. 

7.12 Revankar SG. Therapy for infections caused by dematiaceous fungi. Expert Rev Anti Infect Ther 

2005;3:601-12. 

7.13 Nucci M et al. When primary antifungal therapy fails. Clin Infect Dis 2008;46:1426-33. 

7.14 Cordonnier C et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic 

patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51. 

7.15 de Pauw BE et al. Timely intervention for invasive fungal disease: should the road now lead to the laboratory 

instead of the pharmacy? Clin Infect Dis 2009;48:1052-4. 

7.16 Segal BH. Aspergillosis. N Engl J Med 2009;360:1870-84. 

7.17 Singh N et al. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-69. 

7.18 Barnes PD et al. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North 

Am 2006;20:545-61. 

7.19 Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society 


7.20 Pasqualotto AC et al. Post-operative aspergillosis. Clin Microbiol Infect 2006;12:1060-76. 

7.21 Hassoun A. Cauliflower mass obstructing the left main-stem bronchus. Clin Infect Dis 2008;47:585- 

6. 

7.22 Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006;27:185-91. 

7.23 Shoseyov D et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006;130:222-6. 

7.24 Tillie-Leblond I et al. Allergic bronchopulmonary aspergillosis. Allergy 2005;60:1004-13. 

7.25 Stevens DA et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. State of the art: Cystic 

Fibrosis Foundation consensus conference. Clin Infect Dis 2003;37(suppl. 3):S225-64. 

7.26 Stevens DA et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N 

Engl J Med 2000;342:756-62. 

7.27 Marple BF. Allergic fungal rhinosinusitis: current theories and management strategies. 

Laryngoscope 2001;111:1006-19. 

7.28 Sohail MA et al. Allergic fungal sinusistis: can we predict the recurrence? Otolaryngol Head Neck 

Surg 2004;131:704-10. 

7.29 Ebbens FA et al. Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. 

J Allergy Clin Immunol 2006;118:1149-56. 

7.30 Kim YT et al. Good long-term outcomes after surgical treatment of simple and complex pulmonary 

aspergilloma. Ann Thorac Surg 2005;79:294-8. 

7.31 Okubo K et al. Favorable acute and long-term outcomes after the resection of pulmonary aspergillomas. 

Thorac Cardiovasc Surg 2007;55:108-11. 

7.32 Chatzimichalis A et al. Bronchopulmonary aspergilloma: a reappraisal. Ann Thorac Surg 1998;65: 

927-9. 

7.33 Maertens J et al. New therapies for fungal pneumonia. Curr Opin Infect Dis 2009;22:183-90. 

7.34 Segal BH et al. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir 

Crit Care Med 2006;173:707-17. 

7.35 Doffman SR et al. Invasive pulmonary aspergillosis. Expert Rev Anti Infect Ther 2005;3:613-27. 

7.36 Ruhncke M et al. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007;21: 

659-76. 

7.37 Ader F et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging 

fungal pathogen. Clin Microbiol Infect 2005;11:427-9.

7.38 Meersseman W et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007;45:205- 

16. 

7.39 Upton A et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic 

factors associated with mortality. Clin Infect Dis 2007;44:531-40. 

7.40 Maertens J et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary 

aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009;49:1688-93. 

7.41 Miceli MH et al. Strong correlation between serum Aspergillus galactomannan index and outcome of 

aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 

2008;46:1412-22. 

7.42 Deasi R et al. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive 

aspergillosis. Pediatr Infect Dis J 2009;28:283-6. 

7.43 Meersseman W et al. Galactomannan in bronchoalveolar lavage fluid. A tool for diagnosing aspergillosis 

in intensive care unit patients. Am J Respir Crit Care Med 2008;177:27-34. 

7.44 Hope WW et al. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-22. 

7.45 Pfeiffer CD et al. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. 


7.46 Marr KA et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme 

immuno-assay. Clin Infect Dis 2005;40:1762-9. 

7.47 Greene RE et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of 

the halo sign. Clin Infect Dis 2007;44:373-9. 

7.48 Vandewoude KH et al. Medical imaging and timely diagnosis of invasive pulmonary aspergillosis. Clin 

Infect Dis 2007;44:380-1. 

7.49 Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother 2008;61(suppl. 

1): i41-4. 

7.50 Burgos A et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary 

cases. Pediatrics 2008;121:e1286-94. 

7.51 Maschmeyer G et al. Invasive aspergillosis. Epidemiology, diagnosis, and management in immunocompromised 

patients. Drugs 2007;67:1567-1601. 

7.52 Cornillet A et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis 

in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006;43;577-84. 

7.53 Muñoz P et al. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 

2006;12(suppl. 7):24-39. 

7.54 Segal BH et al. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir 

Crit Care Med 2006;173:707-17. 

7.55 Steinbach WJ. Pediatric aspergillosis. Disease and treatment differences in children. Pediatr Infect 

Dis J 2005;24:358-64. 

7.56 Chandrasekar PH et al. Amphotericin B lipid complex in the management of invasive aspergillosis in 

immunocompromised patients. Clin Infect Dis 2005;40(suppl. 6):S392-400. 

7.57 Mouas H et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin 

Infect Dis 2005;40:1141-7. 

7.58 Zaoutis TE et al. A prospective, multicenter study of caspofungin for the treatment of documented 

Candida or Aspergillus infections in pediatric patients. Pediatrics 2009;123:877-94. 

7.59 Herbrecht R et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N 

Engl J Med 2002;347:408-15. 

7.60 Sambatakou H et al. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. 

Am J Med 2006;119:527.e17-24. 

7.61 Steinbach WJ et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 

cases. Clin Infect Dis 2004;39:192-8. 

7.62 Cornely OA et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized 

trial comparing a high loading-dose regimen with standard dosing (AmBiLoad trial). Clin Infect 

Dis 2007;44:1289-97. 

7.63 Anaissie AJ. Trial design for mold-active agents: time to break the mold – aspergillosis in neutropenic 

adults. Clin Infect Dis 2007;44:1298-306. 

7.64 van der Linden JW et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009; 

48:1111-3. 

7.65 Maertens J et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients 

refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-71. 

7.66 Singh N et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis 

in solid organ transplant recipients: a prospective, multicenter, observational trial. Transplantation 

2006;81:320-6. 

7.67 Petraitis V et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic 

interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-43. 

7.68 Walsh TJ et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory 

to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12. 

7.69 Miceli MH et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis 

recovering from neutropenia: proof of principle, description, and clinical and research implications. 

Cancer 2007;110:112-20. 

7.70 Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004;39:803-5. 

7.71 Pascual A et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves 

efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. 

7.72 Lewis JS. Therapeutic drug monitoring of antifungal agents. Curr Fungal Infect Rep 2009;3:96-102. 

7.73 Trifilio S et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels 

in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. 

7.74 Saccente M et al. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev 2010;23:367- 

81. 

7.75 Bariola JR et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and 

treatment in the modern area. Clin Infect Dis 2010;50:797-804. 

7.76 Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin 

North Am 2006;20:645-62. 

7.77 Chapman SW et al. Clinical practice guidelines for the management of blastomycosis: 2008 update 

by the Infectious Diseases Society of America. Clin Infect Dis 2008;46:1801-12. 

7.78 Bradsher RW et al. Blastomycosis. Infect Dis Clin North Am 2003;17:21-40. 

7.79 Trofa D et al. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008;21:606-

25. 

7.80 Panackal AA et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. 

J Clin Microbiol 2006;44:1740-3. 

7.81 Leroy O et al. Epidemiology, management and risk factors for death of invasive Candida infections in 

critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 

2009;37:1612-8. 

7.82 Viscoli C et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive 

Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of 

Cancer (EORTC). Clin Infect Dis 1999;28:1071-9. 

7.83 Kartsonis N et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis 

or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 

2005;49:3616-23. 

7.84 Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the 

Infectious Diseases Society of America. Clin Infect Dis 2009;48:505-35. 

7.85 Magill SS et al. Triazole cross-resistance among Candida spp.: case report, occurrence among 

bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006;44:529-35. 

7.86 Spellberg BJ et al. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 

42:244-51. 

7.87 Kohli R et al. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am 2005;19:831-51. 

7.88 Smith PB et al. Neonatal candidiasis. Infect Dis Clin North Am 2005;19:603-15. 

7.89 Fichtenbaum CJ et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. 


7.90 Saag MS et al. Treatment of fluconazole refractory oropharyngeal candidiasis with itraconazole oral 

solution in HIV positive patients. AIDS Res Hum Retroviruses 1999;15:1413-7. 

7.91 Ally R et al. A randomized, double blind, double dummy, multicenter trial of voriconazole and fluconazole 

in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 

2001;33:1447-54. 

7.92 Gaitán-Cepeda LA et al. Oral candidosis as a clinical marker of immune failure in patients with HIV/ 

AIDS on HAART. AIDS Patient Care STDs 2005;19:70-7. 

7.93 Epstein JB. Mucositis in the cancer patient and the immunosuppressed host. Infect Dis Clin North 

Am 2007;21:503-22. 

7.94 Sobel JD et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J 

Med 2004;351:876-83. 

7.95 Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am 2008;22:637- 

52. 

7.96 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 


7.97 Say PJ et al. Difficult to manage vaginitis. Clin Obstet Gynecol 2005;48:753-68. 

7.98 Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71. 

7.99 Eckert LO. Acute vulvovaginitis. N Engl J Med 2006;355:1244-52. 

7.100 Spence D et al. Vaginal discharge. Br Med J 2007;335:1147-51. 

7.101 Bassetti M et al. Candida infections in the intensive care unit: epidemiology, risk factors and 

therapeutic strategies. Expert Rev Anti Infect Ther 2006;4:875-85. 

7.102 Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506. 

7.103 Deck DH et al. Pharmacological advances in the treatment of invasive candidiasis. Expert Rev Anti 

Infect Ther 2006;4:137-49. 

7.104 Spellberg BJ et al. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 

42:244-51. 

7.105 Ásmundsdóttir LR et al. Improving survival of patients with candidaemia: analysis of prognostic factors 

from a long term, nationwide study in Iceland. Scand J Infect Dis 2005;37:111-20. 

7.106 Almirante B et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: 

results from population based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 

2005;43:1829-35. 

7.107 Ito JI et al. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 2005; 

40(suppl. 6):S384-91. 

7.108 Blyth CC et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal 

susceptibility in neonatal and pediatric patients. Pediatrics 2009;123:1360-8. 

7.109 Gafter-Gvili A et al. Treatment of invasive candidal infections: systematic review and meta-analysis. 

Mayo Clin Proc 2008;83:1011-21. 

7.110 Morrell M et al. Delaying the empiric treatment of Candida bloodstream infection until positive blood 

culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 

2005;49:3640-5. 

7.111 Garey KW et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: 

a multi-institutional study. Clin Infect Dis 2006;43:25-31. 

7.112 Charlier C et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 

years? J Antimicrob Chemother 2006;57:384-410. 

7.113 Ruan SY et al. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2008;14: 

136-40. 

7.114 Betts RF et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus 

a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 

2009;48:1676-84. 

7.115 Zaoutis TE et al. A prospective, multicenter study of caspofungin for the treatment of documented 

Candida or Aspergillus infections in pediatric patients. Pediatrics 2009;123:877-94. 

7.116 Reboli AC et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356: 

2472-82. 

7.117 Mora-Duarte J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl 

J Med 2002;347:2020-9. 

7.118 Bennett JE. Echinocandins for candidemia in patients without neutropenia. N Engl J Med 2006;355: 

1154-9. 

7.119 Kullberg BJ et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia 

in non neutropenic patients: a randomised non inferiority trial. Lancet 2005;366:1435-42. 

7.120 Nucci M et al. Should vascular catheters be removed from all patients with candidemia? An evidence 

based review. Clin Infect Dis 2002;34:591-9.

7.121 Walsh TJ et al. All catheter related candidemia is not the same: assessment of the balance between 

the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002;34:600-2. 

7.122 Kojic EM et al. Candida infections of medical devices. Clin Microbiol Rev 2004;17:255-67. 

7.123 Rodriguez D et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. 







7.127 Pierrotti LC et al. Fungal endocarditis, 1995-2000. Chest 2002;122:302-10. 

7.128 Johnston PG et al. Late recurrent Candida endocarditis. Chest 1991:99:1531-3. 

7.129 Muehrcke DD et al. Surgical and long term antifungal therapy for fungal prosthetic valve endocarditis. 

Ann Thorac Surg 1995;60:538-43. 

7.130 Cornely OA et al. Caspofungin fot the treatment of less common forms of invasive candidiasis. J Antimicrob 

Chemother 2007;60:363-9. 

7.131 Jiménez-Expósito MJ et al. Native valve endocarditis due to Candida glabrata treated without valvular 

replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect 

Dis 2004;39:e70-3. 

7.132 Rajendram R et al. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve 

replacement. Clin Infect Dis 2005;40:e72-4. 

7.133 Ellis ME et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 

32:50-62. 

7.134 Keynan Y et al. Fungal endocarditis. Curr Fungal Infect Rep 2007;1:25-32. 

7.135 Baddley JW et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:519-29. 

7.136 Zaoutis TE et al. Risk factors for disseminated candidiasis in children with candidaemia. Pediatr Infect 

Dis J 2004;23:635-41. 

7.137 Martίnez-Vázquez C et al. Candida albicans endophthalmitis in brown heroin addicts: response to 

early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998;27:1130-3. 

7.138 Breit SM et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. 

Am J Ophthalmol 2005;139:135-40. 

7.139 Darling K et al. Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid 

complex (ABLC). J Infect 2000;40:92-4. 

7.140 Martίnez-Vázquez C et al. Candida albicans endophthalmitis in brown heroin addicts: response to 

early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998;27:1130-3. 

7.141 Akler ME et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 

20:657-64. 

7.142 Sallam A et al. Endogenous Candida endophthalmitis. Expert Rev Anti Infect Ther 2006;4:675-85. 

7.143 Shah CP et al. Ocular candidiasis: a review. Br J Ophthalmol 2008;92:466-8. 

7.144 Wang AY et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9year 

experience of fungal peritonitis in a single center. Am J Kidney Dis 2000;36:1183-92. 

7.145 Piraino B et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 

2005;25:107-31. 

7.146 Drew RH et al. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 

2005;40:1465-70. 

7.147 Sobel JD et al. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007;44: 

e46-9. 

7.148 Kauffman CA et al. Prospective multicenter surveillance study of funguria in hospitalized patients. 


7.149 Malani AN et al. Candida urinary tract infections: treatment options. Expert Rev Anti Infect Ther 

2007;5:277-84. 

7.150 Lundstrom T et al. Nosocomial candiduria: a review. Clin Infect Dis 2001;32:1602-7. 

7.151 Kauffman CA. Candiduria. Clin Infect Dis 2005;41(suppl. 6):S371-6. 

7.152 Achkar JM et al. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010;23:376-81. 

7.153 Ameen M. Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol 2009; 

34:849-54. 

7.154 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 

7.155 Minotto R et al. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. 

J Am Acad Dermatol 2001;44:585-92. 

7.156 Parish JM et al. Coccidoidomycosis. Mayo Clin Proc 2008;83:343-9. 

7.157 Saubolle MA et al. Epidemiological, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol 

2007;45:26-30. 

7.158 Anstead GM et al. Coccidioidomycosis. Infect Dis Clin North Am 2006;20:621-43. 

7.159 Galgiani JN et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-23. 

7.160 Blair JE et al. Coccidioidomycosis in elderly persons. Clin Infect Dis 2008;47:1513-8. 

7.161 Chiller TM et al. Coccidioidomycosis. Infect Dis Clin North Am 2003;17:41-57. 

7.162 Valdivia L et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg 

Infect Dis 2006;12:958-62. 

7.163 Masannat FY et al. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral 


7.164 Blair JE et al. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005; 

165:113-7. 

7.165 Bergstrom L et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor 

α antagonists. Arthritis Rheum 2004;50:1959-66. 

7.166 Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by 

Coccidioides species. Curr Opin Infect Dis 2008;21:415-20. 

7.167 Blair JE et al. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001;33:1536-44. 

7.168 Braddy CM et al. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant 

2006;6:340-5. 

7.169 Adam RD et al. The spectrum and presentation of disseminated coccidioidomycosis. Am J Med 

2009;122:770-7. 

7.170 Galgiani JN et al. Comparison of oral fluconazole and itraconazole for progressive, non meningeal 

coccidioidomycosis. A randomized, double blind trial. Ann Intern Med 2000;133:676-86.

7.171 Stevens DA et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007;132: 

952-8. 

7.172 Anstead GM et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 

40:1770-6. 

7.173 Catanzaro A et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal 

disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007;45:562-8. 

7.174 Liliang PC et al. Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency 

virus negative patients. Clin Infect Dis 2003;37:673-8. 

7.175 Cortez KJ et al. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 

2003;36:1619-22. 

7.176 Proia LA et al. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob 

Agents Chemother 2004;48:2341. 

7.177 Johnson RH et al. Coccidioidal meningitis. Clin Infect Dis 2006;42:103-7. 

7.178 Stevens DA et al. Posaconazole for chronic refractory coccidioidomycosis. Chest 2007;132:952-8. 

7.179 Perfect JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update 

by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322. 

7.180 Perfect JR. Management of cryptococcosis: how are we doing? PLoS Med 2007;4:e47. 

7.181 Saag MS et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 

2000;30:710-8. 

7.182 Chayakulkeeree M et al. Cryptococcosis. Infect Dis Clin North Am 2006;20:507-44. 

7.183 Lindberg J et al. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg Infect 

Dis 2007;13:178-9. 

7.184 Park MK et al. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. 


7.185 Horcajada JP et al. Invasive cryptococcosis and adalimumab treatment. Emerg Infect Dis 2007;13: 

953-5. 

7.186 Khawcharoenporn T et al. Treatment of cryptococcosis in the setting of HIV coinfection. Expert Rev 


7.187 Bicanic T et al. Cryptococcal meningitis. Br Med Bull 2004;72:99-118. 

7.188 Dromer F et al. Epidemiology of HIV associated cryptococcosis in France (1985-2001): comparison of 

the pre- and post-HAART eras. AIDS 2004;18:555-562. 

7.189 Brouwer AE et al. Combination antifungal therapies for HIV associated cryptococcal meningitis: a randomised 

trial. Lancet 2004;363:1764-7. 

7.190 Sun HY et al. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: 

evidence-based evolving trends. Clin Infect Dis 2009;48:1566-76. 

7.191 Jarvis JN et al. Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis 

2008;21:596-603. 

7.192 Baddour LM et al. Succesful use of amphotericin B lipid complex in the treatment of cryptococcosis. 


7.193 Singh N et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum 

cryptococcal antigen. Clin Infect Dis 2008;46:e12-8. 

7.194 Couppié P et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. 


7.195 Pappas PG et al. Recombinant interferon-γ1b as adjunctive therapy for AIDS related cryptococcal 

meningitis. J Infect Dis 2004;189:2185-91. 

7.196 Pitisuttithum P et al. Activity of posaconazole in the treatment of central nervous system fungal infections. 


7.197 Bicanic T et al. Fungal burden, early fungicidal activity, and outcome of cryptococcal meningitis in antiretroviral-naïve 

or antiretroviral experienced patients treated with amphotericin B or fluconazole. Clin 

Infect Dis 2007;45:76-80. 

7.198 Lortholary O. Management of cryptococcal meningitis in AIDS: the need for specific studies in developing 

countries. Clin infect Dis 2007;45:81-3. 

7.199 Bicanic T et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole 

monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 

43:1069-73. 

7.200 Sungkanuparph S et al. Timing of cryptococcal immune reconstitution inflammatory syndrome after 

antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic 

Syndr 2007;45:595-6. 

7.201 Woodworth GF et al. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension 

without ventriculomegaly secondary to HIV associated cryptococcal meningitis. Surg Neurol 

2005;63:529-32. 

7.202 York J et al. Raised intracranial pressure complicating cryptococcal meningitis: immune reconstitution 

inflammatory syndrome or recurrent cryptococcal disease? J Infect 2005;51:165-71. 

7.203 Schwartz RA. Superficial fungal infections. Lancet 2004;364:1173-82. 

7.204 Gupta AK et al. Optimal management of fungal infections of the skin, hair and nails. Am J Clin Dermatol 

2004;5:225-37. 

7.205 Chang CH et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: 

a meta-analysis. Am J Med 2007;120:791-8. 

7.206 Degreef H. Clinical forms of dermatophytosis (ringworm infection). Mycopathologia 2008;166:257- 

65. 

7.207 Fuller LC. Changing face of tinea capitis in Europe. Curr Opin Infect Dis 2009;22:115-8. 

7.208 Kalivros A et al. Tinea capitis in Brussels: epidemiology and new management strategy. Dermatology 

2003;206:384-7. 

7.209 Sigurgeirsson B et al. Long term effectiveness of treatment with terbinafine versus itraconazole in 

onychomycosis. Arch Dermatol 2002;138:353-7. 

7.210 Havu V et al. A double blind, randomized study to compare the efficacy and safety of terbinafine with 

fluconazole in the treatment of onychomycosis. Br J Dermatol 2000;142:97-102. 

7.211 de Berker D. Fungal nail disease. N Engl J Med 2009;360:2108-16. 

7.212 Gupta AK et al. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008;166:353-67. 

7.213 Gupta AK et al. Therapies for onychomycosis: a review. Dermatol Clin 2006;24:375-9. 

7.214 Gupta AK et al. Onychomycosis therapies: strategies to improve efficacy. Dermatol Clin 2006;24: 

381-6. 

7.215 Gupta AK et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toe-

nail onychomycosis. J Eur Acad Dermatol Venereol 2009;23:256-62. 

7.216 Piraccini BM et al. Long term follow-up of toenail onychomycosis caused by dermatophytes after successful 

treatment with systemic antifungal agents. J Am Acad Dermatol 2010;62:411-14. 

7.217 Daniel CR et al. The illusory tinea unguium cure. J Am Acad Dermatol 2010;62:415-7. 

7.218 Baran R et al. Topical antifungal drugs for the treatment of onychomycosis: an overview of current 

strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005;19:21-9. 

7.219 Roberts DT et al. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-10. 

7.220 olde Hartman TC et al. Fungal nail infection. Br Med J 2008;337:295. 

7.221 Gupta AK et al. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. 

Br J Dermatol 2004;150:537-44. 

7.222 Gupta AK. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002;16:19-33. 

7.223 Gupta AK et al. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin 


7.224 Rezusta A et al. Tinea nigra: a rare imported infection. J Eur Acad Dermatol Venereol 2010;24:89- 

90. 

7.225 Nucci M et al. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007;20: 

695-704. 

7.226 Nucci M et al. Cutaneous infection by Fusarium in healthy and immunocompromised hosts: implications 

for diagnosis and management. Clin Infect Dis 2002;35:909-20. 

7.227 Ho DY et al. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 

50:227-31. 

7.228 Dignani MC et al. Human fusariosis. Clin Microbiol Infect 2004;10(suppl. 1):67-75. 

7.229 Raad II et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying 

hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403. 






7.233 Wheat LJ et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 

update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:807-25. 

7.234 Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007;20:115-32. 

7.235 Kauffman CA. Endemic mycoses: blastomycosis, histoplamosis, and sporotrichosis. Infect Dis Clin 

North Am 2006;20:645-62. 

7.236 Adderson E. Histoplasmosis. Pediatr Infect Dis J 2006;25:73-4. 

7.237 Gutierrez ME et al. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 

cases. Clin Infect Dis 2005;40:1199-202. 

7.238 Wheat LJ et al. Histoplasmosis. Infect Dis Clin North Am 2003;17:1-19. 

7.239 Johnson PC et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin 

B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002;137: 

105-9. 

7.240 Hajjeh RA et al. Multicenter case control study of risk factors for histoplasmosis in human immunodeficiency 

virus infected persons. Clin Infect Dis 2001;32:1215-20. 

7.241 Couppié P et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. 


7.242 Cuellar-Rodriguez J et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience 

at a large transplant center in an endemic area. Clin Infect Dis 2009;49:710-6. 

7.243 Hage CA et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis 

factor blocker therapy. Clin Infect Dis 2010;50:85-92. 

7.244 Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis 

2008;21:421-5. 

7.245 Wheat LJ et al. Diagnosis and management of central nervous system histoplasmosis. Clin Infect 

Dis 2005;40:844-52. 

7.246 Wheat LJ et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis 

in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001;33: 

1910-3. 

7.247 Spellberg B et al. Recent advances in the management of mucormycosis: from bench to bedside. 


7.248 Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008;61 

(suppl. 1):i35-9. 

7.249 Chayakulkeeree M et al. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect 

Dis 2006;25:215-29. 

7.250 Bouza E et al. Mucormycosis: an emerging disease? Clin Microbiol Infect 2006;12(suppl. 7):7-23. 

7.251 Kontoyiannis DP et al. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and 

management. Infect Dis Clin North Am 2006;20:581-607. 

7.252 Zaoutis TE et al. Zygomycosis in children: a systematic review and analysis of reported cases in 

children. Pediatr Infect Dis J 2007;26:723-7. 


7.254 Spellberg B et al. Novel perspectives on mucormycosis: pathophysiology, presentation and management. 


7.255 Roden MM et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect 

Dis 2005;41:634-53. 

7.256 Safar A et al. Early identification of rhinocerebral mucormycosis. J Otolaryngol 2005;34:166-71. 

7.257 Mantadakis E et al. Clinical presentation of zygomycosis. Clin Microbiol Infect 2008;15(suppl. 

1):15-20. 

7.258 Greenberg RN et al. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. 


7.259 Skiada A et al. Cutaneous zygomycosis. Clin Microbiol Infect 2009;15(suppl. 1):41-5. 

7.260 Roilides E et al. Invasive zygomycosis in neonates and children. Clin Microbiol Infect 2008;15 

(suppl. 1):50-4. 

7.261 Petrikkos GL. Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol 

Infect 2009;15(suppl. 1):87-92. 

7.262 Chamilos G et al. Delaying amphotericin B-based frontline therapy significantly increases mortality

among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503-9. 

7.263 Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: 

perspectives from a maxillofacial surgeon. Clin Microbiol Infect 2008;15(suppl. 1):98-102. 

7.264 Cornely OA et al. Current experience in treating invasive zygomycosis with posaconazole. Clin 

Micro-biol Infect 2009;15(suppl. 1):77-81. 

7.265 van Burik JA et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary 

of 93 cases. Clin Infect Dis 2006;42:e61-5. 

7.266 Keating GM. Posaconazole. Drugs 2005;65:1553-67. 

7.267 Greenberg RN et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 

2006;50:126-33. 

7.268 Reed C et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. 


7.269 Tragiannidis A et al. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. 


7.270 Mastroianni A. Paranasal sinus mucormycosis in an immunocompetent host: efficacy and safety of 

combination therapy with liposomal amphotericin B and adjuvant rHuGM-CSF. Infez Med 2004;4: 

278-83. 

7.271 Spellberg B et al. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 2010,12: 

423-9. 


7.273 Garnica M et al. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, 

phaehyphomycosis and chromoblastomycosis. Curr Opin Infect Dis 2009;22:559-63. 

7.274 Ahmed AO et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet 

Infect Dis 2004;4:566-74. 

7.275 Ramos-e-Silva M et al. Paracoccidioidomycosis. Dermatol Clin 2008;26:257-69. 

7.276 Travassos LR et al. Treatment options for paracoccidioidomycosis and new strategies investigated. 



7.278 Vanittanakom N et al. Penicillium marneffei infection and recent advances in the epidemiology and 

molecular biology aspects. Clin Microbiol Rev 2006;19:95-110. 

7.279 Sirisanthana T et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei 

infection in human immunodeficiency virus infected patients. Clin Infect Dis 1998;26:1107-10. 

7.280 Sirisanthana T et al. Epidemiology and management of penicilliosis in human immunodeficiency virus 

infected patients. Int J Infect Dis 1998;3:48-53. 

7.281 Ustianowski AP et al. Penicillium marneffei infection in HIV. Curr Opin Infect Dis 2008;21:31-6. 

7.282 Pastor FJ et al. Alternaria infections: laboratory diagnosis and relevant clinical features. Clin Microbiol 

Infect 2008;14:734-46. 

7.283 Steinbach WJ et al. Scedosporium species infections and treatments. J Chemother 2003;15(suppl. 

2):16-27. 


7.285 Revankar SG et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect 

Dis 2002;34:467-76. 

7.286 Pfaller MA et al. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43 

(suppl. 1):S3-14. 

7.287 Ben-Ami R et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009;48:1033- 

41. 

7.288 Revankar SG. Phaeohyphomycosis. Infect Dis Clin North Am 2006;20:609-20. 

7.289 Li DM et al. Cerebral phaeohyphomycosis – a cure at what lengths? Lancet Infect Dis 2009;9:376- 

83. 

7.290 Bhat SV et al. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: 

successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007;39: 

87-90. 

7.291 Revankar SG et al. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin 

Infect Dis 2004;38:206-16. 

7.292 Perfect JR et al. Voriconazole treatment for less common, emerging or refractory fungal infections. 


7.293 Troke P et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. 


7.294 Garnica M et al. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, 

phaehyphomycosis and chromoblastomycosis. Curr Opin Infect Dis 2009;22:559-63. 

7.295 Stringer JR et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect 

Dis 2002;8:891-6. 

7.296 Calderón EJ et al. Pneumocystis infections in humans: diagnosis and treatment. Expert Rev Anti Infect 

Ther 2010;8:683-701. 

7.297 Tasaka S et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007;131: 

1173-80. 

7.298 Walzer PD et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected 

patients: 1985-2006. Clin Infect Dis 2008;46:625-33. 

7.299 Morris A. Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jirovecii pneumonia 

over the course of the AIDS epidemic. Clin Infect Dis 2008;46:634-6. 

7.300 Thomas CF et al. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98. 

7.301 Kovacs JA et al. New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii 

pneumonia. J Am Med Assoc 2001;286:2450-60. 

7.302 Kovacs JA et al. Evolving health effects of Pneumocystis. One hundred years of progress in diagnosis 

and treatment. J Am Med Assoc 2009;301:2578-85. 

7.303 Benfield T et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia. 

A case series and systematic review. J Acquir Immune Defic Syndr 2008;48:63-7. 

7.304 Cortez KJ et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008;21:157-97. 

7.305 Lamaris GA et al. Scedosporium infection in a tertiary care cancer center: a review of 25 cases 1989-

2006. Clin Infect Dis 2006;43:1580-4. 

7.306 O‘Bryan TA. Pseudallescheriasis in the 21 st century. Expert Rev Anti Infect Ther 2005;3:765-73. 

7.307 Castiglioni B et al. Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid 

organ transplant recipients in a tertiary medical center and review of the literature. Medicine 2002;81: 

333-48. 

7.308 Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against 

opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-8. 

7.309 Carrillo AJ et al. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob 


7.310 Walsh TJ et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal 

infections in children. Pediatr Infect Dis J 2002;21:240-8. 

7.311 Fortún J et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J 

Clin Microbiol Infect Dis 2003;22:408-13. 

7.312 Kauffman CA et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by 

the Infectious Diseases Society of America. Clin Infect Dis 2007;45:1255-65. 

7.313 Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin 

North Am 2006;20:645-62. 

7.314 Bustamante B et al. Sporotrochosis: a forgotten disease in the drug research agenda. Expert Rev 



7.316 Queiroz-Telles F et al. Subcutaneous mycoses. Infect Dis Clin North Am 2003;17:59-85. 



207. 



58(RR-11):1-167. 

8.1 de la Cámara R. Antifungal prophylaxis in haematology patients. Clin Microbiol Infect 2006; 

12(suppl. 7):65-76. 

8.2 Segal BH et al. Prevention and early treatment of invasive fungal infection in patients with cancer and 

neutropenia and in stem cell transplant recipients in the era of new broad-spectrum antifungal agents 

and diagnostic adjuncts. Clin Infect Dis 2007;44:402-9. 

8.3 Hwang YY et al. Antifungal prophylaxis and treatment in patients with hematological malignancies. 


8.4 Sipsas NV et al. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal 

prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006;42:1584-91. 



8.6 Singh N et al. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-69. 

8.7 de la Cámara R. Antifungal prophylaxis in haematology patients. Clin Microbiol Infect 2006;12 

(suppl. 7):65-76. 









(suppl. 7):65-76. 








8.15 Rotstein C et al. Randomized, placebo controlled trial of fluconazole prophylaxis for neutropenic cancer 

patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999;28: 

331-40. 

8.16 Menichetti F et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients 

with hematologic malignancies: a randomized, placebo controlled, double blind, multicenter 

trial. Clin Infect Dis 1999;28:250-5. 

8.17 Powderly WG et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention 

of fungal infections in patients with advanced human immunodeficiency virus infection. N 

Engl J Med 1995;332:700-5. 

8.18 Powderly WG et al. Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. 

AIDS Res Hum Retroviruses 1999;15:1619-23. 

8.19 Saag MS et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS associated 

cryptococcal meningitis. Clin Infect Dis 1999;28:291-6. 

8.20 McKinsey DS et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency 

virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 

1999;28:1049-56. 

8.21 Wheat J et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired 

immunodeficiency syndrome. Ann Intern Med 1993;118:610-6. 


(suppl. 7):65-76. 

8.23 Segal BH et al. Prevention and early treatment of invasive fungal infection in patients with cancer and







8.26 Goldani LZ et al. Paracoccidioidomycosis and AIDS: an overview. Clin Infect Dis 1995;21:1275-81. 


Dis 2002;8:891-6. 


(suppl. 7):65-76. 








8.32 Rodriguez M et al. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus 

negative immunocompromised patients. Clin Microbiol Rev 2004;17:770-82. 


Dis 2002;8:891-6. 

8.34 Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 

1998;42:995-1004. 

8.35 Chan C et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of 

Pneumocystis carinii pneumonia in human immunodeficiency virus infected subjects intolerant of trimethoprim 

or sulfonamides. J Infect Dis 1999;180:369-76. 

8.36 Furrer HJ et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in 

HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med 1999;340:1301-6. 

8.37 Weverling GJ et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly 

active antiretroviral therapy in HIV-1 infection. Lancet 1999;353:1293-8. 

8.38 Schneider MM et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected 

patients treated with highly active antiretroviral therapy. Lancet 1999;353:201-3. 

8.39 Lopez Bernaldo de Quiros JC et al. A randomized trial of the discontinuation of primary and secondary 

prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in 

patients with HIV infection. N Engl J Med 2001;344:159-67. 

8.40 Ledergerber B et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia 

in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001; 

344:168-74. 

8.41 Yangco BG et al. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in 

patients with HIV infection. Ann Intern Med 2000;132:201-5. 

8.42 Mussini C et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic 

encephalitis in human immunodeficiency virus type 1 infected patients: the Changes in Opportunistic 

Prophylaxis Study. J Infect Dis 2000;181:1635-42. 

8.43 Furrer HJ et al. Discontinuation of primary prophylaxis in HIV infected patients at high risk of Pneumocystis 

carinii pneumonia: prospective multicentre study. AIDS 2001;15:501-7. 

8.44 Soriano V et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV infected 

patients receiving highly active antiretroviral therapy. AIDS 2000;14:383-6. 

8.45 Girard PM. Discontinuing Pneumocystis carinii prophylaxis. N Engl J Med 2001;344:222-3. 

8.46 Trikalinos TA et al. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human 

immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis 2001;33:1901-9. 

8.47 Mei Q et al. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate 

synthase gene. Lancet 1998;351:1631-2. 

8.48 Kaplan JE et al. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency 

virus infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. 

J Infect Dis 1998;178:1126-32. 

8.49 Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection 

among adults, adolescents, and children aged

9A.5 Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 

20:679-97. 

9A.6 Segal BH et al. Combination antifungals: an update. Expert Rev Anti Infect Ther 2007;5:883-92. 

9A.7 Kanafani ZA et al. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 

2008;46:120-8. 

9A.8 Masiá Canuto M et al. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002;2: 

550-63. 

9A.9 Morrison VA. Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 2006;4: 

325-42. 

9A.10 Zaas AK. Echinocandins: a wealth of choice. How clinically different are they? Curr Opin Infect Dis 

2008;21:426-32. 

9A.11 Fera MT et al. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of 

resistance. Expert Rev Anti Infect Ther 2009;7:981-98. 

9A.12 European Medicines Agency (EMA). European assessment report (EPAR). Ecalta, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document _library/EPAR_- 

_Product_Information/human/000788/WC500020673.pdf. Accessed on October 6 th 2010. 

9A.13 Vazquez JA et al. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006;43:215-22. 

9A.14 de la Torre P et al. Anidulafungin: a new echinocandin for candidal infections. Expert Rev Anti Infect 

Ther 2007;5:45-52. 

9A.15 Reboli AC et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356: 

2472-82. 

9A.16 European Medicines Agency (EMA). European assessment report (EPAR). Cancidas, summary of 


_-_Product_Information/human/000379/WC500021033.pdf. Accessed on October 6 th 2010. 

9A.17 Fisher BT et al. Caspofungin for the treatment of pediatric fungal infections. Pediatr Infect Dis J 

2008;27:1099-1101. 

9A.18 Merlin E et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. 


9A.19 Klastersky J. Antifungal therapy in patients with fever and neutropenia. More rational and less empirical. 

N Engl J Med 2004;351:1445-7. 

9A.20 Maschmeyer G et al. Pharmacological properties and clinical efficacy of a recently licensed, systemic 

antifungal: caspofungin. Mycoses 2005;48:227-34. 

9A.21 Wegner B et al. Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages 

renal tubular cells. Nephrol Dial Transplant 2005;20:2071-9. 

9A.22 Sable CA et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. 

Transpl Infect Dis 2002;4:25-30. 

9A.23 Morrison VA. Caspofungin: an overview. Expert Rev Anti Infect Ther 2005;3:697-705. 

9A.24 Deresinski SC et al. Caspofungin. Clin Infect Dis 2003;36:1445-57. 

9A.25 European Medicines Agency (EMA). European assessment report (EPAR). Mycamine, summary of 

product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/docu ment_library/EPAR 

_-_Product_Information/human/000734/WC500031075.pdf. Accessed on October 6th 2010. 

9A.26 Fritz JM et al. Micafungin for the prophylaxis and treatment of Candida infections. Expert Rev Anti 

Infect Ther 2008;6:153-62. 

9A.27 Chandrasekar PH et al. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-8. 

9A.28 Collazos J et al. Pulmonary reactions during treatment with amphotericin B: review of published cases 

and guidelines for management. Clin Infect Dis 2001;33:e75-82. 

9A.29 Adler-Moore JP et al. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 

2008;14(suppl. 4):25-36. 

9A.30 Lanternier F et al. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 2008;14 

(suppl. 4):71-83. 

9A.31 Fischer MA et al. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. 


9A.32 Adler-Moore JP et al. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 

2008;14(suppl. 4):25-36. 

9A.33 Alexander BD et al. Study of renal safety in amphotericin B lipid complex treated patients. Clin Infect 

Dis 2005;40(suppl. 6):S414-21. 

9A.34 Gibbs WJ et al. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Anti Infect 

Ther 2005;3:167-81. 

9A.35 Bellmann R et al. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical 

equivalence. Clin Infect Dis 2003;36:1500-1. 

9A.36 Hooshmand-Rad R et al. Use of amphotericin B lipid complex in elderly patients. J Infect 2005;50: 

277-87. 

9A.37 Fera MT et al. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of 

resistance. Expert Rev Anti Infect Ther 2009;7:981-98. 

9A.38 Brüggemann RJ et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs 

with other coadministered agents. Clin Infect Dis 2009;48:1441-58. 

9A.39 Fischer MA et al. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. 


9A.40 Pappas PG et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995;123:354-7. 

9A.41 Caputo R. Itraconazole in superficial and systemic fungal infections. Expert Rev Anti Infect Ther 

2003;1:531-42. 

9A.42 Glasmacher A et al. Current experience with itraconazole in neutropenic patients: a concise overview 

of pharmacological properties and use in prophylactic and empirical antifungal therapy. Clin Microbiol 

Infect 2006;12(suppl. 7):84-90. 

9A.43 Domínguez-Gill Hurlé A et al. Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic 

interactions. Clin Microbiol Infect 2006;12(suppl. 7):97-106. 

9A.44 Lestner JM et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin 

Infect Dis 2009;49:928-30.

9A.45 European Medicines Agency (EMA). European assessment report (EPAR). Noxafil, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_- 


9A.46 Smith WJ et al. Posaconazole‘s impact on prophylaxis and treatment of invasive fungal infections: an 

update. Expert Rev Anti Infect Ther 2009;7:165-81. 

9A.47 Keating GM. Posaconazole. Drugs 2005;65:1553-67. 

9A.48 Nagappan V et al. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 

2007;45: 1610-7. 

9A.49 European Medicines Agency (EMA). European assessment report (EPAR). Vfend, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_- 

_Product_Information/human/000387/WC500049756.pdf. Accessed on Octo-ber 6 th 2010. 

9A.50 Boyd AE et al. Adverse reactions to voriconazole. Clin Infect Dis 2004;39:1241-4. 

9A.51 Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect 

Ther 2004;2:485-97. 

9A.52 Perfect JR et al. Voriconazole treatment for less common, emerging or refractory fungal infections. 


9A.53 Trifilio S et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels 


9A.54 Pascual A et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves 


9A.55 Denning DW et al. Mucocutaneous retinoid effects and facial erythema related to the novel triazole 

antifungal agent voriconazole. Clin Exp Dermatol 2001;26:648-53. 

9A.56 McCarthy KL et al. Severe photosensitivity causing multifocal squamous cell carcinomas secondary 

to prolonged voriconazole therapy. Clin Infect Dis 2007;44:e55-6. 

9A.57 Alkan Y et al. Voriconazole induced QT interval prolongation and ventricular tachycardia: a non concentration 

dependent adverse effect. Clin Infect Dis 2004;39:e49-52. 

9A.58 Zonios DI et al. Hallucinations during voriconazole therapy. Clin Infect Dis 2008;47:e7-10. 

9A.59 Pongas GN et al. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal 

prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009;15 (suppl. 5):93- 

7. 

9A.60 Vermes A et al. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity 

and drug interactions. J Antimicrob Chemother 2000;46:171-9. 

9A.61 McKay DA et al. Terbinafine induced subacute cutaneous lupus erythematosus. Acta Derm Venereol 

2004;84:472-4. 

9B.1 Blyth CC et al. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 

2007;119:772-84. 

9B.2 Wolkowiez-Cohen et al. Pediatric antifungal agents. Curr Opin Infect Dis 2009;22:553-8. 

9C.1 Demirovic JA et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst 

Pharm 2009;66:642-8. 

9C.2 Pai MP et al. Antimicrobial dosing considerations in obese adult patients: insights from the Society of 


9C.3 Erstad BL. Dosing of medications in morbidly obese patients in the intensive care setting. Intensive 

Care Med 2004:30:18-32. 

9C.4 Wurtz R et al. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-8. 

9C.5 Falagas M et al. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 

375:248-51. 

9C.6 Moudgal VV et al. Selecting antifungal agents for the treatment of invasive fungal infections in patients 

with renal failure. Curr Opin Investig Drugs 2004;5:873-8. 

9C.7 Courtney R et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees 

of chronic renal disease. J Clin Pharmacol 2005;45:185-92. 

9C.8 Trotman RL et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement 


9C.9 Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a 


9D.1 Dodds Ashley ES et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43(suppl. 

1):S28-39. 

9D.2 Cisneros Herreros JM et al. Therapeutic armamentarium against systemic fungal infections. Clin Microbiol 

Infect 2006;12(suppl. 7):53-64. 

9D.3 Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 

20:679-97. 

9E.1 Perea S et al. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002;35:1073-80. 

9E.2 Badali H et al. In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates 

of Alternaria species. J Antimicrob Chemother 2009;63:1295-7. 

9E.3 Alastruey-Izquierdo A et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 

2009;16(suppl. 5):71-6. 

9E.4 Stringer JR et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect 

Dis 2002;8:891-6. 



207. 



58(RR-11):1-167. 

11A.3 Winthrop KL et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis

factor and other newly approved biologic therapies: case finding through the emerging infections network. 


11A.4 Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009;22: 

403-9. 

11A.5 Wright A et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the 

Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73. 

11A.6 Devasia RA et al. Fluoroquinolone resistance in Mycobacterium tuberculosis. The effect of duration 

and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365-70. 

11A.7 Lee E et al. Evolution and current use of the tuberculin test. Clin Infect Dis 2002;34:365-70. 

11A.8 American Thoracic Society (ATS) et al. Targeted tuberculin testing and treatment of latent tuberculosis 

infection. Am J Respir Crit Care Med 2000;161(4 suppl.):S221-47. 

11A.9 Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent 

tuberculosis in children and adolescents. Pediatrics 2004;114:1175-201. 

11A.10 Cobelens FG et al. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced 

cutoff values. Clin Infect Dis 2006;43:634-9. 

11A.11 Tissot F et al. Influence of Bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: 

to what size? Clin Infect Dis 2005;40:211-7. 

11A.12 Mandalakas AM et al. Interpretation of repeat tuberculin skin testing in international adoptees. Conversions 

or boosting. Pediatr Infect Dis J 2008;27:913-9. 

11A.13 Slovis BS et al. The case against anergy testing as a routine adjunct to tuberculin skin testing. J Am 

Med Assoc 2000;283:2003-7. 

11A.14 Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma 

release assays to detect Mycobacterium tuberculosis infection. Morb Mortal Wkly Rep 2010;59(RR- 

5):1-25. 

11A.15 Mazurek GH et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-γ 

release assays in persons with suspected tuberculosis.Clin Infect Dis 2007;45:837-45. 

11A.16 Dewan PK et al. Low sensitivity of a whole-blood interferon-γ release assay for detection of active tuberculosis. 


11A.17 Pai M et al. Interferon-γ release assays: what is their role in the diagnosis of active tuberculosis? Clin 

Infect Dis 2007;44:74-7. 

11A.18 Al-Zamel FA. Detection and diagnosis of Mycobacterium tuberculosis. Expert Rev Anti Infect Ther 

2009;7:1099-108. 

11A.19 Lalvani A et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigenspecific 

T cells. Am J Respir Crit Care Med 2001;163:824-8. 

11A.20 Barnes PF. Diagnosing latent tuberculosis infection. The 100-year upgrade. Am J Respir Crit Care 

Med 2001;163:807-8. 

11A.21 Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006; 

174:736-42. 

11A.22 Kim SH et al. Diagnostic usefulness of a T-cell-based assay for extrapulmonary tuberculosis in immunocompromised 

patients. Am J Med 2009;122:189-95. 

11A.23 Menzies D et al. Meta-analysis. New tests for the diagnosis of latent tuberculosis infection: areas of 

uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54. 

11A.24 Dosanjh DP et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008; 

148:325-36. 

11A.25 Bakir M et al. Prognostic value of a T-cell-based, interferon-γ biomarker in children with tuberculosis 

contact. Ann Intern Med 2008;149:777-86. 

11A.26 Zar HJ et al. Diagnosis of pulmonary tuberculosis in children: new advances. Expert Rev Anti Infect 

Ther 2010;8:277-88. 

11A.27 Wallis RS et al. Biomarkers and diagnostics for tuberculosis: progress, needs and translation into 

practice. Lancet 2010;375:1920-37. 

11A.28 Dorman SE et al. New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clin Infect Dis 

2010;50(suppl. 3):S173-7. 

11A.29 Nyendak MR et al. New diagnostic methods for tuberculosis. Curr Opin Infect Dis 2009;22:174-83. 

11A.30 Bergamini BM et al. Performance of commercial blood tests for the diagnosis of latent tuberculosis infection 

in children and adolescents. Pediatrics 2009;123:e419-24. 

11A.31 Vlaamse Vereniging voor Respiratoire gezondheidszorg en Tuberculosebestrijding (VRGT). Gerichte 

opsporing en behandeling van latente tuberculose-infectie. Available at: http://www.vrgt.be/uploads/ 

documentenbank/c4d70b10d8a40db8a94189b949f54fd8.pdf. Accessed on August 9 th 2010. 

11A.32 Fonds des affections Respiratoires et pour l‘Education à la Santé (FARES). Recommendations 

concernant le dépistage ciblé et le traitement de l‘infection tuberculeuse latente. Available at: http:// 

www.fares.be/documents/recomm.pdf. Accessed on August 9 th 2010. 

11A.33 Menzies D et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy 

for latent tuberculosis infection a randomized trial. Ann Intern Med 2008;149:689-97. 

11A.34 Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis 

infection. J Am Med Assoc 2005;293:2776-84. 

11A.35 Jasmer RM et al. Latent tuberculosis infection. N Engl J Med 2002;347:1860-6. 

11A.36 Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl 

J Med 2004;350:2060-7. 

11A.37 American Thoracic Society (ATS) et al. Targeted tuberculin testing and treatment of latent tuberculosis 

infection. Am J Respir Crit Care Med 2000;161(4 suppl.):S221-47. 

11A.38 Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent 

tuberculosis infection in children and adolescents. Pediatrics 2004;114:1175-201. 

11A.39 Nolan CM et al. Hepatotoxicity associated with isoniazid preventive therapy. A 7-year survey from a 

public health tuberculosis clinic. J Am Med Assoc 1999;281:1014-8. 

11A.40 McElroy PD et al. National survey to measure rates of liver injury, hospitalization and death associated 

with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33. 

11A.41 Ijaz K et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide 

for latent tuberculosis infection. Clin Infect Dis 2006;42:346-55. 

11A.42 van Hest R et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis 

treatment. Clin Infect Dis 2004;39:488-96. 

11A.43 Gordin FM et al. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection 

in HIV infected persons: is it different than in HIV uninfected persons? Clin Infect Dis 2004; 

39:561-5.

11A.44 Centers for Disease Control and Prevention (CDC). Adverse event data and revised American Thoracic 

Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent 

tuberculosis infection. Morb Mortal Wkly Rep 2003;52:735-9. 

11A.45 Sneag DB et al. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts 

of multidrug-resistant tuberculosis cases. Pediatr Infect Dis J 2007;26:1142-6. 

11A.46 Schaaf HS. Evaluation of young children with adult multidrug resistant tuberculosis: a 30 months follow-up. 

Pediatrics 2002;109:765-71. 

11A.47 Ena J et al. Short course therapy with rifampin plus isoniazid compared with standard therapy with 

isoniazid for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. 

11A.48 Cook PP et al. Safety and completion rate of short-course therapy for treatment of latent tuberculosis 


11A.49 Spyridis NP et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-months 

regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of 

an 11-year randomized study. Clin Infect Dis 2007;45:715-22. 

11A.50 Vlaamse Vereniging voor Respiratoire gezondheidszorg en Tuberculosebestrijding (VRGT). Behandeling 

van multiresistente tuberculose. Available at: http://www.vrgt.be/uploads/documentenbank/c0f5 

6dd01ebc223b0cefa5fc1babd862.pdf. Accessed on August 9th 2010. 

11A.51 Fonds des affections Respiratoires et pour l‘Education à la Santé (FARES). La tuberculose à germes 

multirésistants. Available at: http://www.fares.be/documents/Faresfr.pdf. Accessed on August 9th 

2010. 

11A.52 Chaulk CP et al. Directly observed therapy for treatment completion of pulmonary tuberculosis. J Am 

Med Assoc 1998;279:943-8. 

11A.53 Bofinger JJ et al. Fever of unknown origin caused by tuberculosis. Infect Dis Clin North Am 2007; 

21:947-62. 

11A.54 Maartens G et al. Tuberculosis. Lancet 2007;370:2030-43. 

11A.55 Connelly Smith K et al. A review of tuberculosis: reflections on the past, present and future of a global 

epidemic disease. Expert Rev Anti Infect Ther 2003;1:483-91. 

11A.56 Centers for Disease Control and Prevention (CDC). Treatment of tuberculosis. Morb Mortal Wkly 

Rep 2003;52(RR-11):1-77. 

11A.57 Myers JP. New recommendations for the treatment of tuberculosis. Curr Opin Infect Dis 2005;18: 

133-40. 

11A.58 Daley CL. Update in tuberculosis 2009. Am J Respir Crit Care Med 2010;181:550-5. 

11A.59 Ralph AP et al. Tuberculosis into the 2010s: is the glass half full? Clin Infect Dis 2009;49:574-83. 

11A.60 Campbell IA et al. Pulmonary tuberculosis: diagnosis and treatment. Br Med J 2006;332:1194-7. 

11A.61 Rikimaru T. Endobronchial tuberculosis. Expert Rev Anti Infect Ther 2004;2:245-51. 

11A.62 Golden MP et al. Extrapulmonary tuberculosis: an overview. Am Fam Physician 2005;72:1761-8. 

11A.63 Jacob JT et al. Acute forms of tuberculosis in adults. Am J Med 2009;122:12-7. 

11A.64 Sharma SK et al. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005;5: 

415-30. 

11A.65 Gardam M et al. Mycobacterial osteomyelitis and arthritis. Infect Dis Clin North Am 2005;19:819-30. 

11A.66 Thwaites GE et al. Effect of antituberculosis drug resistance on response to treatment and outcome in 

adults with tuberculous meningitis. J Infect Dis 2005;192:79-88. 

11A.67 Donald PR bet al. Tuberculous meningitis. N Engl J Med 2004;351:1719-20. 

11A.68 Patel VB et al. Multidrug resistant tuberculous meningitis in KwaZulu – Natal, South Africa. Clin Infect 

Dis 2004;38:851-6. 

11A.69 Rock RB et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol 

Rev 2008;21:243-61. 

11A.70 Donoghue SD et al. Intestinal tuberculosis. Curr Opin Infect Dis 2009;22:490-6. 

11A.71 Jacob JT et al. Male genital tuberculosis. Lancet Infect Dis 2008;8:335-42. 

11A.72 Deiss RG et al. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009;48:72-82. 

11A.73 Thwaites GE et al. Dexamethasone for treatment of tuberculous meningitis in adolescents and adults. 

N Engl J Med 2004;351:1741-51. 

11A.74 Schoeman JF et al. Effect of corticosteroids on intracranial pressure, computed tomographic findings 

and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99:226-31. 

11A.75 Cruz AT et al. Treatment of tuberculosis in children. Expert Rev Anti Infect Ther 2008;6:939-57. 

11A.76 Newton SM et al. Paediatric tuberculosis. Lancet Infect Dis 2008;8:498-510. 

11A.77 Marais BJ et al. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir 

Crit Care Med 2006;173:1078-90. 

11A.78 Bergeron KG et al. Tuberculosis in pregnancy: current recommendations for screening and treatment 

in the USA. Expert Rev Anti Infect Ther 2004;2:589-98. 

11A.79 Swaminathan S et al. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010;50:1377-86. 

11A.80 Sterling TR et al. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect 

Dis 2010;50(suppl. 3):S223-30. 

11A.81 Khan FA et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and 

meta-analysis. Clin Infect Dis 2010;50:1288-99. 

11A.82 Burman WJ et al. Treatment of HIV related tuberculosis in the era of effective antiretroviral therapy. 


11A.83 Chukwuka Onyebunoh P et al. Treatment options for HIV-associated tuberculosis. J Infect Dis 2007; 

196(suppl. 1):S35-45. 



207. 



58(RR-11):1-167. 

11A.86 Nahid P et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care 

Med 2007;175:1199-1206. 

11A.87 Abdool Karim SS et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J 

Med 2010;362:697-706. 

11A.88 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral 

agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/content 

files/ AdultandAdolescentGL.pdf. Accessed on August 9th 2010. 

11A.89 Drobniewski F et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST do-

cument E.DEF 8.1). Report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium 

tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of 

the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 

2007;13:1144-56. 

11A.90 Holtz TH et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and 

relationship to treatment outcome. Ann Intern Med 2006;144:650-9. 

11A.91 Cattamanchi A et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant 

tuberculosis. Clin Infect Dis 2009;48:179-85. 

11A.92 Mak A et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized 

regimens. Am J Respir Crit Care Med 2008;178:306-12. 

11A.93 Kwon YS et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively 

drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502. 

11A.94 Chan ED et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin 

Infect Dis 2008;21:587-95. 

11A.95 Eker B et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 

2008;14:1700-6. 

11A.96 Orenstein EW et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic 

review and meta-analysis. Lancet Infect Dis 2009;9:153-61. 

11A.97 Di Perri G et al. Which agents should we use for the treatment of multidrug resistant Mycobacterium 

tuberculosis? J Antimicrob Chemother 2004;54:593-602. 

11A.98 Chan ED et al. Treatment and outcome analysis of 205 patients with multidrug resistant tuberculosis. 


11A.99 Zignol M et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-85. 

11A.100 Matteelli A et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: 

epidemiology and control. Expert Rev Anti Infect Ther 2007;5:857-71. 

11A.101 van Helden PD et al. Antimicrobial resistance in tuberculosis: an international perspective. Expert 


11A.102 Abdel Aziz M er al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-Tuberculosis 

Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54. 

11A.103 Drobniewski F et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document 

E.DEF 8.1). Report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium 

tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of 

the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 

2007;13:1144-56. 

11A.104 Burman WJ et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. 


11A.105 Conde MB et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, 

randomised, controlled phase II trial. Lancet 2009;373:1183-9. 

11A.106 Dietze R et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. 


11A.107 Schecter GF et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 

50:49-55. 

11A.108 von der Lippe B et al. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB). A 

report of ten cases. J Infect 2006;52:92-6. 

11A.109 LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009;22:167-73. 

11A.110 Madariaga MG et al. Extensively drug-resistant tuberculosis. Am J Med 2008;121:835-44. 

11A.111 Kim DH et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant 

tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82. 

11A.112 Jeon CY et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes 

among patients at a tertiary referral hospital. Clin Infect Dis 2008;46:42-9. 

11A113 Kwon YS et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively 

drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502. 

11A.114 Chan ED et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin 

Infect Dis 2008;21:587-95. 

11A.115 Eker B et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 

2008;14:1700-6. 

11A.116 Banerjee R et al. Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Rev 


11A.117 Jassal M et al. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009;9:19-30. 

11A.118 Cegielski JP. Extensively drug-resistant tuberculosis: ―There must be some kind of way out of here‖. 


11A.119 Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with 

extensive resistance to second-line drugs. Worldwide, 2002-2004. Morb Mortal Wkly Rep 2006;55: 

301-5. 

11A.120 Centers for Disease Control and Prevention (CDC). Extensively drug-resistant tuberculosis. United 

States,1993-2006. Morb Mortal Wkly Rep 2007;56:250-3. 

11A.121 Dukes Hamilton C et al. Extensively drug-resistant tuberculosis: are we learning from history or repeating 

it? Clin Infect Dis 2007;45:338-42. 

11A.122 Ginsburg AS et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect 

Dis 2003;37:1448-52. 

11A.123 Shah NS et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 

2007;13:380-7. 

11A.124 Matteelli A et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology 

and control. Expert Rev Anti Infect Ther 2007;5:857-71. 

11A.125 van Helden PD et al. Antimicrobial resistance in tuberculosis: an international perspective. Expert 


11A.126 Abdel Aziz M er al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-Tuberculosis 

Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54. 

11A.127 Mitnick CD et al Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 

2009;359:563-74. 

11B.1 Griffith DE et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous 

mycobacterial diseases. Am J Respir Crit Care Med 2007;175;367-416.

11B.2 Brown-Elliott BA et al. Clinical and taxonomic status of pathogenic non pigmented or late pigmenting 

rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716-46. 

11B.3 Brown-Elliott BA et al. Newly described or emerging human species of non tuberculous mycobacteria. 

Infect Dis Clin North Am 2002,16:187-220. 

11B.4 De Groote MA et al. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006;42:1756- 

63. 

11B.5 Wagner D et al. Non tuberculous mycobacterial infections: a clinical review. Infection 2004;32:257- 

70. 

11B.6 Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect 

2009;15:906-10. 

11B.7 Piersimoni C et al. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent 

persons. Emerg Infect Dis 2009;15:1351-8. 

11B.8 Griffith DE. Nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2010;23:185-90. 

11B.9 Piersimoni C et al. Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent 

patients. Lancet Infect Dis 2008;8:323-34. 

11B.10 Palenque E. Skin disease and non tuberculous atypical mycobacteria. Int J Dermatol 2000;39:659- 

66. 

11B.11 Bartralot R et al. Cutaneous infections due to non tuberculous mycobacteria: histopathologycal review 

of 28 cases. Comparative study between lesions observed in immunosuppressed patients and normal 

hosts. J Cutan Pathol 2000;27:124-9. 

11B.12 Eid AJ et al. Prosthetic joint infection due to rapidly growing mycobacteria: report of 8 cases and review 

of the literature. Clin Infect Dis 2007;45:687-94. 

11B.13 Griffith DE et al. Early results (at 6 months) with intermittent clarithromycin including regimens for lung 

disease due to Mycobacterium avium complex. Clin Infect Dis 2000;30:288-92. 

11B.14 Iseman MD. Medical management of pulmonary disease caused by Mycobacterium avium complex. 

Clin Chest Med 2002;23:633-41. 

11B.15 Kim RD et al. Pulmonary nontuberculous mycobacterial disease. Prospective study of a distinct preexisting 

syndrome. Am J Respir Crit Care Med 2008;178:1066-74. 

11B.16 Iseman MD et al. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit 

Care Med 2008;178:999-1001. 

11B.17 Wallace RJ et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide 

therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis 2002;186: 

266-73. 

11B.18 Lindeboom JA et al. Surgical excision versus antibiotic treatment for cervical nontuberculous mycobacterial 

lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 

44:1057-64. 

11B.19 Corti M et al. Mycobacterium avium complex disease in HIV/AIDS patients. Expert Rev Anti Infect 

Ther 2008;6:351-63. 

11B.20 Karakousis PC et al. Mycobacterium avium complex in patients with HIV infection in the era of highly 

active antiretroviral therapy. Lancet Infect Dis 2004;4:557-65. 

11B.21 Horsburgh CR et al. Disseminated Mycobacterium avium complex disease among patients infected 

with human immunodeficiency virus, 1985-2000. Clin Infect Dis 2001;33:1938-43. 

11B.22 Benson CA et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin 

in combination with ethambutol or rifabutin or both for the treatment of disseminated Mycobacterium 

avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 

37:1234-43. 

11B.23 Dunne M et al. A randomized, double blind trial comparing azithromycin and clarithromycin in the 

treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency 

virus. Clin Infect Dis 2000;31:1245-52. 

11B.24 Hlavsa MC et al. Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. 


11B.25 Rodwell TC et al. Tuberculosis from Mycobacterium bovis in binational communities, United States. 


11B.26 Brandau S et al. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success 

story with room for improvement. Biomed Pharmacother 2007;61:299-305. 

11B.27 Koya MP et al. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 

175:2004-10. 

11B.28 Piersimoni C et al. Mycobacterium celatum pulmonary infection in the immunocompetent: case report 

and review. Emerg Infect Dis 2003;9:399-402. 

11B.29 Christiansen DC et al. Mycobacterium celatum, an emerging pathogen and cause of false positive 

amplified Mycobacterium tuberculosis direct test. Diagn Microbiol Infect Dis 2004;49:19-24. 

11B.30 Chastain MA et al. Mycobacterium chelonae/abscessus complex infection in a liver transplant recipient. 

Int J Dermatol 2001;40:769-74. 

11B.31 Cremades R et al. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. 

J Infect Chemother 2009;15:46-8. 

11B.32 Jeon K et al. Antibiotic treatment of Mycobacterium abscessus lung disease. A retrospective analysis 

of 65 patients. Am J Respir Crit Care Med 2009;180:896-902. 

11B.33 Mateo L et al. Mycobacterium chelonae tenosynovitis of the hand. Semin Arthritis Rheum 2004;34: 

617-22. 

11B.34 Vemulapalli RK et al. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous 

Mycobacterium chelonae infection: case report and literature review. J Infect 2001;43:163-8. 

11B.35 Hay RJ. Mycobacterium chelonae, a growing problem in soft tissue infection. Curr Opin Infect Dis 

2009;22:99-101. 

11B.36 Winthrop KL et al. The clinical management and outcome of nail salon acquired Mycobacterium fortuitum 

skin infection. Clin Infect Dis 2004;38:38-44. 

11B.37 Vinh DC et al. Breast implant infection with Mycobacterium fortuitum group: report of case and review. 

J Infect 2006;52:e63-7. 

11B.38 Chen HH et al. Successive development of cutaneous polyarteritis nodosa, leucocytoclastic vasculitis 

and Sweet‘s syndrome in a patient with cervical lymphadenitis caused by Mycobacterium fortuitum.

Br J Dermatol 2004;151:1096-100. 

11B.39 Adékambi T. Mycobacterium mucogenicum group infection: a review. Clin Microbiol Infect 2009;15: 

911-8. 

11B.40 Lindeboom JA et al. Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum. 


11B.41 Fairhurst RM et al. Mycobacterium haemophilum infections in heart transplant recipients: case report 

and review of the literature. Am J Transplant 2002;2:476-9. 

11B.42 Stürenberg E et al. Disseminated Mycobacterium haemophilum infection as initial manifestation of 

AIDS. Tuberculosis 2004;84:341-5. 

11B.43 Lindeboom JA et al. Surgical excision versus antibiotic treatment for cervical nontuberculous mycobacterial 

lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 

44:1057-64. 

11B.44 Griffith DE et al. Thrice weekly clarithromycin containing regimen for treatment of Mycobacterium kansasii 

lung disease: results of a preliminary study. Clin Infect Dis 2003;37:1178-82. 

11B.45 Brown-Elliott BA et al. In vitro activity of linezolid against slowly growing non tuberculous mycobacteria. 


11B.46 Guna R et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of 

Mycobacterium kansasii. J Antimicrob Chemother 2005;55:950-3. 

11B.47 Alcaide F et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, 

moxifloxacin and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob 


11B.48 Pardillo FE et al. Methods for the classification of leprosy for treatment purposes. Clin Infect Dis 

2007;44:1096-9. 

11B.49 Britton WJ et al. Leprosy. Lancet 2004;363:1209-19. 

11B.50 Scollard DM et al. The continuing challenges of leprosy. Clin Microbiol Rev 2006;19:338-81. 

11B.51 Agrawal A et al. Neurological manifestations of Hansen‘s disease and their management. Clin Neurol 

Neurosurg 2005;107:445-54. 

11B.52 Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 2004;51: 

417-26. 

11B.53 Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. 


11B.54 Ang P et al. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 2000;39: 

343-7. 

11B.55 Bhatty MA et al. Mycobacterium marinum hand infection: case reports and review of literature. Br J 

Plast Surg 2000;53:161-5. 

11B.56 Jernigan JA et al. Incubation period and sources of exposure for cutaneous Mycobacterium marinum 

infection: case report and review of the literature. Clin Infect Dis 2000;31:439-43. 

11B.57 Hess CL et al. Mycobacterium marinum infections of the upper extremity. Plast Reconstruct Surg 

2005;115:55e-9e. 

11B.58 Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect 

2005;133:383-91. 

11B.59 Bråbäck M et al. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, 

linezolid, moxifloxacin, telithromycin and quinupristin-dalfopristin compared to its susceptibilities 

to reference macrolides and quinolones. Antimicrob Agents Chemother 2002;46:1114-6. 

11B.60 Patel NC et al. Mycobacterium simiae cervical lymphadenitis. Pediatr Infect Dis J 2007;26:362-3. 

11B.61 Al-Abdely HM et al. Disseminated Mycobacterium simiae infection in patients with AIDS. J Infect 

2000;41:143-7. 

11B.62 Safdar A et al. Mycobacterium lentiflavum, a recently identified slow-growing mycobacterial species: 

clinical significance in immunosuppressed cancer patients and summary of reported cases of infection. 


11B.63 Walsh DS et al. Buruli Ulcer (Mycobacterium ulcerans infection): a re-emerging disease. Clin Microbiol 

Newslett 2009;31:119-27. 

11B.64 O‘Brien DP et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic 

therapy: findings from a south-eastern Australian case series. Med J Aust 2007;186:58-61. 

11B.65 Wansbrough-Jones M et al. Buruli ulcer: emerging from obscurity. Lancet 2006;367:1849-58. 

11B.66 Sizaire V et al. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect 

Dis 2006;6:288-96. 

11B.67 Ji B et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, 

linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006;50: 

1921-6. 

11B.68 Wansbrough-Jones M et al. Buruli ulcer. A neglected but treatable disease that unnecessarily scars 

African children for life. Br Med J 2005;330:1402-3. 

11B.69 Etuaful S et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium 

ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005;49: 

3182-6. 

11B.70 Sizaire V et al. Mycobacterium ulcerans infection: control, diagnosis and treatment. Lancet Infect Dis 

2006;6:288-96. 

11B.71 van der Werf TS et al. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003;362:1062-4. 

11B.72 Thangaraj HS et al. Emerging aspects of Buruli ulcer. Expert Rev Anti Infect Ther 2003;1:217-22. 

11B.73 Wansbrough-Jones M et al. Buruli ulcer: emerging from obscurity. Lancet 2006;367:1849-58. 

11B.74 van der Werf TS et al. Mycobacterium ulcerans disease. Bull World Health Organ 2005;83:785-91. 

11B.75 van Ingen J et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. 


11B.76 Jenkins PA et al. Pulmonary disease caused by Mycobacterium xenopi in HIV negative patients: five 

year follow-up of patients receiving standardised treatment. Respir Med 2003;97:439-44. 

11B.77 Kerbiriou L et al. Human immunodefiency virus type 1 related Mycobacterium xenopi infection: a need 

to treat? Clin Infect Dis 2003;37:1250-4. 

11B.78 Lounis N et al. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimi-

crob Agents Chemother 2001;45:3229-30. 

11B.79 Meybeck A et al. Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1 

infected patient: case report and review of the literature. J Clin Microbiol 2005;43:1465-6. 

11B.80 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic 


207. 

11B.81 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treat-ment of 


58(RR-11):1-167. 

12.1 Benson CA et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium 

avium complex disease in patients with AIDS: a randomized, double blind, placebo controlled 

trial. J Infect Dis 2000;181:1289-97. 

12.2 Brooks JT et al. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection 

in HIV infected persons receiving antiretroviral therapy: observations from a large national cohort 

in the United States: 1992-2002. Clin Infect Dis 2005;41:549-53. 

12.3 El-Sadr WM et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in 

HIV infected patients who have a response to antiretroviral therapy. N Engl J Med 2000;342:1085- 

92. 

12.4 Currier JS et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral 

therapy induced increases in CD4 + cell count. Ann Intern Med 2000;133:493-503. 

12.5 Zeller V et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium 

complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002;34:662-7. 

12.6 Zeller V et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium 

complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002;34:662-7. 



207. 

12.8 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treat-ment of 


58(RR-11):1-167. 

13A.1 Saukkonen JJ et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir 

Crit Care Med 2006;174:935-52. 

131.2 Sharma SK et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development 

of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010;50:833-9. 

13A.3 Global Alliance for TB Drug Development. Ethambutol. Tuberculosis 2008;88:102-5. 

13A.4 Griffith DE et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex 

lung disease. Am J Respir Crit Care Med 2005;172:250-3. 

13A.5 Global Alliance for TB Drug Development. Isoniazid. Tuberculosis 2008;88:112-6. 

13A.6 Global Alliance for TB Drug Development. Pyrazinamide. Tuberculosis 2008;88:141-4. 

13A.7 Chang KC et al. Hepatotoxicity of pyrazinamide. Cohort and case-control analyses. Am J Respir Crit 

Care Med 2008;177:1391-6. 



13A.9 Global Alliance for TB Drug Development. Rifampin. Tuberculosis 2008;88:151-4. 

13A.10 Peloquin CA et al. Aminoglycoside toxicity: daily versus thrice weekly dosing for treatment of mycobacterial 

diseases. Clin Infect Dis 2004;38:1538-44. 

13A.11 Global Alliance for TB Drug Development. Streptomycin. Tuberculosis 2008;88:162-3. 

13A.12 Global Alliance for TB Drug Development. Kanamycin. Tuberculosis 2008;88:117-8. 

13A.13 Global Alliance for TB Drug Development. Ethionamide. Tuberculosis 2008;88:106-8. 

13A.14 Global Alliance for TB Drug Development. Amikacin. Tuberculosis 2008;88:87-8. 

13A.15 Global Alliance for TB Drug Development. Clarithromycin. Tuberculosis 2008;88:92-5. 

13A.16 Global Alliance for TB Drug Development. Levofloxacin. Tuberculosis 2008;88:119-21. 

13A.17 Global Alliance for TB Drug Development. Linezolid. Tuberculosis 2008;88:122-25. 

13A.18 Global Alliance for TB Drug Development. Moxifloxacin. Tuberculosis 2008;88:127-31. 

13A.19 Global Alliance for TB Drug Development. Capreomycin. Tuberculosis 2008;88:89-91. 

13A.20 Global Alliance for TB Drug Development. Clofazimine. Tuberculosis 2008;88:96-9. 

13A.21 Global Alliance for TB Drug Development. Cycloserine. Tuberculosis 2008;88:100-1. 

13A.22 Global Alliance for TB Drug Development. Para-aminosalicylic acid. Tuberculosis 2008;88:137-8. 

13A.23 Global Alliance for TB Drug Development. Prothionamide. Tuberculosis 2008;88:139-40. 

13A.24 Hyldahl Olesen H et al. Rifabutin associated uveitis in a child. Pediatr Infect Dis J 2005;24:1023-5. 

13A.25 Global Alliance for TB Drug Development. Rifabutin. Tuberculosis 2008;88:145-7. 

13B.1 Demirovic JA et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst 

Pharm 2009;66:642-8. 

13B.2 Pai MP et al. Antimicrobial dosing considerations in obese adult patients: insights from the Society of 


13B.3 Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive 

Care Med 2004;30:18-32. 

13B.4 Wurtz R et al. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-8. 

13B.5 Falagas ME et al. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 

2010;375:248-51. 

13B.6 Mushatt DM et al. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009;49:433-7. 

13B.7 Livornese LL et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2004;18: 

551-79. 

13B.8 Trotman RL et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement 


13B.9 Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a


14A.1 Okhuysen PC. Traveler‘s diarrhea due to intestinal protozoa. Clin Infect Dis 2001;33:110-4. 

14A.2 Harhay MO et al. Epidemiology and control of human gastrointestinal parasites in children. Expert 


14A.3 Lewthwaite P et al. Gastrointestinal parasites in the immunocompromised. Curr Opin Infect Dis 

2005;18:427-35. 

14A.4 Lean S et al. Management of protozoa-related diarrhea in HIV infection. Expert Rev Anti Infect Ther 

2003;1:455-69. 

14A.5 Derouin F et al. Treatment of parasitic diarrhea in HIV-infected patients. Expert Rev Anti Infect Ther 

2008;6:337-49. 

14A.6 Stark D et al. Clinical significance of enteric protozoa in the immunosuppressed human population. 


14A.7 Salles JM et al. Invasive amebiasis: an update on diagnosis and management. Expert Rev Anti Infect 

Ther 2007;5:893-901. 

14A.8 Haque R et al. Amebiasis. N Engl J Med 2003;348:1565-73. 

14A.9 Stanley SL. Amoebiasis. Lancet 2003;361:1025-34. 

14A.10 Fotedar R et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 2007; 

20:511-32. 

14A.11 Pritt BS et al. Amebiasis. Mayo Clin Proc 2008;83:1154-60. 

14A.12 Rossignol JF et al. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007; 

101:1025-31. 

14A.13 Schuster FL et al. Current world status of Balantidium coli. Clin Microbiol Rev 2008;21:626-38. 

14A.14 Tan KS. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin 

Microbiol Rev 2008;21:639-65. 

14A.15 Moghaddam DD et al. Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/sulfamethoxazole. 

Parasitol Res 2005;96:273-5. 

14A.16 Sohail MR et al. Blastocystis hominis and travelers. Travel Med Infect Dis 2005;3:33-8. 

14A.17 Stensvold CR et al. Pursuing the clinical significance of Blastocystis. Diagnostic limitations. Trends 

Parasitol 2008;25:23-9. 

14A.18 Rossignol JF et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis 

hominis. Clin Gastroenterol Hepatol 2005;3:987-91. 

14A.19 Davies AP et al. Cryptosporidiosis. Br Med J 2009;339:963-7. 

14A.20 Pantenburg B et al. Treatment of cryptosporidiosis. Expert Rev Anti Infect Ther 2009;7:385-91. 

14A.21 Hunter PR et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin Infect 

Dis 2004;39:504-10. 

14A.22 Chen XM et al. Cryptosporidiosis. N Engl J Med 2002;346:1723-31. 

14A.23 Smith HV et al. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004;17:557- 

64. 

14A.24 Thompson RC et al. Cryptosporidium and cryptosporidiosis. Adv Parasitol 2005;59:77-158. 

14A.25 Armson A et al. A review of chemotherapeutic approaches to the treatment of cryptosporidiosis. Expert 


14A.26 Cacciò SM et al. Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis. Expert 


14A.27 Zardi EM et al. Treatment of cryptosporidiosis in immunocompromised hosts still an open question. 

Chemotherapy 2005;51:193-6. 

14A.28 Hewitt RG et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in 

patients with advanced human immunodeficiency virus infection. Clin Infect Dis 2000;31:1084-92. 

14A.29 Ortega YR et al. Update on Cyclospora cayetanensis, a foodborne and waterborne parasite. Clin Microbiol 

Rev 2010;23:818-34. 

14A.30 Verdier RI et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis 

of Isospora belli and Cyclospora cayetanensis infection in HIV infected patients. A randomized, 

controlled trial. Ann Intern Med 2000;132:885-8. 

14A.31 Zimmer SM et al. Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. Clin Infect 

Dis 2007;44:466-7. 

14A.32 Stark D et al. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 2010;82: 

614-9. 

14A.33 Johnson EH et al. Emerging from obscurity: biological, clinical and diagnostic aspects of Dientamoeba 

fragilis. Clin Microbiol Rev 2004;17:553-70. 

14A.34 Stark DJ et al. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol 2006;22: 

92-6. 

14A.35 Vandenberg O et al. Treatment of Dientamoeba fragilis infection with paromomycin. Pediatr Infect 

Dis J 2007;26:88-90. 

14A.36 Gardner TB et al. Treatment of giardiasis. Clin Microbiol Rev 2001;14:114-28. 

14A.37 Nash TE et al. Treatment of patients with refractory giardiasis. Clin Infect Dis 2001;33:22-8. 

14A.38 Verdier RI et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis 

of Isospora belli and Cyclospora cayetanensis infection in HIV infected patients. A randomized, 

controlled trial. Ann Intern Med 2000;132:885-8. 

14A.39 Didier ES et al. Therapeutic strategies for human microsporidia infections. Expert Rev Anti Infect 

Ther 2005;3:419-34. 

14A.40 Mathis A et al. Zoonotic potential of the microsporidia. Clin Microbiol Rev 2005;18:423-45. 

14A.41 Didier ES. Microsporidiosis: an emerging and opportunistic infection in humans and animals. Acta 

Trop 2005;94:61-76. 

14A.42 Groβ U. Treatment of microsporidiosis including albendazole. Parasitol Res 2003;90(suppl. 1):S14- 

8. 

14A.43 Molina JM et al. Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002;346:1963-9. 

14A.44 Fayer R. Sarcocystis spp. in humans. Clin Microbiol Rev 2004;17:894-902. 

14A.45 Sra KK et al. Treatment of protozoan infections. Dermatol Ther 2004;17:513-6. 

14A.46 Walker MD et al. Neuroparasitic infections: cestodes, treamtodes and protozoans. Semin Neurol 

2005;25:262-77. 

14A.47 Haque R et al. Amebiasis. N Engl J Med 2003;348:1565-73. 

14A.48 Visvesvara GS et al. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia 

mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 2007;

50:1-26. 

14A.49 Schuster FL et al. Opportunistic amoebae: prophylaxis and treatment. Drug Resist Updates 2004;7: 

41-51. 

14A.50 Schuster FL et al. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans 

and animals. Int J Parasitol 2004;34:1001-27. 

14A.51 Schuster FL et al. In vitro activity of miltefosine and voriconazole on clinical isolates of free-living 

amebas: Balamuthia mandrillaris, Acanthamoeba spp. and Naegleria fowleri. J Eukaryot Microbiol 

2006;53:121-6. 

14A.52 Schuster FL et al. Under the radar: Balamuthia amebic encephalitis. Clin Infect Dis 2009;48:879-87. 

14A.53 Matin A et al. Increasing importance of Balamuthia mandrillaris. Clin Microbiol Rev 2008;21:435-48. 

14A.54 Jung S et al. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient. Arch Pathol 

Lab Med 2004;128:466-8. 

14A.55 Marciano-Cabral F et al. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 

2003;16:273-307. 

14A.56 Singhal T et al. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. 


14A.57 Deetz TR et al. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. 


14A.58 Slater CA et al. Successful treatment of disseminated Acanthamoeba infection in an immuno-compromised 

patient. N Engl J Med 1994;331:85-7. 

14A.59 Kim JH et al. Effect of therapeutic chemical agents in vitro and on experimental meningoen-cephalitis 

due to Naegleria fowleri. Antimicrob Agents Chemother 2008;52:4010-6. 

14A.60 Vargas-Zepeda J et al. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous 

amphotericicn B, fluconazole and rifampicin. Arch Med Res 2005;36:83-6. 

14A.61 Soltow SM et al. Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in 

vitro and in a mouse model of primary amebic meningoencephalitis. Antimicrob Agents Chemother 

2007;51:23-7. 

14A.62 Gelman BB et al. Amoebic encephalitis due to Sappinia diploidea. J Am Med Assoc 2001;285:2450- 

1. 

14A.63 Wormser GP et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients 

with Babesia microti infection. Clin Infect Dis 2010;50:381-6. 

14A.64 Vannier E et al. Human babesiosis. Infect Dis Clin North Am 2008;22:469-88. 

14A.65 Kuwayama DP et al. Spontaneous splenic rupture caused by Babesia microti infection. Clin Infect 

Dis 2008;46:e92-5. 

14A.66 Wormser GP et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic 



14A.67 Krause PJ. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 

2008;46:370-6. 

14A.68 Powell VI et al. Exchange transfusion for malaria and Babesia infection. Transfus Med Rev 2002;16: 

239-50. 

14A.69 Krause PJ et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000; 

343:1454-8. 

14A.70 Schriefer A et al. Recent developments leading toward a paradigm switch in the diagnostic and therapeutic 

approach to human leishmaniasis. Curr Opin Infect Dis 2008;21:483-8. 

14A.71 Murray HW et al. Advances in leishmaniasis. Lancet 2005;366:1561-77. 

14A.72 Croft SL et al. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19:111-26. 

14A.73 van Griensven J et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010;10: 

184-94. 

14A.74 Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob 


14A.75 Bern C et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 

2006;43:917-24. 

14A.76 Sundar S et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus 

alternate-day infusions. Clin Infect Dis 2007;45:556-61. 

14A.77 Sundar S et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. 


14A.78 Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert 


14A.79 den Boer M et al. Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 2006;4: 

187-97. 

14A.80 Olliaro PL et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies 

done in India, 1980-2004. Lancet Infect Dis 2005;5:763-74. 

14A.81 Antinori S et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008;8:191-9. 

14A.82 Murray HW. Kala-azar. Progress against a neglected disease. N Engl J Med 2002;347:1793-4. 

14A.83 Davidson RN et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B. 


14A.84 Sundar S et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J 

Med 2010;362:504-12. 

14A.85 Sundar S et al. Short course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis 

unresponsive to antimony. Ann Intern Med 1997;127:133-7. 

14A.86 di Martino L et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 

1997;131:271-7. 

14A.87 Syriopoulo V et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean 

visceral leishmaniasis. Clin Infect Dis 2003;36:560-6. 

14A.88 Jacobs S. An oral drug for leishmaniasis. N Engl J Med 2002;347:1737-8. 

14A.89 Sundar S et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46. 

14A.90 Sundar S et al. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. 


14A.91 Soto J et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect 

Dis 2001;33:e57-61. 

14A.92 Lira R et al. Evidence that high incidence of treatment failures in Indian kala-azar is due to the emergence 

of antimony resistant strains of Leishmania donovani. J Infect Dis 1999;180:564-7.

14A.93 Sundar S et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin 

B followed by short-course oral miltefosine. Clin Infect Dis 2008;47:1000-6. 

14A.94 Thakur CP. Sodium antimony gluconate, amphotericin and myocardial damage. Lancet 1998;351: 

1928-9. 

14A.95 Sundar S et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356: 

2571-81. 

14A.96 Sundar S et al. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21day 


14A.97 Blum J et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 

2004;53:158-66. 

14A.98 Schwartz E et al. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006;6:342-9. 

14A.99 Reithinger R et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96. 

14A.100 Magill AJ. Cutaneous leishmaniasis in the returning traveller. Infect Dis Clin North Am 2005;19:241- 

66. 

14A.101 Minodier P et aL. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007;5:150-8. 

14A.102 Hepburn NC. Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infect 

Ther 2003;1:563-70. 

14A.103 Goto H et al. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert 


14A.104 Schwartz E et al. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006;6:342-9. 

14A.105 Arevalo J et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in 

patients with American tegumentary leishmaniasis. J Infect Dis 2007;195:1846-51. 

14A.106 Rojas R et al. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. 

J Infect Dis 2006;193:1375-83. 

14A.107 Miranda-Verastegui C et al. First-line therapy for human cutaneous leishmaniasis in Peru using the 

TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Neglected Trop Dis 2009; 

3:e491. 

14A.108 Arevalo I et al. Successful treatment of drug resistant cutaneous leishmaniasis in humans by use of 

imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51. 

14A.109 Arevalo I et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous 

leishmaniasis. Clin Infect Dis 2007;44:1549-54. 

14A.110 Machado PR et al. Oral pentoxyfilline combined with pentavalent antimony: a randomized trial for mucosal 

leishmaniasis. Clin Infect Dis 2007;44:788-93. 

14A.111 Santos JB et al. Antimony plus recombinant human granulocyte macrophage colony stimulating factor 

applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, 

double-blind, placebo-controlled study. J Infect Dis 2004;190:1793-6. 

14A.112 Soto J et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38:1266-72. 

14A.113 Soto J et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007;44: 

350-6. 

14A.114 Soto J et al. Short report: efficacy of extended (six weeks) treatment with miltefosine for mucosal 

leishmaniasis in Bolivia. Am J Trop Med Hyg 2009;81:387-9. 

14A.115 Reithinger R et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7:581-96. 

14A.116 Blum J et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 

2004;53:158-66. 

14A.117 Crogan J et al. Management of Old World cutaneous leishmaniasis in refugee children. Pediatr 

Infect Dis J 2010;29:357-9. 

14A.118 Goto H et al. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert 


14A.119 Alrajhi AA et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. 

N Engl J Med 2002;346:891-5. 

14A.120 World Health Organization. Guidelines for the treatment of malaria (second edition). Available at: 

http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf. Accessed on August 11th 2010. 

14A.121 Rogerson SJ et al. Treatment and prevention of malaria in pregnancy: opportunities and challenges. 


14A.122 Nosten F et al. Case management of malaria in pregnancy. Lancet Infect Dis 2007;7:118-25. 

14A.123 Ward SA et al. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. 


14A.124 Alvarez JR et al. Malaria in pregnancy. Infect Dis Obstet Gynecol 2005;13:229-36. 

14A.125 Tagbor H et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine 

used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet 2006; 

368:1349-56. 

14A.126 McGready R et al. Malaria and the pregnant traveller. Travel Med Infect Dis 2004;2:127-42. 

14A.127 Crawley J et al. Malaria in children. Lancet 2010;375:1468-81. 

14A.128 Stauffer W et al. Diagnosis and treatment of malaria in children. Clin Infect Dis 2003;37:1340-8. 

14A.129 Lalloo DG et al. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. 


14A.130 Bell DJ et al. Treatment of childhood Plasmodium falciparum malaria: current challenges. Expert Rev 


14A.131 Baird JK. Effectiveness of antimalarial drugs. N Engl J Med 2005;352:1565-77. 

14A.132 Stauffer WM et al. Diagnostic performance of rapid diagnostic tests versus blood smears for malaria 

in US clinical practice. Clin Infect Dis 2009;49:908-13. 

14A.133 Murray CK et al. Update on rapid diagnostic testing for malaria. Clin Microbiol Rev 2008;21:97-110. 

14A.134 Griffith KS et al. Treatment of malaria in the United States. A systematic review. J Am Med Assoc 

2007;297:2264-77. 

14A.135 Whitty CJ et al. Malaria: an update on treatment of adults in non-endemic countries. Br Med J 2006; 

333:241-5. 

14A.136 Ashley E et al. Malaria. Travel Med Infect Dis 2006;4:159-73. 

14A.137 Greenwood BM et al. Malaria. Lancet 2005;365:1487-98. 

14A.138 White NJ. The treatment of malaria. N Engl J Med 1996;335:800-6. 

14A.139 Collins WE et al. Plasmodium malariae: parasite and disease. Clin Microbiol Rev 2007;20:579-92. 

14A.140 Daneshvar C et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect 

Dis 2009;49:852-60. 

14A.141 Putaporntip C et al. Differential prevalence of Plasmodium infections and cryptic Plasmodium knowle-

si malaria in humans in Thailand. J Infect Dis 2009;199:1143-50. 

14A.142 Collins WE et al. Plasmodium knowlesi: finally being recognized. J Infect Dis 2009;199:1107-8. 

14A.143 Cox-Singh J et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially lifethreatening. 


14A.144 White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 2008;46:172-3. 

14A.145 Adjei GO et al. Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children. 


14A.146 Hatz C et al. Treatment of acute uncomplicated falciparum malaria with arthemeter-lumefantrine in 

non-immune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg 2008; 

78:241-7. 

14A.147 Nosten F et al. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 

2007;77(suppl. 6):181-92. 

14A.148 Idro R et al. Pathogenesis, clinical features and neurological outcome of cerebral malaria. Lancet 

Neurol 2005;4:827-40. 

14A.149 Golenser J et al. Conventional and experimental treatment of cerebral malaria. Int J Parasitol 2006; 

36:583-93. 

14A.150 Maitland K et al. Management of severe malaria in children: proposed guidelines for the United Kingdom. 

Br Med J 2005;331:337-43. 

14A.151 South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine 

for treatment of severe Plasmodium falciparum malaria: a randomised trial. Lancet 2005;366:717-25. 

14A.152 Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008;358: 

1829-36. 

14A.153 Pasvol G et al. Management of severe malaria: interventions and controversies. Infect Dis Clin 

North Am 2005;19:211-40. 


2007;77(suppl. 6):181-92. 

14A.155 Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008;358: 

1829-36. 


2007;77(suppl. 6):181-92. 

14A.157 Markley JD et al. Post-malaria neurological syndrome: a case report and review of the literature. J 

Travel Med 2009;16:424-30. 

14A.158 Lell B et al. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 

2002;46:2315-20. 

14A.159 Powell VI et al. Exchnage transfusion for malaria and Babesia infection. Transfus Med Rev 2002;16: 

239-50. 

14A.160 Riddle MS et al. Exchange transfusion as an adjunct therapy in severe Plasmodium falciparum malaria: 

a meta-analysis. Clin Infect Dis 2002;34:1192-8. 

14A.161 Price RN et al. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine 

resistance. Curr Opin Infect Dis 2009;22:430-5. 

14A.162 Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009;22: 

508-34. 

14A.163 Tan LK et al. Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet 

Infect Dis 2008;8:449-54. 

14A.164 Mueller I et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. 


14A.165 Douglas NM et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010;10:405- 

16. 

14A.166 Collins WE et al. Plasmodium ovale: parasite and disease. Clin Microbiol Rev 2005;18:570-81. 

14A.167 Baird JK et al. Primaquine therapy for malaria. Clin Infect Dis 2004;39:1336-45. 

14A.168 Didier ES et al. Therapeutic strategies for human microsporidia infections. Expert Rev Anti Infect 

Ther 2005;3:419-34. 

14A.169 Mathis A et al. Zoonotic potential of the microsporidia. Clin Microbiol Rev 2005;18:423-45. 

14A.170 Didier ES. Microsporidiosis: an emerging and opportunistic infection in humans and animals. Acta 

Trop 2005;94:61-76. 

14A.171 Groβ U. Treatment of microsporidiosis including albendazole. Parasitol Res 2003;90(suppl. 1):S14- 

8. 

14A.172 Coyle CM et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N 

Engl J Med 2004;351:42-7. 

14A.173 Bonfioli AA et al. Toxoplasmosis. Semin Ophtahlmol 2005;20:129-41. 

14A.174 Montoya JG et al. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 

2008;47:554-66. 

14A.175 Kravetz JD et al. Toxoplamosis in pregnancy. Am J Med 2005;118:212-6. 

14A.176 McAuley JB. Toxoplasmosis in children. Pediatr Infect Dis J 2008;27:161-2. 

14A.177 Montoya JG et al. Toxoplasmosis. Lancet 2004;363:1965-76. 

14A.178 Leal FE et al. Toxoplasma gondii pneumonia in immunocompetent subjects: case report and review. 


14A.179 Ciardelli L et al. Early and accurate diagnosis of congenital toxoplamosis. Pediatr Infect Dis J 2008; 

27:125-9. 

14A.180 Petersen E. Prevention and treatment of congenital toxoplasmosis. Expert Rev Anti Infect Ther 

2007;5:285-93. 

14A.181 The SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of prenatal 

treatment for congenital toxoplasmosis: a meta-analysis of individual patients‘ data. Lancet 

2007;369:115-22. 

14A.182 Liesenfeld O et al. Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in 

pregnant women: experience in a US reference laboratory. J Infect Dis 2001;183:1248-53. 

14A.183 Torre D et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine 

for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother 1998; 

42:1346-9. 

14A.184 Remington JS et al. Recent developments for diagnosis of toxoplasmosis. J Clin Microbiol 2004;42: 

941-5. 

14A.185 Nanda N et al. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther 2006;4:125-35. 

14A.186 Okun N et al. Antibiotics for bacterial vaginosis and Trichomonas vaginalis in pregnancy: a systematic

eview. Obstet Gynecol 2005;105:857-68. 

14A.187 Wendel KA et al. Trichomoniasis: challenges to appropriate management. Clin Infect Dis 2007;44 

(suppl. 3):S123-9. 

14A.188 Spence D et al. Vaginal discharge. Br Med J 2007;335:1147-51. 

14A.189 Seña AC et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, 

treatment, and prevention. Clin Infect Dis 2007;44:13-22. 

14A.190 Barrett MP et al. The trypanosomiases. Lancet 2003;362:1469-80. 

14A.191 Brun R et al. Human African trypanosomiasis. Lancet 2010;375:148-59. 

14A.192 Jannin J et al. Treatment and control of human African trypanosomiasis. Curr Opin Infect Dis 2004; 

17:565-70. 

14A.193 Balasegaram M et al. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense 

sleeping sickness in nine Médecins Sans Frontières programmes. Trans R Soc Trop Med 

Hyg 2009;103:280-90. 

14A.194 Schmid C et al. Effectivenes of a 10-day melarsoprol schedule for the treatment of late stage human 

African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005; 

191:1922-31. 

14A.195 Priotto G et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma 

brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 

2009;374:56-64. 

14A.196 Priotto G et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei 

gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007;45:1435-42. 

14A.197 Chappuis F. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the 

way to go. Clin Infect Dis 2007;45:1443-5. 

14A.198 Checchi F et al. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. 

PLoS Neglected Trop Dis 2007;1:e64. 

14A.199 Bisser S et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy 

for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 

2007;195:322-9. 

14A.200 Rassi A et al. Chagas disease. Lancet 2010;375:1398-1402. 

14A.201 Viotto R et al. Side effects of benznidazole as treatment in chronic Chages disease: fears and realities. 


14A.202 Rocha MO et al. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect 

Ther 2007;5:727-43. 

14A.203 Bern C et al. Evaluation and treatment of Chagas disease in the United States. A systematic review. 

J Am Med Assoc 2007;298:2171-81. 

14A.204 Prata A. Clinical and epidemiological aspects of Chagas‘ disease. Lancet Infect Dis 2001;1:92-100. 

14A.205 DiazGranados CA et al. Chagasic encephalitis in HIV patients: common presentation of an evolving 

epidemiological and clinical association. Lancet Infect Dis 2009;9:324-30. 

14A.206 Sgambatti de Andrade AL et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma 

cruzi infection. Lancet 1996;348:1407-13. 

14A.207 Estani SS et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of 

Chagas‘ disease. Am J Trop Med Hyg 1998;59:526-9. 

14A.208 Fernandes CD et al. Efficacy of benznidazol treeatment for asymptomatic chagasic patients from 

state Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 2009; 

104:27-32. 

14A.209 Viotti R et al. Etiological treatment of chronic Chagas disease: neglected ‘evidence‘ by evidence-based 

medicine. Expert Rev Anti Infect Ther 2007;5:717-26. 

14A.210 Viotti R et al. Long term cardiac outcomes of treating chronic Chagas disease with benznidazole versus 

no treatment. A non randomized trial. Ann Intern Med 2006;144:724-34. 

14A.211 Pinazo MJ et al. Successful treatment with posaconazole of a patient with chronic Chagas disease 

and systemic lupus erythematosus. Am J Trop Med Hyg 2010;82:583-7. 

14A.212 Hamer DH. Intestinal nematodes. Infect Dis Clin Pract 1996;5:473-81. 

14A.213 Harhay MO et al. Epidemiology and control of human gastrointestinal parasites in children. Expert 


14A.214 Eziefula AC et al. Intestinal nematodes: disease burden, deworming and the potential importance of 

co-infection. Curr Opin Infect Dis 2008;21:516-22. 

14A.215 Keiser J et al. Efficacy of current drugs against soil-transmitted helminth infections: systematic review 

and meta-analysis. J Am Med Assoc 2008;299:1937-48. 

14A.216 Bethony J et al. Soil-transmitted helminth infections: ascariasis, trichuriasis and hookworm. Lancet 

2006;367:1521-32. 

14A.217 Massara CL et al. Treatment options in the management of Ascaris lumbricoides. Expert Opin Pharmacother 

2004;5:529-39. 

14A.218 Georgiev VS. Chemotherapy of enterobiasis (oxyuriasis). Expert Opin Pharmacother 2001;2:267- 

75. 

14A.219 Heukelbach J et al. Efficacy of ivermectin in a patient population concomitantly infected with intestinal 

helminths and ectoparasites. Arzneimittelforschung 2004;54:416-21. 

14A.220 Keiser J et al. Efficacy of current drugs against soli-transmitted helminth infections: systematic review 


14A.221 Brooker S et al. Human hookworm infection in the 21 st century. Adv Parasitol 2004;58:197-288. 

14A.222 Bethony J et al. Soil transmitted helminth infections: ascariasis, trichuriasis and hookworm. Lancet 

2006;367:1521-32. 

14A.223 Hotez PJ et al. Hookworm infection. N Engl J Med 2004;351:799-807. 

14A.224 Concha R et al. Intestinal strongyloidiasis: recognition, management and determinants of outcome. J 

Clin Gastroenterol 2005;39:203-11. 

14A.225 Satoh M et al. Treatment strategies in controlling strongyloidiasis. Expert Opin Pharmacother 2004; 

5:2293-301. 

14A.226 Igual-Adell R et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. 


14A.227 Roxby AC et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation 

of ivermectin. Clin Infect Dis 2009;49:1411-23. 

14A.228 Pacanowski J et al. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis 

hyperinfection syndrome: a case report. Am J Trop Med Hyg 2005;73:122-4. 

14A.229 Turner SA et al. Parenteral administration of ivermectin in a patient with disseminated strongyloidia-

sis. Am J Trop Med Hyg 2005;73:911-4. 

14A.230 Marty FM et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation 

of ivermectin. Clin Infect Dis 2005;41:e5-8. 

14A.231 Mittermayer S et al. Prevention of strongyloides hyperinfection syndrome: a rheumatological point of 

view. Eur J Intern Med 2009;20:744-8. 

14A.232 Keiser J et al. Efficacy of current drugs against soil-transmitted helminth infections: systematic review 


14A.233 Bethony J et al. Soil transmitted helminth infections: ascariasis, trichuriasis and hookworm. Lancet 

2006;367:1521-32. 

14A.234 Walker MD et al. Neuroparasitic infections: nematodes. Semin Neurol 2005;25:252-61. 

14A.235 Graeff-Teixeira C et al. Update on eosinophilic meningoencephalitis and its clinical relevance. Clin 


14A.236 Ali AB et al. Eosinophilic meningitis due to Angiostrongylus cantonensis in a Belgian traveller. Travel 


14A.237 Ramirez-Avila L et al. Eosinophilic meningitis due to Angiostrongylus and Gnathostoma species. Clin 

Infect Dis 2009;48:322-7. 

14A.238 Wang QP et al. Human angiostrongyliasis. Lancet Infect Dis 2008;8:621-30. 

14A.239 Chotmongkol V et al. Corticosteroid treatment of eosinophilic meningitis. Clin Infect Dis 2000;31: 

660-2. 

14A.240 Chotmongkol V et al. Comparison of prednisolone plus albendazole with prednisolone alone for treatment 

of patients with eosinophilic meningitis. Am J Trop Med Hyg 2009;81:443-5. 

14A.241 Nawa F et al. Sushi delights and parasites: the risk of fishborne and foodborne parasitic zoonoses in 

Asia. Clin Infect Dis 2005;41:1297-1303. 

14A.242 Butt AA et al. Infections related to the ingestion of seafood. Part II: parasitic infections and food safety. 


14A.243 Pacios E et al. Albendazole for the treatment of anisakiasis ileus. Clin Infect Dis 2005;41:1825-6. 

14A.244 Audicana MT et al. Anisakis simplex: from obscure infectious worm to inducer of immune hypersensitivity. 


14A.245 Moore DA et al. Treatment of anisakiasis with albendazole. Lancet 2002;360:54. 

14A.246 Gavin PJ et al. Baylisascariasis. Clin Microbiol Rev 2005;18:703-18. 

14A.247 Murray WJ et al. Raccoon roundworm encephalitis. Clin Infect Dis 2004;39:1484-92. 

14A.248 Heukelbach J et al. Epidemiological and clinical characteristics of hookworm-related cutaneous larva 

migrans. Lancet Infect Dis 2008;8:302-9. 

14A.249 Simon MW et al. Cutaneous larva migrans. Pediatr Emerg Care 2003;19:350-2. 

14A.250 Caumes E. Treatment of cutaneous larva migrans. Clin Infect Dis 2000;30:811-4. 

14A.251 Jelinek T et al. Human dirofilariasis. Int J Dermatol 1996;35:872-5. 

14A.252 Muro A et al. Human dirofilariasis in the European Union. Parasitol Today 1999;15:386-9. 

14A.253 Cairncross S et al. Dracunculiasis (Guinea worm disease) and the eradication initiative. Clin Microbiol 

Rev 2002;15:223-46. 

14A.254 Rohde JE et al. Surgical extraction of Guinea worm: disability reduction and contribution to disease 

control. Am J Trop Med Hyg 1993;48:71-6. 

14A.255 Hoerauf A. New strategies to combat filariasis. Expert Rev Anti Infect Ther 2006;4:211-22. 

14A.256 Padgett JJ et al. Loiasis: African eye worm. Trans R Soc Trop Med Hyg 2008;102:983-9. 

14A.257 Fischer P et al. Treatment of human Mansonella streptocerca infection with ivermectin. Trop Med Int 

Health 1997;2:191-9. 

14A.258 Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. Clin Infect Dis 2007;44:53- 

60. 

14A.259 Hoerauf A et al. Onchocerciasis. Br Med J 2003;326:207-10. 

14A.260 Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. 


14A.261 Bregani ER et al. Comparison of different anthelminthic drug regimens against Mansonella perstans 

filariasis. Trans R Soc Trop Med Hyg 2006;100:458-63. 



14A.263 Coulibaly YI et al. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med 

2009;361:1448-58. 

14A.264 Bockarie MJ et al. Current practices in the management of lymphatic filariasis. Expert Rev Anti Infect 

Ther 2009;7:595-605. 

14A.265 Supali T et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and 

adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008;46: 

1385-93. 

14A.266 Taylor MJ et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a doubleblind, 

randomised, placebo-controlled trial. Lancet 2005;365:2116-21. 



14A.268 Chitkara RK et al. Parasitic pulmonary eosinophilia. Semin Respir Crit Care Med 2006;27:171-84. 

14A.269 Ramirez-Avila L et al. Eosinophilic meningitis due to Angiostrongylus and Gnathostoma species. Clin 

Infect Dis 2009;48:322-7. 

14A.270 Herman JS et al. Gnathostomiasis, another emerging imported disease. Clin Microbiol Rev 2009; 

22:484-92. 

14A.271 Chappuis F et al. Ivermectin treatment of a traveler who returned from Peru with cutaneous gnathostomiasis. 


14A.272 Strady C et al. Long-term follow-up of imported gnathostomiasis shows frequent treatment failure. Am 

J Trop Med Hyg 2009;80:33-5. 

14A.273 Despommier D. Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects. 


14A.274 Smith H et al. How common is human toxocariasis? Towards standardizing our knowledge. Trends 

Parasitol 2009;25:182-8. 

14A.275 Gottstein B et al. Epidemiology, diagnosis, treatment and control of trichinellosis. Clin Microbiol Rev 

2009;22:127-45. 

14A.276 Watt G et al. Areas of uncertainty in the management of human trichinellosis: a clinical perspective. 


14A.277 Pozio E et al. Clinical aspects, diagnosis and treatment of trichinellosis. Expert Rev Anti Infect Ther

2003;1:471-82. 

14A.278 Walker MD et al. Neuroparasitic infections: cestodes, trematodes and protozoans. Semin Neurol 

2005;25:262-77. 

14A.279 Keiser J et al. Food-borne trematodiasis: current chemotherapy and advances with artemisinins and 

synthetic trioxolanes. Trends Parasitol 2007;23:555-62. 

14A.280 Keiser J et al. Food-borne trematodiases. Clin Microbiol Rev 2009;22:466-83. 

14A.281 Marcos LA et al. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. Curr 


14A.282 Lun ZR et al. Clonorchiasis: a key foodborne zoonosis in China. Lancet Infect Dis 2005;5:31-41. 

14A.283 Sing A. Of ants and men (an antology). Clin Infect Dis 2007;44:145-6. 



14A.285 Mas-Coma S et al. Fascioliasis and other plant borne trematode zoonoses. Int J Parasitol 2005;35: 

1255-78. 

14A.286 Keiser J et al. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr 


14A.287 Mas-Coma S et al. Fascioliasis and other plant borne trematode zoonoses. Int J Parasitol 2005;35: 

1255-78. 

14A.288 MacLean JD et al. Common source outbreak of acute infection due to the North American liver fluke 

Metorchis conjunctus. Lancet 1996;347:154-8. 



14A.290 Lane MA et al. Human paragonimiasis in North America following ingestion of raw crayfish. Clin Infect 

Dis 2009;49:e55-61. 

14A.291 Jauréguiberry S et al. Acute schistosomiasis: a diagnostic and therapeutic challenge. Clin Microbiol 

Infect 2010;16:225-31. 

14A.292 Leshem E et al. Acute schistosomiasis outbreak: clinical features and economic impact. Clin Infect 

Dis 2008;47:1499-1506. 

14A.293 Gryseels B et al. Human schistosomiasis. Lancet 2006;368:1106-18. 

14A.294 Blanchard TJ. Schistosomiasis. Travel Med Infect Dis 2004;2:5-11. 

14A.295 Ross AG et al. Schistosomiasis. N Engl J Med 2002;346:1212-20. 

14A.296 Silva LS et al. Treatment of schistosomal myeloradiculopathy with praziquantel and corticosteroids 

and evaluation by magnetic resonance imaging: a longitudinal study. Clin Infect Dis 2004;39:1618- 

24. 

14A.297 Carod-Artal J. Neurological complications of Schistosoma infection. Trans R Soc Trop Med Hyg 

2008;102:107-16. 

14A.298 Ross AG et al. Katayama syndrome. Lancet Infect Dis 2007;7:218-24. 

14A.299 Bottieau E et al. Imported Katayama fever: clinical and biological features at presentation and during 

treatment. J Infect 2006;52:339-45. 

14A.300 Fölster-Holst R et al. Cercarial dermatitis contracted via contact with an aquarium: case report and review. 

Br J Dermatol 2001;145:638-40. 

14A.301 Burkhart CG et al. Swimmer‘s itch: an assessment proposing possible treatment with ivermectin. Int J 

Dermatol 2003;42:917-8. 

14A.302 Raether W et al. Epidemiology, clinical manifestations and diagnosis of zoonotic cestode infections: 

an update. Parasitol Res 2003;91:412-38. 

14A.303 Walker MD et al. Neuroparasitic infections: cestodes, trematodes and protozoans. Semin Neurol 

2005;25:262-77. 

14A.304 Garcia HH. Antiparasitic drugs in neurocysticercosis: albendazole or praziquantel. Expert Rev Anti 

Infect Ther 2008;6:295-8. 

14A.305 Carpio A et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. 

J Neurol Neurosurg Psychiatry 2008;79:1050-5. 

14A.306 Garg RK. Treatment of neurocysticercosis: is it beneficial? Expert Rev Anti Infect Ther 2008;6:435- 

40. 

14A.307 Kaur S et al. Combination therapy with albendazole and praziquantel versus albendazole alone in 

children with seizures and single lesion neurocysticercosis a randomized, placebo-controlled double 

blind trial. Pediatr Infect Dis J 2009;28:403-6. 

14A.308 White AC. New developments in the management of neurocysticercosis. J Infect Dis 2009;199: 

1261-2. 

14A.309 Serpa JA et al. Advances in the diagnosis and management of human neurocysticercosis. Expert 


14A.310 Del Brutto OH et al. Meta-analysis. Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. 

Ann Intern Med 2006;145:43-51. 

14A.311 Schantz PM. Progress in diagnosis, treatment and elimination of echinococcosis and cysticercosis. 

Parasitol Int 2006;5(suppl. 1):S7-13. 

14A.312 García HH et al. Taenia solium cysticercosis. Lancet 2003;362:547-56. 

14A.313 Carpio A. Neurocysticercosis: an update. Lancet Infect Dis 2002;2:751-62. 

14A.314 Garcia HH et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. 

N Engl J Med 2004;350:249-58. 

14A.315 Garcia HH et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). 

Am J Trop Med Hyg 2005;72:3-9. 

14A.316 Abba K et al. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010; 

3:CD000215. 

14A.317 Garg RK. Antiparasitic treatment for solitary cysticercus granuloma: to treat or not to treat? Expert 


14A.318 Baranwal AK et al. Albendazole therapy in children with focal seizures and single small enhancing 

computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. Pediatr Infect 

Dis J 1998;17:696-700. 

14A.319 Proaño JV et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. 

N Engl J Med 2001;345:879-85. 

14A.320 Vazquez ML et al. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. 

Neurology 1987;37:1561-2. 

14A.321 Jung H et al. Dexamethasone increases plasma levels of albendazole. J Neurol 1990;237:279-80. 

14A.322 Mitre E et al. Methotrexate as corticosteroid-sparing agent in complicated neurocysticercosis. Clin In-

fect Dis 2007;44:449-53. 

14A.323 Junghanss T et al. Clinical management of cystic echinococcosis: state of the art, problems and perspectives. 

Am J Trop Med Hyg 2008;79:301-11. 

14A.324 Brunetti E et al. Update on cystic hydatid disease. Curr Opin Infect Dis 2009;22:497-502. 

14A.325 Craig PS et al. Prevention and control of cystic echinococcosis. Lancet Infect Dis 2007;7:375-94. 

14A.326 Schantz PM. Progress in diagnosis, treatment and elimination of echinococcosis and cysticercosis. 

Parasitol Int 2006;5(suppl. 1):S7-13. 

14A.327 Romig T e al. The present situation of echinococcosis in Europa. Parasitol Int 2006;5(suppl. 

1):S187-91. 

14A.328 Jenkins DJ et al. Emergence/re-emergence of Echinococcus spp. A global update. Int J Parasitol 

2005;35:1205-19. 

14A.329 Smego RA et al. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005;9:69-76. 

14A.330 Dervenis C et al. Changing concepts in the management of liver hydatid disease. J Gastrointest 

Surg 2005;9:869-77. 

14A.331 Eckert J et al. Biological, epidemiological and clinical aspects of echinococcosis, a zoonosis of increasing 

concern. Clin Microbiol Rev 2004;17:107-35. 

14A.332 Smego RA et al. Percutaneous aspiration, injection, re-aspiration, drainage plus albendazole or mebendazole 

for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003;37:1073-83. 

14A.333 McManus DP et al. Echinococcosis. Lancet 2003;362:1295-304. 

14A.334 Smego RA et al. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005;9:69-76. 

14A.335 WHO Informal Working Group on Echinococcosis. Guidelines for treatment of cystic and alveolar 

echinococcosis in humans. Bull World Health Organ 1996;74:231-42. 

14A.336 World Health Organization, Department of Communicable Disease, Surveillance and Response. 

PAIR: puncture, aspiration, injection, re-aspiration. An option for the treatment of cystic echinococcosis. 

Available at: http://whqlibdoc.who.int/hq/2001/WHO_CDS_CSR_APH_ 2001. 6.pdf. Accessed 

on October 28 th 2008. 

14A.337 Craig P. Echinococcus multilocularis. Curr Opin Infect Dis 2003;16:437-44. 

14A.338 D‘Alessandro A et al. New aspects of neotropical polycystic (Echinococcus vogeli) and unicystic 

(Echinococcus oligarthrus) echinococcosis. Clin Microbiol Rev 2008;21:380-401. 

14A.339 Harhay OM et al. Epidemiology and control of human gastrointestinal parasites in children. Expert 


14A.340 Scholz T et al. Update on the human broad tapeworm (genus Diphyllobothrium), including clinical relevance. 


14A.341 Harada S et al. A woman who excreted a tape-like substance. Clin Infect Dis 2006;42:572-4. 

14A.342 Weisse ME et al. A neonate with worms. Clin Infect Dis 2008;46:1786-8. 

14A.343 Craig P et al. Intestinal cestodes. Curr Opin Infect Dis 2007;20:524-32. 

14A.344 Wiwanitkit V. A review of human sparganosis in Thailand. Int J Infect Dis 2005;9:312-6. 

14A.345 Heukelbach J et al. Ectoparasites – the underestimated realm. Lancet 2004;363:899-91. 

14A.346 McGraw TL et al. Cutaneous myiasis. J Am Acad Dermatol 2008;58:907-26. 

14A.347 Foucault C et al. Oral ivermectin in the treatment of body lice. J Infect Dis 2006;193:474-6. 

14A.348 Burgess IF. Current treatments for pediculosis capitis. Curr Opin Infect Dis 2009;22:131-6. 

14A.349 Chosidow O et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med 

2010;362:1638-41. 

14A.350 Hill N. Control of head lice: past, present and future. Expert Rev Anti Infect Ther 2006;4:887-94. 

14A.351 Leone PA. Scabies and pediculosis pubis: an update on treatment regimens and general review. Clin 


14A.352 Lebwohl M et al. Therapy for head lice based on life cycle, resistance, and safety considerations. Pediatrics 

2007;119:965-74. 

14A.353 Meinking TL et al. Efficacy of a reduced application time of Ovide ® lotion (0.5% malathion) compared 

to Nix ® crème rinse (1% permethrin) for the treatment of head lice. Pediatr Dermatol 2004;21:670-4. 

14A.354 Jones KN et al. Review of common therapeutic options in the United States for the treatment of pediculosis 

capitis. Clin Infect Dis 2003;36:1355-61. 

14A.355 Currie BJ et al. Permethrin and ivermectin for scabies. N Engl J Med 2010;362:717-25. 

14A.356 Strong M et al. Interventions for treating scabies. Cochrane Database Syst Rev 2007;3:CD000320. 

14A.357 Hu S et al. Treating Scabies. Results from an updated Cochrane review. Arch Dermatol 2008;144: 

1638-40. 

14A.358 Walton SF et al. Problems in diagnosing scabies, a global disease in human and animal populations. 


14A.359 Hengge UR et al. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis 2006;6:769-79. 

14A.360 Johnston G et al. Scabies: diagnosis and treatment. Br Med J 2005;331:619-22. 

14A.361 Chosidow O. Scabies. N Engl J Med 2006;354:1718-27. 

14A.362 Leone PA. Scabies and pediculosis pubis: an update on treatment regimens and general review. Clin 


14A.363 Roberts LJ et al. Crusted scabies: clinical and immunological findings in seventy-eight patients and a 

review of the literature. J Infect 2005;50:375-81. 

14A.364 Heukelbach J et al. Scabies. Lancet 2006;367:1767-74. 

14A.365 Franck S et al. Tungiasis: more than an exotic nuisance. Travel Med Infect Dis 2003;1:159-66. 

14A.366 Heukelbach J. Revision on tungiasis: treatment options and prevention. Expert Rev Anti Infect Ther 

2006;4:151-7. 

14A.367 Drugs for parasitic infections. Treat Guidel Med Lett 2007;5(suppl.):1-15. 



207. 



58(RR-11):1-167. 

14B.1 Schulte C et al. Diagnostic significance of blood eosinophilia in returning travelers. Clin Infect Dis 

2002;34:407-11. 

14B.2 Graeff-Teixeira C et al. Update on eosinophilic meningoencephalitis and its clinical relevance. Clin 


14B.3 Whetham J et al. Investigation of tropical eosinophilia; assessing a strategy based on geographical 

area. J Infect 2003;46:180-5.

14B.4 Checkley AM et al. Eosinophilia in returning travelers and migrants from the tropics: UK recommendations 

for investigation and initial management. J Infect 2010;60:1-20. 

14B.5 Insiropong S et al. Treatment of eosinophilia with albendazole. Southeast Asian J Trop Med Public 

Health 2008;39:517-20. 

14B.6 Meltzer E et al. Eosinophilia among returning travelers: a practical approach. Am J Trop Med Hyg 

2008;78:702-9. 

14B.7 Seybolt LM et al. Diagnostic evaluation of newly arrived asymptomatic refugees with eosinophilia. 


14B.8 Diaz JH. Recognizing and reducing the risks of helminthic eosinophilic meningitis in travelers: differential 

diagnosis, disease management, prevention and control. J Travel Med 2009;16:267-75. 

14B.9 Chitkara RK et al. Parasitic pulmonary eosinophilia. Semin Respir Crit Care Med 2006;27:171-84. 

14B.10 Lim JM et al. Eosinophilic meningitis caused by Angiostrongylus cantonensis: a case report and literature 

review. J Travel Med 2004;11:388-90. 

14B.11 Lo Re V et al. Eosinophilic meningitis due to Angiostrongylus cantonensis in a returned traveler: case 

report and review of the literature. Clin Infect Dis 2001;33:e112-5. 

14B.12 Tsai HC et al. Eosinophilic meningitis caused by Angiostrongylus cantonensis: report of 17 cases. 

Am J Med 2001;111:109-114. 

14B.13 Slom TJ et al. An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers 

returning from the Caribbean. N Engl J Med 2002;346:668-75. 

14B.14 Lo Re V et al. Eosinophilic meningitis. Am J Med 2003;114:217-23. 

14B.15 Page KR et al. Eosinophilia in a patient from South America. J Am Med Assoc 2008;299:437-44. 

14B.16 Lo Re V et al. Eosinophilic meningitis. Am J Med 2003;114:217-23. 

15.1 Fradin MS et al. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 

2002;347:13-8. 

15.2 Goodyer LI et al. Expert review of the evidence base for arthropod bite avoidance. J Travel Med 

2010;17:182-92. 

15.3 Schlagenhauf P et al. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev 

2008;21:466-72. 

15.4 Lalloo DG et al. Preventing malaria in travellers. Br Med J 2008;336:1362-6. 

15.5 Chen LH et al. Controversies and misconceptions in malaria chemoprophylaxis for travelers. J Am 

Med Assoc 2007;297:2251-63. 

15.6 Freedman DO. Malaria prevention in short-term travelers. N Engl J Med 2008;359:603-12. 

15.7 Schlagenhauf P et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan 

Africa: multicentre, randomised, double blind, four arm study. Br Med J 2003;327:1078-83. 

15.8 Petersen E. Malaria chemoprophylaxis: when should we use it and what are the options? Expert Rev 


15.9 Shanks GD et al. Modern malaria chemoprophylaxis. Drugs 2005;65:2091-110. 

15.10 Chen LH et al. New strategies for the prevention of malaria in travelers. Infect Dis Clin North Am 

2005;19:185-210. 

15.11 Chen LH et al. Prevention of malaria in long-term travelers. J Am Med Assoc 2006;296:2234-44. 

15.12 Chen LH et al. Controversies and misconceptions in malaria chemoprophylaxis for travelers. J Am 

Med Assoc 2007;297:2251-63. 

15.13 Franco-Paredes C et al. Problem pathogens: prevention of malaria in travellers. Lancet Infect Dis 

2006;6:139-49. 

15.14 Shetty AK et al. Prevention of malaria in children. Pediatr Infect Dis J 2006;25:1173-6. 

15.15 Lalloo DG et al. Malaria in adolescence: burden of disease, consequences, and opportunities for intervention. 


15.16 Fischer PR et al. Prevention of malaria in children. Clin Infect Dis 2002;34:493-8. 

15.17 McGready R et al. Malaria and the pregnant traveller. Travel Med Infect Dis 2004;2:127-42. 

15.18 Menéndez C et al. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect 

Dis 2007;7:126-35. 

15.19 Rogerson SJ et al. Treatment and prevention of malaria in pregnancy: opportunities and challenges. 


15.20 Bertchy S et al. Discontinuation of maintenance therapy against Toxoplasma encephalitis in AIDS patients 

with sustained response to anti-retroviral therapy. Clin Microbiol Infect 2006;12:666-71. 

15.21 Miro JM et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in 

HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results 

of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006;43:79-89. 

15.22 Bertchy S et al. Discontinuation of maintenance therapy against Toxoplasma encephalitis in AIDS patients 

with sustained response to anti-retroviral therapy. Clin Microbiol Infect 2006;12:666-71. 

15.23 Miro JM et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in 

HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results 

of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006;43:79-89. 

15.24 Montoya JG et al. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 

2008;47:554-66. 

15.25 Petersen E. Prevention and treatment of congenital toxoplasmosis. Expert Rev Anti Infect Ther 

2007;5:285-93. 

15.26 The SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of prenatal 

treatment for congenital toxoplasmosis: a meta-analysis of individual patients‘ data. Lancet 

2007;369:115-22. 

15.27 Kravetz JD et al. Toxoplasmosis in pregnancy. Am J Med 2005;118:212-6. 

15.28 Centers for Disease Control and Prevention (CDC). Preventing congenital toxoplasmosis. Morb Mortal 

Wkly Rep 2000;49(RR-2):59-75. 



207. 



58(RR-11):1-167.

15.31 Drugs for parasitic infections. Treat Guidel Med Lett 2007;5(suppl.):1-15. 

16A.1 Drugs for parasitic infections. Treat Guidel Med Lett 2007;5(suppl.):1-15. 

16A.2 van den Enden E. Pharmacotherapy of helminth infection. Expert Opin Pharmacother 2009;10:435- 

51. 

16A.3 Horton J. Albendazole: a review of anthelminthic efficacy and safety in humans. Parasitology 2000; 

121(suppl. 1):S113-32. 

16A.4 Cui L et al. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev 


16A.5 Ashley EA et al. Artemisinin-based combinations. Curr Opin Infect Dis 2005;18:531-6. 

16A.6 Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 2000;9:1815- 

27. 

16A.7 Adjei GO et al. Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children. 


16A.8 Cui L et al. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti 

Infect Ther 2009;7:999-1013. 

16A.9 Ashley EA et al. Artemisinin-based combinations. Curr Opin Infect Dis 2005;18:531-6. 

16A.10 Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 2000;9:1815- 

27. 

16A.11 Patel SN et al. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti 

Infect Ther 2005;3:849-61. 

16A.12 Pappaioanou M et al. Antibody response to pre-exposure human diploid cell rabies vaccine given 

concurrently with chloroquine. N Engl J Med 1986;314:280-4. 

16A.13 Lefkove B et al. Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors. 


16A.14 Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008;31:91-8. 

16A.15 Dourmishev AL et al. Ivermectin: pharmacology and application in dermatology. Int J Dermatol 2005; 

44:981-8. 

16A.16 Omura S et al. The life and times of ivermectin. A success story. Nat Rev Microbiol 2004;2:984-9. 

16A.17 Thakur CP. Sodium antimony gluconate, amphotericin and myocardial damage. Lancet 1998;351: 

1928-9. 

16A.18 Soto J et al. Miltefosine: an oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 2006;4:177- 

85. 

16A.19 Anderson VR et al. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. 

Drugs 2007;67:1947-67. 

16A.20 White AC. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 

2004;2:43-50. 

16A.21 Fox LM et al. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005;40:1173-80. 

16A.22 Doenhoff MJ et al. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. 


16A.23 Cioli D et al. Praziquantel. Parasitol Res 2003;90(suppl. 1):S3-9. 

16A.24 Berman J. Toxicity of commonly used antimalarial drugs. Travel Med Infect Dis 2004;2:171-84. 

16A.25 White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007;7:549-58. 

16A.26 Taylor WR et al. Antimalarial drug toxicity: a review. Drug Saf 2004;27:25-61. 

16B.1 Demirovic JA et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst 

Pharm 2009;66:642-8. 

16B.2 Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a 


18.1 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral 

agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo. nih.gov/content 

files/AdultandAdolescentGL.pdf. Accessed on August 18th 2010. 

18.2 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral 

agents in HIV-1-infected adults and adolescents. Tables Available at: http:// aidsinfo.nih.gov/ 

contentfiles/AdultandAdolescentGL.pdf. Accessed on August 18 th 2010. 

18.3 European AIDS Clinical Society. Guidelines: clinical management and treatment of HIV infected 

adults in Europe. Available at: http://www.europeanaidsclinicalsociety.org/guidelines pdf/1_Treatment 

_of_HIV_Infected_Adults.pdf. Accessed on August 18 th 2010. 

18.4 European AIDS Clinical Society. Guidelines: prevention and management of non-infectious comorbidities 

in HIV. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/ 2_Non_Infectious 

_Co_Morbidities_in_HIV.pdf. Accessed on August 18 th 2010. 

18.5 Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral 

therapy 2008. HIV Med 2008;9:563-608. 

18.6 Aberg JA et al. Primary care guidelines for the management of persons infected with human immunodeficiency 

virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of 

America. Clin Infect Dis 2009;49:651-81. 

18.7 Yeni P. Prise en charge médicale des personnes infectées par le VIH. Available at: http://lesrap 

ports.ladocumentationfrancaise.fr/BRP/084000593/0000.pdf. Accessed on August 18 th 2010. 

18.8 Hammer SM et al. Antiretroviral treatment of adult HIV infection. 2008 recommendations of the International 

AIDS Society - USA Panel. J Am Med Assoc 2008;300:555-70. 



207. 

18.10 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the 

use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/contentfiles/ 

PediatricGuidelines.pdf. Accessed on August 18 th 2010. 

18.11 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the 

use of antiretroviral agents in pediatric HIV infection. Tables. Available at: http://aidsinfo.nih.gov/con 

tentfiles/Ped_Tables.pdf Accessed on August 18 th 2010.

18.12 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Managing complications 

of HIV infection in HIV-infected children on antiretroviral therapy. Available at: http://aidsinfo. 

nih.gov/contentfiles/PediatricGL_SupII.pdf. Accesssed on August 18 th 2010. 



58(RR-11):1-167. 

18.14 McKellar MS et al. Pediatric HIV infection: the state of antiretroviral therapy. Expert Rev Anti Infect 

Ther 2008;6:167-80. 

18.15 Patel K et al. Long-Term effects of highly active antiretroviral therapy on CD4 + cell evolution among 

children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008;46:1751-60. 

18.16 Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005;353:1702-10. 

18.17 Deeks SG. Antiretroviral treatment of HIV infected adults. Br Med J 2006;332:1498-93. 

18.18 Huang L et al. Intensive care of patients with HIV infection. N Engl J Med 2006;355:173-81. 

18.19 Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis 2007;45(suppl. 4):S221- 

5. 

18.20 Lubinski C et al. HIV Policy: The path forward - a joint position paper of the HIV Medicine Association 

of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect 

Dis 2009;48:1335-44. 

18.21 Deeks SG et al. HIV infection, antiretroviral treatment, ageing and non-AIDS related morbidity. Br 

Med J 2009;338:288-92. 

18.22 Simon V et al. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet Infect Dis 

2006;368:489-504. 

18.23 Giordano TP et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007; 

4:1493-9. 

18.24 Ford N et al. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised 

clinical trials. Lancet 2009;374:2064-71. 

18.25 Tuldràand A et al. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic 

Syndr 2002;31(suppl. 3):S154-7. 

18.26 Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30(suppl. 

2):S171-6. 

18.27 Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy 

can lead to viral suppression. Clin Infect Dis 2006;43:939-41. 

18.28 Gulick RM. Adherence to antiretroviral therapy: how much is enough? Clin Infect Dis 2006;43:942-4. 

18.29 Lazo M et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: 

longitudinal study of men and women. Clin Infect Dis 2007;45:1377-85. 

18.30 García de Olalla P et al. Impact of adherence and highly active antiretroviral therapy on survival in 

HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10. 

18.31 Moore RD et al. CD4 + cell count 6 years after commencement of highly active antiretroviral therapy in 

persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-6. 

18.32 Kassutto S et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during 

acute or early HIV type 1 infection. Clin Infect Dis 2006;42:1024-31. 

18.33 Battegay M et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect 

Dis 2006;6:280-7. 

18.34 Vercauteren J et al. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed 

therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008;24: 

355-62. 

18.35 CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of 

HIV infection and response to first line therapy. AIDS 2006;20:21-8. 

18.36 Sax PE et al. Should resistance testing be performed for treatment naïve HIV infected patients? A 

cost effectiveness analysis. Clin Infect Dis 2005;41:1316-23. 

18.37 European HIV Drug Resistance Guidelines Panel. European HIV drug resistance guidelines. 2009 

update. Available at: http://www.europeanaidsclinicalsociety.org/The%20European%20 HIV%20Drug 

%20Resistance%20Guidelines%202009%20Update.pdf. Accessed on August 18 th 2010. 

18.38 Hirsch MS et al. antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations 

of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-85. 

18.39 Chen TK et al. Review of HIV antiretroviral drug resistance. Pediatr Infect Dis J 2008;27:749-52. 

18.40 Gupta R et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line 

highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008;47:712- 

22. 

18.41 Taylor S et al. Using HIV resistance tests in clinical practice. J Antimicrob Chemother 2009;64:218- 

22. 

18.42 Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from 

structured treatment interruptions. J Infect Dis 2008;197(suppl. 3):S261-71. 

18.43 Wensing AM et al. Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications 

for clinical management. J Infect Dis 2005;192:958-66. 

18.44 Novak RM et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV infected, 

treatment naïve patients: implications for routine resistance screening before initiation of antiretroviral 


18.45 Gupta RK et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in 

adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. 


18.46 Ivanovic J et al. Therapeutic drug monitoring in the management of HIV-infected patients. Curr Med 

Chem 2008;15:1925-39. 

18.47 Wertheimer BZ et al. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin 

Trials 2006;7:59-69. 

18.48 Fraaijj PL et al. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004;26: 

122-6. 

18.49 Gerber JG et al. Therapeutic drug monitoring in the treatment of HIV-infection. J Clin Virol 2003;27: 

117-28. 

18.50 Fidler S et al. Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis 2008;21:4-10. 

18.51 Zetola NM et al. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 2007; 

21:19-48.

18.52 Smith DE et al. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of 

current evidence? AIDS 2004;18:709-18. 



18.91 Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. 


18.92 Robertson J et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying 

clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639-46. 

18.93 Puthanakit T et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human 

immunodeficiency virus infected Thai children. Pediatr Infect Dis J 2006;25:53-8. 

18.94 Lipman M et al. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 2006;19: 

20-5. 

18.95 Burgoyne RW et al. Prolongation and quality of life for HIV-infected adults treated with highly active 

antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother 2008;61:469-73. 

18.96 The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4 + count-guided 

interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96. 



18.98 Temesgen Z et al. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced 

HIV-positive adults. Lancet Infect Dis 2006;6:496-507. 

18.99 Gallant JE. Approach to the treatment-experienced patient. Infect Dis Clin North Am 2007;21:85- 

102. 

18.100 Paton NI. Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis 2008;21: 

25-30. 

18.101 Wilson LE et al. The Management of treatment-experienced HIV-infected patients: new drugs and 

drug combinations. Clin Infect Dis 2009;48:214-21. 



18.103 Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations 

for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health 

and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aids 

info.nih.gov/contentfiles/PerinatalGL.pdf. Accessed on August 18 th 2010. 

18.104 Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations 

for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health 

and interventions to reduce perinatal HIV transmission in the United States. Tables. Available at: http: 

//aidsinfo.nih.gov/contentfiles/Peri_Tables.pdf. Accessed on August 18 th 2010. 



19C.5 McIntyre J. Prevention of mother to child transmission of HIV: treatment options. Expert Rev Anti Infect 

Ther 2005;3:971-80. 

19C.6 Newell ML et al. Antiretroviral therapy and mother to child transmission of HIV-1. Expert Rev Anti Infect 

Ther 2004;2:717-32. 

19C.7 McIntyre J. Strategies to prevent mother-to-child transmission of HIV. Curr Opin Infect Dis 2006;19: 

33-8. 

19C.8 Kourtis AP et al. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet 

Infect Dis 2006;6:726-32. 

19C.9 Chasela CS et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 

2010;362:2271-81. 

19C.10 Coovadia HM et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in 

the first 6 months of life: an intervention cohort study. Lancet 2007;369:1107-16. 

19D.1 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic 


207. 

19D.2 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of 


58(RR-11):1-167. 

19D.3 Willemot P et al. Prevention of HIV associated opportunistic infections and diseases in the age of 

highly active antiretroviral therapy. Expert Rev Anti Infect Ther 2004;2:521-32. 

19D.4 Karp CL et al. Coinfection with HIV and Tropical Infectious Diseases. I. Protozoal Pathogens. Clin 

Infect Dis 2007;45:1208-13. 

19D.5 Karp CL et al. Coinfection with HIV and tropical infectious diseases. II. Helminthic, fungal, bacterial, 

and viral pathogens. Clin Infect Dis 2007;45:1214-20. 

19D.6 Goldman M et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis 

after immunologic response to antiretroviral therapy. Clin Infect Dis 2004;38:1485-9. 

19D.7 Furrer HJ et al. May Pneumocystis prophylaxis be safely discontinued in virologically suppressed 

patients with CD4 counts below 200 cells/μL? Available at: http://retroconference. org/2010/PDFs/ 

789.pdf. Accessed on August 19 th 2010. 

19D.8 Furrer HJ et al. May Pneumocystis prophylaxis be safely discontinued in virologically suppressed 

patients with CD4 counts below 200 cells/μL? Available at: http://retroconference. org/2010/PDFs/ 

789.pdf. Accessed on August 19 th 2010. 

19D.9 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic 


207. 

19D.10 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of 


58(RR-11):1-167. 

19D.11 Willemot P et al. Prevention of HIV-associated opportunistic infections and diseases in the age of 

highly active antiretroviral therapy. Expert Rev Anti Infect Ther 2004;2:521-32. 

20A.1 Mallewa JE et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic 

options. J Antimicrob Chemother 2008;62:648-60. 

20A.2 Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. 

AIDS Rev 2007;9:3-15. 

20A.3 Lundgren JD et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management 

of metabolic diseases in HIV. HIV Med 2008;9:72-81. 

20A.4 Wyles DL et al. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect 

Dis 2005;40:174-81. 


agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/content 

files/AdultandAdolescentGL.pdf. Accessed on August 18th 2010. 


agents in HIV-1-infected adults and adolescents. Tables Available at: http://aidsinfo.nih.gov/ 

contentfiles/AdultandAdolescentGL.pdf. Accessed on August 18 th 2010. 

20A.7 European AIDS Clinical Society. Guidelines: clinical management and treatment of HIV infected 

adults in Europe. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment 

_of_HIV_Infected_Adults.pdf. Accessed on August 18 th 2010. 

20A.8 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the 

use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/contentfiles/ 

PediatricGuidelines.pdf. Accessed on August 18 th 2010. 


use of antiretroviral agents in pediatric HIV infection. Tables. Available at: http://aidsinfo.nih.gov/con 

tentfiles/Ped_Tables.pdf. Accessed on August 18 th 2010. 

20A.10 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Pediatric antiretroviral 

drug information. Available at: http://aidsinfo.nih.gov/contentfiles/Ped_AppB.pdf. Accessed on 

August 18 th 2010. 

20A.11 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Pediatric antiretroviral 

drug information. Available at: http://aidsinfo.nih.gov/contentfiles/PediatricGL_SupI.pdf. Accessed 

on August 18 th 2010. 


use of antiretroviral agents in pediatric HIV infection. Adverse drug effects. Available at: http://aids 

info.nih.gov/contentfiles/PediatricGL_SupIII.pdf. Accessed on August 18 th 2010. 

20A.13 Biswas P et al. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin 


20A.14 European Medicines Agency (EMA). European assessment report (EPAR). Celsentri, summary of 


_-_Product_Information/human/000811/WC500022190.pdf. Accessed on August 20 th 2010. 

20A.15 MacArthur RD et al. Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 

47:236-41. 

20A.16 Sayana S et al. Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther 2009;7:9-19. 

20A.17 Vandekerckhove L et al. Maraviroc: perspectives for use in antiretroviral-naïve HIV-1-infected pa-

tients. J Antimicrob Chemother 2009;63:1087-96. 

20A.18 Vandekerckhove L et al. Maraviroc: integration of a new antiretroviral drug class into clinical practice. 


20A.19 Moyle G et al. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 

infection. AIDS Patient Care STDs 2008;22:459-71. 

20A.20 Fadel H et al. Maraviroc. Drugs Today 2007;43:749-58. 

20A.21 Carter NJ et al. Maraviroc. Drugs 2007;67:2277-88. 

20A.22 Meanwell NA et al. Drug evaluation: maraviroc, a chemokine CCR5 receptor antagonist for the treatment 

of HIV infection and AIDS. Curr Opin Investig Drugs 2007;8:669-81. 

20A.23 Chantry D. HIV entry and fusion inhibitors. Expert Opin Emerg drugs2004;9:1-7. 

20A.24 Rockstroh JK et al. Clinical perspective of fusion inhibitors for treatment of HIV. J Antimicrob Chemother 

2004;52:700-2. 

20A.25 European Medicines Agency (EMA). European assessment report (EPAR). Fuzeon, sum-mary of 



20A.26 Oldfield V et al. Enfuvirtide: a review of its use in the management of HIV infection. Drugs 2005;65: 

1139-60. 

20A.27 Lalezari JP et al. Enfuvirtide. Drugs Today 2004;40:259-69. 

20A.28 Lazzarin A. Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother 2005;6:453-64. 

20A.29 Cooper DA et al. Peptide inhibitors of virus cell fusion: enfuvirtide as a case study in clinical discovery 

and development. Lancet Infect Dis 2004;4:426-36. 

20A.30 Asboe D. Enfuvirtide: antiretroviral class 4, drug 1. HIV Clin Trials 2004;5:1-6. 

20A.31 Poveda E et al. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005;7:139-47. 

20A.32 Lalezari JP et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug resistant HIV infection in North and 

South America. N Engl J Med 2003;348:2175-85. 

20A.33 Kilby JM et al. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003;348: 

2228-38. 

20A.34 Tashima KT et al. Fusion inhibition, a major but costly step forward in the treatment of HIV-1. N Engl 

J Med 2003;348:2249-50. 

20A.35 Palmisano L. Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect 

Ther 2007;5:67-75. 

20A.36 Al-Mawsawi LQ et al. Clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs 

2008;13:213-25. 

20A.37 Dayam R et al. HIV-1 integrase inhibitors: 2005-2006 update. Med Res Rev 2008;28:118-54. 

20A.38 Nair V et al. HIV integrase inhibitors as therapeutic agents in AIDS. Rev Med Virol 2007;17:277-95. 

20A.39 European Medicines Agency (EMA). European assessment report (EPAR). Isentress, summary of 



20A.40 Hicks C et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009;48:931-9. 

20A.41 Sayana S et al. Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV. Expert 


20A.42 Harris M et al. Exacerbation of depression associated with starting raltegravir: a report of four cases. 

AIDS 2008;22:1890-2. 

20A.43 Evering TH et al. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs 2008;17: 

413-22. 

20A.44 Anker M et al. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. 

Expert Opin Investig Drugs 2008;17:97-103. 

20A.45 Evering TH et al. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today 

2007;43:865-77. 

20A.46 Moyle G et al. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 

infection. AIDS Patient Care STDs 2008;22:459-71. 

20A.47 Croxtall JD et al. Raltegravir. Drugs 2008;68:131-8. 

20A.48 Zembower TR et al. Severe rhabdomyolysis associated with raltegravir use. AIDS 2008;22:1382-4. 

20A.49 The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J 

Med 2007;356:1723-35. 

20A.50 Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr 2007; 

45(suppl. 1):S19-26. 

20A.51 Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. 

AIDS Rev 2007;9:3-15. 

20A.52 Hadigan C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human 

immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9. 

20A.53 Wanke CA et al. Clinical evolution and management of metabolic and morphologic abnormallities associated 

with human immunodeficiency virus. Clin Infect Dis 2002;34:248-59. 

20A.54 Sulkowski MS. Drug induced liver injury associated with antiretroviral therapy that includes HIV-1 protease 

inhibitors. Clin Infect Dis 2004;38(suppl. 2):S90-7. 

20A.55 Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J 


20A.56 Walmsley S. Protease inhibitor-based regimens for HIV therapy safety and efficacy. J Acquir 

Immune Defic Syndr 2007;45(suppl. 1):S5-13. 

20A.57 Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92. 

20A.58 European Medicines Agency (EMA). European assessment report (EPAR). Reyataz, summary of 



20A.59 Ly T et al. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect 

Dis 2007;44:e67-8. 

20A.60 Pacanowski J et al. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006;20:2131. 

20A.61 Couzigou C et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007; 

45:e105-8. 

20A.62 Chang HR. Atazanavir urolithiasis. N Engl J Med 2006;355;2158-9. 

20A.63 Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther 2008;6:785-96. 

20A.64 Swainston Harrison T et al. Atazanavir. A review of its use in the management of HIV infection. 

Drugs 2005;65:2309-6. 

20A.65 von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today 2008;44: 103-32.

20A.66 Le Tiec C et al. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin 


20A.67 Fuster D et al. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother 

2005;6:1565-72. 

20A.68 Havlir DV et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004;38:1599- 

604. 

20A.69 Becker S. Atazanavir: improving the HIV protease inhibitor class. Expert Rev Anti Infect Ther 2003; 

1:403-13. 

20A.70 European Medicines Agency (EMA). European assessment report (EPAR). Prezista, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- 


20A.71 Back D et al. Darunavir: pharmacokinetics and drug interactions. Antiviral Ther 2008;13:1-13. 

20A.72 Fenton C et al. Darunavir in the treatment of HIV-1 infection. Drugs 2007;67:2791-801. 

20A.73 El-Atrouni WI et al. Darunavir. Drugs Today 2007;43:671-9. 

20A.74 McCoy C. Darunavir: A nonpeptidic antiretroviral protease inhibitor. Clin Ther 2007;29:1559-76. 

20A.75 Rittweger M et al. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46:739-56. 

20A.76 Molina JM et al. Darunavir: a nonpeptidic antiretroviral protease inhibitor. Expert Opin Pharmacother 

2007;8:1951-64. 

20A.77 European Medicines Agency (EMA). European assessment report (EPAR). Telzir, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_li brary/EPAR_- 


20A.78 Torres HA et al. Fosamprenavir plus ritonavir for HIV infection. Expert Rev Anti Infect Ther 2007;5: 

349-63. 

20A.79 Arvieux C et al. Amprenavir or fosamprenavir plus ritonavir in HIV infection. Pharmacology, efficacy 

and tolerability profile. Drugs 2006;65:633-59. 

20A.80 Chapman TM et al. Fosamprenavir. A review of its use in the management of antiretroviral therapynaive 

patients with HIV infection. Drugs 2004;64:2101-24. 

20A.81 Wire MB et al. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. 

Clin Pharmacokinet 2006;45:137-68. 

20A.82 Becker S et al. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir 

prodrug. Expert Opin Pharmacother 2004;5:1995-2005. 

20A.83 Hester EH et al. Fosamprenavir: drug development for adherence. Ann Pharmacother 2006;40: 

1301-10. 

20A.84 European Medicines Agency (EMA). European assessment report (EPAR). Crixivan, summary of product 


_Product_Information/human/000128/WC500035730.pdf. Accessed on August 20th 2010. 

20A.85 Rayner CR et al. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother 2002; 

36:1230-7. 

20A.86 Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother 

2007;8:957-64. 

20A.87 Plosker GL et al. Indinavir. A review of its use in the management of HIV infection. Drugs 1999;58: 

1165-203. 

20A.88 Wu DS et al. Indinavir urolithiasis. Curr Opin Urol 2000;10:557-61. 

20A.89 Famularo G et al. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000;34: 

1414-8. 

20A.90 Yeh KC et al. Single dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents 

Chemother 1998;42:332-8. 

20A.91 Colson AE et al. Paronychia in association with indinavir treatment. Clin Infect Dis 2001;32:140-3. 

20A.92 Florence E et al. Rheumatological complications associated with the use of indinavir and other protease 

inhibitors. Ann Rheum Dis 2002;61:82-4. 

20A.93 European Medicines Agency (EMA). European assessment report (EPAR). Kaletra, summary of product 



20A.94 Tan D et al. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Expert 


20A.95 Walmsley S et al. The role of lopinavir/ritonavir in the management of HIV infected adults. Expert 


20A.96 Barragan P et al. Lopinavir/ritonavir: a protease inhibitor for HIV-treatment. Expert Opin Pharmacother 

2008;9:2363-75. 

20A.97 von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today 2007;43:221-47. 

20A.98 Oldfield V et al. Lopinavir/ritonavir. A review of its use in the management of HIV infection. Drugs 

2006;66:1275-99. 

20A.99 Kaplan SS et al. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency 

virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005;56:273-6. 

20A.100 Vogel M et al. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency 

virus type 1 (HIV-1) infection. Expert Opin Drug Saf 2005;4:403-20. 

20A.101 Corbett AH et al. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002:36:1193-203. 

20A.102 European Medicines Agency (EMA). European assessment report (EPAR). Viracept, summary of product 



20A.103 Perry CM et al. Nelfinavir. A review of its use in the management of HIV infection. Drugs 2005;65: 

2209-44. 

20A.104 Tebas P et al. Nelfinavir mesylate. Expert Opin Pharmacother 2000;1:1429-40. 

20A.105 European Medicines Agency (EMA). European assessment report (EPAR). Norvir, summary of product 


_Product_Information/human/000127/WC500028728.pdf. Accessed on August 20 th 2010.. 

20A.106 Zeldin RK et al. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor 

therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9. 

20A.107 Cooper CL et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect 

Dis 2003;36:1585-92. 

20A.108 Rathbun RC et al. Low-Dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann 


20A.109 European Medicines Agency (EMA). European assessment report (EPAR). Invirase, summary of pro-

duct characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- 


20A.110 Johnson M et al. Saquinavir/low-dose ritonavir: its use in HIV infection. AIDS Rev 2003;5:44-51. 

20A.111 Plosker GL et al. Saquinavir. A review of its use in boosted regimens for treating HIV infection. Drugs 

2003;63:1299-324. 

20A.112 European Medicines Agency (EMA). European assessment report (EPAR). Aptivus, summary of product 



20A.113 Courter JD et al. Tipranavir: a new protease inhibitor for the pediatric population. Expert Rev Anti Infect 

Ther 2008;6:797-803. 

20A.114 Temesgen et al. Tipranavir: a new option for the treatment of drug-resistant HIV Infection. Clin Infect 

Dis 2007;45:761-9. 

20A.115 Luna B et al. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. 

Clin Ther 2007;29:2309-18. 

20A.116 King JR et al. Tipranavir. A novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 

45:665-82. 

20A.117 Dong BJ et al. Tipranavir: a protease inhibitor for HIV salvage therapy. Ann Pharmacother 2006;40: 

1311-21. 

20A.118 Temesgen Z et al. Tipranavir. Drugs Today 2005;41:711-20. 

20A.119 Croom KF et al. Tipranavir. A ritonavir-boosted protease inhibitor. Drugs 2005;65:1669-77. 

20A.120 Kandula VR et al. Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Rev 


20A.121 Mehandru S et al. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. 

Expert Opin Investig Drugs 2003;12:1821-8. 

20A.122 Justice AC et al. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase 

the risk of intracranial hemorrhage? Clin Infect Dis 2008;47:1226-30. 

20A.123 Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune 

Defic Syndr 2003;34(suppl. 1):S91-4. 

20A.124 European Medicines Agency (EMA). European assessment report (EPAR). Ziagen, summary of product 



20A.125 Hervey PS et al. Abacavir. A review of its clinical potential in patients with HIV infection. Drugs 2000; 

60:447-79. 

20A.126 Yuen GJ et al. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008;47:351-71. 

20A.127 Saag M et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically 

confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46:1111-8. 

20A.128 Mallal S et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568- 

79. 

20A.129 Rauch A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions 

in the Western Australian HIV Cohort Study. Clin Infect Dis 2006;43:99-102. 

20A.130 Hughes CA et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008;42:387-96. 

20A.131 Clay PG et al. Management protocol for abacavir-related hypersensitivity raction. Ann Pharmacother 

2000;34:247-9. 

20A.132 Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502-14. 

20A.133 Behrens GM et al. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010;23:9-14. 

20A.134 D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction 

in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 

371:1417-26. 

20A.135 Moreno S et al. Didanosine enteric-coated capsule current role in patients with HIV-1 infection. Drugs 

2007;67:1441-62. 

20A.136 European Medicines Agency (EMA). European assessment report (EPAR). Emtriva, summary of product 



20A.137 Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin 

Infect Dis 2006;42:126-31. 

20A.138 Frampton JE et al. Emtricitabine. A review of its use in the management of HIV infection. Drugs 

2005; 65:1427-48. 

20A.139 Molina JM et al. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today 2005; 

41:241-52. 

20A.140 Modrzejewski KA et al. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Ann 


20A.141 Cahn P. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Expert Opin Investig 

Drugs 2004;13:55-68. 

20A.142 European Medicines Agency (EMA). European assessment report (EPAR). Epivir, summary of product 



20A.143 Bessesen M et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected 

patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28: 

1032-5. 

20A.144 Sellier P et al. Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation 

of chronic hepatitis B virus infection. Scand J Infect Dis 2004;36:533-5. 

20A.145 European Medicines Agency (EMA). European assessment report (EPAR). Zerit, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro 

duct_Information/human/000110/WC500049165.pdf. Accessed on August 20 th 2010. 

20A.146 Cheer SM et al. Stavudine once daily. Drugs 2002;62:2667-74. 

20A.147 Joly V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy 

from a comparative trial. AIDS 2002;16:2447-54. 

20A.148 Boubaker K et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect 

Dis 2001;33:1931-7. 

20A.149 Coghlan ME et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human 

immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001;33:1914-21. 

20A.150 European Medicines Agency (EMA). European assessment report (EPAR). Viread, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-


20A.151 Gallant JE et al. Tenofovir disoproxil fumarate (Viread TM ) for the treatment of HIV infection. Expert 


20A.152 Lyseng-Williamson KA et al. Tenofovir disoproxil fumarate. A review of its use in the management of 

HIV infection. Drugs 2005;65:413-32. 

20A.153 Stephan C. Tenofovir disoproxil fumarate. A review of its use in the management of HIV infection. 


20A.154 Kearney BP et al. Tenofovir disoproxil fumarate. Clinical pharmacology and pharmacokinetics. Clin 


20A.155 Grim SA et al. Tenofovir disoproxil fumarate. Ann Pharmacother 2003;37:849-59. 

20A.156 Atta MG et al. Tenofovir nephrotoxicity. The disconnect between clinical trials and real-world practice. 

AIDS Reader 2009;13(3):1-3. 

20A.157 Goicoechea M et al. Greater tenofovir-associated renal function decline with protease inhibitor-based 

versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-8. 

20A.158 Zimmermann AE et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple 

drug interactions. Clin Infect Dis 2006;42:283-90. 

20A.159 Malik A et al. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment. 

Case report and review of literature. J Infect 2005;51:e61-5. 

20A.160 Peyrière H et al. Renal tubular dysfunction associated with tenofovir therapy. Report of 7 cases. J 

Acquir Immune Defic Syndr 2004;35:269-73. 

20A.161 Gallant JE et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, 

compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8. 

20A.162 Dieterich DT et al. Drug induced liver injury associated with the use of non nucleoside reverse- 

transcriptase inhibitors. Clin Infect Dis 2004;38(suppl. 2):S80-9. 

20A.163 Sulkowski MS et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral 

therapy: role of hepatitis B and C infections. Hepatology 2002;35:182-9. 

20A.164 European Medicines Agency (EMA). European assessment report (EPAR). Stocrin, summary of product 



20A.165 Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 

2009;64:910-28. 

20A.166 Fortin C et al. Efavirenz for HIV-infection in adults: an overview. Expert Rev Anti Infect Ther 2004;2: 

671-84. 

20A.167 Vrouenraets SM et al. Efavirenz: a review. Expert Opin Pharmacother 2007;8;851-71. 

20A.168 Maggiolo F. Efavirenz. Expert Opin Pharmacother 2007;8:1137-45. 

20A.169 Sheran M. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment 

of HIV. HIV Clin Trials 2005;6:158-68. 

20A.170 Arendt G et al. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6:147- 

54. 

20A.171 Lowenhaupt EA et al. Psychosis in a 12-year-old HIV positive girl with an increased serum concentration 

of efavirenz. Clin Infect Dis 2007;45:e128-30. 

20A.172 European Medicines Agency (EMA). European assessment report (EPAR). Intelence, summary of 



20A.173 Johnson LB et al. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect 

Dis 2009;48:1123-8. 

20A.174 Seminari E et al. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 2008;6: 

427-33. 

20A.175 European Medicines Agency (EMA). European assessment report (EPAR). Viramune, summary of 



20A.176 Milinkovic A et al. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2004;2:367-73. 

20A.177 Pollard RB et al. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the 

treatment of human immunodeficiency virus infection. Clin Ther 1998;20:1071-92. 

20A.178 Sheran M. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment 

of HIV. HIV Clin Trials 2005;6:158-68. 

20A.179 Cooper CL et al. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV 

Med 2007;8:1-7. 

20A.180 Taiwo BO. Nevirapine toxicity. Int J STD AIDS 2006;17:364-70. 

20A.181 Clotet B et al. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003;34 

(suppl. 1):S79-84. 

20A.182 Baylor MS et al. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 

35:538-9. 

20A.183 De Lazzari E et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender 

and CD4 cell counts. HIV Med 2008;9:221-6. 

20A.184 Centers for Disease Contraol and Prevention (CDC). Serious adverse events attributed to nevirapine 

prophylaxis after HIV exposures. Morb Mortal Wkly Rep 2001;49:1153-6. 

20A.185 Bersoff-Matcha SJ et al. Sex differences and nevirapine rash. Clin Infect Dis 2001;32:124-9. 

20A.186 Warren KJ et al. Nevirapine associated Stevens-Johnson syndrome. Lancet 1998;351:567. 

20A.187 Cattelan AM et al. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases 

and review of the literature. J Infect 2001;43:246-54. 

20A.188 Alonso Claudio G et al. DRESS syndrome associated with nevirapine therapy. Arch Intern Med 

2001;161:2501-2. 

20A.189 Barner A et al. Nevirapine and rashes. Lancet 1998;351:1133. 

20A.190 European Medicines Agency (EMA). European assessment report (EPAR). Kivexa, summary of product 



20A.191 Dando TM et al. Abacavir plus lamivudine. A review of their combined use in the management of HIV 

infection. Drugs 2005;65:285-302. 

20A.192 Anderson AM et al. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. 


20A.193 European Medicines Agency (EMA). European assessment report (EPAR). Trizivir, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-


20A.194 Ibbotson T et al. Lamivudine/zidovudine/abacavir triple combination tablet. Drugs 2003;63:1089-98. 

20A.195 Keiser P et al. Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. 


20A.196 European Medicines Agency (EMA). European assessment report (EPAR). Atripla, summary of product 



20A.197 European Medicines Agency (EMA). European assessment report (EPAR). Truvada, summary of product 



20A.198 Muñoz de Benito RM et al. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily 

dual NRTI backbone. Expert Rev Anti Infect Ther 2006;4:523-35. 

20A.199 European Medicines Agency (EMA). European assessment report (EPAR). Combivir, summary of 



20B.1 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Pediatric antiretroviral 

drug information. Available at: http://aidsinfo.nih.gov/contentfiles/Ped_AppB.pdf. Accessed on 

August 18 th 2010. 


Pharm 2009;66:642-8. 



21.1 Nichols WG et al. Respiratory viruses other than influenza virus: impact and therapeutic advances. 


21.2 Anderson EJ. Prevention and treatment of viral diarrhea in pediatrics. Expert Rev Anti Infect Ther 

2010;8:205-17. 

21.3 Wilhelmi I et al. Viruses causing gastro-enteritis. Clin Microbiol Infect 2003;9:247-62. 

21.4 Echavarría M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008;21:704-15. 

21.5 Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006;43:331-9. 

21.6 Leruez-Ville M et al. Real time blood plasma polymerase chain reaction for management of disseminated 

adenovirus infection. Clin Infect Dis 2004;38:45-52. 

21.7 Walls T et al. Adenovirus infection after pediatric bone marrow transplantation: is treatment always 

necessary? Clin Infect Dis 2005;40:1224-9. 

21.8 Calabrese LH et al. Viral Arthritis. Infect Dis Clin North Am 2005;19:963-80. 

21.9 Günther S et al. Lassa virus. Crit Rev Clin Lab Sci 2004;41:339-90. 

21.10 Delgado S et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever 

case in Bolivia. PLoS Pathog 2008;4:e1000047. 

21.11 Walter JE et al. Astrovirus infection in children. Curr Opin Infect Dis 2003;16:247-53. 


2010;8:205-17. 


21.14 Schildgen O et al. Human bocavirus: passenger or pathogen in acute respiratory tract infections? 


21.15 Longtin J et al. Human bocavirus infections in hospitalized children and adults. Emerg Infect Dis 

2008;14:217-21. 

21.16 Cheng WX et al. Human bocavirus in children hospitalized for acute gastroenteritis: a case-control 

study. Clin Infect Dis 2008;47:161-7. 

21.17 Karalar L et al. Prevalence and clinical aspects of human bocavirus infection in children. Clin Microbiol 

Infect 2010;16:633-9. 

21.18 Arnold JL. Human bocavirus in children. Pediatr Infect Dis J 2010;29:557-8. 

21.19 Soldan SS et al. Emerging infectious diseases: the Bunyaviridae? J Neurovirol 2005;11:412-23. 

21.20 Overturf GD. World arboviruses: the bunyaviridae. Pediatr Infect Dis J 2009;28:1014-5. 

21.21 Ergönül Ö et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak 

in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004;39:284-7. 

21.22 Ergönül Ö. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006;6:203-14. 

21.23 Ergönül Ö. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008;78:125-31. 

21.24 Ergönül Ö. Pregnancy and Crimean-Congo hemorrhagic fever. Clin Microbiol Infect 2010;16:647- 

50. 

21.25 Mardani M et al. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in 

Iran. Clin Infect Dis 2003;36:1613-8. 

21.26 Heyman P et al. Hantavirus infections in Europe:from virus carriers to a major public-health problem. 


21.27 Jonsson CB et al. A global perspective on hantavirus ecology, epidemiology and disease. Clin Microbiol 

Rev 2010;23:412-41. 

21.28 Mertz GJ et al. Placebo controlled, double blind trial of intravenous ribavirin for the treatment of 

hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004;39:1307-13. 

21.29 Flick R et al. Rift Valley fever virus. Curr Mol Med 2005;5:827-34. 



2010;8:205-17. 

21.32 Staples JE et al. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. 


21.33 Seneviratne SL et al. Chikungunya viral infections: an emerging problem. J Travel Med 2007;14:320- 

5. 

21.34 Pialoux G et al. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007;7:319-27. 

21.35 Beltrame A et al. Imported Chikungunya infection, Italy. Emerg Infect Dis 2007;13:1264-6. 

21.36 Borgherini G et al. Persistent arthralgia associated with Chikungunya virus: a study of 88 adult patients 

on Reunion Island. Clin Infect Dis 2008;47:469-75. 

21.37 Couderc T et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009;200:516- 

23.



21.39 Kahn JS. Newly identified respiratory viruses. Pediatr Infect Dis J 2007;26:745-6. 

21.40 Chiu SS et al. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized 

with acute respiratory disease in Hong Kong, China. Clin Infect Dis 2005;40:1721-9. 

21.41 van der Hoek L et al. Identification of a new human coronavirus. Nat Med 2004;10:368-73. 

21.42 Esper F et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 

2005;191:499-502. 

21.43 Cheng VC et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging 

infection. Clin Microbiol Rev 2007;20:660-94. 

21.44 Stockman LJ et al. Severe acute respiratory distress syndrome in children. Pediatr Infect Dis J 

2007;26:68-74. 

21.45 Wong SS et al. The management of coronavirus infections with particular reference to SARS. J Antimicrob 

Chemother 2008;62:437-41. 

21.46 Poon LL et al. The aetiology, origins and diagnosis of severe acute respiratory syndrome. Lancet Infect 

Dis 2004;4:663-71. 

21.47 Chihrin S et al. Overview of antiviral and anti-inflammatory treatment for severe acute respiratory 

syndrome. Expert Rev Anti Infect Ther 2005;3:251-62. 

21.48 De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert 


21.49 Gandhi MK et al. Human cytomegalovirus: clinical aspects, immune regulation and emerging treatments. 


21.50 Burny W et al. Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection. 


21.51 Nassetta L et al. Treatment of congenital cytomegalovirus infection: implications for future therapeutic 

strategies. J Antimicrob Chemother 2009;63:832-7. 

21.52 Michaels MG. Treatment of congenital cytomegalovirus: where are we now? Expert Rev Anti Infect 

Ther 2007;5:441-8. 

21.53 Schleiss MR. Antiviral therapy of congenital cytomegalovirus infection. Semin Pediatr Infect Dis 

2004;16:50-9. 

21.54 Nigro G et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N 

Engl J Med 2005;353:1350-62. 

21.55 Limaye AP et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. J Am Med 

Assoc 2008;300:413-22. 

21.56 Galiatsatos P et al. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. 

Dig Dis Sci 2005;50:609-16. 

21.57 Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune 

system. Clin Microbiol Infect 2007;13:953-63. 

21.58 Torres-Madriz G et al. Perspectives in the treatment and prophylaxis of cytomegalovirus disease in 

solid-organ transplant recipients. Clin Infect Dis 2008;47:702-11. 

21.59 Wohl DA et al. Cytomegalovirus viremia, mortality and end organ disease among patients with AIDS 

receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr 2005;38:538-44. 

21.60 Thorne JE et al. Cytomegalovirus retinitis. Expert Rev Ophthalmol 2007;2:583-95. 

21.61 Len O et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. 


21.62 Martin DF et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N 

Engl J Med 2002;346:1119-26. 

21.63 Eid JA et al. Valganciclovir for the treatment of cytomegalovirus retinitis in patients with AIDS. Expert 

Rev Ophthalmol 2007;2:351-61. 

21.64 Cvetković RS et al. Valganciclovir. A review of its use in the management of CMV infection and disease 

in immunocompromised patients. Drugs 2005;65:859-78. 

21.65 Razonable RR et al. Valganciclovir for the prevention and treatment of cytomegalovirus disease in 

immunocompromised hosts. Expert Rev Anti Infect Ther 2004;2:27-42. 

21.66 Katlama C et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice 

daily and three times daily regimens. J Acquir Immune Defic Syndr 1992;5(suppl. 1):S18-24. 

21.67 Chang M et al. Ganciclovir implant in the treatment of cytomegalovirus retinitis. Expert Rev Anti 

Infect Ther 2005;3:421-7. 

21.68 Kappel PJ et al. Outcomes associated with ganciclovir implants in patients with AIDS related cytomegalovirus 

retinitis. Ophthalmology 2006;113:673-83. 

21.69 Deayton J et al. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy 

in the absence of specific anti-CMV therapy. AIDS 1999;13:1203-6. 

21.70 Kempen JH et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency 

syndrome. Clin Infect Dis 2003;37:1365-73. 

21.71 Karavellas MP et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following 

institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700. 

21.72 Stalder N et al. Cytomegalovirus retinitis: decreased risk of bilaterality with increased use of systemic 


21.73 Musch DC et al. Treatment of cytomegalovirus retinitis with a sustained release ganciclovir implant. N 

Engl J Med 1997;337:83-90. 

21.74 Martin BK et al. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus 

retinitis. Clin Infect Dis 2007;44:1001-8. 

21.75 Avery RK. Update in management of ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect 

Dis 2008;21:433-7. 

21.76 Gilbert C et al. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 

2005;49:873-83. 

21.77 Lalezari JP et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A 

randomized, controlled trial. Ann Intern Med 1997;126:257-63. 

21.78 Studies of Ocular Complications of AIDS Research Group and AIDS Clinical Trials Group. Parenteral 

cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus 

retinitis trial. A randomized, controlled trial. Ann Intern Med 1997;126:264-74. 

21.79 Studies of Ocular Complications of AIDS Research Group and AIDS Clinical Trials Group. Combination 

foscarnet and ganciclovir therapy versus monotherapy for the treatment of relapsed cytomegalovirus 

retinitis in patients with AIDS. The cytomegalovirus retreatment trial. Arch Ophthalmol 1996;

114:23-33. 

21.80 Jabs DA et al. Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol 2002;133: 

552-6. 

21.81 Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in 

patients with AIDS. Am J Ophthalmol 2002;133:484-98. 

21.82 McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect 

Dis 1995;20:747-54. 

21.83 Anders HJ et al. Ganciclovir and foscarnet efficacy in AIDS related CMV polyradiculopathy. J Infect 

1998;36:29-33. 

21.84 Anders HJ et al. Cytomegalovirus polyradiculopathy in patients with AIDS. Clin Infect Dis 1998;27: 

345-52. 

21.85 Said G et al. Cytomegalovirus neuropathy in acquired immunodeficiency syndrome: a clinical and 

pathological study. Ann Neurol 1991;29:139-46. 

21.86 Machado CM et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment or preemptive 

ganciclovir therapy. Bone Marrow Transplant 2000;26:413-7. 

21.87 Teixeira MG et al. Diagnosis and management of dengue. Br Med J 2009;339:1189-93. 

21.88 Morens DM. Dengue fever and dengue hemorrhagic fever. Pediatr Infect Dis J 2009;28:635-6. 

21.89 Ligon BL. Dengue fever and dengue hemorrhagic fever: a review of the history, transmission, treatment, 

and prevention. Semin Pediatr Infect Dis 2005;16:60-5. 

21.90 Halstead SB. Dengue. Lancet 2007;370:1644-52. 

21.91 Carroll ID et al. Dengue fever and pregnancy. A review and comment. Travel Med Infect Dis 2007;5: 

183-8. 

21.92 Gibbons RV. Dengue: an escalating problem. Br Med J 2002;324:1563-6. 

21.93 Wilder-Smith A et al. Dengue in travelers. N Engl J Med 2005;353:924-32. 

21.94 Nhan NT et al. Acute management of dengue shock syndrome: a randomized, double blind comparison 

of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001;32:204-13. 

21.95 Ostronoff M et al. Serious thrombocytopenia due to dengue hemorrhagic fever treated with high dosages 

of immunoglobulin. Clin Infect Dis 2003;36:1623-4. 

21.96 Wang SM et al. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect 

Ther 2009;7:735-42. 

21.97 Lee TC et al. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J 2009;28:904-10. 

21.98 Tattevin P et al. Benefits of management strategy adjustments during an outbreak of enterovirus meningitis 

in adults. Scand J Infect Dis 2002;34:359-61. 

21.99 Kupila L et al. Diagnosis of enteroviral meningitis by use of polymerase chain reaction of cerebrospinal 

fluid, stool and serum specimens. Clin Infect Dis 2005;40:982-7. 

21.100 Auwaerter PG. Recent advances in the understanding of mononucleosis: are prospects improved for 

treatment or control? Expert Rev Anti Infect Ther 2006;4:1030-49. 

21.101 Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician 2004;70:1279-87. 

21.102 Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92. 

21.103 Okano M et al. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infections in 

immunocompromised patients. Expert Rev Anti Infect Ther 2007;5:403-13. 

21.104 Macsween KF et al. Epstein-Barr virus: recent advances. Lancet Infect Dis 2003;3:131-40. 

21.105 Tynell E et al. Aciclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, 

double blind, placebo controlled study. J Infect Dis 1996;174:324-31. 

21.106 Thompson SK et al. Infectious mononucleosis and corticosteroids. Arch Otolaryngol Head Neck 

Surg 2005;131:900-4. 

21.107 Bausch DG et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N 

Engl J Med 2006;355:909-19. 

21.108 Feldmann H. Marburg hemorrhagic fever – the forgotten cousin strikes. N Engl J Med 2006;355:866- 

9. 

21.109 Bray M et al. Filoviruses: recent advances and future challenges. Expert Rev Anti Infect Ther 2006; 

4:917-21. 

21.110 Mahanty S et al. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004;4:487-98. 

21.111 Paragas J et al. Development of treatment strategies to combat Ebola and Marburg viruses. Expert 


21.112 Leroy EM et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;348:575-6. 

21.113 Towner JS et al. Marburg virus infection detected in a common African bat. PLoS ONE 2007;2:e764. 

21.114 Solomon T. Flavivirus encephalitis. N Engl J Med 2004;351:370-8. 

21.115 Gould EA et al. Pathogenic flaviviruses. Lancet 2008;371:500-9. 

21.116 Erlanger TE et al. Past, present, and future of Japanese encephalitis. Emerg Infect Dis 2009;15:1-7. 

21.117 Romer JR et al. Powassan encephalitis and Colorado tick fever. Infect Dis Clin North Am 2008;22: 

545-59. 

21.118 Arnež M et al. Tick-borne encephalitis in children: an update on epidemiology and diagnosis. Expert 


21.119 Lindquist L et al. Tick-borne encephalitis. Lancet 2008;371:1861-71. 

21.120 Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am 2008;22:561-75. 

21.121 Jeong SH et al. Hepatitis A: clinical manifestations and management. Intervirology 2010;53:15-9. 

21.122 Koziel MJ et al. Viral hepatitis in HIV infection. N Engl J Med 2007;356:1445-54. 

21.123 Gaglio PJ et al. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and 

recommendations for therapy. Clin Infect Dis 2007;45:618-23. 

21.124 Miailhes P et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis 

B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV 

surface and early antigen seroconversion. Clin Infect Dis 2007;45:624-32. 

21.125 Tillmann HL. Screening for and treating hepatitis B virus in patients with HIV infection. Clin Infect Dis 

2007;45:633-6. 

21.126 Lacombe K et al. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob 

Chemother 2010;65:10-7. 

21.127 Núñez M et al. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 

2005;5:374-82. 

21.128 Thio CL et al, Thomas DL. Treatment of chronic hepatitis B in HIV infected persons: thinking outside 

the black box. Clin Infect Dis 2005;41:1035-40. 

21.129 Shire NJ et al. Management of HBV/HIV co-infected patients. Semin Liver Dis 2005;25(suppl. 1):48- 

57.

21.130 Sorrell MF et al. National Institutes of Health Consensus Development conference statement: management 

of hepatitis B. Ann Intern Med 2009;150:104-10. 

21.131 Cooke GS et al. Treatment for hepatitis B. Br Med J 2010;340:87-91. 

21.132 Alazawi W et al. Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis 2008; 

21:508-15. 

21.133 Singh NA et al. Management of hepatitis B virus. J Antimicrob Chemother 2008;62:224-8. 

21.134 Liaw YF et al. Hepatitis B virus infection. Lancet 2009;373:582-92. 

21.135 Coffin CS et al. Management of patients co-infected with HBV and HCV. Expert Rev Anti Infect 

Ther 2009;7:549-58. 

21.136 Keeffe EB et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the 

United States: an update. Clin Gastroenterol Hepatol 2006;4:936-62. 

21.137 Lok AS et al. Chronic hepatitis B. Hepatology 2007;45:507-39. 

21.138 Lai CL et al. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard 

treatment criteria and endpoints. Ann Intern Med 2007;147:58-61. 

21.139 Di Marco V et al. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti 

Infect Ther 2009;7:281-9. 

21.140 Mauss S et al. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert 


21.141 Wong VW et al. Antiviral therapy for chronic hepatitis B: are we doing any good to patients? J 


21.142 Papatheotoridis GV et al. Therapeutic strategies in the management of patients with chronic hepatitis 

B virus infection. Lancet Infect Dis 2008;8:167-78. 

21.143 Centers for Disease Control and Prevention (CDC). Recommendations for identification and public 

health management of persons with chronic hepatitis B virus infection. Morb Mortal Wkly Rep 2008; 

57(RR-8):1-20. 

21.144 Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500. 

21.145 Pungpapong S et al. Natural history of hepatitis B virus infections: an update for clinicians. Mayo Clin 

Proc 2007;82:967-75. 

21.146 Iorio R et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. 


21.147 Hardikar W et al. Treatment options for chronic hepatitis B and C in children. Expert Rev Anti Infect 

Ther 2006;4:583-91. 

21.148 Ghany MG et al. Assessment and management of chronic hepatitis B. Infect Dis Clin North Am 

2006;20:63-79. 

21.149 Robins GW et al. Peginterferon-α-2a (40KD). A review of its use in the management of patients with 

chronic hepatitis B. Drugs 2005;65:809-25. 

21.150 Van Bömmel F et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected 

patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80. 

21.151 Marcellin P et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N 

Engl J Med 2008;359:2442-55. 

21.152 Hadziyannis SJ et al. Long term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis 

B. N Engl J Med 2005;352:2673-81. 

21.153 Hadziyannis SJ et al. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert 


21.154 Gonzalez SA et al. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect 

Ther 2009;7:1053-62. 

21.155 Goulis I et al. Entecavir monotherapy for lamivudine refractory chronic hepatitis B. Expert Rev Anti 

Infect Ther 2008;6:855-9. 

21.156 Lai CL et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N 

Engl J Med 2006;354:1011-20. 

21.157 Chang TT et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N 

Engl J Med 2006;354:1001-10. 

21.158 Shaw T et al. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004;2: 

853-71. 

21.159 Leung N. Lamivudine for chronic hepatitis B. Expert Rev Anti Infect Ther 2004;2:173-80. 

21.160 Nash KL et al. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet 

Infect Dis 2008;8:444-8. 

21.161 Lau GK et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAG-positive chronic hepatitis 

B. N Engl J Med 2005;352:2682-95. 

21.162 Janssen HL et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg 

positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9. 

21.163 Yuen MF et al. Prevention and management of drug resistance for antihepatitis B treatment. Lancet 

Infect Dis 2009;9:256-64. 

21.164 Pol S et al. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 

2008;47:94-101. 

21.165 Koziel MJ et al. Viral hepatitis in HIV infection. N Engl J Med 2007;356:1445-54. 

21.166 Cacoub P. Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence? Int 

J STD AIDS 2005;16:1-4. 

21.167 Bräu N. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected 

patients in the era of pegylated interferon and ribavirin. Semin Liver Dis 2005:25:33-51. 

21.168 Dore GJ et al. Management and treatment of injection drug users with hepatitis C virus (HCV) infection 

and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005;25:18-32. 

21.169 Sherman KE. Treatment of hepatitis C virus and human immunodeficiency virus co-infection. Clin 

Gastroenterol Hepatol 2005;3(suppl. 2):S118-21. 

21.170 Soriano V et al. New paradigms in the management of HIV and hepatitis C virus co-infection. Curr 


21.171 Rockstroh JK. Management of hepatitis C/HIV co-infection. Curr Opin Infect Dis 2006;19:8-13. 

21.172 Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83. 

21.173 Scott JD et al. Molecular diagnostics of hepatitis C virus infection. A systematic review. J Am Med 

Assoc 2007;297:724-32. 

21.174 Gasink LB et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. 

J Am Med Assoc 2006;296:1843-50. 

21.175 Biggins SW et al. Management of recurrent hepatitis C in liver transplant recipients. Infect Dis Clin

North Am 2006;20:155-74. 

21.176 Nash KL et al. Managing hepatitis C infection. Br Med J 2009;339:37-42. 

21.177 Hellard M et al. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin 

Infect Dis 2009;49:561-73. 

21.178 Coffin CS et al. Management of patients co-infected with HBV and HCV. Expert Rev Anti Infect 

Ther 2009;7:549-58. 

21.179 Heller T et al. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005;25:7-17. 

21.180 Ozaras R et al. Acute hepatitis C: prevention and treatment. Expert Rev Anti Infect Ther 2009;7: 

351-61. 

21.181 Wiegand J et al. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon 

α. J Antimicrob Chemother 2008;62:860-5. 

21.182 Maheshwari A et al. Acute hepatitis C. Lancet 2008;372:321-32. 

21.183 Dionne-Odom J et al. Acute hepatitis C and HIV coinfection. Lancet Infect Dis 2009;9:775-83. 

21.184 Vogel M et al. Treatment of acute hepatitis C in HIV-infection. J Antimicrob Chemother 2010;65:4- 

9. 

21.185 Cox AL et al. Prospective evaluation of community acquired acute phase hepatitis C virus infection. 


21.186 Scott JD et al. Molecular diagnostics of hepatitis C virus infection. A systematic review. J Am Med 

As-soc 2007;297:724-32. 

21.187 De Rosa FG et al. 12-week treatment of acute hepatitis C virus with pegylated interferon-α-2b in injection 

drug users. Clin Infect Dis 2007;45:583-8. 

21.188 Hardikar W et al. Treatment options for chronic hepatitis B and C in children. Expert Rev Anti Infect 

Ther 2006;4:583-91. 

21.189 Davis GL et al. Treatment of chronic hepatitis C infection: one step at a time. Lancet Infect Dis 2005; 

5:524-6. 

21.190 Marcus EL et al. Chronic hepatitis C virus infection in older adults. Clin Infect Dis 2005;41:1606-12. 

21.191 McGinn TG et al. Treating chronic hepatitis C in the primary care setting. Semin Liver Dis 2005;25: 

65-71. 

21.192 Patel K et al. Diagnosis and treatment of chronic hepatitis C infection. Br Med J 2006;332:1013-7. 

21.193 Oh S et al. Antiviral therapy for treatment naïve patients with hepatitis C virus. Infect Dis Clin North 

Am 2006;20:99-113. 

21.194 Mallolas J et al. Pegylated IFN-α2a for treatment-naïve patients coinfected with HCV and HIV. Expert 


21.195 Aghemo A et al. Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect 

Ther 2009;7:925-35. 

21.196 Berenguer J et al. Pegylated interferon α2a plus ribavirin versus pegylated interferon α2b plus ribavirin 

for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009; 

63:1256-63. 

21.197 McHutchison JG et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. 

N Engl J Med 2009;361:580-93. 

21.198 Hoofnagle JH et al. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444- 

51. 

21.199 Keating GM et al. Peginterferon α-2a (40KD) plus ribavirin. A review of its use in the management of 

patients with chronic hepatitis C and and persistently ‗normal‘ ALT levels. Drugs 2005;65:521-36. 

21.200 Ahn J et al. Peginterferon-α2b and ribavirin. Expert Rev Anti Infect Ther 2004;2:17-25. 

21.201 Vogel W. Peginterferon-α2a (40kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. 


21.202 Jara P et al. Efficacy and safety of peginterferon-α2b and ribavirin combination therapy in children 

with chronic hepatitis C infection. Pediatr Infect Dis J 2008;27:142-8. 

21.203 Keeffe EB. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol 

2005;3(suppl. 2):S102-5. 

21.204 Sethi A et al. Approach to the management of patients with chronic hepatitis C who failed to achieve 

sustained virologic response. Infect Dis Clin North Am 2006;20:115-35. 

21.205 Ahmed F et al. Treatment of relapsers after combination therapy for chronic hepattitis C. Infect Dis 

Clin North Am 2006;20:137-53. 

21.206 Bailly F et al. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379- 

95. 

21.207 Mangia A et al. Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3. N 

Engl J Med 2005;352:2609-17. 

21.208 Shiffmann ML et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N 

Engl J Med 2007;357:124-34. 

21.209 Dalton HR et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8: 

698-709. 

21.210 Teo CG. Much meat, much malady: changing perceptions of the epidemiology of hepatitis E. Clin Microbiol 

Infect 2010;16:24-32. 

21.211 Bihl F et al. Hepatitis E virus: a zoonosis adapting to humans. J Antimicrob Chemother 2010;65: 

817-21. 

21.212 Emerson SU et al. Hepatitis E. Pediatr Infect Dis J 2007;26:1147-8. 

21.213 Kamar N et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 

2008;358:811-7. 

21.214 Focher F et al. Sensitivity of monkey B virus (cercopithecine herpesvirus 1) to antiviral drugs: role of 

thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob 


21.215 Jainkittivong A et al. Herpes B virus infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 

1998;85:399-403. 

21.216 Huff JL et al. B virus (cercopithecine herpesvirus 1) infection in humans and macaques: potential for 

zoonotic disease. Emerg Infect Dis 2003;9:246-50. 

21.217 National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention 

(CDC). Cercopithecine herpesvirus 1 (B virus) infection resulting from ocular exposure. Available 

at: http://www.cdc.gov/niosh/docs/99-100/pdfs/99-100.pdf. Accessed on August 27 th 2010. 

21.218 Cohen JI et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine 

herpesvirus 1). Clin Infect Dis 2002;35:1191-203. 

21.219 Wilson SS et al. Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect

Ther 2009;7:559-68. 

21.220 Whitley RJ et al. Herpes simplex virus infections. Lancet 2001;357:1513-8. 

21.221 Bacon TH et al. Herpes simplex virus resistance to aciclovir and penciclovir after two decades of antiviral 

therapy. Clin Microbiol Rev 2003;16:114-28. 

21.222 Tyring SK et al. Valaciclovir for herpes simplex virus infection: long term safety and sustained efficacy 

after 20 years experience with aciclovir. J Infect Dis 2002;186(suppl. 1):S40-6. 

21.223 de Almeoda JR et al. Combined corticosteroid and antiviral treatment for Bell palsy a systematic review 


21.224 Hato N et al. Valacyclovir and prednisolone treatment for Bell’s palsy: a multicenter, randomized, placebo-controlled 

study. Otol Neurotol 2007;28:408-13. 

21.225 Sullivan FM et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med 2007; 

357:1598-607. 

21.226 Gilden DH et al. Bell’s palsy: is glucocorticoid treatment enough? N Engl J Med 2007;357:1653-5. 

21.227 Raschilas F et al. Outcome and prognostic factors for herpes simplex encephalitis in adult patients: 

results of a multicenter study. Clin Infect Dis 2002;35:254-60. 

21.228 De Tiège X et al. Limits of early diagnosis of herpes simplex encephalitis in children: a retrospective 

study of 38 cases. Clin Infect Dis 2003;36:1335-9. 

21.229 Ito Y et al. Exacerbation of herpes simplex encephalitis after successful treatment with aciclovir. Clin 

Infect Dis 2000;30:185-7. 

21.230 Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res 2006;71:141-8. 

21.231 Hjalmarsson A et al. Herpes simplex encephalitis in Sweden, 1991-2001: incidence, morbidity and 

mortality. Clin Infect Dis 2007;45:875-80. 

21.232 Whitley RJ et al. The incidence and severity of herpes simplex encephalitis in Sweden, 1990-2001. 


21.233 Denes E et al. Main adult herpes virus infections of the CNS. Expert Rev Anti Infect Ther 2005;3: 

663-78. 

21.234 Bradford RD et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-α inhibitors. 


21.235 Centres for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 


21.236 Gupta R et al. Genital herpes. Lancet 2007;370:2127-37. 

21.237 Patent R et al. Managing patients with genital herpes and their sexual partners. Infect Dis Clin North 

Am 2005;19:427-38. 

21.238 Sen P et al. Genital herpes and its management. Br Med J 2007;334:1048-52. 

21.239 Kimberlin DW et al. Genital herpes. N Engl J Med 2004;350:1970-7. 

21.240 Auslander BA et al. Genital herpes in adolescents. Semin Pediatr Infect Dis 2005;16:24-30. 

21.241 Baker DA. Antiviral therapy for genital herpes infections in pregnancy. Expert Rev Anti Infect Ther 

2005;3:385-92. 

21.242 Brantley JS et al. Valacyclovir for the treatment of genital herpes. Expert Rev Anti Infect Ther 

2006;4: 367-76. 

21.243 Moomaw MD et al. Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster. 


21.244 Kolokotronis A et al. Herpes simplex virus infection, with particular reference to progression and complications 

of primary herpetic gingivostomatitis. Clin Microbiol Infect 2006;12:202-11. 

21.245 Jensen LA et al. Oral antivirals for the acute treatment of recurrent herpes labialis. Ann Pharmacother 

2004;38:705-9. 

21.246 Spruance SL et al. Clinical significance of antiviral therapy for episodic treatment of herpes labialis: 

exploratory analyses of the combined data from two valaciclovir trials. J Antimicrob Chemother 

2004;53:703-7. 

21.247 Lin L et al. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: 

a randomized, double blind, multicentre, aciclovir controlled trial. J Dermatol Treat 2002;13:67- 

72. 

21.248 Sacks SL et al. Clinical efficacy of topical doconasol 10% cream for herpes simplex labialis: a multicenter, 

randomized, placebo controlled trial. J Am Acad Dermatol 2001;45:222-30. 

21.249 Spruance SL et al. Aciclovir for treatment of herpes simplex labialis: results of two randomized, double 

blind, vehicle controlled, multicenter, clinical trials. Antimicrob Agents Chemother 2002;46: 

2238-43. 



21.251 Ritterband DC. Herpes simplex keratitis: classification, pathogenesis and therapy. Expert Rev Ophthalmol 

2006;1:241-56. 

21.252 The Herpetic Eye Disease Study Group. Aciclovir for the prevention of recurrent herpes simplex virus 

eye disease. N Engl J Med 1998;339:300-6. 

21.253 Landry ML et al. Herpes simplex type-2 meningitis: presentation and lack of standardized therapy. 

Am J Med 2009;122:688-91. 

21.254 Denes E et al. Main adult herpes virus infections of the CNS. Expert Rev Anti Infect Ther 2005;3: 

663-78. 

21.255 Shalabi M et al. Recurrent benign lymphocytic meningitis. Clin Infect Dis 2006;43:1194-7. 

21.256 Ellerin TB et al. Recurrent meningitis of unknown aetiology. Lancet 2004;363:1172. 

21.257 Dylewski JS et al. Mollaret‘s meningitis caused by herpes simplex virus type 2: case report and literature 

review. Eur J Clin Microbiol Infect Dis 2004;23:560-2. 

21.258 Lalezari J et al. A randomized, double blind, placebo controlled trial of cidofovir gel for the treatment 

of aciclovir unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J 

Infect Dis 1997;176:892-8. 

21.259 Kessler HA et al. Pilot study of topical trifluridine for the treatment of aciclovir resistant mucocutaneous 

herpes simplex disease in patients with AIDS (ACTG 172). J Acquir Immune Defic Syndr Hum 

Retrovirol 1996;12:147-52. 

21.260 Safrin S et al. A controlled trial comparing foscarnet with vidarabine for aciclovir resistant mucocutaneous 

herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-5. 

21.261 O‘Riordan DP et al. Herpes simplex virus infections in preterm infants. Pediatrics 2006;118:1612-20. 

21.262 Corey L et al. Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009;361:1376- 

85. 

21.263 Scott LL. Perinatal herpes: current status and obstetric management strategies. Pediatr Infect Dis J

1995;14:827-32. 

21.264 Scott LL. Perinatal herpes: current status and obstetric management strategies. Pediatr Infect Dis J 

1995;14:827-32. 

21.265 Halme L et al. Human herpesvirus 6 infection of the gastroduodenal mucosa. Clin Infect Dis 2008; 

46:434-9. 

21.266 Ward KN. Human herpesviruses-6 and -7 infections. Curr Opin Infect Dis 2005;18:247-52. 

21.267 Isaacson E et al. Evidence of human herpesvirus 6 infection in 4 immunocompetent patients with 

encephalitis. Clin Infect Dis 2005;40:890-3. 

21.268 Whitley RJ et al. Human herpesvirus 6 infection of the central nervous sytem: is it just a case of 

mistaken association? Clin Infect Dis 2005;40:894-5. 

21.269 Zerr DM et al. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell 

transplant recipients. Clin Infect Dis 2002;34:309-17. 

21.270 De Bolle L et al. Update on human herpesvirus 6 biology, clinical features and therapy. Clin 


21.271 Prober C. Sixth disease and the ubiquity of human herpesviruses. N Engl J Med 2005;352:753-5. 

21.272 Zerr DM et al. A population based study of primary human herpesvirus 6 infection. N Engl J Med 

2005;352:768-76. 

21.273 Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 in-fections in 

the immunocompetent. J Clin Virol 2005;32:183-93. 

21.274 Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in 


21.275 Zerr DM et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell 

transplantation. Clin Infect Dis 2005;40:932-40. 

21.276 Ward KN. Human herpesviruses-6 and -7 infections. Curr Opin Infect Dis 2005;18:247-52. 

21.277 Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in 


21.278 Hladik W et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006;355: 

1331-8. 

21.279 Sarid R et al. Virology, pathogenetic mechanisms and associated diseases of Kaposi sarcoma-associated 

herpesvirus (human herpesvirus 8). Mayo Clin Proc 2002;77:941-9. 

21.280 Wyplosz B et al. Initial human herpesvirus-8 rash and multicentric Castleman disease. Clin Infect Dis 

2008;47:684-8. 

21.281 Sullivan RJ et al. Epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus 

disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. 


21.282 Cannon MJ et al. Human herpesvirus 8: current issues. Clin Infect Dis 2003;37:82-7. 

21.283 Casper C et al. Remission of HHV-8 and HIV associated multicentric Castleman disease with ganciclovir 

treatment. Blood 2004;103:1632-4. 

21.284 Glezen WP. Prevention and treatment of seasonal influenza. N Engl J Med 2008;359:2579-85. 

21.285 Beigel JH. Influenza. Crit Care Med 2008;36:2660-6. 

21.286 Nicholson KG et al. Influenza. Lancet 2003;362:1733-45. 

21.287 Couch RB. Prevention and treatment of influenza. N Engl J Med 2000;343:1778-87. 

21.288 Hota S et al. Antivirals and the control of influenza outbreaks. Clin Infect Dis 2007;45:1362-8. 

21.289 Harper SA et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, 

and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society 


21.290 American Academy of Pediatrics. Recommendations for the prevention and treatment of influenza in 

children, 2010-2011. Pediatrics 2010;126:816-26. 

21.291 Rothberg MB et al. Complications of viral influenza. Am J Med 2008;121:258-64. 

21.292 Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73. 

21.293 Monto AS et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza 

A and B virus infections. J Infect Dis 1999;180:254-61. 

21.294 Ng S et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household 

transmission of influenza virus. Clin Infect Dis 2010;50:707-14. 

21.295 Aoki FY et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J 


21.296 Stephenson I et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A 

and B in children. Clin Infect Dis 2009;48:689-96. 

21.297 de Jong MD et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J 

Med 2005;353:2667-72. 

21.298 Kiso M et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 

2004;364:759-65. 

21.299 Hayden FG et al. Management of influenza in households: a prospective, randomized comparison of 

oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189:440-9. 

21.300 Yen HL et al. Virulence may determine the necessary duration and dosage of oseltamivir treatment 

for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005;192:665-72. 

21.301 Jefferson T et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006;367:303- 

13. 

21.302 Nicoll A et al. Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation 

and potential implications. Euro Surveill 2008;13. 

21.303 Watts G. A/H1N1 influenza virus: the basics. Science 2009;339:368-9. 

21.304 Sullivan SJ et al. 2009 H1N1 influenza. Mayo Clin Proc 2010;85:64-76. 

21.305 Working Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. 

Clinical aspects of pandemic (H1N1) 2009 influenza. N Engl J Med 2010;362:1708-19. 

21.306 Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin 

influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15. 

21.307 Peiris JS et al. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007;20: 

243-67. 

21.308 Uyeki TM. Human Infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical 

issues. Clin Infect Dis 2009;49:279-90. 

21.309 Gambotto A et al. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2007;371: 

1464-75. 

21.310 Hien TT et al. Avian influenza (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179-88.

21.311 Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. 

Avian influenza (H5N1) infections in humans. N Engl J Med 2005;353:1374-85. 



21.313 Falsey AR. Human metapneumovirus infection in adults. Pediatr Infect Dis J 2008;27(suppl.):S80- 

3. 

21.314 Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev 2006;19:546-557. 

21.315 Kahn JS. Newly identified respiratory viruses. Pediatr Infect Dis J 2007;26:745-6. 

21.316 Crowe JE. Human metapneumovirus as a major cause of human respiratory tract disease. Pediatr 

Infect Dis J 2004;23(11 suppl.):S215-21. 

21.317 Hamelin ME et al. Human metapneumovirus infection in adults with community acquired pneumonia 

and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:498-502. 

21.318 Williams JV et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy 

infants and children. N Engl J Med 2004;350:443-50. 

21.319 Semple MG et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial 

virus is strongly associated with severe bronchiolitis. J Infect Dis 2005;191:382-6. 

21.320 Meadows KP et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency 

virus infected patients treated with cidofovir. Arch Dermatol 1997;133:987-90. 

21.321 Sliva K et al. From actually toxic to highly specific-novel drugs against poxviruses. Virol J 2007;4:8. 

21.322 Huhn GD et al. Clinical characteristics of human monkeypox and risk factors for severe disease. Clin 

Infect Dis 2005;41:1742-51. 

21.323 Di Giulio DB et al. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 2004;4:15-25. 

21.324 Fleischauer AT et al. Evaluation of human to human transmission of monkeypox from infected patients 

to health care workers. Clin Infect Dis 2005;40:689. 

21.325 Baker RO et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus 

infections. Antiviral Res 2003;57:13-23. 

21.326 Hviid A et al. Mumps. Lancet 2008;371:932-44. 

21.327 Said MA et al. Gastrointestinal flu: norovirus in health care and long-term care facilities. Clin Infect 

Dis 2008;47:1202-8. 

21.328 Patel MM et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg 

Infect Dis 2008;14:1224-31. 


2010;8:205-17. 

21.330 Glass RI et al. Norovirus gastroenteritis. N Engl J Med 2009;361:1776-82. 

21.331 Centers for disease Control and Prevention (CDC). Norwalk-like viruses. Public health consequences 

and outbreak management. Morb Mortal Wkly Rep 2001;50(RR-9):1-17. 

21.332 Dolin R. Noroviruses – challenges to control. N Engl J Med 2007;357:1072-3. 

21.333 Lopman B et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new 

norovirus variant. Lancet 2004;363:682-8. 

21.334 Schiffman M et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. 

21.335 Gravitt PE et al. Diagnosis and management of oncogenic cervical human papillomavirus infection. 


21.336 Dunne EF et al. Genital human papillomavirus infection. Clin Infect Dis 2006;43:624-9. 

21.337 Abdool Karim Q et al. Preventing HIV infection in women: a global health imperative. Clin Infect Dis 

2010;50(suppl. 3):S122-9. 

21.338 Riviera A et al. Therapy of cutaneous human papillomavirus infections. Dermatol Ther 2004;17:441- 

8. 

21.339 Harwood CA et al. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed 

individuals. Br J Dermatol 2005;152:122-9. 

21.340 Cha S et al. Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a 

case report and review of the literature. Transpl Infect Dis 2005;7:158-61. 

21.341 Bacelieri R et al. Cutaneous warts: an evidence based approach to therapy. Am Fam Physician 

2005;72:647-52. 

21.342 Gustafsson L et al. Treatment of skin papillomas with topical α-lactalbumin-oleic acid. N Engl J Med 

2004;350:2663-72. 

21.343 Zacharisen MC et al. Recurrent respiratory papillomatosis in children: masquerader of common respiratory 

diseases. Pediatrics 2006;118:1925-31. 

21.344 Bernard HU. Established and potential strategies against papillomavirus infections. J Antimicrob 

Chemother 2004;53:137-9. 

21.345 Partridge JM et al. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21-31. 

21.346 Lacey CJ. Therapy for genital human papillomavirus related disease. J Clin Virol 2005;32(suppl. 1): 

82-90. 

21.347 Snoeck R et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir 

�(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine�. J Med Virol 1998;54:219-25. 

21.348 Snoeck R et al. Phase II double blind, placebo controlled study of the safety and efficacy of cidofovir 

topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001;33: 

597-602. 

21.349 Horn TD et al. Intralesional immunotherapy of warts with mumps, Candida and Trichophyton skin test 

antigens. A single blinded, randomized and controlled trial. Arch Dermatol 2005;141:589-94. 

21.350 Beutner KR et al. Imiquimod, a patient applied immune response modifier for treatment of external 

genital warts. Antimicrob Agents Chemother 1998;42:789-94. 



21.352 Wolthers KC et al. Human parechoviruses as an important viral cause of sepsislike illness and meningitis 

in young children. Clin Infect Dis 2008;47:358-63. 

21.353 Harvala H et al. Parechoviruses in children: understanding a new infection. Curr Opin Infect Dis 

2010;23:224-30. 

21.354 Pajkrt D et al. Clinical characteristics of human parechoviruses 4-6 infections in children. Pediatr Infect 

Dis J 2009;28:1008-10. 

21.355 Levorson RE et al. Human parechoviruses. Pediatr Infect Dis J 2009;28:831-2. 

21.356 Young NS et al. Parvovirus B19. N Engl J Med 2004;350:586-97. 


Dis 2009;48:1713-23.

21.358 Calabrese LH et al. Viral Arthritis. Infect Dis Clin North Am 2005;19:963-80. 

21.359 Morris CN et al. Parvovirus B19 infection associated with respiratory distress. Clin Infect Dis 1998; 

27:900-1. 

21.360 Barton LL. Cardiorespiratory manifestations of parvovirus B19 infection. Clin Infect Dis 1999;28: 

1343. 

21.361 McGhee SA et al. Persistent parvovirus-associated chronic fatigue treated with high dose intravenous 

immunoglobulin. Pediatr Infect Dis J 2005;24:272-4. 

21.362 Kumar J et al. Long-term remission of recurrent parvovirus B associated anemia in a renal transplant 

recipient induced by treatment with immunoglobulin and positive seroconversion. Transpl Infect Dis 

2005;7:30-3. 

21.363 Kurtzman G et al. Pure red cell aplasia of 10 years‘ duration due to persistent parvovirus B19 infection 

and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-23. 

21.364 Koduri PR et al. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous 

immunoglobulin. A report of eight patients. Am J Hematol 1999;61:16-20. 

21.365 Eid AJ et al. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 

2006;43:40-8. 

21.366 Howard RS. Poliomyelitis and the postpolio syndrome. Br Med J 2005;330:1314-9. 

21.367 Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol 

2004;2:473-82. 

21.368 Hou J et al. Management of infections by the human polyomavirus JC: past, present and future. Expert 


21.369 Cinque P et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 

2009;9:625-36. 

21.370 Shitrit D et al. Progressive multifocal leuko-encephalopathy in transplant recipients. Transpl Int 2005; 

17:658-65. 

21.371 Crowder CD et al. Successful outcome of progressive multifocal leuko-encephalopathy in a renal 

transplant recipient. Am J Transplant 2005;5:1151-8. 

21.372 Chen Y et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J 

Med 2009;361:1067-74. 

21.373 Langer-Gould A et al. Progressive multifocal leuko-encephalopathy in a patient treated with natalizumab. 

N Engl J Med 2005;353:375-81. 

21.374 Van Assche G et al. Progressive multifocal leuko-encephalopathy after natalizumab therapy for 

Crohn‘s disease. N Engl J Med 2005;353:362-8. 

21.375 Kleinschmidt-DeMasters BK et al. Progressive multifocal leuko-encephalopathy complicating treatment 

with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74. 

21.376 Miralles P et al. Treatment of AIDS associated progressive multifocal leuko-encephalopathy with 

highly active antiretroviral therapy. AIDS 1998;12:2467-72. 

21.377 Tantisiriwat W et al. Progressive multifocal leuko-encephalopathy in patients with AIDS receiving 

highly active antiretroviral therapy. Clin Infect Dis 1999;28:1152-4. 

21.378 Hall CD et al. Failure of cytarabine in progressive multifocal leuko-encephalopathy associated with 

human immunodeficiency virus infection. N Engl J Med 1998;338:1345-51. 

21.379 Cesaro S et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect 

Dis 2009;49:233-40. 

21.380 Weinberg GA et al. BK virus nephropathy and other polyomavirus infections. Pediatr Infect Dis J 

2010;29:257-60. 

21.381 Hanssen Rinaldo C et al. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti 

Infect Ther 2007;5:105-15. 

21.382 Muñoz P et al. Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect 

Dis 2005;41:1720-5. 

21.383 Reploeg MD et al. BK virus: a clinical review. Clin Infect Dis 2001;33:191-202. 

21.384 Hirsch HH et al. Polyomavirus BK. Lancet Infect Dis 2003;3:611-23. 

21.385 Vorou RM et al. Cowpox virus infection: an emerging health threat. Curr Opin Infect Dis 2008;21: 

153-6. 

21.386 Moore ZS et al. Smallpox. Lancet 2006;367:425-35. 

21.387 Hosamani M et al. Orf: an update on current research and future perspectives. Expert Rev Anti Infect 

Ther 2009;7:879-93. 

21.388 Baker RO et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. 

Antiviral Res 2003;57:13-23. 

21.389 Rupprecht CE et al. Current and future trends in the prevention, treatment, and control of rabies. 


21.390 Hankins DG et al. Overview, prevention and treatment of rabies. Mayo Clin Proc 2004;79:671-6. 

21.391 Warrell MJ et al. Rabies and other lyssavirus diseases. Lancet 2004;363:959-69. 

21.392 Plotkin SA. Rabies. Clin Infect Dis 2000;30:4-12. 

21.393 Jackson AC et al. Management of rabies in humans. Clin Infect Dis 2003;36:60-3. 

21.394 Willoughby RE et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 

352:2508-14. 

21.395 Srinivasan A et al. Transmission of rabies virus from an organ donor to four transplant recipients. N 

Engl J Med 2005;352:1103-11. 



21.397 Tregoning JS et al. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. 


21.398 Lüsebrink J et al. Novel therapies for an old virus: treatment of RSV infections in the 21 st century. Expert 


21.399 Sikkel MB et al. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr 

Infect Dis J 2008;27(suppl.):S63-70. 

21.400 Boekh M et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial 

virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 

44:245-9. 

21.401 Khanna N et al. Respiratory syncytial virus infection in patients with hematological diseases: singlecentre 

study and review of the literature. Clin Infect Dis 2008;46:402-12. 

21.402 Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52. 

21.403 Empey KM et al. Pharmacologic advances in the treatment and prevention of respiratory syncytial

virus. Clin Infect Dis 2010;50:1258-67. 

21.404 Moscona A. Management of respiratory syncytial virus infections in the immunocompromised child. 


21.405 Han LL et al. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease 

burden. J Infect Dis 1999;179:25-30. 

21.406 Falsey AR et al. Respiratory syncytial virus infections in elderly and high risk adults. N Engl J Med 

2005;352:1749-59. 

21.407 Moler FW et al. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus associated 

respiratory failure. J Pediatr 1996;128:422-8. 

21.408 Guerguerian AM et al. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. Am J Respir 

Crit Care Med 1999;160:829-34. 



21.410 Eccles R. Understanding the symptoms of common cold and influenza. Lancet Infect Dis 2005;5: 

718-25. 

21.411 Mossad SB. Current and future therapeutic approaches to the common cold. Expert Rev Anti Infect 

Ther 2003;1:619-26. 

21.412 Heikkinen T et al. The common cold. Lancet 2003;361:51-9. 

21.413 Tsolia MN et al. Etiology of community acquired pneumonia in hospitalized children: evidence for high 

prevalence of viral infections. Clin Infect Dis 2004;39:681-6. 



2010;8:205-17. 

21.416 Bernstein DI. Rotavirus overview. Pediatr Infect Dis J 2009;28(suppl. 3):S50-3. 

21.417 Dickey M et al. Rotavirus meningoencephalitis in a previously healthy child and a review of the literature. 


21.418 Ramig RF. Systemic rotavirus infection. Expert Rev Anti Infect Ther 2007;5:591-612. 

21.419 Centers for Disease Control and Prevention (CDC). Managing acute gastroenteritis among children. 

Oral rehydration, maintenance, and nutritional therapy. Morb Mortal Wkly Rep 2003;52(RR-16):1- 

18. 

21.420 Verdonck K et al. Human T-lymphotrophic virus 1: recent knowledge about an ancient infection. Lancet 

Infect Dis 2007;7:266-81. 

21.421 Heininger U et al. Varicella. Lancet 2006;368:1365-76. 

21.422 Hambleton S. Chickenpox. Curr Opin Infect Dis 2005;18:235-40. 

21.423 Gnann JW et al. Herpes zoster. N Engl J Med 2002;347:340-6. 

21.424 Whitley RJ. A 70-year-old woman with shingles. Review of herpes zoster. J Am Med Assoc 2009; 

302:73-80. 

21.425 Sampathkumar P et al. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 

84:274-80. 

21.426 Nathwani D et al. Varicella infections in pregnancy and the newborn. J Infect 1998;36(suppl. 1):59- 

71. 

21.427 Wareham DW et al. Herpes zoster. Br Med J 2007;334:1211-5. 

21.428 Dworkin RH et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44 

(suppl. 1):S1-26. 



21.430 Johnson RW et al. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin 


21.431 Mounsey AL et al. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam 

Physician 2005;72:1075-80. 

21.432 Dworkin RH et al. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003;36:877- 

82. 

21.433 Quan D et al. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed 

by oral valacyclovir. Arch Neurol 2006;63:940-2. 

21.434 Davies PS et al. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. 

Drugs 2004;64:937-47. 

21.435 Whitley RJ et al. Herpes zoster: risk categories for persistent pain. J Infect Dis 1999;179:9-15. 

21.436 Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N 

Engl J Med 2005;352:2271-84. 

21.437 Tangsinmankong N et al. Varicella zoster as a manifestation of immune restoration in HIV infected 

children. J Allergy Clin Immunol 2004;113:742-6. 

21.438 Grose C et al. Chickenpox and the geniculate ganglion: facial nerve palsy, Ramsay Hunt syndrome 

and acyclovir treatment. Pediatr Infect Dis J 2002;21:615-7. 

21.439 Kinishi M et al. Acyclovir improves recovery rate of facial nerve palsy in Ramsay Hunt syndrome. Auris 

Nasus Larynx 2001;28:223-6. 

21.440 Opstelten W et al. Managing ophthalmic herpes zoster in primary care. Br Med J 2005;331:147-51. 

21.441 Meduri A et al. Herpes zoster ophthalmicus. Expert Rev Ophthalmol 2009;4:537-45. 

21.442 Gubler DJ. The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis 

2007;45:1039-46. 

21.443 Carson PJ et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. 


21.444 Kramer LD et al. West Nile virus. Lancet Neurol 2007;6:171-81. 

21.445 Bode AV et al. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county 

region of Colorado in 2003. Clin Infect Dis 2006;42:1234-40. 

21.446 Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis and prevention. 

Mayo Clin Proc 2003;78:1137-44. 

21.447 Hayes EB et al. Virology, pathology and clinical manifestations of West Nile virus disease. Emerg Infect 

Dis 2005;11:1174-9. 

21.448 Hayes EB et al. West Nile virus infection: a pediatric perspective. Pediatrics 2004;113:1375-81. 

21.449 Granwehr B et al. West Nile virus: where are we now? Lancet Infect Dis 2004;4:547-56. 

21.450 Ravindra KV et al. West Nile virus associated encephalitis in recipients of renal and pancreas transplants: 

case series and literature review. Clin Infect Dis 2004;38:1257-60. 

21.451 Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis 2007;44:1617-

24. 

21.452 Jeha LE et al. Long term outcome of patients with West Nile virus infection. Infect Dis Clin Pract 

2005;13:101-3. 

21.453 Kalil AC et al. Use of interferon-α in patients with West Nile encephalitis: report of 2 cases. Clin Infect 

Dis 2005;40:764-6. 

21.454 Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007;44:850-6. 



207. 



58(RR-11):1-167. 

22A.1 Nigro G et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N 

Engl J Med 2005;353:1350-62. 

22A.2 Victor JC et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J 

Med 2007;357:1685-95. 

22A.3 Centers for Disease Control and Prevention (CDC). Prevention of hepatitis A through active or passive 

immunization. Morb Mortal Wkly Rep 1999;48(RR-12):1-37. 

22A.4 Sagliocca L et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a 

randomised trial. Lancet 1999;353:1136-9. 

22A.5 Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate 

transmission of hepatitis B virus infection in the United States. Morb Mortal Wkly Rep 2006;55 

(RR-16):1-33. 

22A.6 Ranger-Rogez S et al. Hepatitis B mother to child transmission. Expert Rev Anti Infect Ther 2004;2: 

133-45. 

22A.7 Centers for Disease Control and Prevention (CDC). Recommendations for prevention and control of 

hepatitis C virus (HCV) infection and HCV related chronic disease. Morb Mortal Wkly Rep 1998;47 

(RR-19):1-39. 

22A.8 Centers for Disease Control and Prevention (CDC). Updated U.S. Public Health Service guidelines 

for the management of occupational exposures to HBV, HCV, and HIV and recommendations for 

postexposure prophylaxis. Morb Mortal Wkly Rep 2001;50(RR-11):1-52. 

22A.9 Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. 


22A.10 Sulkowski MS et al. Hepatitis C virus infection as an opportunistic disease in persons infected with 

human immunodeficiency virus. Clin Infect Dis 2000;30(suppl. 1):S77-84. 

22A.11 Jaeckel E et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452- 

7. 

22A.12 National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention 

(CDC). Cercopithecine herpesvirus 1 (B virus) infection resulting from ocular exposure. Available 

at: http://www.cdc.gov/niosh/docs/99-100/pdfs/99-100.pdf. Accessed on August 27 th 2010. 

22A.13 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 


22A.14 Gupta R et al. Genital herpes. Lancet 2007;370:2127-37. 

22A.15 Diaz-Mitoma F et al. Oral famciclovir for the suppression of recurrent genital herpes. J Am Med Assoc 

1998;280:887-92. 

22A.16 Benedetti JK et al. Clinical re-activation of genital herpes simplex virus infection decreases in frequency 

over time. Ann Intern Med 1999;131:14-20. 

22A.17 Celum CL et al. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral 

therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005;191(suppl. 1): 

S107-14. 

22A.18 Barton S et al. The role of anti-HSV therapeutics in the HIV infected host and in controlling the HIV 

epidemic. Herpes 2005;12:15-22. 

22A.19 Committee on Infectious Diseases of the American Academy of Pediatrics. Antiviral therapy and prophylaxis 

for influenza in children. Pediatrics 2007;119:852-60. 

22A.20 Hota S et al. Antivirals and the control of influenza outbreaks. Clin Infect Dis 2007;45:1362-8. 

22A.21 Committee on Infectious Diseases of the American Academy of Pediatrics. Recommendations for 

prevention and control of influenza in children, 2010-2011. Pediatrics 2010;126:816-26. 

22A.22 Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines. 


22A.23 Monto AS et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A 

and B within households. J Infect Dis 2002;186:1582-8. 

22A.24 Nicoll A et al. Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation 

and potential implications. Euro Surveill 2008;13. 

22A.25 Atkins JT et al. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus immunoglobulin 

intravenous among preterm infants of thirty two weeks gestation and less: reduction in incidence, 

severity of illness and cost. Pediatr Infect Dis J 2000;19:138-43. 

22A.26 Committee on Infectious Diseases of the American Academy of Pediatrics. Modified recommendations 

for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 

124:1694-701. 

22A.27 Feltes TF et al. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients 

with congenital heart disease. Expert Opin Biol Ther 2007;7:1471-80. 

22A.28 Fenton C et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus 

infection. Pediatr Drugs 2004;6:177-97. 

22A.29 Centers for Disease Control and Prevention (CDC). Prevention of varicella. Morb Mortal Wkly Rep 

2007;56(RR-4):1-40. 

22A.30 Hambleton S et al. Preventing varicella-zoster disease. Clin Microbiol Rev 2005;18:70-80. 

22A.31 Watson B et al. Postexposure effectiveness of varicella vaccine. Pediatrics 2000;105:84-8. 

22A.32 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of oppor-

tunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 

207. 

22A.33 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treat-ment of 


58(RR-11):1-167. 

22B.1 Centers for Disease Control and Prevention (CDC). Guidelines for the management of occupational 

exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. Morb Mortal 

Wkly Rep 2001;50(RR-11):1-52. 

22C.1 Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for 

postexposure prophylaxis to prevent human rabies. Morb Mortal Wkly Rep 2010;59(RR-2):1-8. 

22C.2 Rupprecht CE et al. Prophylaxis against rabies. N Engl J Med 2004;351:2626-35. 

22C.3 Hankins DG et al. Overview, prevention and treatment of rabies. Mayo Clin Proc 2004;79:671-6. 

22C.4 Rupprecht CE et al. Current and future trends in the prevention, treatment and control of rabies. Expert 


22C.5 Wilde H et al. Rabies update for travel medicine advisors. Clin Infect Dis 2003;37:96-100. 

22C.6 Plotkin SA. Rabies. Clin Infect Dis 2000;30:4-12. 

22C.7 Rupprecht CE et al. Prophylaxis against rabies. N Engl J Med 2004;351:2626-35. 

22C.8 Hankins DG et al. Overview, prevention and treatment of rabies. Mayo Clin Proc 2004;79:671-6. 

22C.9 Rupprecht CE et al. Current and future trends in the prevention, treatment and control of rabies. Expert 


22C.10 Wilde H et al. Rabies update for travel medicine advisors. Clin Infect Dis 2003;37:96-100. 

23A.1 Rottinghaus ST et al. Current non-AIDS antiviral chemotherapy. Expert Rev Anti Infect Ther 2007; 

5:217-30. 

23A.2 Luck S et al. Advances in the antiviral therapy of herpes virus infection in children. Expert Rev Anti 

Infect Ther 2006;4:1005-20. 

23A.3 De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115-33. 

23A.4 Balfour HH. Antiviral drugs. N Engl J Med 1999;340:1255-68. 

23A.5 De Clercq E. Recent highlights in the development of new antiviral drugs. Curr Opin Microbiol 2005; 

8:552-60. 

23A.6 De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004;2:704-20. 

23A.7 European Medicines Agency (EMA). European assessment report (EPAR). Hepsera, summary of 


_-_Product_Information/human/000485/WC500048079.pdf. Accessed on August 31 st 2010. 

23A.8 De Clercq E et al. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug 

Discov 2005;4:928-40. 

23A.9 Danta M et al. Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. Int J Clin Pract 

2004:58:877-86. 

23A.10 Wassilew SW et al. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on 

postherpetic neuralgia. Antiviral Res 2003;59:57-60. 

23A.11 Keam SJ et al. Brivudin (bromovinyl deoxyuridine). Drugs 2004;64:2091-7. 

23A.12 European Medicines Agency (EMA). European assessment report (EPAR). Vistide, summary of product 


_Product_Information/human/000121/WC500052072.pdf. Accessed on August 31 st 2010. 

23A.13 De Clercq E et al. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug 

Discov 2005;4:928-40. 

23A.14 Schliefer K et al. Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet 1997;350:413- 

4. 

23A.15 Dvorak CC et al. Development of herpes simplex virus stomatitis during receipt of cidofovir therapy. 


23A.16 European Medicines Agency (EMA). European assessment report (EPAR). Baraclude, summary of 



23A.17 Cheng PN et al. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naïve 

chronic hepatitis B patients. Expert Rev Anti Infect Ther 2008;6:569-79. 

23A.18 Palumbo E. Entecavir for chronic hepatitis B: a review. Ther Drug Monit 2008;30:1-4. 

23A.19 Min AD et al. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68. 

23A.20 Rivkin A. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. Drugs Today 

2007;43:201-20. 

23A.21 Robinson DM. Entecavir. A review of its use in chronic hepatitis B. Drugs 2006;66:1605-22. 

23A.22 Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 2006;28: 

184-203. 

23A.23 Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol 2006;36:8-12. 

23A.24 Rivkin A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 

2005;21:1845-56. 

23A.25 Shaw T et al. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004;2: 

853-71. 

23A.26 Honkoop P et al. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 

2003;12:683-8. 

23A.27 Palumbo E. New drugs for chronic hepatitis B: a review. Am J Ther 2008;15:167-72. 

23A.28 Andrei G et al. New inhibitors of human CMV. Curr Opin Investig Drugs 2008;9:132-45. 

23A.29 Aiello LP et al. Evolving guidelines for intravitreous injections. Retina 2004;24(suppl. 5):S3-19. 

23A.30 Geary RS et al. Fomivirsen. Clinical pharmacology and potential drug interactions. Clin Pharmacokinet 

2002;41:255-60. 

23A.31 Schaefer M et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with 

chronic hepatitis C. J Hepatol 2005;42:793-8. 

23A.32 Kraus MR et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon

induced functional androgen deficiency or depression? J Endocrinol 2005;185:345-52. 

23A.33 Farel C et al. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients 

treated wilth peginterferon alpha-2a and ribavirin. AIDS 2004;18:1805-9. 

23A.34 Beuthien W et al. Vasculitic complications of interferon-a treatment for chronic hepatitis C virus infection: 

case report and review of the literature. Clin Rheumatol 2005;24:507-15. 

23A.35 European Medicines Agency (EMA). European assessment report (EPAR). Intron A, summary of 



23A.36 Schaefer M et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with 

chronic hepatitis C. J Hepatol 2005;42:793-8. 

23A.37 Kraus MR et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon 

induced functional androgen deficiency or depression? J Endocrinol 2005;185:345-52. 

23A.38 Farel C et al. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients 

treated wilth peginterferon alpha-2a and ribavirin. AIDS 2004;18:1805-9. 

23A.39 Beuthien W et al. Vasculitic complications of interferon-a treatment for chronic hepatitis C virus infection: 

case report and review of the literature. Clin Rheumatol 2005;24:507-15. 

23A.40 Arase Y et al. Significance of ribavirin concentration in combination therapy of interferon and ribavirin 

for chronic hepatitis C. Intervirology 2005;48:138-44. 

23A.41 Rivkin AM et al. Epoietin alfa for the treatment of combination therapy induced hemolytic anemia in 

patients infected with hepatitis C virus. Pharmacotherapy 2005;25:862-75. 

23A.42 Taliani G et al. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for 

chronic hepatitis C. J Chemother 2005;17:212-4. 

23A.43 Doyuk Kartal E et al. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment 

of chronic active hepatitis C. Chemotherapy 2005;51:167-9. 

23A.44 Hurst EA et al. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic 

hepatitis C. Arch Dermatol 2005;141:865-8. 

23A.45 Bini EJ et al. Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with 

asthma and chronic hepatitis C. Mayo Clin Proc 1999;74:367-70. 

23A.46 European Medicines Agency (EMA). European assessment report (EPAR). Zeffix, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document _library/EPAR_- 


23A.47 Min AD et al. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68. 

23A.48 Palumbo E. New drugs for chronic hepatitis B: a review. Am J Ther 2008;15:167-72. 

23A.49 European Medicines Agency (EMA). European assessment report (EPAR). Tamiflu, summary of product 

characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR _- 


23A.50 Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79:1577-86. 

23A.51 Centers for Disease Control and Prevention (CDC). Neuraminidase inhibitors for treatment of influenza 

A and B infections. Morb Mortal Wkly Rep 1999;48(RR-14):1-9. 

23A.52 Gubareva LV et al. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827-35. 

23A.53 Harper SA et al. Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis, 

and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society 


23A.54 Nakamura K et al. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 

H1N1 influenza A infection. Clin Infect Dis 2010;50:e47-9. 

23A.55 European Medicines Agency (EMA). European assessment report (EPAR). Synagis, summary of product 



23A.56 Cardenas S et al. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev 


23A.57 European Medicines Agency (EMA). European assessment report (EPAR). Pegasys, summary of 



23A.58 European Medicines Agency (EMA). European assessment report (EPAR). Pegintron, summary of 



23A.59 European Medicines Agency (EMEA). European assessment report (EPAR). Rebetol, summary of 



23A.60 Ito S et al. Exposure of pregnant women to ribavirin contaminated air: risk assessment and recommendations. 


23A.61 Rendón AL et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic 

response in HIV:hepatitis C virus co-infected patients. J Acquir Immune Defic Syndr 2005; 

39:401-5. 

23A.62 European Medicines Agency (EMA). European assessment report (EPAR). Sebivo, summary of product 



23A.63 Kim JW et al. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother 

2006;40:472-8. 

23A.64 Lui YY et al. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev Anti Infect Ther 

2009;7:259-68. 

23A.65 Lai CL et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 

357:2576-88. 

23A.66 Colman PM. Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev Anti Infect Ther 

2005;3:191-9. 

23A.67 Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79:1577-86. 

23A.68 Centers for Disease Control and Prevention (CDC). Neuraminidase inhibitors for treatment of influenza 

A and B infections. Morb Mortal Wkly Rep 1999;48(RR-14):1-9. 

23A.69 Gubareva LV et al. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827-35.

23B.1 Kimberlin DW et al. Safety of oseltamivir compared with the adamantanes in children less than 12 

months of age. Pediatr Infect Dis J 2010;29:195-8. 

23B.2 Shun-Shin M et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: 

systematic review and meta-analysis of randomised controlled trials. Br Med J 2009;339:b3172. 

23B.3 Piedra PA et al. Effects of oseltamivir on influenza-related complications in children with chronic medical 

conditions. Pediatrics 2009;124:170-8. 


Pharm 2009;66:642-8. 



24.1 Cha S et al. Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a 

case report and review of the literature. Transpl Infect Dis 2005;7:158-61. 

24.2 Snoeck R et al. Phase II double blind, placebo controlled study of the safety and efficacy of cidofovir 

topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001;33: 

597-602. 

24.3 Beutner KR et al. Therapeutic approaches to genital warts. Am J Med 1997;102(suppl. 5A): 28-37. 

25A.1 Hoge Gezondheidsraad. Vaccinatiegids. Available at: http://www.health.belgium.be/internet2Prd/ 

groups/public/@public/@shc/documents/ie2divers/10758445.pdf. Accessed on October 19 th 2010. 

25A.2 Conseil Supérieur de la Santé. Guide de Vaccination. Available at: http://www.health.belgium.be/inter 

net 2Prd/groups/public/@public/@shc/documents/ie2divers/10758445_fr.pdf. Accessed on October 

19 th 2010. 

25A.3 Centers for Disease Control and Prevention (CDC). General recommendations on immunization. 


25A.4 Centers for Disease Control and Prevention (CDC). Recommended immunization schedules for persons 

aged 0 through 18 years — United States, 2010. Morb Mortal Wkly Rep 2010;58:Q1-4. 

25A.5 Pickering LK et al. Immunization programs for infants, children, adolescents, and adults: clinical practice 

guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:817-40. 

25A.6 Abzug MJ. Vaccination in the immunocompromised child: a probe of immune reconstitution. Pediatr 

Infect Dis J 2009;28:233-6. 

25A.7 Centers for Disease Control and Prevention (CDC). Poliomyelitis prevention in the United States. 


25A.8 Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria and pertussis 

among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. 


25A.9 Pichichero ME et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids 

for adolescents. Pediatrics 2006;117:1084-93. 

25A.10 Crowcroft NS et al. Recent developments in pertussis. Lancet 2006;367:1926-36. 

25A.11 Forsyth K. Pertussis, still a formidable foe. Clin Infect Dis 2007;45:1487-91. 

25A.12 Hoge Gezondheidsraad. Advies betreffende de vaccinatie van cochleaire implantatendragers of patiënten 

die kandidaat zijn voor de implantatie.Available at: http://www.health.belgium.be/internet2Prd/ 


25A.13 Conseil Supérieur de la Santé. Avis concernant la vaccination des sujets porteurs d‘implants cochléaires 

ou candidats à l‘implantation. Available at: http://www.health.belgium.be/internet2Prd/groups/ 

public/@public/@shc/documents/ie2divers/4938416_fr.pdf. Accessed on October 19th 2010. 

25A.14 Van Herck K et al. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr 

Infect Dis J 2008;27:861-9. 

25A.15 Poland GA et al. Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351:2832- 

8. 

25A.16 Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate 

transmission of hepatitis B virus in the United States. Part 1: immunization of infants, children 

and adolescents. Morb Mortal Wkly Rep 2005;54(RR-16):1-32. 

25A.17 Centers for Disease Control and Prevention (CDC). Measles, mumps and rubella. Vaccine use and 

strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps. 


25A.18 Gardner P. Prevention of meningococcal disease. N Engl J Med 2006;355:1466-73. 

25A.19 American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal 

disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 

2005;116:496-505. 

25A.20 Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. 



die kandidaat zijn voor de implantatie.Available at: http://www.health.belgium.be/internet2Prd/ 





25A.23 Pavia M et al. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. 

Pediatrics 2009;123:e1103-10. 

25A.24 Whitney CG et al. Decline in invasive pneumococcal disease after the introduction of protein polysaccharide 

conjugate vaccine. N Engl J Med 2003;348:1737-46. 

25A.25 Centers for Disease Control and Prevention (CDC). Preventing pneumococcal disease among infants 

and young children. Morb Mortal Wkly Rep 2000;49(RR-9):1-35. 


die kandidaat zijn voor de implantatie.Available at: http://www.health.belgium.be/internet2Prd 

/groups/public/@public/@shc/documents/ie2divers/4938416.pdf. Accessed on October 18 th 2010.




25A.28 Centers for Disease Control and Prevention (CDC). Pneumococcal vaccination for cochlear implant 

candidates and recipients. Morb Mortal Wkly Rep 2003;52:739-40. 

25A.29 Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants 

and children. Morb Mortal Wkly Rep 2009;58(RR-2):1-24. 

25A.30 American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: 

updated guidelines for use of rotavirus vaccine. Pediatrics 2009;123:1412-20. 

25A.31 Centers for Disease Control and Prevention (CDC). Quadrivalent human papillomavirus vaccine. 

Morb Mortal Wkly Rep 2007;56(RR-2):1. 

25A.32 The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the 

human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebocontrolled 

trial up to 6.4 years. Lancet 2009;374:1975-85. 

25B.1 Centers for Disease Control and Prevention (CDC). Use of Combination measles, mumps, rubella, 

and varicella vaccine. Morb Mortal Wkly Rep 2010;59(RR-3):1-11. 

26A.1 Hoge Gezondheidsraad. Vaccinatiegids. Available at: http://www.health.belgium.be/internet2Prd/ 


26A.2 Conseil Supérieur de la Santé. Guide de Vaccination. Available at: http://www.health.belgium.be/inter 

net2Prd/groups/public/@public/@shc/documents/ie2divers/10758445_fr.pdf. Accessed on October 

19th 2010. 

26A.3 Centers for Disease Control and Prevention (CDC). General recommendations on immunization. 


26A.4 Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule – 

United States, 2010.(CDC). Morb Mortal Wkly Rep 2010;59:Q1-4. 

26A.5 Pickering LK et al. Immunization programs for infants, children, adolescents, and adults: clinical practice 

guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:817-40. 

26A.6 Geretti AM et al. Immunization for HIV-positive individuals. Curr Opin Infect Dis 2010;23:32-8. 

26A.7 Avery RK et al. Update on immunizations in solid organ transplant recipients: what clinicians need to 

know. Am J Transplant 2008;8:9-14. 

26A.8 Chow J et al. Vaccination of solid-organ transplantation candidates. Clin Infect Dis 2009;49:1550-6. 

26A.9 Wilck MB et al. Vaccination after stem cell transplant: a review of recent developments and implications 

for current practice. Curr Opin Infect Dis 2008;21:399-408. 

26A.10 Advice for travelers. Treat Guidel Med Lett 2006;4:25-34. 

26B.1 McIntyre P et al. Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect 

Dis 2009;22:215-23. 

26B.2 Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis 

among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Morb 

Mortal Wkly Rep 2006;55(RR-17):1-36. 

26B.3 Centers for Disease Control and Prevention (CDC). Prevention of pertussis, tetanus, and diphtheria 

among pregnant and postpartum women and their infants. Morb Mortal Wkly Rep 2008;57(RR-5):1- 

50. 

26B.4 Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis 

among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Morb 

Mortal Wkly Rep 2006;55(RR-17):1-36. 

26B.5 Centers for Disease Control and Prevention (CDC). Prevention of pertussis, tetanus, and diphtheria 

among pregnant and postpartum women and their infants. Morb Mortal Wkly Rep 2008;57(RR-5):1- 

50. 

26B.6 Sagliocca L et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a 

randomised trial. Lancet 1999;353:1136-9. 

26B.7 Centers for Disease Control and Prevention (CDC). Prevention of hepatitis A through active or passive 

immunization. Morb Mortal Wkly Rep 2006;55(RR-7):1-23. 

26B.8 Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate 

transmission of hepatitis B virus infection in the United States. Morb Mortal Wkly Rep 2006;55 

(RR-16):1-33. 

26B.9 Zuckerman JN et al. Hepatitis A and B booster recommendations: implications for travelers. Clin Infect 

Dis 2005;41:1020-6. 

26B10 Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Morb Mortal 

Wkly Rep 2010;59(RR-8):1-59. 

26B.11 Mak TK et al. Influenza vaccination in pregnancy: current evidence and selected national policies. 


26B.12 Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines. Morb Mortal 

Wkly Rep 2010;59(RR-1):1-26. 

26B.13 Centers for Disease Control and Prevention (CDC). Measles, mumps, and rubella vaccine use and 

strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. 


26B.14 Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, 

and varicella vaccine. Morb Mortal Wkly Rep 2010;59(RR-3):1-11. 

26B.15 Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. 


26B.16 Centers for Disease Control and Prevention (CDC). Poliomyelitis prevention in the United States. 


26B.17 Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for 

postexposure prophylaxis to prevent human rabies. Morb Mortal Wkly Rep 2010;59(RR-2):1-8. 

26B.18 Centers for Disease Control and Prevention (CDC). Human rabies prevention. Morb Mortal Wkly

Rep 2008;57(RR-3):1-28. 

26B.19 Rupprecht C et al. Current and future trends in the prevention, treatment, and control of human rabies. 


26B.20 Rupprecht CE et al. Prophylaxis against rabies. N Engl J Med 2004;351:2626-35. 

26B.21 Tasker SA et al. Re-immunization with 23-valent pneumococcal vaccine for patients infected with human 

immunodeficiency virus type 1: clinical, immunologic and virologic responses. Clin Infect Dis 

2002;34:813-21. 

26B.22 Centers for Disease Control and Prevention (CDC). Prevention of varicella. Morb Mortal Wkly Rep 

2007:56(RR-4):1-40. 

26B.23 World Health Organization. Cholera, 2009. Wkly Epidemiol Rec 2010;85:293-308. 

26B.24 Centers for Disease Control and Prevention (CDC). Yellow fever vaccine. Morb Mortal Wkly Rep 

2010;59(RR-7):1-26. 

27.1 Yu AS et al. Hepatitis B vaccines. Infect Dis Clin North Am 2006;20:27-45. 

27.2 Confavreux C et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001; 

344:319-26. 

27.3 Ascherio A et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344: 

327-32. 

27.4 European Medicines Agency (EMA). European assessment report (EPAR). Fendrix, summary of product 


_Product_Information/human/000550/WC500021704.pdf Accessed on October 19 th 2010. 

27.5 European Medicines Agency (EMA). European assessment report (EPAR). Hbvaxpro, summary of 



27.6 European Medicines Agency (EMA). European assessment report (EPAR). Twinrix Paediatric, summary 

of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_libra 

ry/EPAR_-_Product_Information/human/000129/WC500044248.pdf. Accessed on October 19 th 2010. 

27.7 European Medicines Agency (EMA). European assessment report (EPAR). Twinrix Adult, summary of 



27.8 European Medicines Agency (EMA). European assessment report (EPAR). Intanza, summary of product 



27.9 European Medicines Agency (EMA). European assessment report (EPAR). Ixiaro, summary of product 



27.10 Marfin AA et al. Yellow fever and Japanese encephalitis vaccines: indications and complications. 


27.11 European Medicines Agency (EMA). European assessment report (EPAR). M-M-R VaxPro, summary 

of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/ 

EPAR_-_Product_Information/human/000604/WC500030170.pdf. Accessed on October 19 th 2010. 

27.12 European Medicines Agency (EMA). European assessment report (EPAR). Cervarix, summary of 



27.13 The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained effi cacy and immunogenicity of the 

human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled 

trial up to 6.4 years. Lancet 2009;374:1975-85. 

27.14 Schwarz TF et al. Immune response to human papillomavirus after prophylactic vaccination with 

AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110(suppl. 1): 

S1-10. 

27.15 Harper DM. Impact of vaccination with Cervarix on subsequent HPV-16/18 infection and cervical 

disease in women 15-25 years of age. Gynecol Oncol 2008;110(suppl. 1):S11-7. 

27.16 Pedersen C et al. Immunization of early adolescent females with human papillomavirus type 16 and 

18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71. 

27.17 Harper DM et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human 

papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 

364:1757-65. 

27.18 Paavonen J et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against 

infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase 

III double-blind, randomised controlled trial. Lancet 2007;369;2161-70. 

27.19 European Medicines Agency (EMA). European assessment report (EPAR). Gardasil, summary of 



27.20 Joura EA et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) 

L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of 

three randomised clinical trials. Lancet 2007;369:1693-702. 

27.21 FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade 

cervical lesions. N Engl J Med 2007;356:1915-27. 

27.22 Garland SM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital 

diseases. N Engl J Med 2007;356:1928-43. 

27.23 American Academy of Pediatrics Committee on Infectious Diseases. Prevention of human papillomavirus 

infection: provisional recommendations for immunization of girls and women with quadrivalent 

human papillomavirus vaccine. Pediatrics 2007;120:666-8. 

27.24 Barr E et al. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 2007;45:609-17. 

27.25 European Medicines Agency (EMA). European assessment report (EPAR). Rotarix, summary of product 



27.26 European Medicines Agency (EMA). European assessment report (EPAR). RotaTeq, summary of



27.27 Glass RI et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006;368:323- 

32. 

27.28 Plotkin SA. New rotavirus vaccines. Pediatr Infect Dis J 2006;25:575-6. 

27.29 Vesikari T et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 

years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370:1757- 

63. 

27.30 Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev 2008;21:198-208. 

27.31 Marfin AA et al. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect 


27.32 European Medicines Agency (EMA). European assessment report (EPAR). Dukoral, summary of product 



27.33 Steffen R et al. Cholera: assessing the risk to travellers and identifying methods of protection. Travel 


27.34 Pollard AJ et al. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000;19: 

333-45. 

27.35 Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate 

vaccines. Clin Infect Dis 2010;50(suppl. 2):S45-53. 

27.36 European Medicines Agency (EMA). European assessment report (EPAR). Prevenar, summary of 



27.37 European Medicines Agency (EMA). European assessment report (EPAR). Prevenar 13, summary of 



27.38 European Medicines Agency (EMA). European assessment report (EPAR). Synflorix, summary of 



27.39 American Academy of Pediatrics Committee on Infectious Diseases. Guide to contraindications and 

precautions to immunizations. Red Book 2009;28:847-53. 

27.40 American Academy of Pediatrics Committee on Infectious Diseases. Guide to contraindications and 

precautions to immunizations. Red Book 2009;28:847-53. 

27.41 Rottem M et al. Vaccination and allergy. Curr Opin Otolaryngol 2004;12:223-31. 

27.42 Ponvert C et al. Vaccine allergy and pseudo-allergy. Eur J Dermatol 2003;13:10-5. 

27.43 American Academy of Pediatrics Committee on Infectious Diseases. Hypersensitivity reactions to 

vaccine constituents. Red Book 2009;28:42-51. 

27.44 James JM et al. Safe administration of the measles vaccine to children allergic to eggs. N Engl J 

Med 1995;332:1262-6. 

27.45 Khakoo GA et al. Recommendations for using MMR vaccine in children allergic to eggs. Br Med J 

2000;320:929-32. 

27.46 Lakshman R et al. MMR vaccine and allergy. Arch Dis Child 2000;82:93-7. 

27.47 Erlewyn-Lajeunesse M et al. Recommendations for the administration of influenza vaccine in children 

allergic to egg. Br Med J 2009;339:912-5. 

27.48 Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol 2002; 

110:834-40. 

27.49 Chung EY et al. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010; 

125:e1024-30. 

28.1 Pichler J et al. An outbreak of febrile gastroenteritis associated with jellied pork contaminated with 

Listeria monocytogenes. Wien Klin Wochenschr 2009;121:149-56. 

28.2 Allerberger F et al. Listeriosis: a resurgent foodborne infection. Clin Microbiol Infect 2010;16:16-23. 

28.3 Su YC et al. Vibrio parahaemolyticus: a concern of seafood safety. Food Microbiol 2007;24:549-58. 

28.4 DuPont HL. The growing threat of foodborne bacterial enteropathogens of animal origin. Clin Infect 

Dis 2007;45:1353-61. 

28.5 DuPont HL. Bacterial diarrhea. N Engl J Med 2009;361:1560-9. 

28.6 Keiser J et al. Emerging foodborne trematodiasis. Emerg Infect Dis 2005;11:1507-14. 

28.7 Nawa Y et al. Sushi delights and parasites: the risk of fishborne and foodborne parasitic zoonoses in 

Asia. Clin Infect Dis 2005;41:1297-303. 

28.8 Keiser J et al. Food-borne trematodiasis. Clin Microbiol Rev 2009;22:466-83. 

28.9 Dawson D. Foodborne protozoan parasites. Int J Food Microbiol 2005;103:207-27. 

28.10 Glass RI et al. Norovirus gastroenteritis. N Engl J Med 2009;361:1776-85. 

28.11 Atreya CD. Major foodborne illness causing viruses and current status of vaccines against the diseases. 

Foodborne Pathog Dis 2004;1:89-96. 

28.12 Bresee JS et al. Foodborne viral gastro-enteritis: challenges and opportunities. Clin Infect Dis 2002; 

35:748-53. 

28.13 Sobel J et al. Illnesses caused by marine toxins. Clin Infect Dis 2005;41:1290-6. 

28.14 Friedman MA et al. Ciguatera fish poisoning: treatment, prevention and management. Mar Drugs 

2008;6:456-79. 

28.15 Centers for Disease Control and Prevention (CDC). Diagnosis and management of foodborne illnesses: 

a primer for physicians and other health care professionals. Morb Mortal Wkly Rep 2004;53 

(RR-4):1-32. 

28.16 Butt AA et al. Infections related to the ingestion of seafood. Part I: viral and bacterial infections. Lancet 

Infect Dis 2004;4:201-12. 

28.17 Butt AA et al. Infections related to the ingestion of seafood. Part II: parasitic infections and food safety. 


28.18 Scallan E. Activities, achievements, and lessons learned during the first 10 years of the Foodborne 

Diseases Active Surveillance Network: 1996-2005. Clin Infect Dis 2007;44:718-25.

28.19 Marcus R. New information about pediatric foodborne infections: the view from FoodNet. Curr Opin 

Pediatr 2008;20:79-84. 

28.20 Kirk MD et al. Gastroenteritis and food-borne disease in elderly people living in long-term care. Clin 

Infect Dis 2010;50:397-404. 

28.21 Oliver SP et al. Foodborne pathogens in milk and the dairy farm environment: food safety and public 

health implications. Foodborne Pathog Dis 2005;2:115-29. 

28.22 Stenfors Arnesen PL et al. From soil to gut: Bacillus cereus and its food poisoning toxins. FEMS Microbiol 

Rev 2008;32:579-606. 

28.23 Panos GZ et al. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients 

with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 2006;24:731-42. 

28.24 Orth D et al. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome 

in shiga toxin producing Escherichia coli infection. Expert Rev Anti Infect Ther 2008;6:101-8. 

28.25 Karch H et al. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 

295:405-18. 

28.26 Mainil JG et al. Verotoxigenic Escherichia coli from animals, humans and foods: who‘s who? J Appl 

Microbiol 2005;98:1332-44. 

28.27 Tarr PI et al. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 

365:1073-86. 

28.28 Karmali MA et al. Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 2010;140:360-70. 

28.29 Hammerum AM et al. Human health hazards from antimicrobial-resistant Escherichia coli of animal 

origin. Clin Infect Dis 2009;48:916-21. 

28.30 Welinder-Olsson C et al. Enterohemorrhagic Escherichia coli (EHEC). Scand J Infect Dis 2005;37: 

405-16. 

28.31 Kluytmans JA. Methicillin-resistant Staphylococcus aureus in food – innocent bystander or serious 

threat? Clin Microbiol Infect 2010;16:11-5. 

28.32 Murray RJ. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern 

Med J 2005;35(suppl. 2):S106-19. 

29A.1 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14. 

29A.2 Bouza E et al. Fever of unknown origin in solid organ transplant recipients. Infect Dis Clin North Am 

2007;21:1033-54. 

29A.3 Martín-Dávila M et al. Transmission of tropical and geographically restricted infections during solidorgan 

transplantation. Clin Microbiol Rev 2008;21:60-96. 

29B.1 Cadena J et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: 

hepatotoxicity and effectiveness. Am J Transplant 2009;9:2085-91. 

29B.2 Husain S et al. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect 

Dis 2006;8:213-8. 

29B.3 Drew RH et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate 

as aerosolized antifungal prophylaxis in lung transplant recipients. Transplantation 2004;77:232-7. 

29B.4 Lowry CM et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for 

prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl 

Infect Dis 2007;9:121-5. 

29B.5 Ullmann AJ et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N 

Engl J Med 2007;356:335-347. 

29B.6 Ben-Ami R et al. Invasive mould infections in the setting of hematopoietic cell transplantation: current 

trends and new challenges. Curr Opin Infect Dis 2009;22:376-84. 

29B.7 Allinson K et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell 

recipients. J Antimicrob Chemother 2008;61:734-42. 

29B.8 Winston DJ et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long 

term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Ann Intern 

Med 2003;138:705-13. 

29B.9 Strasfeld L et al. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: 

current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68. 

29B.10 Narimatsu H et al. Management of fungal infections following allogeneic stem cell transplantation. 


29B.11 Marr KA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving 

allogeneic stem cell transplants. Blood 2004;103:1527-33. 

29B.12 Husain S et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: 

prospective, multicenter, case controlled study. Transplantation 2003;75:2023-9. 

29B.13 Cruciani M et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. 

Liver Transpl 2006;12:850-8. 

29B.14 Marr KA. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications 

of recent studies. Curr Opin Infect Dis 2008;21:409-14. 

29B.15 Marr KA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving 

allogeneic stem cell transplants. Blood 2004;103:1527-33. 



29B.17 Narimatsu H et al. Management of fungal infections following allogeneic stem cell transplantation. Expert 


29B.18 Winston DJ et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long 

term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Ann Intern 

Med 2003;138:705-13. 

29B.19 Legendre C et al. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus 

infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-40. 

29B.20 Singh N. Optimal prevention of late-onset cytomegalovirus (CMV) disease and other sequelae of 

CMV infection in organ transplant recipients. Clin Infect Dis 2008;47:296-7. 

29B.21 Arthurs SK et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and

mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6. 

29B.22 Torres-Madriz G et al. Perspectives in the treatment and prophylaxis of cytomegalovirus disease in 

solid-organ transplant recipients. Clin Infect Dis 2008;47:702-11. 

29B.23 Griffiths P et al. Contemporary management of cytomegalovirus infection in transplant recipients: 

guidelines from an IHMF Workshop, 2007. Herpes 2008;15:4-12. 

29B.24 Hodson EM et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients 

of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365: 

2105-15. 

29B.25 Kalil AC et al. Meta-Analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus 

in solid organ transplant recipients. Ann Intern Med 2005;143:870-80. 

29B.26 Preiksaitis JK et al. Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus 

Management in Solid Ogan Transplantation. Final report. Am J Transplant 2005;5:218-27. 

29B.27 Singh N. Late onset cytomegalovirus disease as a significant complication in solid organ transplant 

recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005; 

40:704-8. 

29B.28 Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients 

of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005;40:709-12. 

29B.29 Mwintshi K et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus 

in solid organ transplant recipients. Expert Rev Anti Infect Ther 2007;5:295-304. 

29B.30 Small LN et al. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis 

comparing prophylactic and preemptive therapies. Clin Infect Dis 2006:43:869-80. 

29B.31 Meylan PR et al. Preemptive versus prophylactic approaches in the management of cytomegalovirus 

disease in solid organ transplant recipients: what we know and what we do not know. Clin Infect Dis 

2006;43:881-3. 

29B.32 Legendre C et al. Improving outcomes for solid-organ transplant recipients at risk from cyto-megalovirus 

infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-40. 

29B.33 van der Heiden PL et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus 

DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. 

Bone Marrow Transplant 2006;37:693-8. 

29B.34 Ayala E et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic 

hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851-6. 

29B.35 Allice T et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem 

cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob 

Chemother 2009;63:600-8. 

29B.36 Busca A et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic 

stemcell transplantation. Transpl Infect Dis 2007;9:102-7. 



29B.38 Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect 

Dis 2002;35:999-1004. 

29B.39 Meijer E et al. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. 


29B.40 Li F et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart 

transplant recipients. Clin Infect Dis 2007;45:439-47. 

29B.41 Avery RK. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma 

of donor-positive/recipient-negative serostatus. Clin Infect Dis 2007;45:448-9. 

29B.42 Levitsky J et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 

2008;8:158-61. 

29B.43 Egli A et al. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review 

of the literature. Transpl Infect Dis 2008;10:27-43. 

29B.44 Singh N et al. Efficacy of valganciclovir administered as pre-emptive therapy for cytomegalovirus disease 

in liver transplant recipients: impact on viral load and late onset cytomegalovirus disease. 

Transplantation 2005;79:85-90. 

29B.45 Singh N et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C 

virus sequelae and mortality) in liver transplant recipients with the use of pre-emptive therapy for 13 

years. Transplantation 2005;79:1428-34. 

29B.46 Zamora MR et al. Management of cytomegalovirus infection in lung transplant recipients: evidence 

based recommendations. Transplantation 2005;80:157-63. 

29B.47 Perrillo RP et al. A Multicenter United States-Canadian trial to assess lamivudine monotherapy before 

and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32. 

29B.48 Naoumov NV et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term 

prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-94. 

29B.49 Coffin CS et al. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007;14 

(suppl. 1):37-44. 

29B.50 Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24 

(suppl. 1):55-62. 

29B.51 Gasink LB et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. 

J Am Med Assoc 2006;296:1843-50. 

29B.52 Biggins SW et al. Management of recurrent hepatitis C in liver transplant recipients. Infect Dis Clin 

North Am 2006;20:155-74. 

29B.53 Miller GG et al. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 

2007;7:741-7. 

29B.54 Erard V et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: 

impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 

196:266-70. 

29B.55 Erard V et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: 

impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 

193:266-70.

29B.56 Rodriguez M et al. Failure of low dose atovaquone prophylaxis against Pneumocystis jiroveci infection 

in transplant recipients. Clin Infect Dis 2004;38:e76-8. 

29B.57 Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004;4(suppl. 10):135-41. 

29B.58 Derouin F et al. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008;14: 

1089-101. 

29B.59 Kun H et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009;48: 

1534-40. 

29B.60 Bern C et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. J 

Am Med Assoc 2007;298:2171-81. 

29B.61 Altclas JD et al. Organ transplantation and Chagas disease. J Am Med Assoc 2008;299:1134-5. 

29B.62 Bestetti RB et al. A systematic review of studies on heart transplantation for patients with end-stage 

Chagas‘ heart disease. J Cardiac Fail 2009;15:249-55. 

29B.63 Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by 

Coccidioides species. Curr Opin Infect Dis 2008;21:415-20. 

29B.64 Soave R. Prophylaxis strategies for solid organ transplantation. Clin Infect Dis 2001;33(suppl. 1): 

S26-31. 

29B.65 Parasitic infections. Am J Transplant 2004;4(suppl. 10):142-55. 

29B.66 Fungal infections. Am J Transplant 2004;4(suppl. 10):110-34. 

29B.67 Cytomegalovirus. Am J Transplant 2004;4(suppl. 10):51-8. 

29B.68 Avery RK. Prophylactic strategies before solid organ transplantation. Curr Opin Infect Dis 2004;17: 

353-6. 

29B.69 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14. 

29B.70 Martín-Dávila M et al. Transmission of tropical and geographically restricted infections during solidorgan 

transplantation. Clin Microbiol Rev 2008;21:60-96. 

29B.71 Sun HY et al. Pharmacotherapy of post-transplant viral infections. Expert Opin Pharmacother 2008; 

9:2409-21. 

29B.72 Bouza E et al. Fever of unknown origin in solid organ transplant recipients. Infect Dis Clin North Am 

2007;21:1033-54. 

29B.73 Hanson K et al. Strategies for the prevention of infection after solid organ transplantation. Expert Rev 


29B.74 Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 

2007;44:857-66. 

29B.75 Tomblyn M et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation 

recipients: a global perspective Biol Blood Marrow Transplant 2009;15:1143-238. 

29B.76 Castagnola E et al. Management of bacteremia in patients undergoing hematopoietic stem cell transplantation. 


30A.1 Provan D et al. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. 

Br Med J 2008;337:990-2. 

31A.1 Kampf G et al. Epidemiologic background of hand hygiene and evaluation of the most important 

agents for scrubs and rubs. Clin Microbiol Rev 2004;17:863-93. 

31A.2 Boyce JM et al. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare 

Infection Control Practices Advisory Committee and the ICPAC/SHEA/APIC/IDSA Hand Hygiene 

Task Force. Infect Control Hosp Epidemiol 2002;23(suppl.):S3-40. 

31A.3 Centers for Disease Control and Prevention (CDC). Guideline for hand hygiene in health-care settings: 

recommendations of the Healthcare Infection Control Practices Advisory Committee and the 

ICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Morb Mortal Wkly Rep 2002;52(RR-16):1-45. 

31A.4 Tanner J et al. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst 

Rev 2008;1:CD004288. 

31A.5 Darouiche RO et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl 

J Med 2010;362:18-26. 

31A.6 Dettenkofer M et al. Hospital disinfection: efficacy and safety issues. Curr Opin Infect Dis 2005;18: 

320-5. 

31A.7 Cozad A et all. Disinfection and the prevention of infectious disease. Am J Infect Control 2003;31: 

243-53. 

31A.8 Daschner F et al. Disinfection and the prevention of infectious disease: No adverse effects? Am J Infect 

Control 2004;32:224-5. 

31A.9 Rutala WA et al. Disinfection and sterilization in health care facilities: what clinicians need to know. 


31A.10 Hota B. Contamination, disinfection and cross colonization: are hospital surfaces reservoirs for nosocomial 

infection? Clin Infect Dis 2004;39:1182-9. 

31A.11 Rutala WA et al. The benefits of surface disinfection. Am J Infect Control 2004;32:226-31. 

31B.1 McDonnell G et al. Antiseptics and disinfectants: activity, action and resistance. Clin Microbiol Rev 

1999;12:147-79. 

31B.2 Sheldon AT. Antiseptic ―resistance‖: real or perceived threat? Clin Infect Dis 2005;40:1650-6. 

31B.3 Russell AD. Bacterial adaptation and resistance to antiseptics, disinfectants and preservatives is not 

a new phenomenon. J Hosp Infect 2004;57:97-104. 

32.1 World Health Organization. WHO model formulary 2008. Available at: http://www.who.int/selection 

_medicines/list/WMF2008.pdf. Accessed on October 19 th 2010. 

32.2 World Health Organization. WHO model formulary for children 2010. Available at: http://www.who.int/ 

selection_medicines/list/WMFc_2010.pdf. Accessed on October 19 th 2010. 

32.3 Green IT et al. Antibiotic, antifungal, and antiviral dosage in hepatic impairment. LA Health Syst 

Pharm 2009;18(4):4-6. 

32.4 Wyles DL et al. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect 

Dis 2005;40:174-81.

33A.1 Kearney BP et al. The penetration of anti-infectives into the central nervous system. Neurol Clin 

1999;17:883-900. 

33A.2 Täuber MG et al. General principles of therapy of pyogenic meningitis. Infect Dis Clin North Am 

1990;4:661-76. 

33A.3 Andes DR et al. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin 

North Am 1999;13:595-618. 

33A.4 Sinner SW et al. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North 

Am 2004;18:581-602. 

33A.5 Markantonis SL et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 

2009;53:4907-10. 

33A.6 Kanellakopoulou K et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: 

implication for a bactericidal effect. J Antimicrob Chemother 2008;61:1328-31. 

33A.7 Black KE et al. Fungal infections of the CNS. Treatment strategies for the immunocompromised patient. 

CNS Drugs 2007;21:293-318. 

33A.8 Kethireddy S et al. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 

2007;3:571-81. 

33B.1 Letendre S et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration 

into the central nervous system. Arch Neurol 2008;65:65-70. 

33B.2 Letendre SL et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disor- 

ders. Ann Neurol 2004;56;416-23. 

33B.3 McGee B et al. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 

2006;7:142-53. 

34.1 Piraino B et al. Peritoneal dialysis-related infections. Recommendations: 2005 update. Perit Dial Int 

2005;25:107-31. 

34.2 de Vin F et al. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility 

and guidance for clinical use. Perit Dial Int 2009;29:5-15. 

36.1 Committee on Drugs of the American Academy of Pediatrics. The transfer of drugs and other 

chemicals into human milk. Pediatrics 2001;108:776-89. 

36.2 Nahum GG et al. Antibiotic use in pregnancy and lactation. What is and is not known about teratogenic 

and toxic risks. Obstet Gynecol 2006;107:1120-38. 

36.3 Ilett KF et al. Drug Use and breastfeeding. Expert Opin Drug Saf 2005;4:745-68. 

36.4 Bar-Oz B et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf 2003;26:925-35. 

36.5 Hale TW. Maternal medications during breastfeeding. Clin Obstet Gynecol 2004;47:696-711. 

37A.1 Win PH et al. Rapid intravenous cephalosporin desensitization. J Allergy Clin Immunol 2005;116: 

225-8. 

37B.1 Matz J et al. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir 

Crit Care Med 1994;149:815-7. 

37C.1 Weiss ME. Evaluation and treatment of patients with prior reactions to �-lactam antibiotics. Curr Clin 

Top Infect Dis 1993;13:131-45. 

37C.2 Turvey SE et al. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. 

Ann Allergy Asthma Immunol 2004;92:426-32. 

37C.3 Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006;6:476-81. 

37D.1 Matz J et al. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir 

Crit Care Med 1994;149:815-7. 

37E.1 Tenant-Flowers M et al. Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis. 

AIDS 1991;5:311-5. 

37F.1 Para MF et al. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary 

prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune 

Defic Syndr 2000;24:337-43. 

37F.2 Tilles SA. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med 

J 2001;94:817-24. 

37F.3 Gluckstein D et al. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in 

prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were pre-viously intolerant 

to TMP-SMZ. Clin Infect Dis 1995;20:849-53. 

TABLE 39B 

ABBREVIATIONS OF JOURNALS REFERRED TO IN THE GUIDE 

Acta Clin Belg Acta Clinica Belgica 

Acta Derm Venereol Acta Dermato-Venereologica 

Acta Ophthalmol Acta Ophthalmologica 

Acta Trop Acta Tropica 

Adv Parasitol Advances in Parasitology 

Adv Skin Wound Care Advances in Skin and Wound Care 

Aesthetic Plast Surg Aesthetic Plastic Surgery 

AIDS Acquired Immune Deficiency Syndrome

AIDS Patient Care STDs Acquired Immune Deficiency Syndrome Patient Care and Sexually Transmit- 

ted Diseases 

AIDS Read Acquired Immune Deficiency Syndrome Reader 

AIDS Res Hum Retroviruses Acquired Immune Deficiency Syndrome Research and Human Retroviruses 

AIDS Res Ther Acquired Immune Deficiency Syndrome Research and Therapy 

AIDS Rev Acquired Immune Deficiency Syndrome Reviews 

Aliment Pharmacol Ther Alimentary Pharmacology and Therapeutics 

Allergy Allergy 

Am Fam Physician American Family Physician 

Am J Clin Dermatol American Journal of Clinical Dermatology 

Am J Clin Pathol American Journal of Clinical Pathology 

Am J Emerg Med American Journal of Emergency Medicine 

Am J Gastroenterol American Journal of Gastroenterology 

Am J Health Syst Pharm American Journal of Health System Pharmacy 

Am J Hematol American Journal of Hematology 

Am J Infect Control American Journal of Infection Control 

Am J Kidney Dis American Journal of Kidney Diseases 

Am J Med American Journal of Medicine 

Am J Ophthalmol American Journal of Ophthalmology 

Am J Respir Crit Care Med American Journal of Respiratory and Critical Care Medicine 

Am J Ther American Journal of Therapeutics 

Am J Transplant American Journal of Transplantation 

Am J Trop Med Hyg American Journal of Tropical Medicine and Hygiene 

Andrologia Andrologia 

Ann Allergy Asthma Immunol Annals of Allergy, Asthma, and Immunology 

Ann Emerg Med Annals of Emergency Medicine 

Ann Intern Med Annals of Internal Medicine 

Ann Neurol Annals of Neurology 

Ann NY Acad Sci Annals of the New York Academy of Sciences 

Ann Oncol Annals of Oncology 

Ann Otol Rhinol Laryngol Annals of Otology, Rhinology and Laryngology 

Ann Pharmacother Annals of Pharmacotherapy 

Ann Rheum Dis Annals of Rheumatic Diseases 

Ann Surg Annals of Surgery 

Ann Thorac Surg Annals of Thoracic Surgery 

Antimicrob Agents Chemother Antimicrobial Agents and Chemotherapy 

Antiviral Res Antiviral Research 

Antiviral Ther Antiviral Therapy 

Arch Dermatol Archives of Dermatology 

Arch Dis Child Archives of Disease in Childhood 

Arch Intern Med Archives of Internal Medicine 

Arch Med Res Archives of Medical Research 

Arch Neurol Archives of Neurology 

Arch Ophthalmol Archives of Ophthalmology 

Arch Otolaryngol Head Neck Surg Archives of Otolaryngology – Head and Neck Surgery 

Arch Pathol Lab Med Archives of Pathology and Laboratory Medicine 

Arch Pediatr Archives de Pédiatrie 

Arch Surg Archives of Surgery 

Arthritis Care Res Arthritis Care and Research 

Arthritis Rheum Arthritis and Rheumatism 

Arzneimittelforschung Arzneimittelforschung 

Auris Nasus Larynx Auris, Nasus, Larynx 

Biol Blood Marrow Transplant Biology of Blood and Marrow Transplantation 

Biomed Pharmacother Biomedicine and Pharmacotherapy 

Blood Blood 

BMC Infect Dis BioMed Central Infectious Diseases 

Bone Marrow Transplant Bone Marrow Transplantation 

Br J Cancer British Journal of Cancer 

Br J Clin Pharmacol British Journal of Clinical Pharmacology 

Br J Dermatol British Journal of Dermatology 

Br J Gen Pract British Journal of General Practice 

Br J Ophthalmol British Journal of Ophthalmology 

Br J Plast Surg British Journal of Plastic Surgery 

Br Med Bull British Medical Bulletin 

Br Med J British Medical Journal 

Bull World Health Organ Bulletin of the World Health Organization 

Can J Infect Dis Med Microbiol Canadian Journal of Infectious Diseases and Medical Microbiology 

Cancer Cancer 

Chemotherapy Chemotherapy 

Chest Chest 

Circulation Circulation 

Clin Chest Med Clinics in Chest Medicine 

Clin Dermatol Clinics in Dermatology 

Clin Exp Dermatol Clinical and Experimental Dermatology 

Clin Gastroenterol Hepatol Clinical Gastroenterology and Hepatology 

Clin Infect Dis Clinical Infectious Diseases 

Clin Liver Dis Clinics in Liver Disease 

Clin Microbiol Infect Clinical Microbiology and Infection 

Clin Microbiol Newslett Clinical Microbiology Newsletter 

Clin Microbiol Rev Clinical Microbiology Reviews 

Clin Neurol Neurosurg Clinical Neurology and Neurosurgery 

Clin Obstet Gynecol Clinical Obstetrics and Gynecology 

Clin Pharmacokinet Clinical Pharmacokinetics

Clin Plast Surg Clinics in Plastic Surgery 

Clin Rheumatol Clinical Rheumatology 

Clin Ther Clinical Therapeutics 

CNS Drugs Central Nervous System Drugs 

Cochrane Database Syst Rev Cochrane Database of Systematic Reviews 

Crit Care Critical Care 

Crit Care Med Critical Care Medicine 

Crit Rev Clin Lab Sci Critical Reviews in Clinical Laboratory Sciences 

Curr Clin Top Infect Dis Current Clinical Topics in Infectious Diseases 

Curr Fungal Infect Rep Current Fungal Infection Reports 

Curr Med Chem Current Medicinal Chemistry 

Curr Med Res Opin Current Medical Research and Opinion 

Curr Mol Med Current Molecular Medicine 

Curr Opin Allergy Clin Immunol Current Opinion in Allergy and Clinical Immunology 

Curr Opin Infect Dis Current Opinion in Infectious Diseases 

Curr Opin Investig Drugs Current Opinion in Investigational Drugs 

Curr Opin Microbiol Current Opinion in Microbiology 

Curr Opin Ophthalmol Current Opinion in Ophthalmology 

Curr Opin Otolaryngol Current Opinion in Otolaryngology 

Curr Opin Pediatr Current Opinion in Pediatrics 

Curr Opin Pulmon Med Current Opinion in Pulmonary Medicine 

Curr Opin Urol Current Opinion in Urology 

Cutis Cutis 

Dermatol Clin Dermatologic Clinics 

Dermatol Ther Dermatologic Therapy 

Dermatology Dermatology 

Diabet Med Diabetic Medicine 

Diabetes Metab Res Rev Diabetes/Metabolism Research and Reviews 

Diagn Microbiol Infect Dis Diagnostic Microbiology and Infectious Disease 

Dig Dis Sci Digestive Diseases and Sciences 

Dis Colon Rectum Diseases of the Colon and Rectum 

Drug Resist Updates Drug Resistance Updates 

Drug Saf Drug Safety 

Drugs Drugs 

Drugs Today Drugs of Today 

Emerg Infect Dis Emerging Infectious Diseases 

Emerg Med Clin North Am Emergency Medicine Clinics of North America 

Emerg Med J Emergency Medicine Journal 

Epidemiol Infect Epidemiology and Infection 

Epilepsia Epilepsia 

Eur Heart J European Heart Journal 

Eur J Cancer Suppl European Journal of Cancer Supplements 

Eur J Cardiothorac Surg European Journal of Cardio-Thoracic Surgery 

Eur J Clin Investig European Journal of Clinical Investigation 

Eur J Clin Microbiol Infect Dis European Journal of Clinical Microbiology and Infectious Diseases 

Eur J Clin Pharmacol European Journal of Clinical Pharmacology 

Eur J Dermatol European Journal of Dermatology 

Eur J Epidemiol European Journal of Epidemiology 

Eur J Haematol European Journal of Haematology 

Eur J Intern Med European Journal of Internal Medicine 

Eur J Med Res European Journal of Medical Research 

Eur J Neurol European Journal of Neurology 

Eur J Pediatr European Journal of Pediatrics 

Eur J Pharmacol European Journal of Pharmacology 

Eur Respir J European Respiratory Journal 

Eur Urol European Urology 

Euro Surveill Eurosurveillance 

Expert Opin Biol Ther Expert Opinion on Biological Therapy 

Expert Opin Drug Metab Toxicol Expert Opinion on Drug Metabolism and Toxicology 

Expert Opin Drug Saf Expert Opinion on Drug Safety 

Expert Opin Emerg Drugs Expert Opinion on Emerging Drugs 

Expert Opin Investig Drugs Expert Opinion on Investigational Drugs 

Expert Opin Pharmacother Expert Opinion on Pharmacotherapy 

Expert Rev Anti Infect Ther Expert Review of Anti-Infective Therapy 

Expert Rev Ophthalmol Expert Review of Ophthalmology 

Eye Contact Lens Eye and Contact Lens 

FEMS Immunol Med Microbiol Federation of European Microbiology Societies Immunology and Medical Mi- 

crobiology 

FEMS Microbiol Rev Federation of European Microbiology Societies Microbiology Reviews 

Food Microbiol Food Microbiology 

Foodborne Pathog Dis Foodborne Pathogens and Disease 

Gastroenterology Gastroenterology 

Gastrointest Endosc Gastrointestinal Endoscopy 

Gut Gut 

Gynecol Oncol Gynecologic Oncology 

Helicobacter Helicobacter 

Hepatology Hepatology 

Herpes Herpes 

HIV Clin Trials Human Immunodeficiency Virus Clinical Trials 

HIV Med Human Immunodeficiency Virus Medicine 

Hum Pathol Human Pathology 

Infect Control Hosp Epidemiol Infection Control and Hospital Epidemiology 

Infect Dis Clin North Am Infectious Disease Clinics of North America

Infect Dis Clin Pract Infectious Diseases in Clinical Practice 

Infect Dis Obstet Gynecol Infectious Diseases in Obstetrics and Gynecology 

Infection Infection 

Infez Med Le Infezioni in Medicina 

Int J Antimicrob Agents International Journal of Antimicrobial Agents 

Int J Clin Pract International Journal of Clinical Practice 

Int J Dermatol International Journal of Dermatology 

Int J Food Microbiol International Journal of Food Microbiology 

Int J Immunopathol Pharmacol International Journal of Immunopathology and Pharmacology 

Int J Infect Dis International Journal of Infectious Diseases 

Int J Med Microbiol International Journal of Medical Microbiology 

Int J Parasitol International Journal for Parasitology 

Int J Pediatr Otorhinolaryngol International Journal of Pediatric Otorhinolaryngology 

Int J STD AIDS International Journal of Sexually Transmitted Diseases and the Acquired Im- 

mune Deficiency Syndrome 

Int J Syst Evol Microbiol International Journal of Systematic and Evolutionary Microbiology 

Intensive Care Med Intensive Care Medicine 

Intern Med J Internal Medicine Journal 

Intervirology Intervirology 

J Adolesc Health Journal of Adolescent Health 

J AIDS Hum Retrovirol Journal of the Acquired Immune Deficiency Syndrome and Human Retroviro- 

logy 

J AIDS Journal of Acquired Immune Deficiency Syndromes 

J Allergy Clin Immunol Journal of Allergy and Clinical Immunology 

J Am Acad Dermatol Journal of the American Academy of Dermatology 

J Am Coll Cardiol Journal of the American College of Cardiology 

J Am Med Assoc Journal of the American Medical Association 

J Antimicrob Chemother Journal of Antimicrobial Chemotherapy 

J Appl Microbiol Journal of Applied Microbiology 

J Bone Joint Surg Journal of Bone and Joint Surgery 

J Burn Care Res Journal of Burn Care and Research 

J Cardiac Fail Journal of Cardiac Failure 

J Cataract Refract Surg Journal of Cataract and Refractive Surgery 

J Chemother Journal of Chemotherapy 

J Clin Gastroenterol Journal of Clinical Gastroenterology 

J Clin Microbiol Journal of Clinical Microbiology 

J Clin Neurosci Journal of Clinical Neuroscience 

J Clin Oncol Journal of Clinical Oncology 

J Clin Pharmacol Journal of Clinical Pharmacology 

J Clin Virol Journal of Clinical Virology 

J Cutan Pathol Journal of Cutaneous Pathology 

J Dermatol Treat Journal of Dermatological Treatment 

J Drugs Dermatol Journal of Drugs in Dermatology 

J Endocrinol Journal of Endocrinology 

J Eukaryot Microbiol Journal of Eukaryotic Microbiology 

J Eur Acad Dermatol Venereol Journal of the European Academy of Dermatology and Venereology 

J Fam Pract Journal of Family Practice 

J Gastrointestinal Surg Journal of Gastrointestinal Surgery 

J Hand Surg Journal of Hand Surgery 

J Hepatol Journal of Hepatology 

J Hosp Infect Journal of Hospital Infection 

J Infect Journal of Infection 

J Infect Chemother Journal of Infection and Chemotherapy 

J Infect Dis Journal of Infectious Diseases 

J Med Microbiol Journal of Medical Microbiology 

J Med Virol Journal of Medical Virology 

J Microbiol Immunol Infect Journal of Microbiology, Immunology and Infection 

J Neurol Journal of Neurology 

J Neurol Neurosurg Psychiatry Journal of Neurology, Neurosurgery and Psychiatry 

J Neurovirol Journal of Neurovirology 

J Obstet Gynaecol Can Journal of Obstetrics and Gynaecology Canada 

J Otolaryngol Journal of Otolaryngology 

J Pediatr Journal of Pediatrics 

J Pediatr Gastroenterol Nutr Journal of Pediatric Gastroenterology and Nutrition 

J Trauma Journal of Trauma 

J Travel Med Journal of Travel Medicine 

J Urol Journal of Urology 

J Viral Hepat Journal of Viral Hepatitis 

LA Health Syst Pharm Louisiana Health System Pharmacist 

Lancet Lancet 

Lancet Infect Dis Lancet Infectious Diseases 

Lancet Neurol Lancet Neurology 

Laryngoscope Laryngoscope 

Liver Int Liver International 

Liver Transpl Liver Transplantation 

Mar Drugs Marine Drugs 

Mayo Clin Proc Mayo Clinic Proceedings 

Med Clin North Am Medical Clinics of North America 

Med J Aust Medical Journal of Australia 

Med Res Rev Medicinal Research Reviews 

Medicine Medicine 

Mem Inst Oswaldo Cruz Memorias do Instituto Oswaldo Cruz 

Morb Mortal Wkly Rep Morbidity and Mortality Weekly Report

Mycopathologia Mycopathologia 

Mycoses Mycoses 

N Engl J Med New England Journal of Medicine 

Nat Clin Pract Gastroenterol He- Nature Clinical Practice – Gastroenterology and Hepatology 

patol 

Nat Clin Pract Neurol Nature Clinical Practice – Neurology 

Nat Med Nature Medicine 

Nat Rev Drug Discov Nature Reviews Drug Discovery 

Nat Rev Microbiol Nature Reviews Microbiology 

Nature Nature 

Ned Tijdschr Geneeskd Nederlands Tijdschrift voor Geneeskunde 

Nephrol Dial Transplant Nephrology, Dialysis, Transplantation 

Neth J Med Netherlands Journal of Medicine 

Neurol Clinics Neurologic Clinics 

Neurology Neurology 

Obstet Gynecol Obstetrics and Gynecology 

Ophthalmology Ophthalmology 

Oral Surg Oral Med Oral Pathol Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 

Oral Radiol Endod 

Otol Neurotol Otology and Neurotology 

Otolaryngol Head Neck Surg Otolaryngology – Head and Neck Surgery 

Parasitol Int Parasitology International 

Parasitol Res Parasitology Research 

Parasitol Today Parasitology Today 

Parasitology Parasitology 

Pathol Biol Pathologie Biologie 

Pathology Pathology 

Pediatr Dermatol Pediatric Dermatology 

Pediatr Drugs Pediatric Drugs 

Pediatr Emerg Care Pediatric Emergency Care 

Pediatr Infect Dis J Pediatric Infectious Disease Journal 

Pediatr Int Pediatrics International 

Pediatr Rev Pediatrics in Review 

Pediatrics Pediatrics 

Perit Dial Int Peritoneal Dialysis International 

Pharmacoeconomics Pharmacoeconomics 

Pharmacotherapy Pharmacotherapy 

Plast Reconstruct Surg Plastic and Reconstructive Surgery 

PloS Med Public Library of Science Medicine 

PLoS Neglected Trop Dis Public Library of Science Neglected Tropical Diseases 

PloS One Public Library of Science One 

PLoS Pathog Public Library of Science Pathogens 

Postgrad Med J Postgraduate Medical Journal 

Pract Neurol Practice in Neurology 

Presse Med Presse Médicale 

Prim Care Respir J Primary Care Respiratory Journal 

Respir Med Respiratory Medicine 

Retina Retina 

Rev Infect Dis Reviews of Infectious Diseases 

Rev Med Interne La Revue de Médecine Interne 

Rev Med Virol Reviews in Medical Virology 

Scand J Infect Dis Scandinavian Journal of Infectious Diseases 

Science Science 

Semin Arthritis Rheum Seminars in Arthritis and Rheumatism 

Semin Liver Dis Seminars in Liver Disease 

Semin Neurol Seminars in Neurology 

Semin Ophthalmol Seminars in Ophthalmology 

Semin Pediatr Infect Dis Seminars in Pediatric Infectious Diseases 

Semin Perinatol Seminars in Perinatology 

Semin Respir Crit Care Med Seminars in Respiratory and Critical Care Medicine 

Sex Transm Dis Sexually Transmitted Diseases 

Sex Transm Infect Sexually Transmitted Infections 

South Med J Southern Medical Journal 

Southeast Asian J Trop Med Pu- Southeast Asian Journal of Tropical Medicine and Public Health 

blic Health 

Surg Infect Surgical Infections 

Surg Neurol Surgery Neurology 

Surgery Surgery 

Tech Vasc Intervent Radiol Techniques in Vascular and Interventional Radiology 

Ther Drug Monit Therapeutic Drug Monitoring 

Thorac Cardiovasc Surg Thoracic and Cardiovascular Surgeon 

Thorax Thorax 

Thromb J Thrombosis Journal 

Trans R Soc Trop Med Hyg Transactions of the Royal Society of Tropical Medicine and Hygiene 

Transfus Med Rev Transfusion Medicine Reviews 

Transpl Infect Dis Transplant Infectious Disease 

Transpl Int Transplant International 

Transplantation Transplantation 

Travel Med Infect Dis Travel Medicine and Infectious Disease 

Treat Guidel Med Lett Treatment Guidelines from the Medical Letter 

Trends Parasitol Trends in Parasitology 

Trop Med Int Health Tropical Medicine and International Health 

Tuberculosis Tuberculosis

Vaccine Vaccine 

Vet Microbiol Veterinary Microbiology 

Virol J Virology Journal 

Wien Klin Wochenschr Wiener Klinische Wochenschrift 

Wkly Epidemiol Rec Weekly Epidemiological Record

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?